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ABSTRACT	  
The	  skin	  barrier	  plays	  an	  essential	  role	  in	  protecting	  the	  body	  from	  external	  assaults	  and	  maintaining	  homeostasis.	  The	  differentiation	  of	  keratinocytes	  into	  toughened	  corneocytes	  begins	  in	  the	  basal	  layer	  of	  the	  epidermis	  and	  culminates	  in	  the	  formation	  of	  the	  stratum	  corneum	  (SC).	  Corneocytes	  are	  terminally	  differentiated	  cells	  which	  form	  a	  protective	  shield	  consisting	  of	  insoluble	  structural	  proteins	  cross-­‐linked	  to	  the	  lipid	  envelope	  of	  the	  cornified	  cell	  envelope.	  In	  recent	  years,	  many	  molecular	  participants	  behind	  the	  extensive	  remodeling	  of	  the	  epidermis	  have	  been	  uncovered,	  and	  a	  spectrum	  of	  epidermal	  diseases	  have	  been	  shown	  to	  be	  associated	  with	  mutations	  coding	  for	  structural	  or	  enzymatic	  proteins	  involved	  in	  the	  complex	  processes	  of	  differentiation.	  However,	  genetic	  determinants	  for	  many	  epidermal	  barrier	  disorders	  are	  still	  unknown.	  The	  work	  in	  this	  thesis	  focuses	  on	  identifying	  the	  gene	  responsible	  for	  the	  phenotype	  of	  the	  
Mattma/ma	  (matted)	  mouse,	  which	  was	  first	  documented	  in	  1957.	  To	  hunt	  this	  elusive	  gene	  down,	  extensive	  mapping	  of	  the	  murine	  epidermal	  differentiation	  complex	  (EDC)	  was	  carried	  out	  and	  the	  gene	  identified	  as	  transmembrane	  79	  
(Tmem79).	  Further	  work	  characterizing	  the	  human	  ortholog	  of	  TMEM79	  showed	  that	  the	  protein	  localized	  to	  the	  membranes	  of	  lamellar	  granules	  (LG)	  in	  keratinocytes	  in	  the	  upper	  granular	  layers.	  Various	  human	  populations	  with	  skin	  diseases	  were	  screened,	  but	  no	  predisposition	  was	  identified	  between	  TMEM79	  and	  allergic	  phenotypes.	  In	  conclusion,	  Tmem79	  is	  responsible	  for	  the	  phenotype	  seen	  in	  the	  Mattma/ma	  mouse,	  leading	  to	  spontaneous	  dermatitis	  due	  to	  a	  skin	  barrier	  defect.	  This	  novel	  gene	  encodes	  for	  a	  protein	  that	  is	  involved	  in	  desquamation	  of	  cornified	  layers,	  where	  an	  aberrant	  TMEM79	  results	  in	  dysfunction	  LG	  transport/secretion.
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1. INTRODUCTION	  The	  differentiation	  of	  the	  epidermis	  is	  a	  concerted	  effort	  of	  maturation	  involving	  many	  players.	  However,	  there	  are	  still	  many	  questions	  regarding	  this	  sophisticated	  process.	  For	  instance,	  it	  is	  still	  unknown	  how	  the	  desmosome	  is	  modified	  to	  form	  corneodesmosomes,	  or	  how	  the	  nucleus	  and	  mitochondria	  are	  degraded	  during	  terminal	  differentiation.	  Further	  identification	  and	  understanding	  of	  the	  proteins	  involved	  in	  epidermal	  differentiation	  will	  not	  only	  aid	  us	  in	  understanding	  these	  processes,	  but	  will	  help	  to	  elucidate	  the	  mechanisms	  behind	  skin	  diseases	  and	  ultimately	  guide	  us	  in	  how	  to	  treat	  them.	  	  
1.1 STRUCTURE	  OF	  THE	  SKIN	  The	  skin	  is	  the	  largest	  organ	  in	  the	  body	  and	  consists	  of	  one	  continuous	  surface.	  It	  provides	  protection	  by	  acting	  as	  a	  physical	  barrier	  against	  mechanical,	  chemical	  and	  thermal	  stress,	  as	  well	  as	  ultraviolet	  light.	  Small	  peripheral	  nerves	  within	  the	  dermis	  facilitate	  the	  ability	  to	  sense	  touch,	  pressure,	  pain	  and	  temperature.	  Thermoregulation	  of	  the	  body	  is	  regulated	  through	  body	  hair,	  sub-­‐cutaneous	  fat,	  the	  action	  of	  perspiration	  and	  the	  vascular	  network	  under	  the	  surface	  of	  the	  skin	  through	  the	  increase	  or	  decrease	  in	  blood	  flow.	  	  Adipose	  fat	  tissue	  acts	  as	  a	  form	  of	  energy	  storage	  in	  the	  form	  of	  triglycerides,	  and	  the	  metabolic	  functions	  of	  the	  skin	  also	  include	  the	  synthesis	  of	  vitamin	  D.	  	  Skin	  at	  different	  body	  sites	  varies	  in	  thickness,	  color	  and	  the	  presence	  of	  hairs	  and	  glands	  due	  to	  different	  functional	  demands.	  Despite	  these	  differences,	  there	  is	  a	  general	  structure	  to	  all	  skin	  types.	  The	  outermost	  layer	  of	  the	  skin	  is	  known	  as	  the	  epidermis,	  and	  it	  is	  thickest	  on	  palmoplantar	  skin.	  The	  epidermis	  lies	  above	  the	  dermis,	  which	  is	  nourished	  and	  connected	  to	  the	  rest	  of	  the	  body	  by	  the	  vascular	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  system.	  Epidermal	  appendages	  such	  as	  the	  hair	  follicles,	  sweat	  glands,	  sebaceous	  glands	  and	  nails	  extend	  upwards	  from	  the	  epithelium.	  
	  
Figure	  1.	  1	  A	  cartoon	  of	  the	  epidermis	  with	  examples	  of	  layer-­‐specific	  
markers.	  As	  keratinocytes	  differentiate	  and	  move	  upwards	  through	  the	  different	  layers,	  they	  express	  layer-­‐specific	  markers.	  	  Epidermal	  cells	  undergo	  growth	  and	  differentiation	  while	  migrating	  from	  the	  bottom	  to	  the	  top	  layer,	  acquiring	  distinct	  structural,	  functional	  and	  chemical	  characteristics	  in	  the	  process.	  Skin	  is	  characterized	  by	  squamous	  stratified	  cells	  with	  the	  ability	  for	  self-­‐renewal	  and	  repair	  due	  to	  the	  presence	  of	  epidermal	  stem	  cells	  (ESCs).	  The	  differentiation	  of	  skin	  cells	  (herein	  called	  keratinocytes),	  are	  marked	  by	  the	  expression	  of	  various	  layer-­‐specific	  markers	  (Figure	  1.	  1).	  The	  bottom-­‐most	  layer	  is	  the	  stratum	  basale	  layer,	  consisting	  of	  a	  single	  layer	  of	  cuboidal	  cells	  that	  separate	  the	  epidermis	  from	  the	  dermis	  by	  a	  basement	  membrane.	  Basal	  cells	  are	  bound	  to	  the	  basement	  membrane	  by	  hemi-­‐
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  desmosomes.	  ESCs	  are	  generally	  located	  within	  the	  stratum	  basale	  layer	  of	  interfollicular	  epidermis	  and	  also	  within	  the	  bulge	  region	  of	  the	  hair	  follicle.	  These	  cells	  divide	  asymmetrically,	  with	  one	  daughter	  cell	  undergoing	  differentiation	  and	  the	  remaining	  cell	  as	  the	  parent	  stem	  cell,	  designated	  to	  keep	  the	  population	  of	  keratinocytes	  constant	  within	  the	  epidermis	  (Blanpain	  et	  al.,	  2004).	  Cells	  within	  the	  stratum	  spinosum	  (spinous)	  layer	  are	  larger	  and	  polyhedral	  in	  shape.	  In	  the	  next	  layer,	  the	  stratum	  granulosum,	  granular	  keratinocytes	  are	  characterized	  by	  numerous	  keratohyalin	  granules	  (seen	  as	  star-­‐shaped	  granules	  in	  Figure	  1.	  1)	  consisting	  of	  loricrin	  (L-­‐granules)	  or	  filaggrin	  (F-­‐granules)	  (Ishida-­‐Yamamoto	  et	  al.,	  1993;	  Steven	  et	  al.,	  1990).	  It	  is	  within	  the	  granular	  layer	  that	  cells	  begin	  the	  final	  stages	  of	  terminal	  differentiation,	  secreting	  lamellar	  granules	  (also	  known	  as	  lamellar	  bodies	  or	  Odland	  bodies)	  into	  the	  intercellular	  space	  and	  crosslinking	  keratin	  filaments	  with	  the	  lipid	  envelope.	  Keratinocytes	  begin	  the	  process	  of	  degrading	  the	  nucleus	  and	  intracellular	  organelles	  in	  this	  layer	  so	  that	  when	  keratinocytes	  reach	  the	  stratum	  corneum,	  they	  are	  anucleate	  and	  devoid	  of	  organelles.	  This	  process	  is	  called	  cornification,	  where	  the	  cornified	  envelope	  is	  cross-­‐linked	  to	  lamellae	  sheets	  within	  the	  intercellular	  space.	  The	  flattened	  keratinocytes	  of	  the	  stratum	  corneum	  (corneocytes)	  are	  shed	  at	  the	  surface	  during	  desquamation,	  a	  process	  which	  maintains	  skin	  homeostasis.	  	  Skin	  pigmentation	  is	  conferred	  by	  the	  presence	  of	  melanocytes	  within	  the	  basal	  cell	  layer.	  The	  number	  of	  melanocytes	  are	  constant	  between	  individuals	  of	  different	  races	  and	  skin	  pigmentation	  is	  the	  result	  of	  the	  amount	  of	  melanin	  produced	  by	  the	  melanocytes	  (Burkitt	  et	  al.,	  1993;	  Iyengar,	  2013).	  Melanocytes	  transfer	  melanin	  to	  neighbouring	  keratinocytes	  by	  using	  dendrites	  and	  this	  bestows	  protection	  of	  keratinocyte	  genetic	  material	  from	  UV	  radiation	  (Slominski	  et	  al.,	  2004).	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  The	  sensory	  component	  of	  the	  skin	  is	  known	  as	  the	  neuro-­‐immuno-­‐cutaneous	  system	  (NICS)	  and	  involves	  neurons,	  keratinocytes,	  melanocytes,	  Langerhans	  cells	  and	  Merkel	  cells.	  Merkel	  cells	  are	  located	  within	  the	  basal	  layer	  of	  the	  epidermis	  and	  are	  found	  in	  high	  concentrations	  in	  touch-­‐sensitive	  areas.	  	  Under	  an	  electron	  microscope,	  they	  appear	  as	  a	  cluster	  of	  clear	  oval-­‐shaped	  cells	  at	  nerve	  terminals	  (Halata	  et	  al.,	  2003).	  They	  act	  as	  mechanoreceptors	  and	  convert	  mechanical	  stimuli	  into	  nerve	  action	  potentials	  through	  the	  release	  of	  intracellular	  calcium	  and	  neurotransmitters	  (Slominski	  et	  al.,	  2004).	  Langerhans	  cells	  are	  present	  throughout	  the	  lower	  epidermal	  layers	  and	  have	  long	  dendritic	  processes	  extending	  between	  keratinocytes	  to	  detect	  pathogens	  before	  priming	  T	  cells	  within	  lymph	  nodes	  (Villadangos	  and	  Schnorrer,	  2007).	  	  There	  are	  two	  types	  of	  glands	  prevalent	  in	  the	  skin:	  the	  sebaceous	  gland	  and	  the	  sweat	  gland.	  The	  sebaceous	  gland	  is	  found	  throughout	  the	  human	  body	  apart	  from	  palmoplantar	  regions.	  They	  are	  usually	  found	  in	  the	  close	  vicinity	  of	  a	  hair	  follicle,	  forming	  the	  pilosebaceous	  unit.	  The	  main	  purpose	  of	  the	  sebaceous	  gland	  is	  to	  secrete	  sebum	  via	  the	  holocrine	  rupture	  (disintegration	  of	  whole	  cells)	  of	  mature	  sebocytes	  onto	  the	  surface	  of	  the	  skin	  (Smith	  and	  Thiboutot,	  2008).	  There	  are	  glands	  on	  other	  parts	  of	  the	  body	  which	  carry	  out	  the	  same	  action;	  for	  example	  Fordyce	  spots	  on	  the	  lip	  and	  buccal	  mucosa,	  Meibomian	  glands	  and	  glands	  of	  the	  Zeiss	  on	  the	  eyelids	  and	  Montgomery	  areolar	  tubercles	  associated	  with	  lactiferous	  ducts.	  The	  exact	  function	  of	  sebum	  is	  unknown,	  although	  the	  overproduction	  of	  sebum	  has	  been	  identified	  as	  the	  major	  contributor	  of	  acne	  (Thiboutot,	  2004).	  There	  are	  two	  types	  of	  sweat	  glands	  in	  the	  human	  body;	  eccrine	  sweat	  glands	  found	  in	  most	  areas	  of	  the	  skin	  and	  apocrine	  sweat	  glands	  located	  in	  the	  axilla	  and	  genital	  regions	  (Burkitt	  et	  al.,	  1993;	  Zouboulis	  et	  al.,	  2007).	  	  Eccrine	  sweat	  glands	  are	  located	  on	  the	  majority	  of	  the	  skin	  surface,	  and	  are	  simple	  tubular	  glands	  that	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  secrete	  water	  and	  NaCl	  to	  the	  skin	  surface	  in	  response	  to	  increased	  temperature	  or	  fear-­‐provoking	  stimuli.	  Apocrine	  sweat	  glands	  are	  associated	  with	  hair	  follicles	  and	  secrete	  a	  viscous	  and	  odiferous	  secretion	  into	  the	  hair	  follicles	  upon	  activation	  during	  puberty;	  e.g.	  pheromones.	  	  
1.2 THE	  SKIN	  AS	  A	  BARRIER	  The	  skin	  is	  capable	  of	  self-­‐renewal	  and	  its	  main	  purpose	  is	  to	  act	  as	  a	  barrier	  to	  protect	  the	  organism	  from	  the	  environment	  by	  preventing	  water	  loss	  and	  the	  entry	  of	  pathogens	  and	  allergens.	  There	  are	  two	  major	  components	  that	  make	  up	  the	  barrier:	  the	  stratum	  corneum	  and	  the	  lower	  nucleated	  epidermis.	  The	  cells	  of	  the	  stratified	  epidermis	  express	  specific	  cellular	  junctions,	  such	  as	  the	  desmosomes	  and	  adherens	  junctions	  which	  are	  mainly	  located	  within	  the	  basal,	  spinous	  and	  granular	  cell	  layers,	  and	  tight	  junctions	  and	  gap	  junctions	  within	  the	  granular	  layers.	  These	  intercellular	  junctions	  are	  critical	  in	  maintaining	  cell-­‐cell	  adhesion,	  as	  evidenced	  by	  the	  wide	  range	  of	  genodermatoses	  associated	  with	  mutations	  in	  the	  genes	  that	  encode	  for	  juncitonal	  proteins,	  however,	  the	  focus	  of	  this	  thesis	  is	  on	  the	  role	  of	  the	  skin	  as	  a	  barrier,	  with	  particular	  emphasis	  on	  the	  formation	  of	  the	  stratum	  corneum.	  	  
1.2.1 Components	  of	  the	  stratum	  corneum	  The	  physical	  protective	  functions	  of	  the	  skin	  are	  conferred	  largely	  by	  the	  stratum	  corneum.	  The	  cells	  of	  the	  stratum	  corneum	  consist	  of	  anucleated	  squamous	  epithelial	  cells,	  also	  known	  as	  corneocytes,	  embedded	  within	  a	  highly	  ordered	  non-­‐polar	  lipid-­‐enriched	  extracellular	  matrix.	  These	  lipids	  arise	  from	  the	  contents	  of	  lamellar	  granules	  (LG),	  and	  secretion	  occurs	  at	  the	  junction	  between	  the	  stratum	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  granulosum	  (SG)	  and	  stratum	  corneum	  (SC).	  The	  properties	  of	  the	  SC	  are	  made	  up	  of	  two	  parts:	  the	  protein	  envelope	  and	  the	  lipid	  envelope.	  The	  protein	  envelope	  consists	  of	  proteins	  covalently	  cross-­‐linked	  by	  transglutaminases	  and	  sulfhydryl	  oxidases.	  In	  turn,	  the	  lipid	  envelope	  reinforces	  the	  protein	  envelope	  and	  provides	  the	  ‘glue’	  that	  holds	  the	  cells	  of	  the	  SC	  together.	  	  Transglutaminases	  (TGase)	  catalyze	  the	  covalent	  cross-­‐linking	  between	  proteins	  via	  transamidation	  of	  glutamine	  residues	  in	  the	  presence	  of	  calcium	  (Hitomi,	  2005).	  The	  highest	  levels	  of	  calcium	  are	  found	  within	  the	  granular	  layer,	  where	  calcium	  is	  important	  for	  both	  the	  regulation	  of	  transglutaminases	  and	  the	  initiation	  of	  epidermal	  differentiation	  (Hitomi,	  2005).	  Expression	  of	  the	  various	  structural	  proteins	  of	  the	  SC	  is	  thought	  to	  be	  influenced	  by	  the	  presence	  of	  intracellular	  calcium.	  Within	  the	  skin,	  calcium	  is	  expressed	  at	  low	  levels	  in	  the	  basal	  level,	  lower	  levels	  in	  the	  spinous	  layers,	  the	  highest	  concentrations	  in	  the	  granular	  layer	  and	  low	  concentrations	  in	  the	  stratum	  corneum.	  Besides	  playing	  an	  important	  role	  in	  the	  initiation	  of	  keratinocyte	  differentiation	  and	  suppressing	  proliferation	  (Bikle	  and	  Pillai,	  1993),	  it	  affects	  lamellar	  body	  secretion	  (Menon	  et	  al.,	  1994),	  and	  also	  proteolytic	  enzyme	  activity	  within	  the	  stratum	  corneum	  (Behne	  and	  Jensen,	  2012).	  	  The	  impact	  of	  calcium	  signaling	  is	  induced	  by	  the	  interactions	  between	  calcium	  and	  calcium-­‐sensing	  receptors	  (CaR)	  in	  keratinocytes	  and	  allows	  a	  direct	  feedback	  loop	  between	  the	  integrity	  of	  barrier	  function	  and	  a	  recovery	  response	  (Elias	  et	  al.,	  2002;	  Tu	  et	  al.,	  2001).	  Mutations	  affecting	  genes	  involved	  with	  the	  transport	  and	  secretion	  of	  calcium	  have	  been	  shown	  to	  lead	  to	  Darier’s	  and	  Hailey-­‐Hailey	  diseases,	  resulting	  in	  an	  intercellular	  split	  among	  suprabasal	  keratinocytes	  (Proksch	  et	  al.,	  2008).	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  Cells	  in	  the	  uppermost	  layer	  of	  the	  SG	  are	  linked	  to	  the	  SC	  by	  desmosomes,	  while	  adjacent	  corneocytes	  are	  connected	  by	  corneodesmosomes,	  both	  of	  which	  are	  vital	  during	  the	  process	  of	  desquamation	  (Proksch	  et	  al.,	  2008).	  At	  the	  junctions	  of	  corneocytes,	  corneodesmosomes	  form	  intercellular	  covalent	  links	  with	  the	  cornified	  envelope.	  This	  junctional	  structure	  was	  identified	  as	  a	  marker	  for	  terminal	  epidermal	  differentiation,	  as	  they	  were	  exclusively	  identified	  in	  the	  SC	  (Serre	  et	  al.,	  1991)	  and	  will	  be	  discussed	  in	  Chapter	  1.2.1.4.	  	  
1.2.1.1 Proteins	  of	  the	  cornified	  envelope	  The	  corneocyte	  is	  formed	  during	  the	  final	  stages	  of	  terminal	  differentiation	  where	  keratinocytes	  move	  towards	  the	  surface	  of	  the	  skin.	  During	  this	  process,	  keratinocytes	  lose	  their	  cellular	  organelles,	  become	  flattened	  and	  contain	  parallel	  bundles	  of	  keratin	  filaments.	  The	  cornified	  envelope	  is	  made	  up	  of	  a	  number	  of	  proteins	  which	  are	  cross-­‐linked	  (Table	  1.	  1).	  	  Involucrin	  (IVL)	  is	  located	  within	  the	  epidermal	  differentiation	  complex	  (EDC)	  and	  is	  encoded	  by	  one	  single	  exon.	  It	  has	  a	  high	  rate	  of	  polymorphism	  in	  humans	  and	  the	  number	  of	  potential	  glutamine	  residues	  available	  for	  cross-­‐linking	  is	  thought	  to	  confer	  an	  evolutionary	  benefit	  (Eckert	  and	  Green,	  1986).	  IVL	  makes	  up	  2-­‐5%	  of	  the	  protein	  in	  the	  cornified	  envelope	  (Nemes	  and	  Steinert,	  1999).	  The	  expression	  of	  involucrin	  is	  initiated	  at	  the	  start	  of	  terminal	  differentiation	  in	  keratinocytes	  and	  is	  ubiquitously	  expressed	  in	  all	  skin	  sites	  (Robinson	  et	  al.,	  1997),	  and	  this	  is	  regulated	  via	  the	  distal	  or	  proximal-­‐regulatory	  (DRR	  or	  PRR)	  elements	  found	  upstream	  of	  IVL.	  These	  two	  sites	  act	  in	  concert,	  and	  are	  thought	  to	  form	  a	  complex	  that	  interacts	  with	  basal	  transcription	  machinery	  to	  drive	  IVL	  transcription	  (Eckert	  et	  al.,	  2004).	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  Molecules	   Genes	   Function	   References	  Involucrin	   IVL	   Structural	  protein	  of	  cornified	  cell	  envelope	   	  (Candi	  et	  al.,	  2005)	  Loricrin	   LOR	   Structural	  protein	  of	  cornified	  cell	  envelope	   	  (Ishida-­‐Yamamoto	  et	  al.,	  2000)	  Envoplakin	   EVPL	   Structural	  protein	  of	  cornified	  cell	  envelope	   (Kalinin	  et	  al.,	  2004;	  Karashima	  and	  Watt,	  2002)	  	  	  Periplakin	   PPL	   Structural	  protein	  of	  cornified	  cell	  envelope	  Small	  proline-­‐rich	  proteins	  (SPRs)	   	  SPR1a	   Structural	  protein	  of	  cornified	  cell	  envelope	   	  (Kartasova	  et	  al.,	  1996;	  Li	  et	  al.,	  2008)	  Keratins	   KRT1,	  KRT10,	  
KRT2	  
Structural	  protein	  of	  intermediate	  filaments	   	  (Nishifuji	  and	  Yoon,	  2013)	  
Filaggrin	   FLG	   Aggregation	  of	  keratin	  intermediate	  filaments	  in	  cornified	  cells	   	  (Sandilands	  et	  al.,	  2009)	  Cystatin	  A	   	  CSTA	   Inhibitor	  of	  cell-­‐cell	  adhesion	   	  (Blaydon	  et	  al.,	  2011)	  
Corneodesmosin	   CDSN	   Component	  of	  corneodesmosomes	   	  (Ishida-­‐Yamamoto	  and	  Kishibe,	  2011)	  ATP-­‐binding	  cassette	  subfamily	  A	  member	  	   ABCA12	   Lipid	  transporter	  responsible	  for	  cholesterol	  efflux	  from	  epidermal	  keratinocytes	   	  (Sakai	  et	  al.,	  2007)	  
Table	  1.	  1	  List	  of	  stratum	  corneum	  proteins	  involved	  in	  terminal	  
differentiation	  of	  keratinocytes.	  This	  process	  is	  tightly	  regulated	  and	  each	  protein	  has	  an	  important	  function	  in	  the	  maturation	  of	  keratinocytes	  into	  corneocytes.	  	  Loricrin	  (LOR)	  is	  the	  most	  abundant	  protein	  in	  the	  epidermal	  cornified	  envelope.	  It	  is	  cross-­‐linked	  into	  the	  cornified	  envelope	  at	  a	  late	  stage	  in	  differentiation	  and	  distributed	  in	  a	  diffuse	  manner	  across	  the	  cytoplasm	  of	  keratinocytes	  (Mehrel	  et	  al.,	  1990;	  Steven	  et	  al.,	  1990).	  LOR’s	  glutamine-­‐rich	  and	  lysine-­‐rich	  domains	  are	  act	  as	  a	  substrate	  for	  TGase1	  and	  TGase3	  (Candi	  et	  al.,	  1995),	  and	  the	  N-­‐terminal	  domain	  has	  been	  shown	  to	  interact	  with	  filaggrin	  and	  keratin	  10	  (Yoneda	  et	  al.,	  2012).	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  Small	  proline-­‐rich	  proteins	  (SPRs)	  are	  a	  family	  of	  proteins	  with	  different	  expression	  levels	  in	  various	  epithelia,	  with	  SPR1a	  (cornifin	  α)	  and	  SPRR2	  expressed	  in	  the	  epidermis	  (Fujimoto	  et	  al.,	  1993;	  Hohl	  et	  al.,	  1995).	  It	  is	  predicted	  that	  this	  gene	  family	  consists	  of	  two	  genes	  for	  SPRR1,	  seven	  genes	  for	  SPRR2,	  and	  a	  single	  gene	  each	  for	  SPRR3	  and	  SPRR4	  (Cabral	  et	  al.,	  2001;	  Gibbs	  et	  al.,	  1993).	  The	  proline-­‐rich	  repeats	  are	  flanked	  by	  glutamine,	  lysine	  and	  proline	  residues,	  and	  similar	  to	  loricrin,	  are	  substrates	  for	  TGases.	  There	  appears	  to	  be	  a	  relationship	  between	  the	  amount	  of	  SPRs	  present	  in	  the	  cornified	  envelope	  and	  the	  epithelial	  sites	  expected	  to	  be	  exposed	  to	  trauma,	  for	  example,	  human	  buccal	  and	  gingiva	  contain	  >20%	  SPRs	  compared	  to	  human	  foreskin	  of	  ~5%	  SPRs	  (Steinert	  et	  al.,	  1998a;	  Steinert	  et	  al.,	  1998b).	  This	  group	  of	  proteins	  is	  thought	  to	  be	  expressed	  in	  response	  to	  an	  innate	  defense	  response	  after	  injury	  or	  after	  inflammation;	  for	  example,	  SPRR1B	  expression	  in	  response	  to	  inflammation	  at	  the	  ocular	  surface	  (Li	  et	  al.,	  2008),	  SPRR2A	  expression	  in	  response	  to	  gastric	  injury	  by	  Helicobacter	  
pylori	  (Mueller	  et	  al.,	  2003)	  and	  SPRR4	  epidermal	  expression	  in	  response	  to	  UV	  light	  (Cabral	  et	  al.,	  2001).	  An	  increase	  of	  SPRR1A	  expression	  in	  chronic	  lesional	  AD	  skin	  has	  been	  observed	  and	  is	  hypothesized	  to	  be	  a	  compensatory	  mechanism	  for	  the	  decrease	  of	  LOR	  (Jarzab	  et	  al.,	  2010).	  Keratin	  intermediate	  filaments	  are	  integral	  components	  of	  the	  corneocyte,	  with	  keratin	  1,	  keratin	  2	  and	  keratin	  10	  making	  up	  80%	  of	  the	  protein	  content	  of	  a	  corneocyte	  (Eckert	  et	  al.,	  1997;	  Eckhart	  et	  al.,	  2013).	  Pairs	  of	  type	  I	  (acidic)	  and	  II	  (basic)	  keratin	  intermediate	  filaments	  make	  up	  the	  cytoskeleton,	  and	  type	  II	  keratin	  filaments	  are	  cross-­‐linked	  via	  a	  single	  lysine	  residue	  to	  the	  cornified	  cell	  envelope	  during	  terminal	  differentiation	  in	  squamous	  cell	  epithelium	  (Candi	  et	  al.,	  1998b).	  This	  crosslinking	  allows	  integration	  of	  keratin	  intermediate	  filaments	  with	  the	  cornified	  cell	  envelope	  resulting	  in	  an	  insoluble	  corneocytic	  structure.	  Recently	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  it	  has	  been	  discovered	  that	  plasminogen	  activator	  inhibitor-­‐2	  (PAI-­‐2)	  promotes	  differentiation	  by	  increasing	  expression	  of	  involucrin,	  keratin	  10	  and	  loricrin	  in	  cultured	  epidermal	  keratinocytes	  (Jang	  et	  al.,	  2010).	  Profilaggrin	  (FLG)	  is	  encoded	  within	  the	  EDC	  and	  is	  the	  precursor	  for	  filaggrin,	  which	  is	  released	  by	  dephosphorylation	  and	  proteolysis	  at	  the	  N-­‐terminus	  (Kam	  et	  al.,	  1993;	  Resing	  et	  al.,	  1993).	  After	  release	  from	  keratohyalin	  granules,	  filaggrin	  binds	  to	  keratin	  intermediate	  filaments	  causing	  them	  to	  form	  tight	  bundles	  that	  are	  a	  characteristic	  feature	  of	  the	  corneocyte.	  A	  proportion	  of	  filaggrin	  is	  cross-­‐linked	  to	  cornified	  cell	  envelope	  proteins	  (Steinert	  and	  Marekov,	  1995)	  and	  it	  is	  thought	  that	  the	  amino	  terminal	  fragments	  are	  incorporated	  into	  the	  cornified	  envelope	  (Dale	  et	  al.,	  1997).	  The	  process	  of	  deamination	  is	  a	  post-­‐translational	  modification	  that	  occurs	  at	  the	  interface	  between	  the	  granular	  and	  cornified	  layer,	  and	  is	  catalyzed	  by	  the	  Ca2+	  dependent	  enzymes,	  peptidylarginine	  deiminase	  (PADs).	  Deamination	  is	  the	  conversion	  of	  arginine	  residues	  to	  citrulline	  residues	  and	  this	  process	  alters	  protein	  structure,	  increasing	  protein	  solubility	  and	  electrophoretic	  mobility	  and	  thus	  providing	  a	  better	  substrate	  for	  TGase	  crosslinking	  action.	  Keratin1,	  filaggrin	  and	  trichohyalin	  are	  all	  known	  substrates	  of	  PADs	  in	  the	  epidermis	  (Senshu	  et	  al.,	  1996;	  Tarcsa	  et	  al.,	  1996;	  Wang	  and	  Wang,	  2013).	  	  Cystatin	  A	  (CSTA)	  is	  a	  cysteine	  protease	  inhibitor	  that	  has	  been	  shown	  to	  be	  a	  potent	  inhibitor	  of	  house	  dust	  mite	  allergens	  Der	  p	  1	  and	  Der	  f	  1	  (Kato	  et	  al.,	  2005).	  Mutation	  of	  vital	  residues	  within	  CSTA	  has	  been	  predicted	  to	  alter	  protein	  tertiary	  structure	  and	  affect	  binding	  to	  potential	  cathepsin	  substrates,	  resulting	  in	  exfoliative	  ichthyosis.	  Within	  patients	  with	  loss-­‐of-­‐function	  mutations,	  there	  is	  loss	  in	  number	  and	  loosening	  of	  desmosomal	  junctions	  within	  the	  lower	  suprabasal	  layers	  as	  well	  as	  a	  decrease	  in	  the	  number	  of	  desmosomes	  (Blaydon	  et	  al.,	  2011).	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  In	  recent	  years,	  new	  late	  cornified	  envelope	  (LCE)	  proteins	  have	  been	  discovered	  (Henry	  et	  al.,	  2012).	  LCE	  2B	  (formerly	  known	  as	  XP-­‐5)	  is	  expressed	  late	  in	  envelope	  assembly	  and	  shares	  similarity	  with	  other	  cornified	  envelope	  proteins	  with	  regards	  to	  their	  amino	  acid	  composition	  (Marshall	  et	  al.,	  2001).	  Another	  LCE,	  NICE-­‐1,	  was	  found	  to	  have	  the	  highest	  expression	  level	  in	  differentiating	  keratinocytes,	  and	  is	  now	  known	  as	  chromosomal	  1	  open	  reading	  frame	  10	  (C1orf10)	  (Marenholz	  et	  al.,	  2001).	  More	  recently,	  LCE3B	  and	  LCE3C	  have	  been	  associated	  with	  psoriasis,	  rheumatoid	  arthritis	  and	  allergic	  contact	  dermatitis	  (Ammar	  et	  al.,	  2012;	  Bergboer	  et	  al.,	  2012;	  Molin	  et	  al.,	  2011).	  	  	  
1.2.1.2 Lipid	  envelope	  Lipids	  extruded	  into	  the	  extracellular	  space	  hold	  the	  corneocytes	  of	  the	  SC	  together	  with	  corneodesmosomes.	  These	  lipids	  originate	  from	  lamellar	  granules	  (LG)	  by	  secretion	  from	  keratinocytes	  and	  contain	  acylated/glucosylated/hydroxylated	  ceramides,	  cholesterol	  and	  free	  fatty	  acids	  (Downing	  et	  al.,	  1993).	  LG	  are	  sensitive	  to	  calcium	  levels	  and	  during	  the	  ascent	  to	  the	  upper	  granular	  layers,	  deliver	  their	  contents	  into	  the	  intercellular	  space.	  These	  contents	  are	  further	  modified	  to	  form	  highly	  ordered	  lipid	  sheets	  that	  run	  parallel	  to	  the	  cell	  surfaces	  (Mandal	  and	  Downing,	  1993).	  The	  LG	  membranes	  are	  absorbed	  into	  the	  plasma	  cell	  membrane	  and	  consist	  of	  lipids	  with	  sufficient	  length	  (>C30)	  to	  span	  the	  lipid	  bilayer	  (of	  the	  plasma	  membrane)	  (Kalinin	  et	  al.,	  2001).	  The	  lipid	  envelope	  acts	  as	  a	  scaffold	  for	  the	  arrangement	  of	  intercellular	  lamellae.	  Following	  secretion	  of	  LG,	  polar	  lipids	  are	  enzymatically	  converted	  into	  non-­‐polar	  lipids.	  The	  major	  lipids	  found	  in	  the	  stratum	  corneum	  are	  derived	  from	  the	  hydrolysis	  of	  glycosphingolipids	  into	  ceramides,	  conversion	  of	  phospholipids	  into	  free	  fatty	  acids	  and	  cholesterol	  which	  is	  derived	  from	  triglyceride	  catabolism	  (Downing	  et	  al.,	  1987).	  They	  play	  a	  vital	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  role	  in	  antimicrobial	  defense,	  by	  conferring	  an	  acidic	  pH	  to	  the	  stratum	  corneum,	  rendering	  it	  inhospitable	  to	  microorganisms	  (Behne	  et	  al.,	  2002).	  Ceramide	  substrates	  become	  covalently	  attached	  to	  cornified	  envelope	  proteins	  such	  as	  involucrin	  (Nemes	  et	  al.,	  1999a;	  Nemes	  et	  al.,	  1999b),	  envoplakin	  and	  periplakin.	  Enzymes	  such	  as	  ceramide	  synthase	  (CerS)	  and	  ceramide	  hydroxylase/desaturase	  are	  involved	  in	  ceramide	  biosynthesis,	  and	  result	  in	  substrates	  such	  as	  are	  ω-­‐hydroxyceramides	  (Marekov	  and	  Steinert,	  1998;	  Mizutani	  et	  al.,	  2009).	  This	  accounts	  for	  40%	  of	  the	  lipid	  content	  in	  the	  stratum	  corneum,	  but	  is	  absent	  in	  the	  granular,	  spinous	  and	  basal	  cell	  layers,	  and	  is	  characteristic	  of	  terminal	  differentiation.	  	  The	  role	  of	  esterified	  version	  of	  ceramide	  (ω-­‐hydroxyceramide)	  is	  thought	  to	  act	  as	  a	  substitute	  for	  desmosomes	  in	  the	  stability	  of	  extracellular	  lamellar	  structures	  in	  cornified	  envelope	  cells	  (Wertz,	  1997).	  	  Free	  fatty	  acids	  and	  cholesterol	  are	  essential	  structural	  players	  in	  the	  formation	  of	  the	  skin	  barrier.	  The	  absence	  or	  reduced	  levels	  of	  either	  component	  results	  in	  a	  deficient	  skin	  barrier	  and	  can	  even	  result	  in	  lethality	  (Herrmann	  et	  al.,	  2003;	  Kelsell	  et	  al.,	  2005;	  Proksch	  et	  al.,	  1992;	  Thauvin-­‐Robinet	  et	  al.,	  2005).	  	  
1.2.1.3 Transglutaminases	  Transglutaminases	  (TGase)	  1,	  3	  and	  5	  are	  expressed	  in	  the	  epidermis.	  They	  play	  a	  vital	  role	  in	  the	  development	  of	  the	  cornified	  envelope.	  	  TGase	  1	  is	  expressed	  in	  the	  granular	  layer	  of	  differentiating	  keratinocytes	  (Steinert	  et	  al.,	  1996a)	  and,	  after	  activation	  by	  proteolysis,	  is	  attached	  to	  the	  plasma	  membrane	  by	  its	  N-­‐terminus	  (Steinert	  et	  al.,	  1996b).	  It	  plays	  several	  roles	  in	  cornified	  envelope	  formation:	  it	  aids	  protein	  envelope	  formation	  by	  cross-­‐linking	  various	  structural	  proteins	  and	  in	  lipid	  envelope	  formation	  by	  cross-­‐linking	  ceramides	  onto	  cornified	  envelope	  proteins	  (Nemes	  et	  al.,	  1999a;	  Nemes	  et	  al.,	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  1999b).	  TGase	  3	  has	  different	  substrates	  from	  TGase	  1,	  and	  both	  have	  been	  shown	  to	  act	  on	  different	  lysine	  and	  glutamine	  residues	  of	  loricrin	  (Candi	  et	  al.,	  1995),	  and	  SPRs	  (Tarcsa	  et	  al.,	  1998).	  	  Expression	  of	  TGase3	  is	  localized	  to	  the	  granular	  and	  cornified	  layers	  with	  a	  diffuse	  cytoplasmic	  distribution	  pattern.	  TGase	  5	  is	  also	  located	  within	  the	  granular	  layer	  and	  has	  been	  shown	  to	  cross-­‐link	  loricrin,	  involucrin	  and	  SPRs	  (Candi	  et	  al.,	  2001).	  	  
1.2.1.4 Corneodesmosomes	  The	  discovery	  of	  a	  protein	  exclusive	  to	  the	  cornified	  layer,	  corneodesmosin	  (CDSN),	  revealed	  a	  marker	  for	  late	  epidermal	  differentiation.	  In	  the	  lower	  stratum	  granular	  layers,	  CDSN	  appears	  to	  be	  in	  the	  cytoplasm,	  but	  migrates	  to	  LG	  in	  the	  upper	  stratum	  granular	  layers,	  before	  finally	  heading	  to	  the	  center	  of	  corneodesmosomes	  in	  the	  SC	  (Serre	  et	  al.,	  1991).	  CDSN	  has	  a	  strikingly	  high	  serine	  and	  glycine	  content	  and	  is	  thought	  to	  confer	  adhesive	  properties	  at	  cell-­‐cell	  junctions	  via	  its	  glycine	  loop	  domains	  (Steinert	  et	  al.,	  1991).	  Proteolysis	  of	  CDSN	  occurs	  in	  corneocytes	  committed	  to	  desquamation;	  a	  small	  degradation	  product	  of	  33kDa	  is	  found	  in	  the	  outermost	  corneocytes,	  and	  the	  full-­‐length	  form	  is	  absent	  (55kDa)	  (Serre	  et	  al.,	  1991).	  	  Besides	  being	  localized	  to	  the	  stratum	  corneum,	  expression	  of	  CDSN	  is	  also	  found	  within	  all	  three	  layers	  of	  the	  inner	  root	  sheath	  as	  well	  as	  the	  hair	  follicle	  (Gallinaro	  et	  al.,	  2004;	  Mils	  et	  al.,	  1992;	  Serre	  et	  al.,	  1991).	  It	  is	  vital	  in	  the	  desquamation	  process,	  where	  it	  is	  progressively	  proteolyzed	  by	  kallikrein-­‐related	  peptidases	  (KLKs)	  and	  cathepsins	  (Bernard	  et	  al.,	  2003;	  Igarashi	  et	  al.,	  2004;	  Simon	  et	  al.,	  2001).	  As	  cells	  migrate	  upwards,	  desquamation	  of	  corneocytes	  occurs.	  Corneodesmosomes	  located	  on	  the	  apical	  and	  basolateral	  sides	  are	  degraded	  first,	  leaving	  those	  on	  the	  lateral	  sides	  intact	  up	  till	  the	  surface	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  of	  the	  skin	  (Haftek	  et	  al.,	  2011;	  Igawa	  et	  al.,	  2011).	  Skin	  diseases	  involved	  with	  abnormal	  degradation	  of	  corneodesmosomes	  are	  described	  in	  Chapter	  1.4.1.	  
1.2.2 Components	  of	  the	  nucleated	  epidermis	  Even	  though	  the	  stratum	  corneum	  performs	  the	  protective	  function	  of	  a	  physical	  barrier,	  the	  lower	  epidermal	  cell	  layers	  also	  play	  an	  important	  role	  as	  a	  second	  line	  of	  defense.	  The	  removal	  of	  the	  stratum	  corneum	  by	  a	  method	  called	  tape	  stripping	  is	  far	  from	  life	  threatening	  and	  results	  in	  an	  increase	  in	  transepidermal	  water	  loss	  (TEWL).	  Loss	  of	  the	  stratum	  corneum	  and	  granular	  layers	  through	  disease,	  e.g.	  staphylococcal	  scalded	  skin	  syndrome,	  is	  not	  life	  threatening	  (Elias	  et	  al.,	  1977).	  However,	  the	  removal	  of	  the	  suprabasal	  and	  subepidermal	  layers	  as	  a	  result	  of	  blistering	  diseases	  (e.g.	  pemphigus	  vulgaris,	  toxic	  epidermal	  necrolysis)	  and	  severe	  burns	  are	  life	  threatening	  due	  to	  extensive	  water	  loss	  and	  secondary	  bacterial	  infections.	  Foil	  or	  a	  grease	  ointment	  can	  be	  applied	  to	  act	  as	  an	  artificial	  barrier,	  reducing	  death	  rates	  significantly,	  demonstrating	  the	  importance	  of	  the	  lower	  epidermal	  layers	  (Honari,	  2004).	  	  	  
1.2.2.1 Tight	  junctions,	  adherens	  junctions	  and	  gap	  junctions	  Tight	  junctions	  (TJ)	  form	  cell-­‐cell	  junctions	  and	  act	  as	  a	  barrier,	  separating	  the	  apical	  and	  basolateral	  membrane	  and	  controlling	  the	  migration	  of	  paracellular	  molecules.	  Various	  TJ	  proteins	  have	  been	  identified	  in	  different	  layers	  of	  the	  epidermis.	  These	  include	  claudins	  1,	  3,	  5,	  7	  and	  17,	  occludin,	  JAM-­‐A,	  zonal	  occludin-­‐1,	  MUPP-­‐1	  and	  cingulin	  (Kirschner	  and	  Brandner,	  2012).	  TJ	  barriers	  in	  keratinocytes	  are	  important	  in	  ion	  transport	  (Kirschner	  et	  al.,	  2009)	  and	  in	  preventing	  the	  entry	  of	  allergens	  and	  pathogens.	  It	  is	  thought	  that	  when	  Langerhans	  cells	  elongate	  their	  dendrites	  through	  the	  granular	  layer,	  the	  TJ	  barrier	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  is	  still	  intact	  (Kubo	  et	  al.,	  2009).	  Claudin-­‐1	  and	  7	  are	  found	  in	  all	  epidermal	  layers,	  occludin	  is	  localized	  to	  the	  granular	  layer	  and	  zonal	  occludin-­‐1	  and	  claudin-­‐4	  found	  in	  the	  suprabasal	  layers.	  Adherens	  junctions	  (AJ)	  are	  situated	  directly	  below	  tight	  junctions,	  and	  are	  composed	  of	  a	  nectin-­‐afadin	  complex	  and	  a	  cadherin-­‐catenin	  complex.	  This	  junction	  provides	  the	  cell	  with	  the	  structurally	  adhesive	  connection	  with	  the	  actin	  cytoskeleton	  between	  cells.	  Nectin,	  α-­‐catenin	  and	  β-­‐catenin	  have	  been	  shown	  to	  bind	  to	  actin	  filaments	  (Drees	  et	  al.,	  2005;	  Niessen,	  2007)	  and	  α-­‐catenin	  is	  thought	  to	  regulate	  signaling	  receptors	  and	  affects	  asymmetric	  cell	  division	  in	  the	  basal	  layers	  (Lechler	  and	  Fuchs,	  2005).	  	  A	  major	  component	  of	  gap	  junctions	  are	  connexins	  (Cx),	  and	  these	  form	  hexagonal	  hemi-­‐channels	  between	  adjacent	  cells	  to	  allow	  for	  the	  intercellular	  movement	  of	  signaling	  molecules	  or	  ions,	  or	  between	  the	  cytoplasm	  and	  extracellular	  space.	  Traffic	  of	  such	  molecules	  is	  dependent	  on	  activation	  by	  extracellular	  Ca2+	  concentrations	  that	  lead	  to	  conformational	  changes	  within	  the	  hemi-­‐channel	  structure	  (Bao	  et	  al.,	  2004;	  Ebihara,	  1996;	  Stout	  et	  al.,	  2002).	  Within	  keratinocytes,	  there	  is	  expression	  of	  Cx26	  and	  Cx43	  within	  human	  skin,	  but	  predominant	  expression	  of	  Cx43	  in	  the	  basal	  and	  spinous	  layer	  of	  follicular	  and	  interfollicular	  epidermis	  (Salomon	  et	  al.,	  1994;	  Xu	  and	  Nicholson,	  2013).	  Cx26	  and	  Cx43	  act	  together	  to	  regulate	  epidermal	  differentiation	  from	  basal	  keratinocytes,	  and	  was	  shown	  to	  severely	  impair	  overall	  growth	  and	  differentiation	  in	  in	  vitro	  experiments	  with	  rat	  epidermal	  keratinocytes	  (Langlois	  et	  al.,	  2007).	  These	  junctions	  play	  an	  important	  role	  in	  preventing	  the	  entry	  of	  pathogens,	  for	  instance,	  Clostridium	  difficile	  secretes	  toxins	  that	  disassociate	  occludin,	  ZO-­‐1	  and	  ZO-­‐2	  at	  TJ	  of	  gastric	  epithelial	  (Nusrat	  et	  al.,	  2001),	  increasing	  epithelium	  permeability.	  Another	  method	  of	  entry	  is	  seen	  with	  the	  herpes	  simplex	  virus,	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  where	  the	  virus	  directly	  binds	  to	  nectin-­‐1	  of	  AJ	  in	  order	  to	  gain	  access	  into	  epithelial	  cells	  (Connolly	  et	  al.,	  2003).	  The	  invasion	  of	  Shigella	  flexneri	  via	  the	  gastrointestinal	  pathway	  occurs	  by	  manipulating	  Cx26	  channels	  inducing	  a	  release	  of	  ATP	  resulting	  in	  the	  retraction	  of	  filopodia,	  allowing	  bacterial	  evasion	  (Romero	  et	  al.,	  2011).	  	  
1.2.2.2 Desmosomes	  
	  
Figure	  1.	  2	  Simplified	  model	  of	  desmosomes.	  Keratin	  intermediate	  filaments	  associate	  with	  the	  C-­‐terminus	  of	  desmoplakin	  to	  confer	  intracellular	  structural	  stability	  to	  keratinocytes	  while	  desmoglein	  and	  desmoplakin	  form	  adhesion	  complexes	  for	  intercellular	  adhesion	  (Fuchs	  and	  Raghavan,	  2002).	  	  	  Desmosomes	  form	  the	  intercellular	  junctions	  between	  keratinocytes	  of	  the	  granular	  layer.	  Recently,	  a	  hypothesis	  suggested	  that	  desmosomes	  are	  “hyper-­‐adhesive”	  structures.	  This	  is	  a	  term	  describing	  the	  state	  in	  which	  the	  strong	  adhesive	  state	  of	  demosomes	  was	  resistant	  to	  disintegrating	  in	  the	  absence	  of	  Ca2+,	  unlike	  the	  other	  junctions	  (Garrod	  and	  Kimura,	  2008;	  Hobbs	  and	  Green,	  2012).	  	  They	  are	  formed	  from	  a	  complex	  of	  proteins	  that	  include	  desmoplakin,	  members	  of	  the	  armadillo	  family,	  desmosomal	  cadherins	  and	  accessory	  proteins	  essential	  for	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  adhesive	  function	  like	  Perp	  (P53	  Apoptosis	  Effector	  Related	  to	  PMP22)	  (Ihrie	  and	  Attardi,	  2005)	  and	  CDSN	  in	  modified	  desmosomes.	  	  Desmoplakin	  plays	  an	  important	  role	  in	  desmosomal	  adhesion	  by	  interacting	  with	  keratin	  intermediate	  filaments	  through	  their	  carboxy	  termini	  (Figure	  1.	  2)	  (Godsel	  et	  al.,	  2008).	  Recent	  evidence	  also	  shows	  possible	  involvement	  in	  the	  regulation	  of	  microtubule	  organization	  (Lechler	  and	  Fuchs,	  2007),	  as	  well	  as	  the	  association	  of	  desmoplakin	  with	  the	  actin	  cytoskeleton	  through	  their	  amino-­‐terminal	  domains	  (Kalinin	  et	  al.,	  2002).Two	  structural	  homologues	  of	  desmoplakin,	  envoplakin	  and	  periplakin,	  have	  been	  shown	  to	  be	  located	  at	  the	  desmosomal	  junctions	  of	  epithelial	  cells	  (Ruhrberg	  et	  al.,	  1997).	  	  Armadillo	  proteins	  include	  plakoglobin	  (PG;	  γ-­‐catenin)	  and	  plakophillins	  (PKPs)	  1-­‐3.	  PG	  and	  PKPs	  show	  localization	  to	  the	  nucleus	  and	  adherens	  junctions,	  and	  are	  mostly	  found	  in	  desmosomes	  where	  they	  bind	  to	  DSGs	  and	  DSCs.	  All	  three	  members	  of	  the	  plakophillin	  (PKP)	  family	  are	  expressed	  in	  the	  epidermis	  with	  differentiation-­‐specific	  patterns	  of	  expression	  (Garrod	  and	  Chidgey,	  2008).	  This	  is	  mediated	  by	  p120-­‐related	  desmosomal	  protein	  PKP1,	  which	  associates	  with	  actin	  and	  induces	  formation	  of	  filopodia	  (Hatzfeld	  et	  al.,	  2000).	  Desmosomal	  cadherins	  include	  the	  three	  desmocollins	  (DSC	  1-­‐3)	  and	  four	  desmogleins	  (DSG	  1-­‐4).	  All	  of	  them	  are	  expressed	  in	  the	  epidermis	  in	  a	  differentiation-­‐dependent	  manner	  (Garrod	  and	  Chidgey,	  2008)	  and	  regulate	  intracellular	  signaling	  and	  differentiation	  through	  promoting	  the	  expression	  of	  molecules	  e.g.	  EGFR	  and	  MAPKs	  (Simpson	  et	  al.,	  2011).	  	  Some	  of	  the	  diseases	  that	  occur	  when	  these	  intercellular	  junctions	  are	  compromised,	  affect	  tissues	  subjected	  to	  tremendous	  mechanical	  stress,	  such	  as	  the	  heart	  and	  skin.	  Mutations	  in	  PG	  result	  in	  arrhythmogenic	  right	  ventricular	  cardiomyopathy	  (ARVC),	  where	  patients	  are	  characterized	  by	  non-­‐epidermolytic	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  PPK,	  wooly	  hair	  and	  heart	  failure.	  ARVC	  has	  also	  been	  linked	  to	  mutations	  in	  DSP,	  DSG2	  and	  DSC	  isoforms	  (Al-­‐Jassar	  et	  al.,	  2013).	  Desmosomes	  mature	  into	  corneodesmosomes	  between	  the	  upper	  granular	  layers	  and	  the	  stratum	  corneum,	  and	  it	  is	  hypothesized	  that	  the	  desmosome	  is	  modified	  in	  some	  way	  (Kitajima,	  2013).	  Studies	  of	  ultra	  thin	  sections	  show	  that	  the	  desmosome	  appears	  to	  have	  an	  electron-­‐dense	  midline	  structure,	  and	  this	  structure	  is	  not	  seen	  in	  corneodesmosomes.	  Another	  difference	  is	  that	  in	  granular	  cells,	  keratin	  filaments	  extend	  into	  the	  desmosomal	  plaque,	  whereas	  in	  the	  corneodesmosomes,	  this	  association	  is	  no	  longer	  seen	  (Larabell	  et	  al.,	  1993).	  	  	  
1.2.3 Assembly	  of	  the	  cornified	  envelope	  The	  initiation	  of	  terminal	  differentiation	  in	  keratinocytes	  is	  triggered	  by	  an	  increase	  in	  intracellular	  Ca2+	  concentration	  together	  with	  other	  signals	  that	  trigger	  the	  assembly	  of	  the	  epidermal	  cell	  envelope,	  summarized	  in	  Figure	  1.	  3	  (Fischer	  et	  al.,	  2011;	  Kalinin	  et	  al.,	  2001)	  Expression	  of	  periplakin	  and	  envoplakin	  occurs	  at	  the	  start	  of	  terminal	  differentiation.	  Periplakin	  is	  associated	  with	  keratin	  intermediate	  filaments	  and	  envoplakin	  is	  association	  with	  desmosomal	  junctions.	  Envoplakin	  and	  periplakin	  form	  hetero-­‐tetramers	  that	  re-­‐distribute	  to	  the	  plasma	  membrane	  in	  a	  Ca2+-­‐dependent	  manner.	  Shortly	  afterwards,	  TGase	  1	  and	  involucrin	  are	  expressed	  and	  associate	  with	  the	  membrane	  via	  its	  N-­‐terminus	  (TGase	  1)	  and	  glutamate	  residues	  (involucrin).	  Involucrin	  begins	  intra-­‐chain	  head-­‐to-­‐head	  and	  head-­‐to-­‐tail	  crosslinking	  as	  well	  as	  inter-­‐chain	  crosslinking	  with	  envoplakin	  and	  involucrin,	  to	  form	  an	  intracellular	  layer	  underlying	  the	  cell	  plasma	  membrane.	  This	  forms	  the	  scaffold,	  with	  the	  inclusion	  of	  desmosomes	  and	  other	  cell	  envelope	  proteins.	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  Simultaneously,	  lamellar	  granules	  (LG)	  fuse	  together	  with	  the	  cell	  membrane	  and	  secrete	  their	  contents	  into	  the	  intercellular	  space.	  The	  LG	  membrane,	  made	  up	  of	  long-­‐chain	  ω-­‐hydroxy	  ceramides	  become	  ester-­‐linked	  to	  the	  scaffold	  proteins	  by	  TGase	  1,	  eventually	  replacing	  the	  plasma	  membrane.	  The	  extruded	  lipids	  begin	  to	  form	  intercellular	  lamellae	  that	  appear	  as	  broad	  multilamellar	  lipid	  sheets	  (Landmann,	  1986),	  and	  covalently	  attach	  to	  the	  long	  chain	  ceramides	  making	  up	  the	  lipid	  envelope	  in	  an	  interdigitating-­‐fashion.	  	  The	  reinforcement	  phase	  then	  begins,	  with	  TGase	  3	  cross-­‐linking	  loricrin	  and	  SPRs	  together	  to	  form	  more	  insoluble	  complexes,	  which	  may	  act	  as	  substrates	  for	  subsequent	  crosslinking	  by	  TGase	  1	  to	  the	  scaffold	  (Steinert	  et	  al.,	  1999).	  The	  presence	  of	  SPRs	  increases	  the	  mechanical	  properties	  of	  the	  tissue,	  and	  it	  is	  thought	  that	  LEP/XP5	  may	  act	  in	  a	  similar	  way.	  The	  keratin	  intermediate	  filament-­‐filaggrin	  complex	  becomes	  cross-­‐linked	  to	  the	  cornified	  cell	  envelope	  and	  lipid	  lamellae,	  forming	  the	  bulk	  of	  the	  corneocytes.	  There	  is	  bulk	  degradation	  of	  organelles	  such	  as	  the	  nucleus,	  mitochondria,	  ER	  and	  lysosomes,	  and	  although	  the	  mechanism	  is	  yet	  to	  be	  understood,	  there	  is	  evidence	  for	  the	  removal	  of	  nuclear	  DNA	  by	  DNase1L2	  in	  the	  hair	  and	  nails	  (Fischer	  et	  al.,	  2011).	  	  
	  
Figure	  1.	  3	  Assembly	  of	  the	  cornified	  cell	  envelope.	  Begins	  in	  the	  spinous	  layers	  (1)	  with	  formation	  of	  a	  protein	  scaffold,	  followed	  by	  formation	  of	  the	  lipid	  envelope	  within	  the	  granular	  layers	  (2).	  In	  the	  final	  reinforcement	  phase	  (3),	  further	  crosslinking	  of	  CE	  proteins	  into	  the	  protein	  scaffold	  for	  structural	  stability	  in	  the	  cornified	  layers.	  Image	  adapted	  from	  Kalinin	  et	  al.,	  2001.
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1.3 THE	  HAIR	  FOLLICLE	  
	  	  
Figure	  1.	  4	  Diagram	  of	  the	  human	  hair	  follicle.	  Other	  skin	  appendages	  are	  depicted	  within	  close	  proximity	  with	  the	  hair	  follicle.	  E.g.	  sweat	  glands,	  nerve	  endings	  and	  oil	  (sebaceous)	  glands.	  Stock	  image	  obtained	  from	  dijitalimaj.com.	  	  Hairs	  are	  filamentous	  structures	  made	  of	  densely	  packed	  keratin	  filaments	  that	  project	  out	  from	  the	  surface	  of	  the	  skin.	  The	  lower	  follicle	  begins	  in	  the	  dermis,	  and	  the	  hair	  shaft	  extends	  out	  onto	  the	  surface	  of	  the	  epidermis	  (Figure	  1.	  4).	  Other	  appendages	  include	  the	  sebaceous	  gland	  and	  follicle	  pigmentation	  unit.	  	  
1.3.1 Structure	  The	  human	  hair	  follicle	  is	  made	  up	  several	  concentric	  layers:	  radiating	  from	  the	  middle	  is	  the	  medulla,	  surrounded	  by	  the	  inner	  root	  sheath	  (IRS)	  followed	  by	  the	  outer	  root	  sheath	  (ORS)	  (Figure	  1.	  5).	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Figure	  1.	  5	  Cross-­‐section	  of	  the	  human	  hair	  follicle.	  The	  different	  layers	  are	  shown	  in	  different	  colours;	  bORS,	  basal	  layer	  of	  outer	  root	  sheath;	  cl,	  companion	  layer;	  He,	  Henle	  layer;	  Hu,	  Huxley	  layer,	  icu,	  inner	  cuticle	  layer;	  cu,	  cuticle	  layer;	  ma/co,	  matrix,	  cortex;	  dp,	  dermal	  papillae.	  Image	  taken	  from	  Langbein	  et	  al.,	  2002.	  	  	  The	  epidermis	  is	  contiguous	  with	  the	  outer	  root	  sheath	  with	  two	  visible	  layers;	  the	  suprabasal	  layer	  expresses	  keratins	  5,	  6,	  14,	  16	  and	  17	  whilst	  the	  basal	  layer	  expresses	  keratins	  5,	  14	  and	  19	  (Winter	  et	  al.,	  1998).	  Cells	  of	  the	  companion	  layer	  	  (cl)	  lie	  between	  the	  ORS	  and	  IRS,	  and	  are	  morphologically	  distinct;	  they	  lack	  desmosomes	  and	  appear	  elongated	  and	  flattened,	  with	  expression	  of	  only	  one	  specific	  epithelial	  keratin,	  keratin	  75	  as	  well	  as	  non-­‐specific	  keratins	  such	  as	  keratins	  6,	  16	  and	  17	  (Langbein	  and	  Schweizer,	  2005).	  The	  inner	  root	  sheath	  links	  the	  hair	  follicle	  to	  the	  interfollicular	  epidermis	  and	  can	  be	  further	  divided	  into	  three	  layers	  starting	  from	  the	  innermost	  layer:	  the	  inner	  cuticle	  (icu),	  the	  Huxley	  layer	  (Hu)	  and	  the	  Henle	  layer	  (He).	  This	  transient	  compartment	  allows	  the	  exit	  of	  the	  hair	  shaft	  on	  the	  skin	  surface	  (Alibardi,	  2004;	  Orwin,	  1979)	  and	  eventually	  detaches	  from	  the	  hair	  shaft	  in	  the	  isthmus	  region,	  in	  the	  presence	  of	  sebaceous	  duct-­‐secreted	  enzymes	  that	  degrade	  the	  IRS	  (Langbein	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  and	  Schweizer,	  2005).	  Adherens	  junctions	  and	  desmosomes	  have	  been	  seen	  to	  connect	  cells	  between	  the	  IRS	  and	  the	  companion	  layer	  (Alibardi	  and	  Bernd,	  2013;	  Orwin	  et	  al.,	  1973).	  The	  presence	  of	  such	  cell	  junctions	  allows	  the	  IRS	  to	  prevent	  water	  loss	  through	  the	  hair	  follicle,	  as	  well	  as	  preventing	  the	  entry	  of	  foreign	  pathogens	  into	  the	  follicle	  (Rogers,	  2004).	  Henle	  cells	  can	  be	  identified	  by	  the	  appearance	  of	  trichohyalin	  in	  their	  cytoplasm	  and	  undergo	  keratinization	  (Orwin,	  1971).	  The	  Henle	  layer	  expresses	  keratins	  25,	  27,	  28	  and	  71,	  while	  the	  Huxley	  layer	  expresses	  the	  same	  keratins	  as	  well	  as	  a	  layer-­‐specific	  keratin,	  keratin	  74	  (Langbein	  et	  al.,	  2010).	  	  The	  cuticle	  layer	  (cu)	  encircles	  the	  hair-­‐forming	  compartment	  and	  is	  made	  up	  of	  the	  cortex	  (co)	  and	  matrix	  (ma).	  The	  matrix	  contains	  proliferative	  cells	  surrounding	  the	  dermal	  papilla	  (DP).	  Synthesis	  and	  regulation	  of	  the	  hair	  follicle	  is	  dependent	  on	  various	  molecular	  factors	  and	  expression	  of	  receptors,	  leading	  to	  the	  deposition	  of	  keratin	  proteins	  within	  the	  cortex	  strengthened	  by	  disulphide	  bonds	  (Powell	  and	  Rogers,	  1997;	  Wang	  et	  al.,	  2000).	  Several	  keratins	  have	  cuticle-­‐specific	  expression:	  keratins	  26,	  72	  and	  73	  (Langbein	  et	  al.,	  2010).	  Formation	  of	  inter-­‐	  and	  intra-­‐molecular	  disulfide	  bonds	  between	  keratin	  intermediate	  filaments	  and	  associated	  proteins	  gives	  rise	  to	  tightly	  packed	  cortex	  cells	  within	  the	  hair.	  Long-­‐chain	  fatty	  acids	  have	  been	  observed	  in	  the	  scale	  cells	  of	  the	  cuticle,	  conferring	  properties	  of	  hydrophobicity	  to	  the	  hair	  surface	  (Lee,	  2011).	  It	  is	  thought	  that	  these	  fatty	  acids	  are	  linked	  to	  the	  scale	  cell	  envelope	  by	  thioester	  bonds	  (Jones	  and	  Rivett,	  1997).	  	  The	  matrix	  surrounds	  the	  DP,	  a	  group	  of	  cells	  responsible	  for	  follicle	  induction	  and	  hair	  growth.	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1.3.2 Hair	  cycle	  The	  hair	  cycle	  has	  classically	  been	  described	  as	  having	  three	  phases:	  anagen	  (fibre	  production/active	  growth),	  catagen	  (regression/breakdown),	  telogen	  (resting),	  before	  regrowth	  at	  the	  anagen	  phase	  again	  (Figure	  1.	  6).	  In	  humans,	  the	  length	  of	  time	  for	  each	  phase	  varies	  dramatically	  between	  follicles,	  from	  a	  few	  weeks	  to	  several	  years	  (Bernard,	  2012),	  in	  a	  seemingly	  independent	  and	  random	  manner.	  Various	  signaling	  pathways	  and	  factors	  have	  recently	  been	  discovered	  to	  be	  are	  involved:	  Wnt,	  BMP,	  Shh,	  Notch	  and	  other	  signaling	  pathways	  involving	  EGFs	  and	  TGFα	  as	  well	  as	  other	  transcription	  factors	  (Lee	  and	  Tumbar,	  2012).	  These	  different	  signaling	  cascades	  act	  in	  a	  concerted	  effort	  at	  various	  stages	  of	  hair	  follicle	  development	  (Baker	  and	  Murray,	  2012).	  	  	  
	  
Figure	  1.	  6	  Diagram	  showing	  the	  three	  phases	  of	  the	  hair	  cycle.	  During	  telogen,	  the	  hair	  follicle	  (HF)	  is	  resting,	  before	  entering	  and	  growing	  in	  anagen,	  and	  terminates	  differentiatin	  in	  catagen.	  IRS,	  inner	  root	  sheath;	  E,	  epidermis;	  HS,	  hair	  shaft;	  ORS,	  outer	  root	  sheath;	  DP,	  dermal	  papilla;	  M,	  matrix;	  CTS,	  connective	  tissue	  sheath;	  B,	  bulge;	  S,	  sebaceous	  gland	  (Steingrimsson	  et	  al.,	  2005).	  	  	  	  During	  anagen,	  proliferating	  matrix	  cells	  move	  upwards	  and	  differentiate	  into	  one	  of	  the	  six	  lineages	  of	  the	  IRS	  and	  hair	  shaft	  (HS):	  Henley,	  Huxley,	  IRS	  cuticle	  layers	  and	  HS	  cuticle,	  cortex	  and	  medulla	  layers.	  Terminally	  differentiating	  HS	  cells	  extrude	  their	  organelles,	  resulting	  in	  a	  compact	  cell	  with	  bundles	  of	  cross-­‐linked	  hair	  keratin	  filaments.	  It	  is	  suggested	  that	  the	  ORS	  is	  the	  result	  of	  a	  downward	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  migrating	  epithelium	  (Reynolds	  and	  Jahoda,	  1991).	  Keratinization	  of	  the	  IRS	  gives	  it	  its	  ability	  to	  support	  the	  hair	  shaft	  during	  differentiation.	  The	  IRS-­‐HS	  complex	  orientates	  itself	  by	  using	  the	  companion	  layer	  of	  the	  ORS	  as	  a	  slippage	  plane	  for	  movement	  towards	  the	  surface	  of	  the	  skin	  (Ito,	  1986),	  and	  cells	  of	  the	  IRS	  release	  the	  HS	  as	  they	  reach	  the	  upper	  follicle.	  The	  coordinated	  expression	  of	  keratins	  is	  thought	  to	  be	  the	  result	  of	  locus	  control	  regions	  (LCR)	  that	  direct	  the	  activation	  of	  keratin	  genes	  by	  allowing	  physical	  accessibility	  of	  chromatin	  domains	  (Powell	  and	  Beltrame,	  1994),	  resulting	  in	  a	  structure	  made	  up	  of	  Type	  I	  and	  Type	  II	  keratin	  intermediate	  filaments	  and	  a	  matrix	  of	  keratin-­‐associated	  proteins	  (Powell	  and	  Rogers,	  1997;	  Rogers,	  2004).	  Between	  the	  IRS	  and	  HS,	  desmosomes,	  tight	  junctions	  and	  gap	  junctions	  are	  present	  in	  varying	  amounts.	  During	  keratinization,	  the	  junctions	  are	  replaced	  with	  a	  new	  cell	  membrane	  complex	  that	  develops	  into	  a	  continuous	  layer	  between	  the	  cells	  (Rogers,	  1959).	  Wnt	  signaling	  is	  critical	  for	  the	  induction	  of	  hair	  follicle	  induction	  (Petiot	  et	  al.,	  2003).	  As	  the	  hair	  shaft	  increases	  in	  length	  and	  passes	  the	  lower	  third	  of	  the	  follicle,	  chromatin	  is	  degraded	  though	  the	  nuclear	  membrane	  remains	  insoluble	  and	  the	  keratinized	  cell	  forms	  an	  elongated	  structure	  in	  the	  cortex	  (Rice	  et	  al.,	  1994).	  Between	  anagen	  to	  catagen,	  there	  is	  a	  temporary	  phase	  of	  amplification	  where	  matrix	  cells	  undergo	  a	  limited	  number	  of	  divisions	  before	  differentiating.	  Bmp	  signallng	  is	  critical	  for	  this	  transition	  (Andl	  et	  al.,	  2004),	  where	  the	  number	  of	  matrix	  cells	  decreases	  and	  HS	  and	  IRS	  differentiation	  is	  retarded.	  Various	  molecules	  have	  been	  identified	  in	  the	  anagen-­‐catagen	  transition,	  but	  their	  exact	  mechanism	  and	  how	  they	  act	  together	  are	  still	  unknown.	  In	  various	  mouse	  models,	  a	  range	  of	  molecules	  have	  been	  implicated	  in	  the	  transition	  to	  catagen	  phase;	  FGF5,	  TGF-­‐β1,	  BDNF	  (brain-­‐derived	  neurotrophic	  factor),	  EGF,	  IGF-­‐1	  and	  BMPR1a	  (BMP	  receptor)	  (Andl	  et	  al.,	  2004;	  Foitzik	  et	  al.,	  2000;	  Hansen	  et	  al.,	  1997;	  Hebert	  et	  al.,	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  1994).	  Some	  factors	  that	  are	  known	  to	  retain	  the	  hair	  follicle	  in	  anagen	  phase	  are	  SGK3	  and	  Msx2	  (Alonso	  et	  al.,	  2005;	  Ma	  et	  al.,	  2003).	  Hair	  pigmentation	  also	  takes	  place	  during	  anagen,	  through	  regulation	  of	  the	  follicle	  pigmentation	  unit	  by	  melanocortins	  and	  a	  whole	  host	  of	  other	  factors	  (Kauser	  et	  al.,	  2005;	  Slominski	  et	  al.,	  2004).	  	  At	  the	  start	  of	  catagen,	  there	  is	  a	  dramatic	  withdrawing	  of	  the	  hair	  follicle	  where	  apoptosis	  and	  terminal	  differentiation	  takes	  place	  (Lindner	  et	  al.,	  1997).	  As	  the	  HS	  stops	  differentiating,	  a	  structure	  called	  the	  club	  hair	  is	  formed	  at	  the	  bottom	  as	  it	  seals	  off.	  A	  temporary	  structure,	  called	  the	  epithelial	  strand,	  is	  formed	  between	  the	  receding	  lower	  follicle	  and	  the	  DP,	  which	  is	  destroyed	  as	  the	  DP	  moves	  upwards	  and	  rests	  beneath	  the	  remnant	  club	  hair.	  This	  regression	  appears	  to	  be	  linked	  to	  β-­‐catenin,	  FGF5	  and	  Dlx3	  expression	  in	  the	  DP	  (Lee	  and	  Tumbar,	  2012).	  Hair	  follicles	  are	  in	  a	  dormant	  phase	  during	  telogen,	  and	  the	  growth	  is	  kick-­‐started	  once	  again,	  when	  stem	  cells	  near	  the	  base	  of	  the	  follicle	  are	  activated	  to	  produce	  a	  new	  hair	  shaft	  (Blanpain	  et	  al.,	  2004).	  	  
1.4 DEFECTIVE	  SKIN	  BARRIER	  DISEASE	  The	  cornified	  envelope	  (CE)	  is	  present	  in	  all	  stratified	  squamous	  epithelia	  and	  since	  its	  main	  role	  is	  to	  provide	  protection,	  any	  defects	  in	  the	  cornified	  layer	  are	  likely	  to	  result	  in	  disease.	  A	  number	  of	  genetic	  diseases	  have	  been	  discovered	  to	  be	  caused	  by	  mutations	  in	  genes	  that	  code	  for	  molecules	  involved	  with	  the	  cornified	  envelope.	  These	  defective	  molecules	  lead	  to	  changes	  in	  structural	  properties,	  metabolism	  of	  skin	  lipids	  or	  transglutaminase-­‐related	  defects.	  Inherited	  skin	  disorders,	  or	  genodermatoses,	  fall	  into	  three	  categories;	  single	  gene	  disorders,	  chromosomal	  disorders	  and	  complex	  traits.	  In	  monogenic	  disorders,	  the	  inheritance	  pattern	  is	  normally	  autosomal	  dominant	  or	  recessive,	  with	  a	  smaller	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  number	  of	  X-­‐linked	  dominant	  or	  X-­‐linked	  recessive	  disorders.	  A	  pedigree	  may	  help	  to	  identify	  the	  pattern	  of	  inheritance.	  Some	  examples	  of	  autosomal	  dominant	  skin	  disorders	  are	  KRT5	  or	  KRT14	  in	  epidermolysis	  bullosa	  simplex	  (EBS),	  where	  dominant-­‐negative	  mutant	  keratin	  proteins	  disrupts	  the	  ability	  of	  wild-­‐type	  keratin	  to	  form	  intermediate	  filaments	  (Coulombe	  et	  al.,	  2009).	  In	  dominantly	  inherited	  skin	  disorders,	  haploinsufficiency	  may	  also	  be	  observed.	  This	  occurs	  when	  an	  affected	  individual	  has	  only	  a	  single	  functioning	  copy	  of	  a	  gene,	  resulting	  in	  an	  insufficient	  amount	  of	  functioning	  protein.	  For	  example,	  a	  mutation	  resulting	  in	  a	  prematurely	  truncating	  desmoplakin	  has	  been	  reported	  in	  individuals	  with	  striate	  palmoplantar	  keratoderma	  (PPK),	  where	  the	  dosage	  of	  desmoplakin	  is	  critical	  in	  maintaining	  desmosomal	  adhesion	  and	  structural	  integrity	  (Armstrong	  et	  al.,	  1999).	  In	  autosomal	  recessive	  disorders,	  two	  copies	  of	  the	  mutant	  allele	  are	  required	  in	  order	  for	  manifestation	  of	  the	  disease,	  these	  patients	  may	  be	  homozygous	  for	  the	  same	  mutation	  on	  each	  allele,	  or	  compound	  heterozygote	  for	  different	  mutations	  on	  each	  allele.	  Recessive	  diseases	  may	  be	  the	  result	  of	  consanguinity	  within	  the	  pedigree	  and	  are	  often	  severe.	  An	  example	  of	  a	  recessive	  autosomal	  disorder	  is	  harlequin	  ichthyosis	  (Chapter	  1.4.2).	  Not	  all	  disorders	  however,	  have	  complete	  penetrance,	  where	  all	  patients	  express	  the	  same	  clinical	  phenotype	  caused	  by	  the	  same	  mutant	  allele.	  Incomplete	  penetrance	  occurs	  when	  some	  individuals	  have	  the	  mutant	  allele	  but	  do	  not	  show	  evidence	  of	  disease.	  The	  variety	  of	  phenotypes	  seen	  in	  a	  single	  disease	  caused	  by	  the	  same	  mutation,	  could	  be	  caused	  by:	  modifier	  genes,	  which	  may	  alter	  the	  expression	  of	  another	  gene,	  environmental	  factors,	  allelic	  variation	  and	  complex	  interactions	  between	  genes	  and	  the	  environment	  (Lobo,	  2008).	  	  Genodermatoses	  result	  in	  a	  range	  of	  phenotypes,	  from	  dry	  skin	  to	  extremely	  severe	  forms	  that	  result	  in	  lethality,	  and	  these	  are	  described	  in	  greater	  detail	  in	  the	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  following	  sub-­‐chapters.	  Although	  desmosomes	  do	  play	  a	  central	  role	  in	  causing	  skin	  barrier	  disorders	  (Al-­‐Jassar	  et	  al.,	  2013),	  they	  have	  been	  briefly	  discussed	  in	  Chapter	  1.2.2.2,	  and	  are	  not	  the	  focus	  of	  this	  chapter,	  which	  is	  centered	  on	  disorders	  relating	  to	  corneocytic	  components.	  	  
1.4.1 Skin	  disorders	  resulting	  from	  structural	  defects	  	  The	  balance	  between	  proliferation	  and	  desquamation	  in	  healthy	  epidermis	  is	  a	  tightly	  controlled	  process,	  and	  many	  skin	  disorders	  are	  the	  result	  of	  altered	  structural	  proteins	  in	  causing	  a	  disturbance	  in	  the	  formation	  of	  the	  epidermis.	  Some	  examples	  are	  listed	  in	  Table	  1.	  2.	  Point	  mutations	  within	  keratin	  genes	  have	  been	  shown	  to	  impair	  the	  assembly	  of	  keratin	  intermediate	  filaments	  (KIF),	  and	  therefore	  are	  mainly	  inherited	  in	  an	  autosomal-­‐dominant	  manner	  (Porter	  and	  Lane,	  2003).	  Pathogenic	  mutations	  tend	  to	  occur	  within	  the	  helix	  initiation	  and	  helix	  termination	  motifs	  of	  the	  rod-­‐domain,	  which	  are	  critical	  for	  KIF	  assembly	  (Goldman	  et	  al.,	  1996;	  Haines	  and	  Lane,	  2012;	  Uitto	  et	  al.,	  2007).	  Multiple	  keratin	  genes	  have	  been	  implicated	  in	  various	  skin	  disorders,	  and	  these	  are	  listed	  in	  Table	  1.	  2	  (Szeverenyi	  et	  al.,	  2008).	  Mutations	  within	  the	  KRT1	  gene	  have	  been	  associated	  with	  epidermolytic	  hyperkeratosis	  (EHK)	  and	  epidermolytic	  palmar	  planter	  keratoderma	  (EPPK).	  These	  disorders	  are	  characterized	  by	  hyperkeratosis,	  skin	  fragility,	  a	  thickened	  stratum	  corneum	  and	  formation	  of	  blisters	  (DiGiovanna	  and	  Bale,	  1994).	  The	  mutations	  in	  KRT1	  occur	  either	  within	  the	  rod-­‐domain	  motifs	  as	  mentioned	  above,	  or	  within	  lysine	  residues	  on	  the	  head	  domain	  that	  are	  key	  for	  crosslinking	  KIFs	  to	  the	  cornified	  envelope	  (Candi	  et	  al.,	  1998b).	  In	  addition	  to	  causing	  disruption	  to	  the	  keratin	  filament	  cytoskeleton,	  mutations	  appear	  to	  affect	  lamellar	  granule	  secretion,	  resulting	  in	  an	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  abnormal	  cornified-­‐envelope	  lipid	  scaffold	  (Schmuth	  et	  al.,	  2001).	  Several	  other	  keratins	  implicated	  in	  barrier	  disorders	  are	  listed	  in	  Table	  1.	  2.	  	  
Diseases	   OMIM	  	   Genes	  involved	   Reference	  Epidermolytic	  hyperkeratosis	  (EHK)	   ♯113800	   KRT1	   (Rothnagel	  et	  al.,	  1992)	  
KRT10	  Epidermolytic	  palmoplantar	  keratoderma	  (EPPK)	   ♯144200	   KRT1	   (Covello	  et	  al.,	  1998)	  KRT9	   (Reis	  et	  al.,	  1994)	  
KRT16	   (Terrinoni	  et	  al.,	  2000)	  Ichthyosis	  bullosa	  of	  Siemens	   ♯146800	   KRT2	   (McLean	  et	  al.,	  1994)	  Epidermolysis	  bullosa	  simplex	  (EBS)	   ♯131900	   KRT5	   (Dong	  et	  al.,	  1993)	  KRT14	   (Bonifas	  et	  al.,	  1992)	  
Pachyonychia	  congenita	  
♯167200	   KRT6A	   (Bowden	  et	  al.,	  1995)	  
KRT16	   (McLean	  et	  al.,	  1995)	  
♯167210	   KRT6B	   (Smith	  et	  al.,	  1998)	  KRT17	  
	  
KRT6C	  
(McLean	  et	  al.,	  1995)	  	  (Wilson	  et	  al.,	  2010)	  Vohwinkel	  syndrome	  (variant)	   ♯604117	  	  
♯133200	  	  	  
♯604117	  	  
LOR	  
(Maestrini	  et	  al.,	  1996)	  	  	  Progressive	  symmetric	  erythrokeratoderma	  	   (Ishida-­‐Yamamoto	  et	  al.,	  1997)	  Loricrin	  keratoderma	  	   (Matsumoto	  et	  al.,	  2001)	  Ichthyosis	  vulgaris	  (IV)	   ♯146700	  
FLG	  
(Smith	  et	  al.,	  2006)	  Atopic	  dermatitis	  (AD)	   ♯605803	   (Palmer	  et	  al.,	  2006)	  Peeling	  skin	  syndrome	  (PSS)	   ♯270300	   CDSN	   (Oji	  et	  al.,	  2010a)	  Hypothrichosis	  simplex	  of	  scalp	  1	   ♯146520	   CDSN	   (Levy-­‐Nissenbaum	  et	  al.,	  2003)	  
Table	  1.	  2	  A	  list	  of	  skin	  disorders	  resulting	  from	  structural	  defects.	  Genodermatoses	  associated	  with	  defects	  in	  the	  structural	  components	  of	  the	  protein	  envelope	  within	  the	  cornified	  envelope	  and	  the	  papers	  in	  which	  they	  were	  first	  published	  (OMIM,	  Online	  Mendelian	  Inheritance	  in	  Man®).	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  The	  cornified	  envelope	  protein	  loricrin	  has	  been	  implicated	  in	  a	  variant	  form	  of	  Vohwinkel	  syndrome	  and	  progressive	  symmetric	  erythrokeratodermia	  (PSEK).	  An	  autosomal	  dominant	  single	  nucleotide	  deletion	  in	  LOR	  gives	  rise	  to	  a	  frameshift	  mutation,	  causing	  a	  loss	  of	  Gln	  and	  Lys	  crosslinking	  sites	  (Ishida-­‐Yamamoto	  et	  al.,	  1997;	  Korge	  et	  al.,	  1997;	  Maestrini	  et	  al.,	  1996).	  A	  variant	  form	  of	  Vohwinkel’s	  syndrome	  (VS)	  is	  characterized	  by	  palmoplantar	  hyperkeratosis	  and	  progressive	  constriction	  of	  the	  digits	  of	  the	  hands	  and	  feet,	  which	  may	  lead	  to	  auto-­‐amputation.	  In	  classical	  VS,	  patients	  present	  with	  starfish-­‐shaped	  hyperkeratosis	  and	  acoustic	  impairment	  caused	  by	  mutations	  in	  Cx26.	  Patients	  with	  PSEK	  also	  suffer	  from	  palmoplantar	  hyperkeratosis,	  along	  with	  erythematous	  plaques	  covering	  the	  body.	  The	  VS	  mutation	  identified	  by	  Maestrini	  et	  al.	  in	  a	  4	  generation	  pedigree,	  was	  a	  1-­‐bp	  insertion	  at	  the	  C-­‐terminus	  (730insG)	  of	  LOR,	  the	  same	  mutation	  was	  reported	  by	  Matsumoto	  et	  al.	  in	  a	  Japanese	  family,	  described	  as	  having	  loricrin	  keratoderma.	  Both	  group	  of	  patients	  have	  very	  different	  clinical	  phenotypes.	  The	  Japanese	  family	  with	  loricrin	  keratoderma	  reported	  by	  Matsumoto	  et	  al.,	  was	  initially	  diagnosed	  as	  having	  non-­‐bullous	  congenital	  ichthyosiform	  erythroderma	  (NCIE),	  and	  were	  born	  as	  collodion	  babies	  with	  fine	  white	  scales	  in	  addition	  to	  constricting	  bands	  around	  the	  digits.	  They	  were	  identified	  as	  having	  a	  1-­‐bp	  insertion	  (709insC).	  In	  both	  cases,	  the	  insertions	  resulted	  in	  a	  replacement	  of	  the	  C-­‐terminus	  with	  additional	  amino	  acids	  that	  would	  be	  expected	  to	  impair	  and	  disrupt	  cross-­‐linking	  activity.	  Mutant	  loricrin	  has	  been	  shown	  to	  be	  retained	  within	  the	  nucleus	  due	  to	  the	  additional	  amino	  acids	  mimicking	  nuclear	  localization	  sequences	  (Korge	  et	  al.,	  1997).	  The	  reason	  for	  the	  difference	  in	  phenotype	  seen	  in	  these	  disorders	  could	  be	  because	  loricrin	  disorders	  are	  a	  heterogenous	  group	  of	  diseases.	  There	  does	  not	  appear	  to	  be	  any	  genotype-­‐phenotype	  correlation,	  possibly	  because	  there	  were	  no	  proper	  clinical	  descriptors	  or	  because	  other	  mutations	  in	  other	  genes	  could	  be	  responsible	  
	   32	  for	  the	  variant	  phenotypes.	  The	  variation	  in	  disease	  severity	  within	  families	  could	  also	  be	  linked	  to	  differences	  in	  expression	  or	  polymorphisms	  in	  the	  LOR	  gene	  (Ishida-­‐Yamamoto,	  2003).	  Filaggrin	  (FLG)	  has	  been	  implicated	  in	  ichthyosis	  vulgaris	  (IV),	  which	  is	  a	  skin	  disorder	  characterized	  by	  dry,	  scaly	  skin	  and	  palmoplantar	  hyperlinearity	  with	  an	  increased	  risk	  of	  eczema,	  food	  allergies	  and	  asthma	  (McAleer	  and	  Irvine,	  2013;	  Wells	  and	  Kerr,	  1966).	  Patients	  have	  an	  absence	  or	  reduced	  levels	  of	  keratohyalin	  granules	  in	  the	  epidermis	  with	  mild	  hyperkeratosis.	  Several	  loss-­‐of-­‐function	  mutations	  have	  been	  discovered	  since	  the	  gene	  was	  first	  linked	  to	  IV	  (Hamada	  et	  al.,	  2008;	  Nomura	  et	  al.,	  2007;	  Sandilands	  et	  al.,	  2006;	  Sandilands	  et	  al.,	  2007;	  Smith	  et	  al.,	  2006).	  IV	  is	  inherited	  in	  a	  semi-­‐dominant	  manner;	  heterozygous	  patients	  exhibit	  a	  milder	  phenotype	  compared	  to	  homozygous	  patients	  who	  have	  severe	  scaling	  and	  eczema	  (Smith	  et	  al.,	  2006).	  In	  these	  patients,	  a	  decrease	  or	  absence	  of	  filaggrin	  impairs	  skin	  barrier	  function.	  Further	  examination	  of	  structural	  abnormalities	  in	  IV	  patients	  revealed	  abnormal	  extracellular	  lamellar	  bilayer	  maturation	  and	  organization	  (Gruber	  et	  al.,	  2011).	  Along	  with	  a	  decrease	  of	  acidic	  filaggrin	  breakdown	  products,	  there	  is	  an	  increase	  in	  skin	  pH	  levels,	  which	  can	  result	  in	  the	  degradation	  of	  lipid-­‐processing	  enzymes	  through	  the	  increased	  activity	  of	  skin	  serine	  proteases	  (Hachem	  et	  al.,	  2003).	  It	  has	  been	  shown	  that	  topical	  ceramide-­‐dominant	  moisturizers	  help	  to	  replace	  deficient	  epidermal	  ceramides	  and	  to	  maintain	  the	  integrity	  of	  the	  skin	  (Sajic	  et	  al.,	  2012).	  FLG	  mutations	  R501X	  and	  2282del4	  were	  found	  to	  be	  strong	  predisposing	  factors	  for	  atopic	  dermatitis	  as	  well	  as	  other	  atopic	  diseases	  such	  as	  symptoms	  of	  allergies	  including	  asthma,	  food	  allergies	  and	  allergic	  rhinitis	  (Palmer	  et	  al.,	  2006).	  Previously,	  nonsense	  mutations	  within	  the	  corneodesmosin	  (CDSN)	  gene	  were	  associated	  with	  hypotrichosis	  simplex	  of	  the	  scalp,	  an	  autosomal	  dominant	  disease	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  characterized	  by	  an	  initial	  loss	  of	  scalp	  hairs	  that	  progresses	  to	  complete	  baldness	  (Levy-­‐Nissenbaum	  et	  al.,	  2003),	  but	  recently,	  nonsense	  mutations	  in	  CDSN	  have	  been	  linked	  with	  peeling	  skin	  syndrome	  (PSS)	  (Israeli	  et	  al.,	  2011;	  Oji	  et	  al.,	  2010a).	  	  This	  rare	  autosomal	  dominant	  disorder	  can	  be	  categorized	  into	  inflammatory	  or	  non-­‐inflammatory	  with	  superficial	  peeling	  of	  the	  upper	  epidermis.	  	  	  
1.4.2 Skin	  disorders	  resulting	  from	  lipid-­‐related	  defects	  Impaired	  lipid	  synthesis	  may	  result	  in	  a	  group	  of	  disorders	  described	  as	  ichthyosiform	  disease,	  or	  in	  other	  words,	  cutaneous	  scaling.	  A	  decrease	  in	  the	  amount	  of	  epidermal	  lipids	  within	  the	  skin	  barrier	  would	  lead	  to	  dry	  skin,	  as	  the	  ability	  to	  prevent	  excessive	  loss	  of	  water	  is	  lost,	  through	  alteration	  of	  the	  epidermal	  lamellar	  granules	  (LG)	  (Jungersted	  et	  al.,	  2008;	  Khnykin	  et	  al.,	  2011;	  Menon	  et	  al.,	  1992).	  Some	  examples	  of	  lipid	  disorders	  are	  listed	  in	  Table	  1.	  3.	  X-­‐linked	  ichthyosis	  is	  an	  autosomal	  recessive	  disease	  caused	  by	  an	  accumulation	  of	  cholesterol	  sulfate	  within	  the	  extracellular	  space,	  due	  to	  a	  deficiency	  in	  steroid	  sulfatase	  (STS)	  (Basler	  et	  al.,	  1992).	  This	  inhibits	  the	  crosslinking	  activity	  of	  involucrin	  to	  the	  cell	  envelope	  by	  TGase	  1	  and	  esterification	  to	  the	  lipid	  envelope	  (Nemes	  et	  al.,	  2000).	  	  A	  group	  of	  heterogenous	  disorders	  known	  as	  autosomal	  recessive	  congenital	  ichthyosis	  (ARCI)	  consists	  of	  lamellar	  ichthyosis	  (LI),	  nonbullous	  congenital	  ichthyosiform	  erythroderma	  (NCIE)	  and	  Harlequin	  ichthyosis	  (Oji	  et	  al.,	  2010b).	  The	  most	  severe	  congenital	  ichthyosis	  is	  the	  autosomal	  recessive	  Harlequin	  ichthyosis,	  where	  babies	  are	  born	  with	  a	  severe	  covering	  of	  thick	  white	  scales	  over	  their	  whole	  bodies,	  deep	  fissures	  in	  the	  dermis	  and	  severe	  out-­‐turning	  of	  the	  eyelids	  and	  lips	  (ectropion	  and	  eclabium),	  renal	  dysfunction	  and	  cholestatic	  jaundice.	  Epidermal	  restrictions	  around	  the	  limbs	  restrict	  movement	  and	  the	  babies	  are	  at	  risk	  of	  auto-­‐amputation	  of	  the	  digits.	  It	  was	  shown	  that	  mutations	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  within	  the	  ABCA12	  gene	  (coding	  for	  adenine	  triphosphate-­‐binding	  cassette	  transporter)	  were	  associated	  with	  this	  severe	  disease	  (Kelsell	  et	  al.,	  2005),	  with	  patients	  having	  nonsense	  mutations	  or	  frameshift	  mutations	  resulting	  in	  expression	  of	  truncated	  proteins	  (Akiyama	  et	  al.,	  2005;	  Thomas	  et	  al.,	  2006).	  	  The	  ABCA12	  gene	  encodes	  a	  6-­‐transmembrane	  transporter	  protein	  that	  is	  localized	  to	  the	  LG	  in	  upper	  epidermal	  keratinocytes	  (Sakai	  et	  al.,	  2007).	  Patients	  suffering	  from	  Harlequin	  ichthyosis	  have	  absent	  extracellular	  lipid	  lamellar	  due	  to	  defective	  LG	  secretion	  (Dale	  and	  Kam,	  1993).	  Mutations	  found	  within	  ABCA12	  are	  mostly	  loss-­‐of-­‐function	  mutations,	  that	  are	  hypothesized	  to	  affect	  protein	  function	  by	  altering	  nucleotide-­‐binding	  fold	  domains	  and/or	  transmembrane	  domains	  (Akiyama,	  2010).	  
Diseases	   OMIM	  	   Genes	  involved	   Reference	  X-­‐linked	  ichthyosis	   ♯308100	   STS	   (Basler	  et	  al.,	  1992)	  Harlequin	  ichthyosis	  (HI;	  ARC4B)	   ♯242500	   ABCA12	   (Kelsell	  et	  al.,	  2005)	  Arthrogryposis,	  renal	  dysfunction	  and	  cholestasis	  (ARC)	   ♯208085	   VPS33B	   (Gissen	  et	  al.,	  2004)	  Nonbullous	  congenital	  ichthyosiform	  erythroderma	  (NCIE)	  (ARCI2)	   ♯242100	  
ALOX12B	   (Jobard	  et	  al.,	  2002)	  
ALOXE3	  Refsum	  disease	   ♯266500	   PHYH	   (Mihalik	  et	  al.,	  1997)	  Sjogren-­‐Larsson	  syndrome	  (SLS)	   ♯270200	   ALDH3A2	   (De	  Laurenzi	  et	  al.,	  1996)	  Gaucher	  disease	  type	  II	   ♯230900	   GBA	   (Tsuji	  et	  al.,	  1987)	  Cerebral	  dysgensis,	  neuropathy,	  ichthyosis,	  and	  plamaplantar	  keratoderma	  syndrome	  (CEDNIK)	   ♯609528	   SNAP29	  
(Sprecher	  et	  al.,	  2005)	  	  (Fuchs-­‐Telem	  et	  al.,	  2011)	  Chanarin-­‐Dorfman	  syndrome	  (CDS)	   ♯275630	   CGI58	   (Lefevre	  et	  al.,	  2001)	  
Table	  1.	  3	  A	  list	  of	  skin	  disorders	  resulting	  from	  epidermal	  lipid	  defects.	  Disorders	  of	  the	  skin	  barrier	  caused	  by	  genes	  involved	  in	  the	  transport	  or	  metabolism	  of	  epidermal	  lipids	  within	  the	  cornified	  envelope	  and	  the	  papers	  in	  which	  they	  were	  first	  published	  (OMIM,	  Online	  Mendelian	  Inheritance	  in	  Man®).	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  Arthrogryposis,	  renal	  dysfunction	  and	  cholestasis	  (ARC)	  syndrome	  patients	  are	  thought	  to	  have	  an	  abnormal	  LG	  secretion	  and	  delayed	  desquamation,	  as	  they	  develop	  athrogryposis,	  renal-­‐dysfunction,	  cholestatic	  jaundice	  and	  severe	  ichthyosis.	  ARC	  was	  linked	  to	  a	  loss-­‐of-­‐function	  mutation	  in	  VPS33B,	  a	  protein	  hypothesized	  to	  be	  involved	  in	  transportation	  and/or	  secretion	  of	  LG	  (Gissen	  et	  al.,	  2004).	  The	  VPS33	  gene	  encodes	  a	  homologue	  of	  the	  yeast	  protein	  Vps33,	  which	  regulates	  vesicle-­‐membrane	  fusion	  during	  late-­‐stage	  protein	  trafficking	  (Huizing	  et	  al.,	  2001).	  	  Reduced	  expression	  of	  SNAP29,	  a	  soluble	  n-­‐ethylmaleimide	  sensitive	  factor	  attachment	  protein	  (SNAP)	  receptor	  (SNARE)	  protein,	  results	  in	  abnormal	  maturation	  and	  secretion	  of	  LG,	  causing	  a	  neuro-­‐cutaneous	  disease	  known	  as	  cerebral	  dysgenesis-­‐neuropathy-­‐ichthyosis-­‐keratoderma	  (CEDNIK)	  syndrome	  (Fuchs-­‐Telem	  et	  al.,	  2011;	  Sprecher	  et	  al.,	  2005).	  Nonbullous	  congenital	  ichthyosiform	  erythroderma	  (NCIE)	  shares	  similar	  characteristics	  with	  all	  the	  other	  lamellar	  ichthyosis	  (LI),	  but	  with	  fine	  white	  scales	  with	  nail	  dystrophy,	  scalp	  involvement	  and	  loss	  of	  eyebrows	  and	  lashes	  (Fischer	  et	  al.,	  2000).	  Mutations	  within	  lipoxygenase-­‐3	  or	  12R	  are	  thought	  to	  affect	  the	  secretion	  of	  LG	  (Jobard	  et	  al.,	  2002).	  Patients	  with	  Refsum	  disease	  have	  the	  main	  characteristics	  of	  retinitis	  pigmentosa,	  peripheral	  neuropathy,	  cerebellar	  ataxia	  and	  elevated	  CSF	  protein	  concentrations,	  along	  with	  minor	  ichthyosis,	  skeletal	  abnormalities	  and	  cardiac	  impairments	  (Skjeldal	  et	  al.,	  1987).	  This	  is	  the	  result	  of	  an	  accumulation	  of	  phytanic	  acid	  (long	  branched	  chain	  fatty	  acid)	  due	  to	  mutations	  within	  the	  phytanoyl-­‐CoA	  hydroxylase	  (PHYH)	  gene	  (Jansen	  et	  al.,	  1997;	  Mihalik	  et	  al.,	  1997).	  An	  accumulation	  of	  phytanic	  acid	  is	  thought	  to	  interfere	  with	  peroxisomal-­‐mediated	  import	  of	  proteins	  to	  organelles,	  although	  the	  exact	  mechanism	  is	  unknown	  (Waterham	  and	  Cregg,	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  1997).	  	  The	  symptoms	  of	  Refsum	  disease	  are	  later	  onset	  and	  have	  different	  characteristics	  than	  patients	  with	  Sjogren-­‐Larsson	  syndrome	  (SLS),	  even	  though	  both	  disorders	  have	  been	  shown	  to	  accumulate	  phytanic	  acid.	  SLS	  is	  characterized	  by	  ichthyosis,	  spastic	  diplegia	  or	  tetraplegia	  and	  mental	  retardation.	  Mutations	  in	  the	  fatty	  aldehyde	  dehydrogenase	  gene,	  ALDH3A2,	  affects	  the	  enzymatic	  oxidation	  of	  long-­‐chain	  aliphatic	  fatty	  aldehydes	  to	  fatty	  acids,	  and	  have	  been	  discovered	  in	  patients	  (De	  Laurenzi	  et	  al.,	  1996).	  In	  addition	  to	  disrupted	  LG	  formation	  and	  barrier	  formation,	  the	  neurological	  symptoms	  associated	  with	  SLS	  may	  be	  due	  to	  the	  common	  ectodermal	  origin	  of	  the	  skin	  and	  brain,	  but	  more	  work	  needs	  to	  be	  done	  in	  order	  to	  identify	  the	  pathological	  mechanisms	  (Rizzo,	  2013).	  Gaucher	  disease	  is	  an	  autosomal	  recessive	  inherited	  disease	  where	  a	  subset	  of	  type	  II	  Gaucher	  patients	  present	  with	  early	  lethality	  by	  2	  years	  of	  age.	  Acute	  neuropathic	  type	  II	  form	  of	  Gaucher’s	  has	  characteristics	  of	  hepatosplenomegaly,	  developmental	  regression,	  neurologic	  deterioration	  and	  cutaneous	  scaling	  abnormalities.	  Mutations	  in	  the	  β-­‐glucocerebrosidase	  gene,	  an	  enzyme	  required	  for	  the	  hydrolysis	  of	  glucosylceramide	  into	  ceramide,	  impair	  the	  processing	  of	  lamellar	  lipids	  and	  affect	  the	  epidermal	  permeability	  barrier	  leading	  to	  an	  accumulation	  of	  glucosylceramide	  (Stone	  et	  al.,	  2000;	  Tsuji	  et	  al.,	  1987;	  Wigderson	  et	  al.,	  1989).	  	  The	  result	  of	  a	  ceramide	  deficiency	  in	  the	  contents	  of	  lamellar	  bodies	  leads	  to	  disordered	  lamellar-­‐body	  sheets	  in	  the	  intercellular	  space	  of	  the	  cornified	  cells,	  with	  increased	  transepidermal	  water	  loss	  (Holleran	  et	  al.,	  1994).	  The	  defective	  β-­‐glucocerebrosidase	  also	  disrupts	  macrophage	  or	  antigen-­‐presenting	  cell	  functions,	  promoting	  inflammation	  and	  a	  loss	  of	  neuronal	  activity	  leading	  to	  CNS	  disease	  (Grabowski,	  2012).	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  Chanarin-­‐Dorfman	  syndrome	  (CDS)	  has	  similar	  features	  to	  NCIE,	  with	  fine	  white	  scaling,	  bilateral	  ectropion	  and	  eclabion	  and	  patients	  are	  often	  born	  as	  colloidion	  babies.	  In	  this	  autosomal	  recessive	  disease,	  there	  is	  an	  inherited	  lipid	  storage	  disorder	  caused	  by	  a	  mutation	  in	  the	  CGI-­‐58	  gene,	  resulting	  in	  an	  accumulation	  of	  lipid	  droplets	  in	  multiple	  tissues	  (Lefevre	  et	  al.,	  2001).	  	  It	  is	  hypothesized	  that	  mutations	  affect	  the	  interaction	  of	  CGI-­‐58	  protein	  with	  periphilin,	  which	  are	  unable	  to	  be	  localized	  to	  lipid	  droplets	  in	  adipocytes,	  resulting	  in	  abundance	  of	  abnormal	  LG	  and	  lamellar	  structures	  (Yamaguchi	  et	  al.,	  2004).	  	  	  	  
1.4.3 Skin	  disorders	  resulting	  from	  transglutaminase-­‐related	  defects	  Lamellar	  ichthyosis	  (LI)	  is	  an	  autosomal	  recessive	  life	  threatening	  disease	  that	  presents	  with	  characteristic	  dark	  brown,	  plate-­‐like	  scales	  throughout	  the	  body	  (collodion	  membrane)	  at	  birth.	  Within	  the	  first	  few	  weeks	  of	  life,	  this	  membrane	  is	  shed,	  leaving	  the	  patient	  with	  scarring	  alopecia	  and	  a	  defective	  skin	  barrier	  (Huber	  et	  al.,	  1995b).	  It	  was	  discovered	  that	  several	  mutations	  within	  the	  TGase1	  gene	  resulted	  in	  a	  decrease	  in	  enzymatic	  activity,	  these	  include	  nonsense,	  frameshift	  or	  splice-­‐site	  alterations	  (Candi	  et	  al.,	  1998a;	  Huber	  et	  al.,	  1995a;	  Parmentier	  et	  al.,	  1995;	  Petit	  et	  al.,	  1997).	  The	  loss	  of	  enzymatic	  activity	  of	  TGase1	  impairs	  the	  process	  of	  crosslinking	  of	  ceramide	  lipids	  to	  the	  CE,	  leading	  to	  barrier	  impairment.	  The	  location	  of	  TGase1	  mutations	  appear	  to	  have	  an	  effect	  on	  disease	  pathophysiology,	  where	  patients	  with	  mutations	  p.Gly278Arg	  and	  p.Asp490Gly	  appeared	  to	  self-­‐heal	  and	  the	  mechanism	  suggested	  is	  that	  these	  mutations	  lock	  the	  enzyme	  in	  an	  inactive	  trans	  confirmation	  under	  elevated	  hydro-­‐static	  pressure	  (in	  utero),	  and	  when	  the	  water	  molecules	  are	  removed	  after	  birth,	  the	  enzyme	  is	  able	  to	  isomerized	  back	  to	  a	  partially	  active	  cis	  form	  (Raghunath	  et	  al.,	  2003).	  Other	  studies	  have	  shown	  that	  some	  LI	  patients	  have	  mutations	  in	  ALOXE3	  and	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  ALOX12B,	  lipoxygenase	  genes	  on	  17q13	  (Krebsova	  et	  al.,	  2001;	  Osorio	  et	  al.,	  2012),	  and	  ABCA12	  (ATP-­‐binding-­‐cassette	  transporter	  gene)	  (Lefevre	  et	  al.,	  2003)	  on	  2q33-­‐35	  (Parmentier	  et	  al.,	  1996).	  Mutations	  within	  the	  ABCA12	  causing	  LI	  are	  missense	  mutations,	  in	  comparison	  to	  HI,	  and	  predicted	  to	  have	  a	  less	  dramatic	  effect	  on	  protein	  function	  (Akiyama,	  2010).	  Recent	  work	  in	  patients	  with	  acral	  peeling	  skin	  syndrome	  (APSS,	  OMIM	  ♯609796)	  discovered	  prematurely	  truncating	  or	  missense	  mutations	  within	  the	  TGase5	  gene	  (Cassidy	  et	  al.,	  2005;	  Kharfi	  et	  al.,	  2009;	  Pigors	  et	  al.,	  2012).	  	  Patients	  suffering	  from	  this	  autosomal	  recessive	  skin	  disorder	  present	  with	  blistering	  and	  peeling	  of	  the	  outermost	  layers	  of	  the	  palmoplantar	  epidermis	  (Shwayder	  et	  al.,	  1997).	  	  The	  absence	  of	  TGase5	  activity	  severely	  impairs	  the	  incorporation	  of	  loricrin	  into	  the	  cornified	  envelope,	  increasing	  the	  amount	  of	  abnormal	  keratohyalin	  granules	  in	  the	  epidermal	  granular	  cells	  (Kalinin	  et	  al.,	  2001).	  	  
1.4.4 Skin	  disorders	  resulting	  from	  protease-­‐related	  defects	  Netherton	  syndrome	  (OMIM	  ♯256500)	  is	  caused	  by	  mutations	  in	  the	  SPINK5	  gene,	  which	  encodes	  for	  a	  serine	  protease	  inhibitor,	  lymphyo-­‐epithelial	  Kazal-­‐type-­‐related	  inhibitor	  (LEKTI1)	  (Chavanas	  et	  al.,	  2000;	  Sprecher	  et	  al.,	  2001).	  The	  loss-­‐of-­‐function	  mutations	  involved	  range	  from	  nonsense	  mutations,	  splice-­‐site	  variants	  and	  insertion/deletions.	  This	  is	  an	  autosomal	  recessive	  disease	  where	  patients	  show	  congenital	  erythroderma,	  ichthyosis,	  trichorrexis	  invaginata	  and	  generalized	  atopy	  with	  high	  levels	  of	  IgE,	  hayfever	  and	  hypereosinophilia.	  	  Mutations	  within	  cathepsin	  C	  gene	  (CTSC)	  have	  been	  linked	  to	  the	  Papillon-­‐Lefèvre	  syndrome	  (PALS,	  OMIM	  ♯245000),	  where	  patients	  were	  characterized	  with	  palmoplantar	  hyperkeratosis	  and	  severe	  early	  onset	  of	  periodontitis	  (Hart	  et	  al.,	  2000).	  The	  exact	  mechanism	  is	  still	  undiscovered,	  although	  it	  is	  thought	  that	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  mutations	  within	  CTSC	  is	  associated	  with	  a	  reduced	  host	  response	  against	  infection,	  and	  is	  involved	  in	  epithelial	  differentiation	  or	  desquamation	  (Toomes	  et	  al.,	  1999).	  	  
1.5 MOUSE	  MODELS	  FOR	  SKIN	  BARRIER	  DISEASE	  The	  mouse	  is	  well	  suited	  as	  an	  animal	  model	  for	  experimental	  use.	  They	  have	  the	  advantage	  of	  being	  small,	  easy	  and	  inexpensive	  to	  maintain,	  with	  a	  short	  lifespan.	  The	  mouse	  genome	  shares	  many	  similarities	  with	  humans	  in	  terms	  of	  genomic	  organization	  and	  is	  very	  well	  characterized.	  Inbred	  mouse	  strains	  make	  it	  easier	  for	  breeders	  to	  identify	  new	  phenotypes	  which	  can	  occur	  either	  spontaneously	  or	  through	  large-­‐scale	  mutagenesis	  programmes.	  	  
	  
Figure	  1.	  7	  Comparison	  of	  human	  and	  mouse	  epidermis.	  H&E	  stained	  sections	  of	  human	  skin	  and	  mouse	  dorsal	  skin.	  Mouse	  epidermis	  and	  dermis	  is	  significantly	  thinner	  compared	  to	  human	  epidermis,	  and	  comprises	  of	  more	  hair	  follicles.	  	  The	  skin	  of	  mice	  is	  noticeably	  thinner	  compared	  to	  humans,	  with	  only	  three	  cell	  epidermal	  cell	  layers,	  whereas	  human	  epidermis	  usually	  comprises	  of	  6	  –	  10	  epidermal	  cell	  layers	  (Figure	  1.	  7).	  Skin	  from	  the	  footpad	  of	  the	  mouse	  most	  closely	  resembles	  human	  epidermis,	  as	  it	  is	  the	  thickest	  here.	  Ear	  epidermis	  is	  the	  thinnest,	  therefore	  this	  body	  site	  is	  typically	  used	  in	  sensitization	  studies	  in	  mice,	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  where	  the	  allergen	  is	  applied	  epicutaneously.	  Although	  the	  mouse	  is	  densely	  covered	  with	  hair	  and	  changes	  to	  the	  skin	  may	  not	  be	  immediately	  apparent,	  appendages	  such	  as	  the	  hair,	  whiskers,	  tail,	  and	  nails,	  are	  useful	  indicators	  when	  searching	  for	  mouse	  mutants	  with	  dermatological	  defects.	  For	  example,	  flaky	  tail	  mice	  which	  have	  a	  frameshift	  in	  the	  Flg	  gene,	  have	  pronounced	  tail	  constrictions.	  	  It	  is	  important	  to	  note	  that	  mutant	  and	  genetically	  engineered	  mice	  may	  not	  always	  replicate	  completely	  the	  same	  phenotype	  that	  is	  observed	  in	  humans.	  Many	  human	  skin	  diseases	  are	  not	  the	  result	  of	  a	  complete	  knockout	  of	  a	  gene,	  and	  merely	  have	  a	  reduced	  expression.	  An	  example	  of	  this	  is	  the	  ML.VS	  transgenic	  mouse	  model	  for	  Vohwinkel	  syndrome	  and	  PSEK,	  where	  a	  truncated	  form	  of	  loricrin	  (observed	  in	  patients)	  is	  expressed.	  The	  mutant	  form	  of	  loricrin	  appears	  to	  interfere	  with	  epidermal	  differentiation	  and	  homozygous	  knockout	  mice	  show	  a	  severe	  phenotype,	  but	  have	  a	  normal	  cornified	  envelope	  (Suga	  et	  al.,	  2000).	  These	  mice	  were	  observed	  to	  have	  severe	  erythroderma,	  epidermal	  barrier	  dysfunction,	  ichthyosis,	  tail	  constrictions	  and	  nonepidermolytic	  hyperkeratosis	  around	  the	  footpads.	  	  In	  loricrin	  knockout	  mice,	  there	  is	  increased	  susceptibility	  to	  mechanical	  stress,	  and	  newborn	  mice	  appeared	  to	  have	  erythroderma	  and	  shiny	  translucent	  skin	  (Koch	  et	  al.,	  2000).	  In	  another	  example,	  mice	  in	  which	  involucrin	  was	  completely	  knocked	  out	  by	  homologous	  recombination	  show	  a	  normal	  CE	  with	  no	  histopathological	  changes	  (Djian	  et	  al.,	  2000).	  Periplakin-­‐null	  mice	  developed	  normally,	  and	  have	  a	  normal	  cornified	  envelope	  (Aho	  et	  al.,	  2004),	  as	  do	  envoplakin-­‐null	  mice	  did	  not	  develop	  any	  substantial	  phenotype	  as	  well	  (Maatta	  et	  al.,	  2001).	  However,	  when	  a	  triple	  knockout	  mouse	  of	  involucrin,	  periplakin	  and	  envoplakin	  was	  made,	  the	  mice	  were	  observed	  to	  have	  delayed	  embryonic	  formation	  and	  postnatal	  hyperkeratosis,	  with	  structurally	  abnormal	  CE	  (Sevilla	  et	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  al.,	  2007).	  This	  suggests	  that	  there	  are	  compensatory	  effects	  by	  the	  other	  CE	  scaffold	  proteins	  in	  the	  single	  knockout	  mice.	  Some	  mouse	  models	  do	  accurately	  reflect	  human	  disease	  and	  these	  include	  the	  Gaucher	  disease	  mouse	  model	  which	  was	  created	  by	  targeted	  ablation	  of	  the	  murine	  glucocerebrosidase	  gene	  (Tybulewicz	  et	  al.,	  1992).	  Homozygous	  mice	  die	  within	  24	  hours	  of	  birth	  and	  demonstrate	  accumulation	  of	  glucocerebrosidase	  in	  lysosomes,	  similar	  to	  the	  symptoms	  of	  the	  human	  disease.	  A	  Spink5	  deficient	  mouse	  with	  a	  complete	  absence	  of	  LEKTI	  presents	  with	  a	  similar	  features	  to	  Netherton	  syndrome,	  and	  studies	  showed	  that	  there	  was	  hyperactivity	  of	  stratum	  corneum	  tryptic	  enzyme	  (SCTE)	  and	  abnormal	  degradation	  of	  desmoglein	  1	  and	  desmoplakin	  resulting	  in	  a	  detached	  SC	  (Descargues	  et	  al.,	  2005).	  The	  complete	  absence	  of	  LEKTI	  was	  postnatally	  lethal,	  so	  the	  authors	  performed	  skin	  grafts	  from	  KO	  mice	  onto	  nude	  mice	  in	  order	  to	  observe	  phenotypic	  changes	  of	  the	  mutant	  mice.	  These	  grafts	  were	  observed	  to	  have	  acanthosis,	  hyperkeratosis	  of	  the	  SC,	  focal	  parakeratosis	  and	  hypergranulosis.	  Mice	  deficient	  for	  ABCA12	  closely	  resemble	  the	  phenotype	  of	  Harlequin	  ichthyosis,	  with	  lamellar	  granule	  abnormalities	  and	  lipid	  envelope.	  These	  mice	  underwent	  rapid	  neonatal	  lethality,	  and	  showed	  a	  surprising	  involvement	  of	  ABCA12	  in	  the	  lung,	  along	  with	  skin	  barrier	  formation	  (Yanagi	  et	  al.,	  2008).	  Alteration	  of	  other	  genes	  involved	  with	  lipid	  barrier	  formation	  proved	  lethal	  in	  the	  mouse,	  such	  as	  12R	  lipoxygenase	  implicated	  in	  human	  lamellar	  ichthyosis	  and	  fatty	  acid	  transport	  protein	  4	  (FATP4)	  in	  ichthyosis	  prematurity	  syndrome	  (Nishifuji	  and	  Yoon,	  2013).	  In	  certain	  cases,	  it	  might	  be	  difficult	  to	  draw	  parallels	  between	  certain	  mouse	  models	  and	  human	  skin	  disorders	  as	  the	  mouse	  may	  not	  be	  responding	  in	  exactly	  the	  same	  way	  as	  in	  humans.	  Even	  though	  caution	  should	  be	  applied	  to	  data	  obtained	  from	  mouse	  models,	  they	  are	  still	  a	  good	  model	  organism	  for	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  understanding	  disease	  pathophysiology	  and	  molecular	  mechanisms	  in	  genodermatoses.	  	  
1.5.1 History	  of	  the	  Mattma/maFlgft/ft	  mouse	  The	  Mattma/ma	  (matted)	  mouse	  arose	  in	  1952,	  in	  the	  University	  College	  London,	  as	  a	  spontaneous	  mutation	  in	  the	  CBA/Gr	  strain	  and	  was	  later	  outcrossed	  to	  the	  C57BL/Gr	  strain.	  	  By	  performing	  reciprocal	  backcrosses,	  it	  was	  determined	  that	  the	  gene	  responsible	  was	  a	  single	  fully	  penetrant	  recessive	  gene	  (Searle	  and	  Spearman,	  1957).	  In	  the	  same	  paper,	  the	  authors	  went	  on	  to	  describe	  the	  phenotype	  of	  the	  matted	  mice.	  Homozygous	  mice	  had	  a	  distinctly	  fragile	  hair	  phenotype,	  with	  a	  propensity	  to	  develop	  alopecia.	  The	  coats	  were	  thin	  with	  clumps	  of	  hairs	  that	  were	  resistant	  to	  any	  sort	  of	  grooming.	  The	  loss	  of	  hair	  was	  also	  found	  to	  be	  exacerbated	  by	  scratching	  or	  by	  friction	  between	  the	  coat	  and	  the	  mouse’s	  environment.	  Stress	  tests	  on	  the	  hair	  were	  carried	  out	  by	  bending	  individual	  hairs	  and	  this	  was	  found	  to	  cause	  splitting	  along	  the	  cortex,	  indicating	  reduced	  flexibility	  (Figure	  1.	  8a,	  b).	  The	  hair	  phenotype	  was	  more	  pronounced	  as	  the	  length	  of	  the	  hairs	  increased,	  which	  tended	  to	  split	  longitudinally	  due	  to	  brittleness.	  Originally,	  this	  phenotype	  gave	  rise	  to	  the	  initial	  notion	  that	  the	  Mattma/ma	  mouse	  would	  be	  an	  appropriate	  animal	  model	  for	  the	  human	  disease,	  trichorrhexis	  nodosa	  due	  to	  perceived	  similarities	  between	  the	  hair	  defects	  of	  the	  human	  disease	  and	  Mattma/ma	  mouse.	  	  A	  second	  spontaneous	  mutation	  arose	  on	  the	  Mattma/ma	  background	  in	  1958;	  this	  mouse	  strain	  was	  identified	  as	  having	  a	  flaky	  tail	  (ft),	  and	  this	  double	  homozygote	  has	  been	  maintained	  at	  The	  Jackson	  Laboratory	  (Bar	  Habor,	  ME)	  ever	  since.	  The	  flaky	  tail	  phenotype	  is	  relatively	  mild,	  consisting	  of	  dry,	  flaky	  skin,	  with	  tail	  and	  paw	  constrictions,	  therefore	  the	  overt	  hair	  phenotype	  of	  the	  Mattma/ma	  allowed	  the	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Flgft/ft	  mice	  to	  be	  identified.	  The	  matted	  hair	  phenotype	  appears	  earlier	  than	  the	  transient	  flaky-­‐tail	  scaling	  phenotype	  and	  is	  permanently	  visible.	  The	  flaky	  tail	  mouse	  shows	  reduced	  profilaggrin	  expression	  and	  expresses	  a	  truncated	  version	  of	  the	  profilaggrin	  protein	  (~215kDa	  instead	  of	  >500kDa)	  (Presland	  et	  al.,	  2000).	  Involucrin	  and	  trichohyalin	  were	  expressed	  normally	  in	  these	  double	  mutants;	  therefore	  it	  was	  suspected	  that	  there	  was	  a	  mutation	  within	  the	  Flg	  gene,	  which	  was	  later	  identified	  as	  a	  frameshift	  mutation	  in	  the	  6th	  filaggrin	  repeat	  (Fallon	  et	  al.,	  2009).	  As	  a	  result	  of	  this	  work,	  the	  double	  mutant	  has	  been	  used	  as	  an	  animal	  model	  for	  studies	  of	  filaggrin	  deficient	  skin	  (Moniaga	  et	  al.,	  2010;	  Moniaga	  et	  al.,	  2013;	  Oyoshi	  et	  al.,	  2009;	  Scharschmidt	  et	  al.,	  2009).	  The	  hairs	  from	  matted	  mice	  were	  examined	  microscopically	  (Jarrett	  and	  Spearman,	  1957)	  and	  apart	  from	  having	  a	  defective	  cuticle	  with	  increased	  permeability	  to	  the	  medulla,	  other	  inter-­‐follicular	  epidermal	  keratins	  were	  normal.	  The	  hair-­‐cycle	  of	  the	  matted	  mice	  were	  normal	  for	  the	  first	  two	  generations,	  but	  had	  more	  rapid	  regeneration,	  possibly	  due	  to	  increased	  hair-­‐loss	  in	  the	  animals	  owing	  to	  mechanical	  stress.	  Subsequent	  genetic	  studies	  of	  the	  matted	  mice	  determined	  linkage	  of	  the	  ma	  gene	  with	  the	  histocompatibility	  loci	  on	  chromosome	  3,	  with	  the	  locus	  an	  estimated	  1.5	  cM	  distance	  from	  the	  ft	  gene	  (Eicher	  and	  Lane,	  1980;	  Lane,	  1972;	  Lane	  and	  Eicher,	  1979;	  Meisler	  and	  Seldin,	  1991;	  Mobraaten	  et	  al.,	  1984)	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Figure	  1.	  8	  Phenotype	  of	  the	  Mattma/ma	  (matted)	  mouse.	  Hair-­‐shaft	  fragility	  was	  demonstrated	  by	  stress	  tests	  (a)	  and	  hair	  phenotype	  was	  looked	  at	  in	  detail	  by	  scanning	  electron	  microscopy	  and	  showed	  rough	  hair	  cuticles	  (b;	  (Searle	  and	  Spearman,	  1957)).	  Visually	  obvious	  differences	  between	  the	  wildtype	  C57BL/6J,	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1.5.2 Recent	  work	  on	  the	  matted	  mouse	  
Mattma/ma	  and	  double	  mutant	  (DM)	  mice	  develop	  significant	  skin	  inflammation	  with	  some	  exhibiting	  lesions	  and	  excoriation	  with	  blepharitis	  and	  periocular	  edema	  (Figure	  1.	  9).	  The	  development	  of	  progressive	  dermatitis-­‐like	  skin	  inflammation	  in	  Mattma/ma	  and	  DM	  mice	  was	  not	  seen	  in	  Flgft/ft.	  Our	  collaborators	  (Padraic	  Fallon	  et	  al,	  Trinity	  College,	  Dublin)	  looked	  at	  the	  immune	  profile	  of	  the	  various	  mouse	  strains	  in	  further	  detail	  and	  Mattma/ma	  mice	  show	  elevated	  levels	  of	  IgE,	  IgG1	  and	  IgG2a	  (Appendix	  I).	  
	  
Figure	  1.	  9	  Significant	  ocular	  inflammation	  in	  the	  Mattma/ma	  mouse.	  Peri-­‐ocular	  inflammation	  nvolving	  upper	  and	  lower	  eyelids,	  eyelashes	  and	  meibomian	  glands	  of	  the	  Mattma/ma	  and	  DM	  mice	  that	  is	  not	  seen	  in	  the	  Flgft/ft	  mouse.	  
Atopic	  dermatitis	  (AD)	  is	  a	  major	  inflammatory	  condition	  of	  the	  skin	  due	  to	  skin	  barrier	  deficiency,	  with	  mutations	  in	  FLG	  conferring	  incomplete	  penetrance	  to	  the	  development	  of	  AD.	  Although	  these	  DM	  mice	  develop	  spontaneous	  dermatitis,	  genetically	  engineered	  Flgft/ft	  mice	  do	  not	  (Kawasaki	  et	  al.,	  2012).	  In	  this	  thesis,	  I	  set	  out	  to	  identify	  the	  gene	  responsible	  for	  the	  spontaneous	  dermatitis-­‐like	  phenotype	  of	  the	  Mattma/ma	  mouse,	  and	  to	  clarify	  its	  pathophysiological	  mechanisms.	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CHAPTER	  2	  
	  	  	  	  
	  
	  
Discovery	  and	  identification	  of	  the	  matted	  
gene	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2.1. AIMS	  OF	  CHAPTER	  Since	  the	  Mattma/ma	  (matted)	  mouse	  represents	  a	  potential	  animal	  model	  for	  human	  atopic	  disease,	  it	  was	  necessary	  to	  identify	  the	  genetic	  mutation/s	  responsible	  for	  the	  matted	  phenotype.	  The	  goal	  of	  this	  chapter	  is	  to	  identify	  the	  causative	  gene	  and	  in	  order	  to	  achieve	  this	  aim,	  the	  regions	  of	  chromosomal	  crossover	  between	  Mattma/ma	  and	  the	  backcross	  strain,	  C57BL/6J,	  had	  to	  be	  identified	  before	  candidate	  genes	  could	  be	  short-­‐listed	  and	  investigated	  within	  this	  locus.	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2.2. MATERIALS	  AND	  METHODS	  
2.2.1. The	  matted	  mouse	  strain	  A	  genotyping	  method	  specific	  for	  the	  ft	  allele,	  Padraic	  Fallon	  and	  his	  group	  (Trinity	  College,	  Dublin)	  was	  used	  to	  separate	  the	  ft	  and	  ma	  alleles	  using	  a	  backcross-­‐intercross	  protocol	  (Figure	  2.	  1,	  page	  56).	  The	  matted	  hair	  phenotype	  allowed	  easy	  identification	  of	  the	  Mattma/ma	  homozygotes	  and	  further	  backcrossing	  onto	  the	  C57BL/6J	  wild	  type	  strain.	  For	  simplification,	  the	  matted	  mice	  homozygotes	  will	  be	  referred	  to	  as	  Mattma/ma,	  flaky	  tail	  homozygotes	  as	  Flgft/ft,	  and	  double	  homozygotes	  as	  DM.	  All	  Mattma/ma	  mice	  samples	  used	  in	  this	  chapter	  were	  F6	  generation	  on	  the	  C57BL/6J	  background.	  	  
	  
2.2.2. Mapping	  of	  homozygous	  and	  heterozygous	  regions	  Skin	  samples	  were	  obtained	  from	  4-­‐day	  old	  neonatal	  C57BL/6J	  and	  Mattma/ma	  mice	  (F6),	  and	  DNA	  was	  extracted	  using	  the	  DNA	  Purification	  Kit	  (Promega.	  Wisconsin,	  
USA).	  Genomic	  DNA	  was	  amplified	  using	  GoTaq®	  Flexi	  DNA	  Polymerase	  (Promega,	  Wisconsin,	  USA).	  50	  ng	  of	  template	  DNA	  was	  amplified	  in	  a	  25	  μL	  reaction	  containing	  1x	  PCR	  buffer	  (Promega,	  Wisconsin,	  USA),	  1.5	  mM	  MgCl2,	  5	  pmol	  forward	  primer,	  5	  pmol	  reverse	  primer,	  2.5	  mM	  of	  each	  dNTP	  (Bioline),	  4%	  DMSO	  (v/v)	  and	  0.5	  units	  of	  GoTaq®	  Flexi	  DNA	  Polymerase	  (Promega,	  Wisconsin,	  USA).	  PCR	  conditions	  used	  were:	  one	  cycle	  of	  94°C	  for	  5	  min	  and	  32	  –	  36	  cycles	  of	  94°C	  for	  30	  seconds,	  54°C	  –	  58°C	  for	  30	  seconds,	  72°C	  for	  1	  minute	  with	  a	  final	  extension	  of	  72°C	  for	  5	  minutes.	  All	  samples	  were	  sequenced	  using	  the	  ABI	  3730	  DNA	  System	  and	  was	  carried	  out	  by	  the	  DNA	  Sequencing	  Service	  (College	  of	  Life	  Sciences,	  University	  of	  Dundee).	  All	  mapping	  primers	  used	  to	  amplify	  and	  identify	  SNPs	  on	  mouse	  chromosome	  3:	  87,000,000	  –	  95,000,000	  are	  listed	  in	  Appendix	  II.	  	  All	  mutations	  were	  confirmed	  by	  bidirectional	  sequencing.	  Matted	  genomic	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  sequences	  were	  compared	  to	  C57BL/6J	  to	  identify	  regions	  of	  homozygozity.	  This	  mapping	  strategy	  was	  employed	  initially,	  as	  previous	  genetic	  linkage	  studies	  showed	  that	  the	  matted	  gene	  was	  close	  to	  the	  ft	  gene,	  and	  initially	  seemed	  a	  fairly	  straightforward	  way	  of	  identifying	  the	  gene.	  The	  identification	  of	  a	  fairly	  large	  critical	  homozygous	  region	  prompted	  the	  use	  of	  next	  generation	  sequencing.	  	  	  
2.2.3. Next	  Generation	  Sequencing	  and	  bioinformatics	  Mouse	  skin	  (30	  mg)	  was	  disrupted	  using	  the	  TissueLyser	  LT	  (Qiagen	  Gmbh,	  Hilden,	  Germany)	  and	  total	  RNA	  was	  extracted	  using	  the	  RNeasy	  kit	  (Qiagen,	  Gmbh,	  Hilden,	  Germany)	  with	  the	  addition	  of	  Proteinase	  K	  (Roche,	  Mannheim,	  Germany)	  and	  RNase-­‐free	  DNase	  (Qiagen,	  Gmbh,	  Hilden,	  Germany).	  The	  integrity	  and	  concentration	  of	  RNA	  was	  assessed	  by	  Agilent	  2100	  Bioanalyzer	  (Tayside	  Tissuebank,	  Dundee,	  UK).	  All	  samples	  had	  RNA	  Integrity	  Number	  (RIN)	  values	  between	  8.60	  –	  8.90.	  	  Approximately	  10	  μg	  of	  total	  RNA	  (three	  replicates	  for	  each	  genotype;	  C57BL/6J	  and	  Mattma/ma)	  was	  submitted	  for	  Next	  Generation	  sequencing	  to	  GenePool	  (University	  of	  Edinburgh,	  UK).	  Two	  replicates	  were	  run	  per	  lane	  on	  an	  Illumina	  GAIIx	  and	  HiSeq	  2000	  using	  v3	  sequencing	  chemistry	  and	  the	  Roche	  454	  Titanium	  workflow	  that	  guaranteed	  150	  M	  reads	  per	  duplex.	  The	  raw	  fastq	  data	  provided	  had	  between	  67	  M	  –	  105	  M	  76	  bp	  paired-­‐end	  reads	  per	  replicate	  and	  was	  analysed	  by	  Dr.	  Christian	  Cole	  (Bioinformatics	  Research	  Group,	  University	  of	  Dundee).	  	  Fastqc	  (v0.10.0	  http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/)	  was	  used	  to	  check	  read	  quality	  before	  alignment	  to	  the	  Ensembl	  66	  mouse	  genome	  (Flicek	  et	  al.,	  2012)	  with	  the	  BWA	  short	  read	  aligner	  (Li	  and	  Durbin,	  2009)(v0.5.9-­‐r16	  setting	  fastq	  format	  to	  Illumina	  v1.3+,	  parameter	  ‘-­‐I’)).	  Read	  counts	  were	  assigned	  to	  genes	  with	  HTSeq-­‐	  count:	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  http://www.huber.embl.de/users/anders/HTSeq/doc/count.html	  using	  the	  following	  parameters:	  mode=union;	  type=exon;	  idattr=gene_id.	  	  The	  Ensembl	  66	  GTF	  file	  was	  used	  for	  gene	  annotations,	  resulting	  in	  28,007	  genes	  expressed	  in	  at	  least	  one	  of	  the	  replicates.	  Differential	  gene	  expression	  between	  the	  C57BL/6J	  and	  the	  Mattma/ma	  samples	  was	  performed	  with	  DESeq	  (v1.6.1)	  (Anders	  and	  Huber,	  2010)	  and	  R	  (v2.14.0)	  with	  significant	  genes	  defined	  as	  those	  with	  p<0.01.	  In	  order	  to	  concentrate	  on	  genes	  with	  the	  most	  reliable	  read	  counts,	  genes	  with	  <120	  reads	  in	  total	  (i.e.	  on	  average	  <20	  reads	  per	  sample)	  across	  all	  six	  samples	  were	  removed,	  leaving	  18,078	  genes	  across	  the	  mouse	  genome.	  
	  
2.2.4. SNP	  and	  InDel	  detection	  methodology	  All	  replicates	  were	  combined	  into	  one	  BAM	  file	  per	  sample	  and	  the	  aligned	  reads	  were	  passed	  through	  SAMtools	  v0.1.18	  (Li	  and	  Durbin,	  2009)	  for	  calling	  SNPs	  and	  InDels	  with	  the	  standard	  command:	  samtools	  mpileup	  -­‐C50	  -­‐DS	  –uf	  <ref>	  <bams>|	  bcftools	  view	  -­‐bvcg	  >	  raw.bcf.	  The	  called	  SNPs/InDels	  were	  filtered	  to	  report	  only	  those	  with	  a	  minimum	  read	  depth	  of	  20.	  SNPs/InDels	  were	  compared	  between	  the	  C57BL/6J	  and	  Mattma/ma	  samples	  and	  only	  those	  found	  in	  the	  Mattma/ma	  samples	  were	  retained	  for	  further	  analysis.	  383	  SNPs	  and	  InDels	  were	  identified	  in	  the	  EDC	  region	  (chromosome	  3:	  87,000,000-­‐95,000,000)	  as	  being	  unique	  to	  the	  Mattma/ma	  	  sample.	  The	  parameters	  and	  settings	  were	  determined	  by	  Dr.	  Christian	  Cole.	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2.2.5. Analysis	  and	  identification	  of	  murine	  Tmem79	  gene	  Each	  of	  the	  four	  exons	  was	  amplified	  individually	  by	  PCR	  using	  the	  genomic	  primers	  listed	  in	  Table	  2.	  1	  using	  the	  following	  conditions	  for	  all	  exons:	  one	  cycle	  of	  94°C	  for	  5	  minutes;	  35	  cycles	  of	  94°C	  for	  30	  seconds,	  54°C	  for	  30	  seconds	  and	  72°C	  for	  1	  minute;	  and	  a	  final	  extension	  at	  72°C	  for	  5	  minutes.	  	  
Gene/mRNA	  Location	  on	  mouse	  Chr3	   	   F	  primer	  (5'-­‐3')	   R	  primer	  (5'-­‐3')	  
Tmem79	   88132575:88183555	  
exon	  1	   TTTGGAGACACAGGCAAG	   TCTCTACAGCCAAGGGTCA	  exon	  2.1	   TTCCTCCCCACAGTGTTCT	   AATGGCTCCTCCGACTTAG	  exon	  2.2	   CAGAGGCACCTACTAAGTCG	   AGTGGCAGGTTCAGGATAC	  exon	  3	   GGTTTCTCTTCATTCTGCTG	   AAGGCAATGGATTCAACAC	  exon	  4.1	   GGTGTTTGGAGTAGTATCGGC	  TTTTCCTTCTCCTTGGCG	  exon	  4.2	   ACACTTCCTTCTTGGGCAG	   GCTTGGAAGGCAGTTAGTTTC	  exon	  4.3	   CAAGCCTCTCTCTGTCTTCC	   TGCTCCCAGTAAGTTGTCC	  
Table	  2.	  1	  Primers	  used	  to	  amplify	  and	  sequence	  murine	  Tmem79.	  
	  
2.2.6. Mouse	  genotyping	  assay	  A	  644	  bp	  PCR	  product	  encompassing	  the	  third	  exon	  of	  Tmem79	  was	  digested	  with	  
restriction	  enzyme	  CviQI	  (New	  England	  Biolabs©	  Inc.,	  Massachusetts,	  USA)	  at	  25°C	  for	  1	  hour	  and	  the	  digested	  fragments	  were	  separated	  according	  to	  size	  on	  a	  1%	  (w/v)	  agarose	  gel	  by	  electrophoresis.	  Primers	  used	  for	  amplification	  of	  Tmem79	  
exon	  3	  are	  shown	  in	  Table	  2.	  1.	  The	  Flgft	  mutation	  was	  genotyped	  by	  Padraic	  Fallon	  (Trinity	  College,	  Dublin,	  Ireland)	  as	  previously	  described	  (Morita	  et	  al.,	  1995).	  	  
2.2.7. Semi-­‐quantitative	  RT-­‐PCR	  of	  Tmem79	  in	  skin	  Mouse	  skin	  (30	  mg)	  was	  disrupted	  using	  the	  TissueLyser	  LT	  (Qiagen	  Gmbh,	  Hilden,	  Germany)	  and	  total	  RNA	  was	  extracted	  using	  the	  RNeasy	  kit	  (Qiagen,	  Gmbh,	  Hilden,	  Germany)	  with	  the	  addition	  of	  Proteinase	  K	  (Roche,	  Mannheim,	  Germany).	  1	  μg	  of	  RNA	  was	  reverse	  transcribed	  to	  obtain	  cDNA	  using	  the	  ImProm-­‐IITM	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  Reverse	  Transcription	  System	  (Promega,	  Madison,	  USA).	  	  PCR	  primers	  which	  spanned	  exons	  3	  and	  4	  of	  the	  Tmem79	  gene	  were	  used	  for	  amplification	  of	  cDNA.	  Primers	  to	  mouse	  Krt14	  exon	  8	  were	  used	  as	  a	  positive	  control.	  Primers	  sequences	  are	  shown	  in	  Table	  2.	  2.	  
Murine	  cDNA	  primers	   F	  primer	  (5'	  -­‐	  3')	   R	  primer	  (5'	  -­‐	  3')	   Chromosome	  position	   Expected	  mRNA	  size	  (bp)	  
Tmem79	   CATCTTCTTCCCCTGTCTG	   CAAGAGTGGCAGGAAAGTC	   chr3:88,133,776-­‐88,136,947	   427	  Krt14	   ACTCACTCGCTCACTTGCTCA	   ATCTTGCTCTTCAGGTCCTC	   chr11:100,068,255-­‐100,068,804	   580	  
Table	  2.	  2	  Primers	  used	  to	  amplify	  across	  exon	  3	  –	  4	  of	  murine	  Tmem79	  cDNA.	  	  
2.2.8. Quantitative	  PCR	  of	  Tmem79	  in	  multiple	  tissue	  array	  Expression	  levels	  of	  murine	  Tmem79	  were	  measured	  across	  a	  multiple	  tissue	  panel	  which	  contained	  cDNA	  from	  36	  different	  NIH	  Swiss	  murine	  tissues	  (Origene	  Technologies,	  Rockville	  MD)	  using	  a	  TaqMan®	  Gene	  Expression	  Assay	  (Mm00470360_g1,	  Life	  Technologies	  Corporation,	  Applied	  Biosystems,	  USA).	  This	  probe	  spans	  exons	  3	  and	  4	  of	  Tmem79	  and	  gives	  an	  amplicon	  length	  of	  89bp.	  Target	  location	  of	  the	  assay	  probe	  is	  Chr3:	  88328653–88334433.	  Exons	  3	  –	  4	  of	  
Tmem79	  were	  amplified	  with	  primers	  spanning	  exon	  3	  –	  4	  (Table	  2.	  2)	  and	  cloned	  into	  vector	  pCR2.1	  (Life	  Technologies	  Corporation,	  Invitrogen,	  Maryland,	  USA)	  in	  order	  to	  provide	  a	  DNA	  standard	  for	  quantification	  of	  expression	  levels.	  Standard	  curve	  was	  calculated	  using	  the	  formulae	  provided	  by	  Applied	  Biosystems.	  (“http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldocuments/cms_042486.pdf”.)	  cDNA	  samples	  extracted	  from	  Mattma/ma	  and	  C57BL/6J	  epidermis	  were	  used	  as	  positive	  controls.	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2.2.9. Immunofluorescent	  analysis	  of	  TMEM79	  in	  mouse	  skin	  Back	  skin	  was	  obtained	  from	  4	  day	  old	  Mattma/ma	  and	  C57BL/6J	  neonatal	  mice	  and	  snap	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  4-­‐5	  μm	  cryosections	  of	  mouse	  skin	  were	  cut	  and	  fixed	  in	  1:1	  methanol:acetone	  (-­‐20°C),	  washed	  in	  PBS	  three	  times	  then	  blocked	  in	  10	  %	  (v/v)	  goat	  serum	  (Sigma-­‐Aldrich,	  Missouri,	  USA)	  or	  10	  %	  (v/v)	  donkey	  serum	  (Sigma-­‐Aldrich,	  Missouri,	  USA)	  for	  20	  minutes.	  Incubation	  with	  primary	  antibodies	  was	  carried	  out	  at	  room	  temperature	  for	  1	  hour.	  Sections	  were	  then	  washed	  three	  times	  with	  PBS,	  and	  subsequently	  incubated	  for	  1	  hour	  at	  room	  temperature	  with	  secondary	  antibodies.	  The	  same	  washing	  steps	  were	  repeated	  as	  above,	  and	  nuclei	  were	  counter-­‐stained	  with	  4,6-­‐	  diamidino-­‐2-­‐phenylindole	  (DAPI),	  (Sigma-­‐Aldrich,	  Missouri,	  USA)	  at	  a	  final	  concentration	  of	  1	  μg/mL.	  Sections	  were	  mounted	  in	  Prolong®	  Gold	  antifade	  reagent	  (Invitrogen,	  Life	  Technologies	  Corporation,	  Applied	  Biosystems,	  USA).	  Images	  were	  collected	  using	  either	  a	  Zeiss	  LSM700	  confocal	  microscope	  or	  a	  Nikon	  ECLIPSE	  E600W	  microscope	  and	  analysed	  using	  SPOT	  imaging	  software	  v3.5.	  The	  primary	  antibodies	  used	  and	  their	  working	  dilutions	  for	  immunofluorescence	  on	  tissue	  sections	  are	  listed	  in	  Table	  3.3,	  page	  79.	  	  
2.2.10. Nile	  red	  staining	  A	  0.5	  μg/mL	  of	  Nile	  red	  working	  solution	  was	  freshly	  made	  up	  in	  a	  75:25	  glycerol-­‐water	  mixture.	  Frozen	  skin	  sections	  were	  incubated	  for	  5	  mins	  with	  Nile	  red	  working	  solution	  and	  1	  μg/mL	  of	  DAPI	  (Sigma-­‐Aldrich,	  Missouri,	  USA).	  Sections	  were	  mounted	  immediately	  and	  imaged.	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2.2.11. Lipid	  analysis	  Lipid	  analysis	  of	  Mattma/ma	  and	  C57BL/6J	  whole	  skin	  was	  outsourced	  to	  My1nefield	  Research	  Services	  (Dundee,	  UK).	  Lipids	  were	  extracted	  from	  frozen	  skin	  using	  an	  adaptation	  of	  lipid	  extraction	  from	  animal	  tissues	  using	  chloroform-­‐methanol-­‐potassium	  chloride	  in	  the	  ratio	  2:1:0.88	  v/v/v	  (Folch	  et	  al.,	  1957).	  Three	  types	  of	  analysis	  were	  carried	  out:	  
1-­‐D	  lipid	  class	  identification	  –	  murine	  skin	  extract	  was	  dissolved	  in	  solvent	  and	  spotted	  onto	  a	  thin	  liquid	  chromatography	  (TLC)	  plate	  together	  with	  known	  standards	  and	  separated	  in	  one	  direction	  using	  80:20:2	  iso-­‐hexane/diethyl	  ether/formic	  acid.	  2-­‐D	  phospholipid	  species	  identification	  –	  phospholipid	  species	  were	  separated	  from	  murine	  skin	  extract	  using	  two	  solvent	  systems;	  chloroform/methanol/water	  (65:25:4)	  followed	  by	  chloroform/methanol/acetic	  acid/water	  (80:12:15:4).	  1-­‐D	  separation	  for	  ceramides	  –	  Murine	  skin	  extract	  was	  separated	  in	  one	  directiom	  using	  three	  different	  solvent	  mixtures;	  dichlormethane/ethyl	  acetate/acetone	  (80:16:4),	  chloroform/acetone/methanol	  (76:8:16)	  and	  isohexane/chloroform/acetone	  (6:80:14).	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2.3. RESULTS	  	  
2.3.1. Identification	  of	  retained	  ma/ma	  regions	  In	  order	  to	  identify	  the	  region	  harbouring	  the	  matted	  gene,	  a	  breeding	  strategy	  for	  maintaining	  a	  colony	  of	  Mattma/ma	  mice	  was	  devised	  by	  our	  collaborators	  in	  Trinity	  College,	  Dublin.	  The	  matted	  hair	  phenotype	  allowed	  easy	  identification	  of	  
Mattma/ma	  homozygotes	  and	  therefore,	  the	  matted	  mutation	  was	  selected	  and	  retained	  (Figure	  2.	  1).	  	  The	  Mattma/ma	  mouse	  line	  underwent	  successive	  backcrosses	  onto	  the	  C57BL/6J	  background.	  Figure	  2.	  2	  shows	  the	  breeding	  strategy	  that	  was	  used.	  As	  the	  successive	  rounds	  of	  backcrosses	  between	  C57BL/6J	  wild	  type	  mice	  and	  matted	  mice	  proceeded,	  the	  disease-­‐causing	  locus	  would	  be	  expected	  to	  decrease	  in	  size	  due	  to	  random	  meiotic	  recombination,	  resulting	  in	  two	  uneven	  flanking	  regions	  of	  heterozygosity.	  We	  had	  also	  previously	  sequenced	  a	  BAC	  clone	  prepared	  from	  
Mattma/maFlgft/ft	  double	  homozygotes,	  which	  effectively	  excluded	  Hrnr	  and	  Flg-­‐2	  as	  the	  causative	  gene	  (Dr	  Aileen	  Sandilands,	  University	  of	  Dundee).	  The	  mapping	  experiments	  carried	  out	  in	  this	  chapter,	  were	  on	  C57BL/6J	  and	  Mattma/ma	  F6	  generation	  progeny,	  with	  mapping	  primers	  designed	  across	  the	  region	  of	  chr3:	  80,000,000-­‐95,000,000	  (Appendix	  II)	  to	  identify	  any	  genomic	  differences	  between	  C57BL/6J	  and	  Mattma/ma	  mice.	  The	  primers	  were	  designed	  at	  regular	  intervals	  with	  special	  attention	  paid	  to	  cover	  non-­‐annotated	  genes.	  Approximately	  1000	  mapping	  primers	  were	  designed	  and	  a	  total	  of	  142	  variants	  between	  C57BL/6J	  and	  
Mattma/ma	  were	  identified.	  All	  sequencing	  reads	  were	  mapped	  against	  the	  reference	  mouse	  genome	  (July	  2007	  (NCBI37/mm9))	  and	  two	  regions	  of	  heterozygous	  regions	  (blue)	  were	  identified	  which	  flanked	  the	  homozygous	  region	  (red)	  that	  contained	  the	  mutation-­‐harboring	  gene	  (Figure	  2.	  3a).	  A	  complete	  list	  of	  all	  the	  variants	  identified	  are	  listed	  in	  Appendix	  III,	  with	  a	  selection	  represented	  in	  Figure	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  2.	  3a.	  The	  homozygous	  region	  was	  narrowed	  to	  an	  area	  between	  chr3:	  87,336,555-­‐88,392,125(Figure	  2.	  3b).	  	  	  
	  
Figure	  2.	  1	  Breeding	  strategy	  employed	  to	  isolate	  the	  Mattma/ma	  mouse.	  A	  series	  of	  reciprocal	  backcrosses	  and	  intercrosses	  were	  performed	  to	  isolate	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Figure	  2.	  2	  Schematic	  cartoon	  demonstrating	  the	  hypothesis	  behind	  reducing	  
the	  critical	  matted	  homozygous	  region.	  Backcrosses	  between	  wildtype	  (C57BL/6J,	  blue	  chromosomal	  regions)	  and	  Mattma/ma	  (red	  chromosomal	  regions)	  harboring	  the	  mutant	  matted	  gene	  mutation	  (yellow	  dot)	  to	  give	  rise	  to	  heterozygous	  offspring	  (F1).	  Random	  intercrosses	  between	  F1	  offspring	  result	  in	  homozygous	  Mattma/ma	  F2,	  which	  are	  selected	  by	  their	  phenotype.	  Backcrossing	  between	  homozygous	  Mattma/ma	  F2	  and	  wildtype	  is	  repeated	  to	  obtain	  a	  congenic	  
Mattma/ma	  strain	  with	  C57BL/6J	  background.	  Each	  backcross	  results	  in	  random	  meiotic	  recombination	  and	  as	  a	  result,	  the	  region	  of	  Mattma/ma	  surrounding	  the	  matted	  gene	  is	  reduced.	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Figure	  2.	  3	  Representation	  of	  mutations	  discovered	  within	  the	  critical	  
homozygous	  region	  of	  interest.	  Variants	  identified	  with	  murine	  chr3:	  80,000,000	  –	  95,000,000	  were	  mapped	  using	  MacVector	  v12.7	  (a).	  An	  overview	  of	  heterozygous	  regions	  flanking	  the	  retained	  homozygous	  Mattma/ma	  area	  containing	  the	  mutation-­‐harboring	  gene	  on	  chromosome	  3	  and	  the	  distance	  from	  the	  Flg	  gene	  (b).	  For	  both	  panels,	  the	  heterozygous	  regions	  are	  denoted	  in	  blue	  and	  retained	  homozygous	  Mattma/ma	  regions	  in	  red.	  
a
b
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2.3.2. Next	  Generation	  Sequencing	  and	  bioinformatics	  Reads	  obtained	  from	  the	  transcriptome	  sequencing	  of	  C57BL/6J	  and	  Mattma/ma	  skin	  RNA	  were	  compared	  to	  each	  other	  and	  a	  total	  of	  383	  SNPs	  and	  InDels	  were	  identified	  within	  the	  epidermal	  differentiation	  complex	  on	  chromosome	  3	  (region	  between	  chr3:	  87,000,000	  –	  95,000,000;	  Appendix	  IV).	  Based	  on	  the	  information	  obtained	  by	  genomic	  mapping,	  the	  critical	  region	  of	  homozygosity	  between	  chr3:	  87,336,555	  -­‐	  88,392,125	  yielded	  a	  shortlist	  of	  210	  SNPs	  within	  potential	  candidate	  genes.	  These	  potential	  candidate	  genes	  were	  analyzed	  by	  locating	  all	  possible	  open	  reading	  frames	  (ORFs)	  for	  potential	  protein	  coding	  regions,	  and	  determining	  whether	  the	  mutations	  introduced	  had	  any	  impact	  on	  protein	  coding.	  This	  was	  achieved	  using	  a	  software	  program	  called	  the	  Integrated	  Genome	  Browser	  (Nicol	  et	  al.,	  2009).	  Several	  mutations	  that	  affected	  coding	  were	  uncovered	  within	  potential	  candidate	  genes,	  but	  a	  single	  nonsense	  mutation	  c.840C>G	  (p.Y280*),	  within	  the	  Tmem79	  gene	  was	  identified	  within	  the	  homozygous	  1.05	  Mb	  interval.	  Comparison	  of	  gene	  expression	  levels	  between	  the	  Mattma/ma	  and	  C57BL/6J	  mice	  identified	  114	  genes	  with	  differential	  expression	  (Appendix	  V).	  There	  were	  60	  up-­‐regulated	  genes	  and	  52	  down-­‐regulated	  genes	  across	  the	  genome	  of	  the	  Mattma/ma	  mice	  using	  the	  most	  up-­‐to-­‐date	  version	  of	  DSeq	  with	  p	  <	  0.01	  (March	  2012).	  They	  were	  categorized	  according	  to	  their	  Gene	  Ontology	  description	  (Figure	  2.	  4).	  The	  largest	  group	  of	  up-­‐regulated	  genes	  was	  related	  to	  immune	  response,	  which	  would	  correlate	  with	  the	  observed	  atopic	  phenotype	  of	  Mattma/ma	  mice.	  Tmem79	  was	  under-­‐expressed	  in	  Mattma/ma	  mice	  (base	  mean	  of	  695),	  with	  a	  differential	  expression	  of	  -­‐1.75	  log2fold	  change	  in	  comparison	  to	  C57BL/6J	  (base	  mean	  of	  2330).	  The	  other	  genes	  of	  interest	  encoded	  for	  proteins	  with	  functions	  relating	  to	  “catalytic	  activity”,	  ion	  binding	  and	  metabolic	  processes	  involving	  fatty	  acid	  and	  lipids,	  with	  the	  largest	  group	  of	  genes	  having	  an	  unknown	  function.	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Figure	  2.	  4	  Differential	  expression	  of	  genes	  with	  p	  <	  0.01	  when	  comparing	  













































































a Upregulated genes in the Mattma/ma mouse
b Downregulated genes in the Mattma/ma mouse
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2.3.3. Analysis	  and	  identification	  of	  murine	  Tmem79	  gene	  Further	  investigation	  of	  Tmem79	  was	  carried	  out	  by	  performing	  conventional	  Sanger	  sequencing	  of	  PCR	  products.	  The	  presence	  of	  the	  c.840C>G	  mutation	  at	  chromosomal	  position	  chr3:	  88,136,485	  was	  confirmed	  in	  homozygous	  Mattma/ma	  mice,	  within	  exon	  3	  of	  Tmem79.	  This	  mutation	  was	  not	  present	  in	  wildtype	  C57BL/6J	  or	  Flgft/ft	  mice	  (Figure	  2.	  6a).	  Genomic	  DNA	  from	  the	  original	  matted	  mice	  from	  Jackson	  Laboratory	  and	  Mattma/maFlgft/ft	  double	  mutants	  (DM)	  maintained	  by	  our	  collaborators	  from	  Trinity	  College	  both	  harbored	  the	  same	  mutation.	  It	  was	  decided	  that	  the	  mutant	  allele	  should	  be	  called	  Mattma.	  	  
Tmem79	  is	  located	  on	  mouse	  chromosome	  3qF1	  and	  spans	  5,781	  bp	  of	  genomic	  DNA.	  With	  a	  total	  of	  four	  exons,	  the	  first	  exon	  is	  untranslated	  and	  the	  other	  three	  encode	  for	  a	  391	  amino	  acid	  protein	  with	  a	  predicted	  molecular	  weight	  43.5	  kDa.	  Protein	  analysis	  predicts	  5	  transmembrane	  domains	  and	  the	  mutation	  p.Y280*	  truncates	  TMEM79	  before	  the	  third	  transmembrane	  domain	  (Figure	  2.	  5).	  	  	  
	  
Figure	  2.	  5	  Bioinformatics	  protein	  analysis	  prediction	  of	  TMEM79.	  Tmem79	  is	  predicted	  to	  encode	  for	  a	  5	  transmembrane	  protein	  and	  the	  matted	  mutation	  p.Y280*	  truncates	  TMEM79	  between	  the	  second	  and	  third	  transmembrane	  domain	  (numbered	  rectangles	  =	  transmembrane	  domains).	  	  	  
2.3.4. Mouse	  genotyping	  assay	  A	  restriction	  enzyme	  digest	  was	  designed	  to	  enable	  quick	  genotyping	  of	  mice.	  A	  single	  nucleotide	  base	  change	  from	  C	  to	  G	  occurs	  within	  the	  exon	  3	  of	  Tmem79	  gene.	  It	  also	  conveniently	  occurs	  within	  a	  restriction	  site	  for	  CviQI,	  which	  recognizes	  a	  G∨TAC	  sequence.	  There	  are	  two	  CviQI	  restriction	  digest	  sites	  within	  
	   62	  wildtype	  (C57BL/6J)	  genomic	  exon	  3	  sequence,	  resulting	  in	  three	  fragments:	  380bp,	  186bp	  and	  78bp.	  Within	  the	  homozygous	  Mattma/ma	  mice,	  the	  C	  to	  G	  change	  results	  in	  one	  less	  restriction	  site,	  giving	  only	  two	  fragments:	  458bp	  and	  186bp	  (Figure	  2.	  6b).	  	  	  
2.3.5. Protein	  expression	  Using	  a	  commercially	  available	  rabbit	  polyclonal	  antibody	  against	  the	  C-­‐terminus	  of	  human	  TMEM79,	  our	  collaborators	  in	  Dublin	  performed	  an	  immunoblot	  on	  protein	  extracts	  from	  mouse	  epidermis,	  and	  a	  single	  band	  of	  ~49kDa	  was	  seen	  in	  C57BL/6J	  and	  Flgft/ft	  mice	  which	  was	  absent	  from	  Mattma/ma	  and	  Mattma/maFlgft/ft	  double	  mutants	  (DM)	  (Figure	  2.	  6c),	  confirming	  that	  the	  p.Y280*	  mutations	  results	  in	  undetectable	  levels	  of	  the	  full-­‐length	  protein.	  
	  
Figure	  2.	  6	  Further	  confirmation	  of	  the	  matted	  mutation	  in	  various	  mouse	  
strains.	  Chromatograms	  of	  sequenced	  PCR	  products	  showing	  c.840C>G	  in	  the	  isolated	  Mattma/ma,	  original	  DM	  from	  Jackson	  Laboratories	  (JAX)	  and	  the	  DM	  from	  Ireland.	  This	  mutation	  was	  not	  seen	  in	  C57BL/6J	  or	  Flgft/ft	  (a).	  Genotyping	  assay	  utilizing	  the	  single	  base	  change	  which	  abolishes	  one	  of	  the	  CviQI	  restriction	  sites	  within	  the	  amplification	  product	  (b).	  Immunoblotting	  protein	  extracts	  from	  mice	  skin	  shows	  complete	  absence	  of	  protein	  within	  Mattma/ma	  homozygous	  murine	  neonatal	  epidermis	  (c).	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2.3.6. Expression	  analysis	  of	  Tmem79	  	  Murine	  Tmem79	  cDNA	  was	  amplified	  using	  primers	  that	  spanned	  exon	  3	  and	  4.	  A	  faint	  band	  was	  detected	  in	  Mattma/ma	  samples	  compared	  to	  that	  seen	  in	  C57BL/6J	  (Figure	  2.	  7a).	  In	  order	  to	  quantify	  Tmem79	  transcript	  levels	  in	  the	  epidermis	  of	  either	  mouse	  strain,	  a	  TaqMan®	  assay	  that	  spanned	  exons	  3	  –	  4	  was	  performed.	  
Mattma/ma	  mice	  had	  7584	  copies	  of	  total	  Tmem79	  while	  in	  comparison	  C57BL/6J	  mice	  had	  36840	  copies.	  Errors	  bars	  in	  the	  graph	  show	  the	  standard	  deviation	  across	  three	  replicates	  for	  Mattma/ma	  (374.78)	  and	  C57BL/6J	  mice	  (4806.5;	  Figure	  2.	  7b).	  This	  shows	  a	  nearly	  5–fold	  decrease	  in	  Tmem79	  message	  in	  Mattma/ma,	  suggesting	  that	  the	  p.Y280*	  nonsense	  mutation	  results	  in	  post-­‐transcriptional	  degradation	  of	  the	  mutant	  ma	  transcript.	  	  The	  same	  TaqMan®	  assay	  was	  then	  performed	  on	  a	  commercially	  available	  multiple	  murine	  tissue	  array,	  and,	  although	  high	  amounts	  of	  Tmem79	  message	  was	  seen	  in	  the	  stomach	  and	  bladder,	  surprisingly	  low	  amounts	  were	  seen	  in	  the	  skin	  sample	  (Figure	  2.8),	  which	  was	  a	  contradiction	  to	  the	  high	  amounts	  seen	  in	  control	  C57BL/6J	  epidermis	  (Figure	  2.	  7).	  According	  to	  the	  company	  that	  supplied	  the	  panel,	  the	  cDNA	  panel	  was	  supposed	  to	  be	  normalized	  to	  Gapdh	  so	  that	  all	  samples	  were	  the	  same,	  but	  a	  standard	  Gapdh	  assay	  showed	  that	  the	  samples	  were	  not	  equal	  across	  all	  tissue	  types	  (Figure	  2.9),	  which	  might	  contribute	  to	  the	  false	  negative	  results	  for	  Tmem79	  in	  murine	  skin.	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Figure	  2.	  7	  Investigation	  into	  Tmem79	  transcript	  levels	  in	  Mattma/ma	  mice.	  RT-­‐PCR	  analysis	  of	  mouse	  skin	  cDNA	  showed	  a	  decrease	  in	  Tmem79	  transcript	  levels,	  using	  primers	  spanning	  exon	  3	  –	  4	  and	  Krt14	  was	  used	  as	  a	  positive	  control	  (a).	  Quantification	  of	  Tmem79	  using	  a	  Taqman®	  Gene	  Expression	  Assay,	  spanning	  exon	  3	  –	  4	  showing	  a	  decrease	  of	  nearly	  5-­‐fold	  for	  Tmem79	  message	  in	  Mattma/ma	  mice	  compared	  to	  C57BL6/J.	  Error	  bars	  show	  standard	  deviation	  (three	  animals	  per	  genotype)	  (b).	  
	  	  
	  
Figure	  2.	  8	  Multiple	  tissue	  expression	  analysis	  of	  Tmem79.	  Multiple	  tissue	  cDNA	  arrays	  for	  murine	  tissues	  showing	  unexpectedly	  low	  levels	  of	  Tmem79	  in	  the	  skin	  across	  three	  replicates.	  Error	  bars	  show	  standard	  deviation	  across	  3	  multiple	  tissue	  arrays.
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2.3.7. Analysis	  of	  TMEM79	  localization	  and	  lipid	  patterns	  in	  Mattma/ma	  mice	  Immunofluorescence	  microscopy	  of	  dorsal	  epidermis	  from	  Mattma/ma	  and	  C57BL/6J	  showed	  that	  TMEM79	  was	  localized	  to	  the	  upper	  granular	  layers	  in	  the	  C57BL/6J	  mice,	  but	  was	  absent	  in	  the	  Mattma/ma	  animals	  (Figure	  2.	  10a,	  b;	  green).	  Expression	  was	  also	  seen	  in	  the	  hair	  follicle	  of	  C57BL/6J	  mice	  (Figure	  2.	  10a;	  white	  arrow)	  compared	  to	  its	  absence	  in	  Mattma/ma	  (Figure	  2.	  10b).	  	  Staining	  with	  lipophilic	  Nile	  Red	  dye	  revealed	  highly	  ordered	  stacked	  of	  cornified	  cell	  envelopes	  in	  the	  stratum	  corneum	  of	  C57BL/6J	  animals,	  but	  these	  seemed	  to	  be	  disorganized	  in	  Mattma/ma	  mice	  (Figure	  2.	  10c,	  d).	  There	  appeared	  to	  be	  a	  buildup	  of	  lipid	  at	  the	  SG/SC	  interface,	  with	  less	  Nile	  Red	  staining	  in	  the	  SC	  of	  
Mattma/ma	  mice	  compared	  to	  C57BL/6J.	  
	  




Figure	  2.	  10	  Analysis	  of	  TMEM79	  localization	  and	  lipid	  patterns	  in	  Mattma/ma	  
dorsal	  epidermis.	  Confocal	  microscopy	  of	  mouse	  dorsal	  epidermis	  stained	  with	  rabbit	  anti-­‐TMEM79	  polyclonal	  antibody	  (green)	  showing	  absence	  of	  TMEM79	  in	  











The	  recent	  discovery	  of	  a	  frameshift	  mutation	  in	  the	  FLG	  gene	  in	  flaky	  tail	  mice	  has	  led	  to	  the	  use	  of	  Mattma/maFlgft/ft	  double	  mutant	  (DM)	  as	  a	  model	  for	  skin	  barrier	  disease.	  Several	  publications	  have	  used	  the	  DM	  as	  an	  animal	  model	  for	  skin	  barrier	  abnormality	  studies	  (Moniaga	  et	  al.,	  2010;	  Moniaga	  et	  al.,	  2013;	  Oyoshi	  et	  al.,	  2009;	  Scharschmidt	  et	  al.,	  2009).	  The	  stratum	  corneum	  of	  the	  DM	  has	  been	  shown	  to	  be	  exceptionally	  permeable	  to	  externally	  applied	  molecules,	  showing	  that	  the	  animals	  have	  a	  severe	  barrier	  abnormality	  (Scharschmidt	  et	  al.,	  2009)	  as	  well	  as	  abnormal	  lamellar	  granule	  (LG)	  secretion,	  resulting	  in	  a	  buildup	  of	  unsecreted	  LG	  at	  the	  SG-­‐SC	  interface.	  There	  appears	  to	  be	  normal	  LG	  formation,	  but	  the	  process	  of	  LG	  secretion	  is	  hampered,	  leading	  to	  a	  decrease	  in	  secreted	  material	  and	  lamellar	  bilayers	  in	  these	  DM	  mice.	  Barrier	  abnormality	  in	  DM	  mice	  results	  in	  an	  overall	  elevated	  immune	  response	  driven	  by	  both	  TH2-­‐mediated	  inflammation	  (Moniaga	  et	  al.,	  2013;	  Oyoshi	  et	  al.,	  2009)	  and	  TH1/TC1-­‐mediated	  responses	  (Moniaga	  et	  al.,	  2010).	  Since	  these	  experiments	  were,	  however,	  performed	  on	  DM	  animals,	  it	  cannot	  be	  determined	  whether	  the	  resulting	  inflammatory	  profile	  is	  the	  result	  of	  the	  ft	  or	  ma	  mutation.	  The	  only	  publication	  to	  date,	  working	  on	  Flgft/ft	  only	  mice,	  shows	  abnormal	  keratin	  aggregation	  within	  the	  lower	  SC	  layers,	  suggesting	  that	  these	  mice	  are	  more	  susceptible	  to	  mechanical	  stress	  (Kawasaki	  et	  al.,	  2012).	  In	  addition,	  Flgft/ft	  mice	  are	  susceptible	  to	  percutaneous	  sensitization	  and	  exhibit	  an	  exaggerated	  dermatitis-­‐type	  response.	  Interestingly,	  the	  paper	  went	  on	  to	  comment	  that	  the	  Flgft/ft	  animals	  showed	  normal	  LG	  secretion	  and	  lamellar	  bilayers	  at	  the	  SG-­‐SC	  interfaces.	  	  From	  this,	  we	  can	  deduce	  that	  while	  Flg	  does	  play	  an	  important	  role	  in	  skin	  barrier	  formation,	  the	  cause	  of	  abnormal	  LG	  secretion	  could	  be	  attributed	  to	  the	  ma	  gene.	  
	  	  
70	  The	  breeding	  strategy	  we	  used	  allowed	  isolation	  of	  the	  Mattma/ma	  mutation,	  and	  mapping	  primers	  led	  us	  to	  identify	  a	  critical	  homozygous	  region	  of	  1.05	  Mb	  on	  chromosome	  3.	  Traditionally,	  disease	  genes	  have	  been	  identified	  using	  karyotyping,	  linkage	  analysis,	  homozygosity	  mapping,	  copy	  number	  variation	  analysis	  and	  SNP-­‐based	  association	  analysis.	  Homozygosity	  mapping	  was	  chosen	  initially,	  because	  prior	  genetic	  linkage	  studies	  showed	  that	  the	  matted	  gene	  was	  approximately	  1.5	  cM	  away	  from	  Flg,	  and	  would	  be	  relatively	  easy	  to	  find.	  However,	  that	  was	  not	  the	  case	  and	  next	  generation	  sequencing	  had	  to	  be	  employed.	  If	  next	  generation	  sequencing	  has	  been	  carried	  out	  initially,	  it	  would	  have	  reduced	  the	  disease	  gene	  identification	  from	  two-­‐step,	  to	  a	  one-­‐step	  approach	  (Gilissen	  et	  al.,	  2012).	  A	  shortlist	  of	  candidate	  genes	  was	  identified	  from	  whole	  transcriptome	  sequencing	  data,	  and	  Transmembrane79	  (Tmem79)	  was	  shown	  to	  have	  a	  nonsense	  mutation	  that	  would	  generate	  a	  non-­‐functional	  protein.	  Differential	  gene	  expression	  data	  identified	  a	  significant	  decrease	  in	  the	  amount	  of	  mRNA	  transcripts	  in	  the	  
Mattma/ma	  mouse,	  suggesting	  that	  the	  mutant	  Tmem79	  transcript	  was	  undergoing	  nonsense-­‐mediated	  decay.	  Expression	  analysis	  of	  Mattma/ma	  epidermis	  showed	  a	  similar	  decrease	  in	  Tmem79	  mRNA	  compared	  to	  C57BL6/J	  animals.	  The	  results	  from	  differential	  gene	  analysis	  across	  the	  entire	  genome	  of	  the	  Mattma/ma	  mouse	  only	  identified	  Tmem79	  within	  the	  epidermal	  differentiation	  complex	  on	  chromosome	  3	  as	  showing	  any	  difference	  in	  expression.	  Taking	  this	  into	  consideration,	  it	  would	  perhaps	  have	  minimized	  the	  amount	  of	  work	  carried	  out	  for	  homozygosity	  mapping	  if	  whole	  transcriptome	  analysis	  were	  carried	  out	  first.	  Homozygosity	  mapping	  did	  highlight	  the	  critical	  region	  of	  genes	  and	  allowed	  analysis	  of	  fewer	  genes	  within	  the	  entire	  EDC,	  but	  a	  combination	  of	  data	  from	  differential	  gene	  analysis	  and	  SNPs/InDels	  identified	  by	  whole	  transcriptome	  
	  	  
71	  analysis	  would	  have	  flagged	  up	  Tmem79	  initially,	  which	  could	  then	  be	  confirmed	  with	  Sanger	  sequencing.	  	  	  The	  data	  generated	  from	  whole	  transcriptome	  analysis	  of	  Mattma/ma	  reflected	  a	  huge	  increase	  in	  the	  expression	  of	  genes	  involved	  in	  the	  immune	  response.	  The	  majority	  of	  these	  immune-­‐related	  genes	  code	  for	  histocompatibility	  class	  2	  molecules,	  which	  are	  involved	  in	  antigen	  presentation	  by	  phagocytes.	  Other	  transcripts	  coding	  for	  proteins	  involved	  in	  inflammatory	  pathways	  that	  were	  upregulated	  in	  the	  Mattma/ma	  animal	  are	  caspase	  1	  and	  lysozyme	  2.	  This	  correlates	  well	  with	  the	  atopic	  phenotype	  of	  the	  Mattma/ma	  mouse,	  showing	  that	  the	  apparent	  skin	  barrier	  defect	  results	  in	  a	  hypersensitized	  immune	  system.	  	  The	  Wdfy1	  (WD	  repeat	  and	  FYVE	  domain	  containing	  1)	  message	  showed	  a	  four-­‐fold	  increase	  in	  expression	  in	  the	  Mattma/ma	  mouse,	  which	  may	  be	  significant	  since	  the	  Fyve	  domain	  is	  able	  to	  target	  proteins	  to	  membrane	  lipids	  via	  an	  interaction	  with	  phosphatidylinositol-­‐3-­‐phosphate,	  a	  possible	  interaction	  partner	  with	  the	  TMEM79.	  CD1d1	  and	  lipoprotein	  lipase	  showed	  a	  close	  to	  2-­‐fold	  increase	  in	  expression	  in	  Mattma/ma	  mice,	  with	  the	  former	  protein	  belonging	  to	  a	  family	  of	  glycolipid	  antigen-­‐presenting	  MHC-­‐like	  molecules	  with	  a	  role	  in	  Th1	  and	  Th2	  type	  responses.	  The	  latter	  protein	  is	  involved	  in	  the	  enzymatic	  hydrolysis	  of	  triglycerides.	  Two	  genes	  encoding	  for	  lipid-­‐related	  proteins	  showed	  decreased	  expression	  in	  the	  Mattma/ma	  mouse,	  and	  they	  are	  fatty	  acid	  desaturase	  6	  (Fads6)	  and	  epidermal	  fatty	  acid	  binding	  protein	  5	  (Fabp5).	  The	  overall	  landscape	  of	  gene	  expression	  in	  Mattma/ma	  suggests	  that	  TMEM79	  is	  required	  for	  normal	  lipid	  homeostasis	  within	  the	  epidermis,	  and	  defects	  in	  lipid	  homeostasis	  alter	  the	  functionality	  of	  skin	  barrier,	  leading	  to	  an	  elevated	  immune	  response.	  In	  our	  experiments,	  we	  used	  epidermis	  from	  4-­‐day	  old	  animals	  in	  order	  to	  evaluate	  the	  normal-­‐state	  of	  murine	  epidermis	  before	  the	  overt	  reactive	  inflammatory	  
	  	  
72	  phenotype	  of	  the	  Mattma/ma	  adult	  mice	  developed.	  It	  is	  possible	  that	  the	  inflammatory	  pathways/immune	  responses	  of	  the	  Mattma/ma	  animal	  could	  change	  over	  time,	  and	  it	  would	  be	  interesting	  to	  look	  at	  the	  immune	  profile	  of	  the	  
Mattma/ma	  mouse	  at	  different	  ages.	  An	  attempt	  to	  perform	  pathway	  analysis	  using	  STRING	  (v9.05)	  was	  performed	  using	  the	  list	  of	  genes	  with	  differential	  expression,	  but	  no	  obvious	  patterns	  or	  interactions	  between	  the	  genes	  were	  discerned.	  This	  could	  be	  due	  to	  the	  complexity	  of	  the	  challenges	  in	  trying	  to	  annotate	  these	  genes	  as	  most	  of	  them	  were	  “unknown”,	  and	  the	  difficulties	  involved	  in	  predicting	  interactions	  between	  such	  a	  wide	  range	  of	  genes	  which	  may	  be	  under-­‐represented	  in	  various	  pathways.	  Lipid	  analysis	  did	  not	  show	  any	  differences	  in	  epidermal	  lipid	  contents	  (phospholipids,	  fatty	  acids,	  polar	  or	  non-­‐polar	  lipids	  and	  ceramides)	  between	  the	  
Mattma/ma	  and	  C57BL/6J	  animals,	  even	  though	  nile	  red	  staining	  showed	  disordered	  cornified	  cell	  envelope	  stacks	  in	  the	  stratum	  corneum.	  Flgft/ft	  mice	  have	  been	  shown	  to	  have	  an	  abnormal	  increase	  in	  levels	  of	  ceramide	  and	  cholesterol	  of	  the	  SC,	  which	  affects	  the	  hydrophobicity	  of	  the	  SC	  and	  the	  penetration	  of	  haptens/allergens	  (Kawasaki	  et	  al.,	  2012).	  As	  shown	  in	  a	  previous	  paper	  (Scharschmidt	  et	  al.,	  2009),	  there	  could	  be	  a	  build	  up	  of	  entombed	  lamellar	  bodies	  at	  the	  SG-­‐SC	  interface	  in	  Mattma/ma	  mice,	  and	  whilst	  the	  overall	  lipid	  profile	  may	  appear	  normal,	  they	  may	  not	  be	  at	  the	  appropriate	  sub-­‐cellular	  locations	  for	  lamellae	  formation.	  The	  Mattma/ma	  mouse	  has	  a	  mutant	  TMEM79	  protein	  missing	  two	  thirds	  of	  its	  C-­‐terminus.	  The	  location	  of	  Tmem79	  within	  the	  EDC	  suggests	  that	  it	  is	  involved	  in	  the	  maturation	  or	  differentiation	  processes	  of	  the	  epidermis,	  and	  could	  be	  engaged	  with	  the	  biosynthesis	  and/or	  transport	  of	  epidermal	  lipids.	  This	  process	  is	  a	  vital	  part	  of	  epidermal	  differentiation	  between	  the	  SG	  and	  SC	  layers,	  where	  lamellar	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3.1. AIMS	  OF	  CHAPTER	  The	  identification	  of	  the	  novel	  murine	  gene	  Tmem79	  in	  Chapter	  2	  of	  this	  thesis,	  has	  revealed	  the	  genetic	  cause	  of	  the	  mouse	  mutant	  Mattma/ma.	  TMEM79	  appeared	  to	  be	  affecting	  epidermal	  lipids	  in	  the	  Mattma/ma	  mouse,	  giving	  rise	  to	  an	  eczema-­‐like	  inflammatory	  skin	  condition.	  In	  this	  chapter,	  I	  attempt	  to	  characterize	  the	  human	  ortholog	  of	  TMEM79,	  and	  identify	  any	  involvement	  with	  epidermal	  barrier	  formation	  or	  differentiation.	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3.2. MATERIALS	  AND	  METHODS	  
3.2.1. Identification	  of	  human	  TMEM79	  	  Primers	  were	  designed	  to	  amplify	  the	  human	  TMEM79	  gene	  on	  chr1:	  156254070-­‐156262234	  using	  similar	  PCR	  conditions	  described	  in	  Chapter	  2.2.2	  (page	  48),	  with	  annealing	  temperatures	  for	  primer	  pairs	  for	  all	  exons	  54°C,	  apart	  from	  primers	  used	  for	  exon	  2.2,	  which	  have	  an	  annealing	  temperature	  of	  58°C	  (Table	  3.	  1).	  
Gene/mRNA	  Location	  on	  human	  chr1	   	   F	  primer	  (5'	  -­‐	  3')	   R	  primer	  (5'	  -­‐	  3')	  
TMEM79	   156254070:156262234	  
exon	  1	   GCCTGCTGCTACCAAATCT	   CTTTACTCCTATGTGATGCTCG	  exon	  2.1	   TGGACGGCATTTGATGTC	   TGTAGGTCAATAGGCACGAAG	  exon	  2.2	   GACGATGCCAACCTGCTG	   AGGGTAGGGTCAGAAAAGGC	  exon	  3	   TTTCCCTTCACTTGACCTG	   GAAATCGGCTTCCATCTG	  exon	  4.1	   TACCAGCCATACCCACCAAC	   ACGGCTGTCCACCTTTTTC	  exon	  4.2	   CAGGGAAAAAGGTGGACA	   TAACATCAACCACCGCAC	  
Table	  3.	  1	  PCR	  and	  sequencing	  primers	  for	  human	  TMEM79	  gene.	  	  
3.2.2. Semi-­‐quantitative	  RT-­‐PCR	  of	  TMEM79	  transcript	  variants	  Exon-­‐specific	  forward	  primers	  were	  designed	  for	  each	  TMEM79	  transcript	  variant,	  each	  of	  the	  forward	  primers	  in	  exon	  1	  were	  designed	  to	  span	  the	  first	  intron	  using	  the	  same	  reverse	  primer	  located	  within	  exon	  2.	  Primers	  were	  also	  designed	  to	  identify	  transcript	  variant	  of	  exon	  2,	  with	  the	  expectation	  of	  a	  smaller	  sized	  product	  for	  transcript	  variant	  2	  (425	  bp),	  shown	  in	  Table	  3.	  2.	  	  A	  diagrammatic	  representation	  of	  transcript	  variant	  primers	  are	  shown	  in	  Figure	  3.	  2	  (page	  90)	  as	  blue/green	  (forward)	  and	  red	  (reverse)	  arrows.	  Semi-­‐quantitative	  RT-­‐PCR	  was	  carried	  out	  on	  cDNA	  obtained	  from	  frozen	  normal	  human	  skin	  (Tayside	  Tissue	  Bank,	  Dundee),	  human	  primary	  keratinocytes	  (HPK)	  and	  HaCaT	  cells	  using	  the	  same	  protocol	  detailed	  in	  Chapter	  2.2.7	  (page	  51).	  Primers	  amplifying	  human	  keratin	  14	  cDNA	  were	  used	  as	  a	  positive	  control.	  	  
	  	  
77	  Human	  cDNA	  primers	   Chromosome	  position	   F	  primer	  (5’	  –	  3’)	   R	  primer	  (5’	  -­‐3’)	   Expected	  mRNA	  size	  (bp)	  
TMEM79	  exon	  1a	   chr1:156252766+156255694	   CAAACCCTTGCGAAAAAC	   ACATCAAACGGCAGGAAG	  	  
811	  
TMEM79	  exon	  1b	   chr1:156254113+156255694	   CTTGCAGAGCCAGCAGGTA	   847	  
TMEM79	  exon	  2	   chr1:156255013+156255694	   CCAGGATGACAGAACAGGAG	   683	  or	  425	  Keratin	  14	   chr17:39740024-­‐39742699	   CTGGACAAGGTGCGTGCTCTG	   CCATTCCTCGGCATCCTTGC	   528	  
Table	  3.	  2	  Primers	  used	  to	  amplify	  TMEM79	  transcript	  variants.	  Forward	  primers	  used	  were	  specific	  for	  each	  exon	  1	  transcript	  variant.	  Exon	  2	  primers	  are	  expected	  to	  give	  425	  bp-­‐sized	  product	  if	  exon	  2	  transcript	  variant	  is	  present.	  	  
3.2.3. Quantitative	  PCR	  of	  human	  cDNA	  tissue	  array	  for	  TMEM79	  transcript	  
variants	  Expression	  levels	  for	  human	  TMEM79	  were	  quantified	  across	  a	  multiple	  tissue	  panel	  containing	  cDNA	  from	  48	  different	  human	  tissues	  (Origene	  Technologies,	  Inc.,	  Maryland,	  USA)	  using	  a	  TaqMan®	  Gene	  Expression	  Assay	  (Hs00260483_m1,	  Life	  Technologies	  Corporation,	  Applied	  Biosystems,	  USA).	  The	  human	  multiple	  tissue	  cDNA	  array	  had	  been	  standardized	  and	  undergone	  quality	  control	  against	  human	  GAPDH	  with	  RT-­‐PCR	  and	  standard	  PCR.	  The	  TMEM79	  probe	  spans	  exon	  3	  to	  4	  and	  gives	  an	  amplicon	  length	  of	  65	  bp	  and	  will	  detect	  all	  transcript	  variants.	  The	  location	  of	  the	  assay	  probe	  within	  TMEM79	  is	  Chr1:	  156252704-­‐156262234.	  The	  DNA	  standards	  used	  in	  this	  quantitative	  assay	  was	  a	  commercially	  available	  plasmid	  containing	  the	  full-­‐length	  wild	  type	  TMEM79	  cDNA	  (Origene	  Technologies	  Inc.,	  Maryland,	  USA).	  Hs01076300_m1	  was	  used	  as	  a	  gene	  expression	  assay	  for	  




3.2.4. Histological	  tissue	  section	  expression	  	  Human	  scalp	  and	  cheek	  skin	  (Tayside	  Tissue	  Bank,	  Dundee)	  were	  snap	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  –	  80°C	  until	  needed.	  8	  μm	  cryosections	  were	  cut	  and	  processed	  in	  an	  identical	  manner	  to	  that	  stated	  in	  Chapter	  2.2.9,	  page	  53.	  Primary	  antibodies	  used	  and	  their	  working	  dilutions	  for	  indirect	  immunofluorescence	  on	  tissue	  sections	  are	  listed	  in	  Table	  3.3.	  
Primary	  antibodies	  against	  hair	  follicle	  keratins	  32,	  74	  and	  75	  were	  a	  kind	  gift	  from	  Dr	  Lutz	  Langbeing	  (DKFZ,	  Heidelberg,	  Germany).	  For	  hair	  follicle	  staining,	  frozen	  scalp	  sections	  were	  stained	  as	  above	  but	  with	  an	  additional	  permeabilization	  step	  using	  1%	  (v/v)	  NP-­‐40	  (AppliChem	  GmbH,	  Darmstadt,	  Germany)	  prior	  to	  blocking	  with	  10%	  (v/v)	  goat	  serum	  in	  PBS.	  
All	  secondary	  antibodies	  were	  used	  at	  1:1000	  dilution	  in	  10%	  (v/v)	  goat	  serum	  in	  PBS.	  They	  include	  AlexaFluor®	  Goat-­‐anti-­‐mouse	  488,	  AlexaFluor®	  Goat-­‐anti-­‐rabbit	  594,	  AlexaFluor®	  Goat-­‐anti-­‐rabbit	  488,	  AlexaFluor®	  Donkey-­‐anti-­‐rabbit	  488	  and	  AlexaFluor®	  Goat-­‐anti-­‐mouse	  594	  and	  AlexaFluor®	  Goat-­‐anti-­‐guinea	  pig	  594	  (Invitrogen,	  Life	  Technologies	  Corporation,	  Maryland,	  USA).	  




3.2.5. Immuno-­‐gold	  labeling	  of	  ultra-­‐thin	  skin	  sections	  The	  Microscopy	  Unit,	  University	  of	  Dundee	  (John	  James),	  performed	  the	  preparation	  and	  ultra-­‐thin	  cryosectioning	  of	  normal	  human	  abdominal	  skin	  (Tayside	  Tissue	  Bank,	  Dundee).	  The	  methods	  employed	  are	  described	  below.	  Human	  skin	  sections	  were	  trimmed	  down	  to	  ~1	  mm2	  cubes	  and	  fixed	  in	  4%	  (w/v)	  paraformaldehyde	  with	  0.2	  M	  piperazine-­‐N,	  N’-­‐bis	  (2-­‐ethanesulfonic	  acid)	  (PIPES	  buffer)	  at	  37°C	  and	  transferred	  into	  2.1	  M	  sucrose	  for	  storage	  at	  4°C.	  Dermis	  was	  trimmed	  using	  a	  Leica	  EM	  FCS	  ultramicrotome	  to	  remove	  as	  much	  as	  possible	  from	  the	  epidermis.	  Each	  90	  nm	  ultra-­‐thin	  section	  was	  retrieved	  from	  the	  diamond	  knife	  onto	  a	  hexagonal	  100-­‐mesh	  copper	  grid	  coated	  with	  pioloform	  and	  carbon.	  Grids	  were	  suspended	  within	  a	  1:1	  solution	  of	  2.3	  M	  sucrose	  and	  2%	  (v/v)	  methylcellulose	  droplet	  on	  a	  stainless	  steel	  loop	  and	  allowed	  to	  dry	  before	  suspending	  on	  water	  for	  short-­‐term	  storage.	  	  Each	  copper	  grid	  was	  washed	  twice	  in	  PBS	  at	  1	  min	  each,	  and	  blocked	  in	  0.5	  %	  (w/v)	  fish	  skin	  gelatin	  in	  PBS	  (FSG/PBS)	  for	  10	  mins.	  The	  grids	  were	  then	  transferred	  into	  primary	  antibody	  in	  FSG/PBS	  for	  30	  mins,	  before	  washing	  in	  PBS	  three	  times,	  5	  mins	  each.	  The	  appropriate	  gold	  conjugate	  secondary	  antibody	  was	  applied	  for	  20	  mins,	  and	  grids	  were	  washed	  six	  times	  in	  PBS	  for	  5	  mins	  each,	  then	  a	  further	  10	  ten	  washes	  in	  distilled	  water	  for	  1	  min	  each,	  before	  counterstaining	  the	  sections	  in	  2%	  (v/v)	  methyl	  cellulose	  and	  3	  %	  (w/v)	  uranyl	  acetate.	  Sections	  were	  examined	  in	  a	  Jeol	  1200	  Ex	  electron	  microscope,	  images	  photographed	  on	  digital	  imaging	  plates	  and	  scanned	  in	  a	  high	  resolution	  imaging	  plate	  scanner	  (DITABIS,	  Pforzheim,	  Germany).	  Antibodies	  used	  and	  their	  respective	  secondary	  antibodies	  for	  immuno-­‐gold	  labelling	  were	  diluted	  in	  FSG/PBS:	  	  1:4	  dilution	  of	  anti-­‐TMEM79	  with	  1:50	  dilution	  of	  goat	  anti-­‐rabbit	  10nm	  Au.	  
	  	  
81	  1:4	  dilution	  of	  anti-­‐CDSN	  with	  1:50	  dilution	  of	  goat	  anti-­‐mouse	  15	  nm	  Au.	  1:2	  dilution	  of	  anti-­‐KLK8	  with	  1:50	  dilution	  of	  goat	  anti-­‐mouse	  15	  nm	  Au.	  	  All	  gold	  conjugate	  secondary	  antibodies	  used	  were	  from	  British	  Biocell	  International,	  Cardiff,	  United	  Kingdom.	  	  
3.2.6. Protein	  extraction	  from	  skin	  samples	  Normal	  frozen	  human	  samples	  (Tayside	  Tissue	  Bank)	  were	  cut	  into	  small	  pieces	  and	  ground	  into	  powder	  using	  a	  mortar	  and	  pestle.	  The	  powder	  was	  then	  homogenized	  on	  ice	  in	  a	  Dounce	  homogenizer	  with	  lysis	  buffer	  containing;	  7	  M	  Urea,	  0.1	  M	  dithiothreitol,	  0.05%	  (v/v)	  Triton	  X,	  25	  mM	  NaCl	  and	  20	  mM	  HEPES,	  pH	  8.0.	  After	  sufficient	  homogenization,	  the	  extract	  was	  transferred	  to	  an	  eppendorf	  tube	  and	  incubated	  at	  37°C	  for	  an	  hour.	  	  
3.2.7. Cloning	  of	  TMEM79-­‐GFP	  constructs	  Using	  a	  commercially	  available	  myc-­‐tagged	  Homo	  sapiens	  TMEM79	  (RC202998,	  Origene	  Technologies,	  Inc.,	  Rockville,	  Maryland,	  USA),	  as	  a	  template,	  full-­‐length	  transcripts	  were	  amplified	  using	  primers	  incorporating	  restriction	  enzymes	  sites	  to	  facilitate	  downstream	  cloning.	  The	  sequence	  used	  as	  a	  template	  was	  transcript	  variant	  1a.	  Primers	  were	  designed	  and	  conditions	  were	  optimized	  (Table	  3.	  4).	  Following	  amplification,	  1.2	  μL	  of	  PCR	  product	  was	  cloned	  into	  pCR®2.1-­‐TOPO	  vector	  using	  a	  TOPO	  TA	  Cloning	  kit	  (Life	  Technologies	  Corporation,	  Invitrogen,	  Maryland,	  USA)	  according	  to	  manufacturer’s	  instructions.	  Ligation	  products	  were	  transformed	  into	  DH5α	  cells,	  and	  spread	  on	  a	  LB	  ampicillin	  plate	  containing	  40	  μg/mL	  X-­‐gal	  and	  0.2	  mM	  IPTG	  and	  incubated	  at	  37°C	  overnight.	  	  Selected	  white	  colonies	  were	  suspended	  in	  50	  µL	  of	  LB	  broth	  and	  colony-­‐PCR	  was	  carried	  out	  using	  the	  initial	  amplification	  primers.	  After	  confirming	  the	  correct	  band	  size	  on	  an	  
	  	  
82	  agarose	  gel,	  the	  colony	  was	  grown	  in	  2	  mL	  liquid	  culture	  overnight	  at	  37°C	  with	  the	  appropriate	  antibiotics.	  Plasmids	  were	  isolated	  from	  the	  culture	  using	  a	  Qiaprep	  Spin	  Miniprep	  kit	  (Qiagen,	  Gmbh,	  Hilden,	  Germany)	  according	  to	  manufacturer’s	  instructions	  and	  plasmid	  DNA	  sent	  for	  sequencing.	  Sequences	  for	  each	  plasmid	  were	  checked	  for	  base	  changes	  and	  insert	  orientation.	  For	  subcloning	  into	  pEGFP-­‐C1	  and	  pEGFP-­‐N1	  vectors,	  cloned	  products	  were	  digested	  with	  1	  unit	  of	  the	  appropriate	  restriction	  enzyme	  (New	  England	  Biolabs,	  Maryland,	  USA),	  in	  a	  total	  reaction	  volume	  of	  20	  µL.	  Controls	  for	  vector	  only,	  single	  digest	  and	  double	  digest	  were	  carried	  out.	  The	  pEGFP-­‐C1	  and	  pEGFP-­‐N1	  vectors	  (Clontech	  Laboratories	  Inc.,	  Takara	  Bio	  Company,	  California,	  USA)	  were	  similarly	  digested	  and	  the	  vectors	  were	  treated	  with	  1	  unit	  of	  Calf	  Intestinal	  Alkaline	  Phosphatase	  (CIP)	  (New	  England	  Biolabs,	  Maryland,	  USA)	  at	  37°C	  for	  3	  hours.	  Digested	  products	  were	  run	  on	  an	  agarose	  gel,	  the	  band	  of	  interest	  extracted	  and	  purified	  using	  QIAquick	  PCR-­‐Purification	  kit	  (Qiagen,	  Gmbh,	  Hilden,	  Germany).	  Ligation	  with	  T4	  DNA	  ligase	  (New	  England	  Biolabs,	  Maryland,	  USA)	  was	  carried	  out	  at	  16°C	  for	  12	  hours.	  DH5α	  cells	  were	  transformed	  with	  the	  ligated	  product	  and	  plated	  on	  LB	  kanamycin	  plates	  overnight	  at	  37°C.	  	  Several	  colonies	  per	  clone	  were	  selected	  and	  2	  mL	  starter-­‐cultures	  were	  grown	  overnight	  at	  37°C.	  The	  plasmids	  were	  isolated	  with	  Qiaprep	  Spin	  Miniprep	  kit.	  Each	  plasmid	  was	  double-­‐digested	  with	  their	  respective	  restriction	  enzymes	  to	  ensure	  the	  presence	  of	  the	  correct	  sized	  insert	  before	  transformation	  and	  a	  final	  plating	  on	  kanamycin-­‐infused	  LB	  plates	  overnight	  at	  37°C.	  Two	  colonies	  were	  selected	  for	  each	  fusion	  protein	  and	  inoculated	  into	  100	  mL	  of	  LB	  media	  with	  the	  appropriate	  antibiotics	  (in	  a	  flask	  that	  was	  at	  least	  five	  times	  the	  volume	  of	  liquid)	  and	  left	  overnight	  to	  grow	  at	  37°C	  to	  ensure	  maximal	  bacterial	  growth.	  Plasmids	  were	  harvested	  the	  next	  day	  with	  QIAprep	  Plasmid	  Maxi	  Kit	  (Qiagen,	  Gmbh,	  Hilden,	  Germany).	  Small	  stocks	  of	  1	  -­‐	  2	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  mL	  of	  culture	  were	  mixed	  with	  80	  %	  (v/v)	  glycerol	  and	  stored	  at	  -­‐80°C	  for	  future	  use.	  
Primer	  name	   Primer	  sequence	  (5'	  -­‐	  3')	   RE	  site	   Size	  (bp)	  TMEM79-­‐FL-­‐GFPN-­‐F	   ATCCGGTACCGAGGAGATCT	   BglII	   ~1220	  TMEM79-­‐FL-­‐GFPN-­‐R	   TGCTCGACCGGTCGCGTACGC	   AgeI	  TMEM79-­‐FL-­‐GFPC-­‐F	   ATCCGGTACCGAGGAGATCT	   BglII	  TMEM79-­‐FL-­‐GFPC-­‐R	   GCT	  CCT	  GCA	  GCC	  GCG	  TAC	  GCT	  AGC	  C	   PstI	  
Table	  3.	  4	  Primers	  used	  in	  amplifying	  protein	  constructs	  for	  full-­‐length	  (FL)	  TMEM79,	  with	  introduced	  restriction	  enzyme	  (RE)	  sites	  and	  their	  expected	  sizes.	  	  	  
3.2.8. Site-­‐directed	  mutagenesis	  The	  full-­‐length	  TMEM79/pEGFPC1	  clone	  was	  used	  as	  a	  template	  for	  site-­‐directed	  mutagenesis	  to	  introduce	  the	  mutation	  c.T847A	  (p.Y283*),	  the	  human	  equivalent	  of	  the	  matted	  mouse	  mutation	  p.Y280*.	  Primers	  were	  designed	  taking	  several	  factors	  into	  consideration;	  length	  should	  be	  between	  25	  –	  45	  bp	  with	  a	  melting	  temperature	  of	  >78°C,	  the	  desired	  mutation	  to	  be	  in	  the	  middle	  of	  the	  primer,	  a	  minimum	  GC	  content	  of	  40	  %	  and	  HPLC-­‐purified	  (Table	  3.	  5).	  The	  mutant	  strand	  was	  synthesized	  in	  a	  50	  μL	  amplification	  reaction	  with	  2.5	  U/μL	  PfuUltra	  Fusion	  HotStart	  DNA	  Polymerase	  and	  1x	  PfuUltra	  II	  reaction	  buffer	  (Agilent	  Technologies,	  California,	  USA),	  125	  ng	  each	  of	  forward	  and	  reverse	  primer	  and	  2.5	  mM	  of	  each	  dNTP	  (Bioline).	  Conditions	  for	  amplification	  used	  were:	  one	  cycle	  of	  95°C	  and	  16	  cycles	  of	  95°C	  for	  30	  seconds,	  55°C	  for	  1	  minute	  and	  68°C	  for	  6	  minutes.	  The	  reaction	  was	  allowed	  to	  cool	  to	  4°C	  before	  the	  addition	  of	  1	  μL	  of	  restriction	  enzyme,	  DpnI,	  then	  incubated	  at	  37°C	  for	  1	  hour	  to	  ensure	  complete	  digestion	  of	  methylated	  parental	  strands.	  DH5α	  cells	  were	  transformed	  with	  the	  digested	  product	  and	  plated	  on	  kanamycin-­‐infused	  LB	  plates	  overnight.	  Colony	  PCR	  was	  carried	  out	  the	  next	  day	  on	  individual	  colonies	  to	  ensure	  that	  the	  correct	  sized	  insert	  was	  present	  and	  overnight	  cultures	  started	  up	  in	  2	  mL	  of	  LB	  with	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  kanamycin.	  Colonies	  were	  isolated,	  purified	  and	  sequenced	  to	  check	  for	  the	  presence	  of	  the	  mutated	  base.	  Primer	  name	   Primer	  sequence	  (5'	  -­‐	  3')	   RE	  site	   Size	  (bp)	  t3904a_F	   GGAGATCCACCGGCGATAAGTGGCCCAGT	   BglII	   ~1220	  t3904a_R	   ACTGGGCCACTTATCGCCGGTGGATCTCC	   PstI	  
Table	  3.	  5	  Primers	  designed	  for	  site-­‐directed	  mutagenesis	  of	  the	  Mattma/ma	  mutation,	  c.T847A	  (p.Y283*;	  base	  change	  highlighted	  in	  red)	  with	  restriction	  enzyme	  (RE)	  sites	  and	  expected	  size.	  	  
3.2.9. Cell	  culture	  HaCaT	  keratinocytes	  (Boukamp	  et	  al.,	  1988)	  were	  grown	  and	  maintained	  in	  antibiotic-­‐free	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  (Gibco,	  Life	  Technologies	  Corporation,	  Maryland,	  USA)	  containing	  1.8	  mM	  calcium	  chloride,	  4.5	  g/L	  glucose,	  L-­‐glutamine	  and	  pyruvate,	  together	  with	  10%	  Fetal	  Calf	  Serum	  (Hyclone,	  Thermo	  Scientific	  Inc.,	  Illinois,	  USA).	  Normal	  human	  keratinocytes	  were	  obtained	  from	  CELLnTECH	  and	  cultured	  in	  defined	  serum-­‐free	  growth	  medium	  CnT57	  (TCS	  Cellworks	  Ltd,	  Buckingham,	  UK).	  All	  cell	  lines	  were	  maintained	  in	  a	  monolayer	  in	  a	  5%	  CO2	  environment	  at	  37°C,	  with	  media	  being	  changed	  every	  2	  days	  until	  approximately	  80	  -­‐	  90%	  confluency.	  	  	  
3.2.10. Transient	  overexpression	  of	  TMEM79	  constructs	  Cells	  were	  grown	  in	  6-­‐well	  plates	  (Greiner	  Bio-­‐one,	  MEDTEC	  Europe,	  Stuttgart,	  Germany)	  containing	  4	  sterile	  13	  mm	  glass	  coverslips	  (VWR	  International	  Inc.,	  Chicago,	  USA)	  per	  well.	  	  Transfection	  of	  TMEM79-­‐fusion	  protein	  constructs	  was	  performed	  using	  Lipofectamine™	  2000	  (Invitrogen,	  Life	  Technologies,	  Maryland,	  USA).	  The	  volumes	  of	  Lipofectamine	  and	  Optimem	  used	  were	  optimized	  to	  6	  µL	  and	  100	  µL	  per	  well	  respectively.	  The	  mixture	  of	  Lipofectamine	  +	  Optimem	  and	  Lipofectamine	  +	  Plasmid	  DNA	  (0.2	  μg	  –	  2.0	  μg)	  was	  incubated	  for	  20	  minutes	  at	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  room	  temperature.	  	  Whilst	  waiting,	  media	  in	  each	  well	  was	  changed	  and	  after	  incubation,	  the	  complex	  added	  to	  each	  well	  and	  mixed	  by	  swirling	  gently.	  Cells	  were	  incubated	  at	  37°C	  for	  the	  appropriate	  incubation	  time	  (24	  	  –	  72	  hours).	  	  All	  plasmids	  used	  for	  transfection	  are	  shown	  in	  Figure	  3.	  1.	  
	  
Figure	  3.	  1	  Overexpression	  assays	  using	  various	  TMEM79	  constructs.	  TMEM79-­‐fusion	  constructs	  used	  for	  transient	  overexpression	  with	  different	  tags,	  myc	  (yellow)	  and	  EGFP	  (green).	  The	  sequence	  from	  RC202998	  was	  used	  as	  the	  template	  for	  the	  generation	  of	  the	  other	  constructs.	  	  	  
3.2.11. Protein	  extraction	  from	  transfected	  monolayers	  Transfected	  HaCaT	  cells	  grown	  in	  6-­‐well	  plates	  were	  washed	  twice	  with	  PBS	  on	  ice.	  	  Cells	  in	  each	  well	  were	  lysed	  with	  100	  μL	  of	  lysis	  buffer	  containing	  50	  mM	  Tris-­‐HCl	  pH	  7.4,	  150	  mM	  NaCl,	  1	  %	  (v/v)	  Triton	  X-­‐100,	  1%	  (w/v)	  sodium	  deoxycholate,	  0.1	  %	  (w/v)	  SDS,	  1	  mM	  EDTA,	  1x	  protease	  inhibitors	  (Sigma-­‐Aldrich,	  Missouri,	  USA)	  and	  2	  μL	  benzonase	  (Merck	  KGaA,	  Darmstadt,	  Germany)	  before	  collecting	  and	  shaking	  horizontally	  for	  10	  minutes	  at	  room	  temperature.	  Each	  lysate	  was	  centrifuged	  at	  12,000	  rpm	  at	  4°C	  for	  8	  minutes	  and	  the	  supernatant	  collected	  and	  stored	  at	  -­‐80°C	  until	  needed.	  	  Samples	  were	  denatured	  at	  70°C	  for	  10	  minutes	  with	  NuPage®	  LDS	  sample	  buffer	  containing	  NuPage®	  sample	  reducing	  agent	  and	  10	  μg/μL	  of	  total	  protein	  per	  sample	  were	  run	  on	  a	  Novex®	  NuPage®	  4	  –	  12	  %	  Bis-­‐Tris	  gel	  at	  200	  V	  for	  1	  hour	  using	  NuPage®	  MOPS	  SDS	  running	  buffer.	  Separated	  proteins	  were	  transferred	  onto	  nitrocellulose	  paper,	  using	  an	  XCell	  SureLock®	  Mini-­‐Cell	  (all	  components	  
	  	  
86	  stated	  above	  are	  from	  Life	  Technologies	  Corporation,	  Applied	  Biosystems,	  USA)	  at	  30	  V	  for	  50	  minutes.	  Nitrocellulose	  paper	  was	  washed	  in	  deionized	  water	  and	  stained	  with	  PonceauS	  (Sigma	  Aldrich,	  Life	  Technologies	  Corporation,	  Maryland,	  USA)	  for	  5	  minutes	  and	  washed	  in	  water	  to	  visualize	  bands.	  Molecular	  weight	  standards	  (SeeBlue®	  Plus2	  Prestained;	  Life	  Technologies	  Corporation,	  Applied	  Biosystems,	  USA)	  were	  marked	  with	  a	  pencil,	  and	  nitrocellulose	  was	  blocked	  with	  5	  %	  (w/v)	  Marvel	  (Chivers	  Ireland	  Ltd,	  Coolock,	  Dublin)	  in	  0.2	  %	  (v/v)	  Tween-­‐20	  in	  Tris-­‐Buffered	  Saline	  (TTBS)	  overnight	  at	  4°C	  before	  incubation	  with	  the	  primary	  antibody	  diluted	  to	  the	  appropriate	  concentration	  in	  0.06%	  (v/v)	  TTBS	  for	  1	  hour	  at	  37°C.	  The	  blot	  was	  washed	  once	  with	  Tris	  Buffered	  Saline	  (TBS),	  thrice	  with	  TTBS	  and	  a	  final	  wash	  with	  TBS,	  for	  5	  minutes	  each	  wash	  at	  room	  temperature.	  Incubation	  with	  the	  appropriate	  secondary	  antibody	  (LI-­‐COR	  Biosciences	  Ltd,	  Cambridge,	  United	  Kingdom)	  was	  carried	  out	  for	  1	  hour	  before	  washing	  (same	  as	  above),	  and	  imaging	  carried	  out	  with	  an	  Odyssey	  imaging	  system	  (LI-­‐COR	  Biosciences	  Ltd,	  Cambridge,	  United	  Kingdom).	  	  Primary	  antibodies	  and	  dilutions	  used	  for	  Western	  blotting:	  Anti-­‐EGFP	  mouse	  monoclonal	  at	  1:1000	  (Roche	  Diagnostic	  Ltd,	  West	  Sussex,	  United	  Kingdom)	  Anti-­‐TMEM79	  rabbit	  polyclonal	  at	  1:1000	  (Abgent,	  California,	  USA)	  All	  LI-­‐COR	  secondary	  antibodies	  were	  used	  at	  a	  dilution	  of	  1:5000.	  	  
3.2.12. Indirect	  immunofluorescence	  of	  monolayer	  cultures	  HaCaT	  cells	  grown	  in	  monolayers	  on	  coverslips	  were	  fixed	  at	  room	  temperature	  in	  1:1	  (v/v)	  methanol:acetone	  (stored	  -­‐20°C)	  and	  stained	  using	  the	  same	  method	  described	  earlier	  (Chapter	  2.2.9,	  page	  53).	  All	  antibodies	  used	  for	  labeling	  are	  listed	  in	  Table	  3.3	  (page	  79).
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3.2.13. Transmission	  electron	  microscopy	  HaCaT	  cells	  were	  grown	  on	  gridded	  coverslips	  (Cellocate,	  discontinued,	  Eppendorf,	  Hamburg,	  Germany)	  in	  DMEM	  with	  10%	  (v/v)	  FCS	  at	  37°C	  in	  sterile	  conditions.	  Transfection	  using	  TMEM79/pEGFPC1	  was	  carried	  out	  according	  to	  the	  protocol	  detailed	  in	  Chapter	  3.2.9.	  Transfected	  cells	  were	  identified	  and	  highlighted	  for	  easy	  identification	  on	  the	  labeled	  grid	  by	  fluorescence	  microscopy.	  The	  coverslips	  were	  fixed	  in	  4%	  paraformaldehyde,	  2.5%	  glutaraldehyde	  in	  0.1	  M	  sodium	  cocodylate	  buffer	  at	  pH	  7.3	  and	  post-­‐fixed	  in	  1%	  aqueous	  osmium	  tetroxide.	  The	  following	  steps	  were	  performed	  by	  John	  James	  (Microscopy	  Unit,	  University	  of	  Dundee).	  Samples	  were	  dehydrated	  in	  graded	  ethanols	  and	  propylene	  oxide	  and	  embedded	  in	  Durafan	  resin	  (Sigma-­‐Aldrich,	  Missouri,	  USA).	  	  Sections	  were	  cut	  on	  a	  Leica	  Ultracut	  UCT	  ultramicrotome,	  and	  collected	  on	  hexagonal	  200mesh	  copper	  grids	  then	  stained	  with	  uranyl	  acetate	  and	  lead	  citrate.	  Sections	  were	  examined	  in	  a	  Jeol	  1200	  Ex	  electron	  microscope	  and	  photographed	  on	  digital	  imaging	  plates	  which	  were	  then	  scanned	  in	  a	  high	  resolution	  imaging	  plate	  scanner	  (DITABIS,	  Pforzheim,	  Germany).	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3.3. RESULTS	  	  
3.3.1. Identification	  and	  quantification	  of	  human	  TMEM79	  and	  transcript	  	  
variants	  The	  syntenic	  human	  ortholog	  TMEM79	  is	  located	  on	  chromosome	  1q23.1,	  with	  an	  identical	  exon-­‐intron	  organization	  to	  the	  murine	  Tmem79	  gene.	  According	  to	  the	  UCSC	  Genome	  Browser	  (Meyer	  et	  al.,	  2013),	  there	  are	  three	  possible	  transcript	  variants	  of	  TMEM79:	  two	  transcript	  variants	  of	  exon	  1;	  uc010phi.2,	  uc009wrw3,	  which	  will	  be	  referred	  to	  as	  transcript	  variant	  1a	  and	  1b	  respectively,	  and	  uc001fod.3,	  which	  will	  be	  referred	  to	  as	  transcript	  variant	  2	  for	  convenience	  (Figure	  3.	  2).	  Specific	  PCR	  primers	  were	  designed	  for	  TMEM79	  transcript	  variants	  to	  detect	  their	  presence	  in	  tissues.	  From	  cDNA	  extracted	  from	  human	  epidermis,	  
TMEM79	  transcript	  variant	  1b	  was	  found	  to	  be	  the	  major	  transcript	  variant	  with	  only	  a	  low	  level	  of	  transcript	  variant	  1a	  and	  no	  transcript	  variant	  2.	  In	  comparison,	  human	  primary	  keratinocytes	  in	  a	  monolayer	  culture	  expressed	  both	  transcript	  variant	  1a	  and	  1b	  in	  equal	  amounts.	  cDNA	  from	  HaCaT	  cells,	  an	  immortalized	  human	  keratinocyte	  cell	  line,	  produced	  no	  detectable	  band	  for	  transcript	  variant	  1a,	  and	  very	  little	  product	  for	  transcript	  variant	  1b	  (contrast	  was	  turned	  up	  to	  show	  presence	  of	  a	  very	  faint	  band),	  and	  no	  transcript	  variant	  2	  was	  seen.	  Although	  a	  683	  bp	  band	  is	  visible	  in	  the	  PCR	  analysis	  for	  transcript	  variant	  2,	  had	  it	  been	  present,	  we	  would	  have	  seen	  a	  smaller	  band	  of	  425	  bp	  (Figure	  3.	  3a).	  In	  this	  analysis,	  transcript	  variant	  2	  was	  undetectable	  in	  all	  samples.	  	  Immunofluorescence	  staining	  of	  HaCaT	  and	  human	  primary	  keratinocytes	  (HPKs)	  with	  anti-­‐TMEM79	  rabbit	  polyclonal	  antibody	  show	  no	  visible	  expression	  of	  endogenous	  TMEM79,	  suggesting	  that	  even	  though	  the	  message	  is	  present,	  no	  TMEM79	  protein	  is	  being	  expressed	  (Figure	  3.	  3b,	  c).	  Controls	  are	  shown	  in	  Figure	  3.	  3d	  and	  e,	  where	  HaCaT	  cells	  and	  HPKs	  were	  transfected	  with	  0.2	  μg	  
	  	  
89	  TMEM79/pEGFPC1	  and	  co-­‐immunofluorescence	  with	  anti-­‐TMEM79	  antibody	  shows	  co-­‐localization	  with	  EGFP	  signal.	  The	  existence	  of	  transcript	  variant	  1a	  and	  1b	  in	  human	  epidermis	  was	  supported	  by	  quantitative	  RT-­‐PCR	  of	  a	  human	  multiple	  tissue	  array	  using	  a	  predesigned	  ABI	  TaqMan®	  probe	  for	  human	  TMEM79	  (Figure	  3.	  4),	  which	  showed	  high	  expression	  of	  TMEM79	  in	  stratified	  epithelial	  tissues;	  cervix,	  skin	  and	  tongue.	  The	  highest	  expression	  of	  TMEM79	  was	  found	  in	  prostate	  tissue.	  The	  probe	  used	  for	  TMEM79	  spans	  across	  exons	  3	  and	  4,	  and	  would	  amplify	  all	  proposed	  transcript	  variants	  of	  




Figure	  3.	  2	  Genomic	  location	  of	  human	  TMEM79	  with	  predicted	  transcript	  
variants.	  Location	  of	  human	  ortholog	  of	  TMEM79	  on	  chromosome	  1q23.1,	  showing	  the	  location	  of	  TMEM79	  in	  relation	  to	  the	  other	  EDC	  genes	  (Trichohyalin,	  
TCHH;	  Repetin,	  RPTN;	  Hornerin,	  HRNR;	  Filaggrin,	  FLG;	  Filaggrin2,	  FLG2;	  Cornulin,	  




Figure	  3.	  3	  Semi-­‐quantification	  of	  TMEM79	  transcript	  levels	  in	  various	  cells	  
lines	  with	  no	  detectable	  endogenous	  TMEM79.	  Semi-­‐quantitative	  RT-­‐PCR	  of	  
TMEM79	  cDNA	  from	  human	  epidermis,	  human	  primary	  keratinocytes	  (HPKs)	  and	  HaCaT	  cells	  show	  high	  quantities	  of	  TMEM79	  transcript	  variant	  1b	  in	  epidermis	  and	  HPKs.	  No	  transcript	  variant	  2	  was	  detected	  (425	  bp).	  Keratin	  14	  was	  used	  as	  a	  positive	  control	  (a).	  Immunofluorescent	  analysis	  of	  endogenous	  TMEM79	  show	  no	  detectable	  expression	  in	  HaCaT	  cells	  (b)	  or	  in	  HPKs	  (c)	  with	  anti-­‐TMEM79	  rabbit	  polyclonal	  antibody.	  HaCaT	  cells	  transfected	  with	  TMEM79/pEGFPC1	  and	  stained	  with	  anti-­‐TMEM79	  (red)	  co-­‐fluorescing	  with	  EGFP	  (green)	  (d	  and	  e).	  Scale	  bar	  =	  10	  μm
Figure	  3.	  4	  Multiple	  tissue	  expression	  analysis	  of	  total	  TMEM79.	  PCR	  quantification	  of	  human	  multiple	  tissue	  array	  with	  probe	  against	  total	  TMEM79	  (exon	  3-­‐4),	  showing	  highest	  expression	  in	  stratified	  tissues:	  prostate,	  skin,	  cervix	  and	  tongue.	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3.3.2. TMEM79	  cDNA	  sequence	  similarity	  searches	  In	  order	  to	  investigate	  if	  TMEM79	  was	  present	  in	  other	  species	  apart	  from	  human	  and	  mice,	  a	  sequence	  similarity	  search	  was	  performed	  using	  the	  human	  cDNA	  
TMEM79	  sequence	  (uc010phi.2,	  transcript	  variant	  1a)	  from	  the	  Uniprotkb	  database	  using	  BLASTX	  version	  2.0MP-­‐WashU	  (Gish	  and	  States,	  1993).	  The	  results	  returned	  showed	  that	  the	  highest	  identities	  were	  found	  in	  the	  apes,	  chimpanzees,	  gibbons	  and	  gorillas,	  with	  close	  to	  90%	  identity	  similarity	  and	  this	  included	  other	  mammals	  such	  as	  bats,	  horses,	  cows,	  dogs	  and	  cats	  (labeled	  as	  “sequence	  match”	  in	  Figure	  3.	  6).	  The	  search	  also	  identified	  transcripts	  with	  high	  similarity	  to	  TMEM79	  in	  zebra	  fish,	  turtles	  and	  chicken;	  these	  transcripts	  were	  ranked	  according	  to	  identity	  match,	  with	  red	  being	  the	  most	  similar	  and	  blue	  the	  least	  (Figure	  3.	  6).	  However,	  as	  the	  cDNA	  sequences	  were	  not	  well	  characterized	  in	  most	  other	  species,	  apart	  from	  human	  and	  mouse,	  most	  sequences	  from	  5’	  and	  3’	  untranslated	  regions	  were	  unavailable.	  A	  search	  for	  protein	  sequence	  similarity	  was	  also	  carried	  out	  (labeled	  as	  subject	  match	  in	  Figure	  3.	  6),	  showing	  high	  identity	  matches	  for	  all	  amino	  acids	  of	  the	  human	  TMEM79	  protein.	  	  	  
	  
Figure	  3.	  6	  cDNA	  sequence	  alignment	  search	  across	  species	  using	  WU-­‐BLAST.	  Colour	  spectrum	  indicates	  sequence	  similarity	  to	  human	  




3.3.3. TMEM79	  protein	  structure	  prediction	  Bioinformatics	  analysis	  predicts	  that	  the	  TMEM79	  protein	  consists	  of	  a	  long	  N-­‐terminal	  domain,	  5	  transmembrane	  domains	  and	  a	  short	  C-­‐terminus	  (Figure	  3.	  7),	  and	  this	  arrangement	  is	  hypothesized	  for	  both	  transcript	  variants	  of	  exon	  1,	  since	  both	  share	  identical	  translational	  sequences	  (Figure	  3.	  2).	  Protein	  analysis	  was	  carried	  out	  by	  Dr.	  George	  Schneider	  (Bioinformatics	  Institute,	  A*STAR,	  Singapore;	  Appendix	  VII)	  and	  shows	  that	  TMEM79	  shares	  domain	  homology	  with	  members	  of	  the	  MAPEG	  (Membrane	  Associated	  Proteins	  in	  Eicosanoid	  and	  Glutathione	  metabolism)	  superfamily.	  An	  alignment	  with	  other	  members	  of	  the	  MAPEG	  family	  suggest	  that	  the	  N-­‐terminal	  domain	  is	  located	  on	  the	  inside	  of	  a	  membrane,	  and	  the	  C-­‐terminus	  on	  the	  outside	  (Figure	  3.	  7).	  Although	  TMEM79	  is	  predicted	  to	  have	  five	  transmembrane	  domains,	  MAPEG	  members	  only	  have	  four.	  The	  transmembrane	  helices	  contain	  proline	  residues,	  which	  are	  a	  feature	  of	  channel	  or	  transporter	  proteins,	  and	  TMEM79	  protein	  also	  contains	  key	  residues	  at	  amino	  acid	  positions	  66,	  70	  and	  126,	  which	  are	  predicted	  to	  be	  involved	  in	  glutathione	  binding.	  
	   	  
Figure	  3.	  7	  A	  cartoon	  of	  proposed	  secondary	  structure	  for	  TMEM79.	  Bioinformatics	  analysis	  predicts	  5	  transmembrane	  domains,	  with	  a	  long	  N-­‐terminal	  domain	  and	  a	  short	  external	  C-­‐terminal	  domain.	  Arrow	  shows	  the	  location	  of	  the	  matted	  mutation,	  p.Y280*,	  on	  the	  first	  internal	  loop.	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  Pairwise	  alignment	  between	  human	  and	  mouse	  TMEM79	  protein	  sequences	  show	  that	  they	  share	  83%	  identity	  (SIM,	  ExPaSy	  Bioinformatics	  Resource	  Portal;	  Figure	  3.	  8).	  Murine	  TMEM79	  protein	  has	  3	  amino	  acids	  less	  than	  human	  TMEM79	  protein,	  and	  this	  distinction	  is	  located	  within	  the	  N-­‐terminal	  region.	  Due	  to	  the	  close	  homology	  of	  both	  proteins,	  it	  can	  be	  assumed	  that	  both	  proteins	  would	  have	  very	  similar	  functions	  in	  their	  respective	  hosts.	  
	  
Figure	  3.	  8	  Pairwise	  alignment	  between	  human	  and	  murine	  TMEM79	  protein	  
sequences.	  ‘	  *	  ’	  indicates	  identical	  residues.	  With	  83%	  identity	  match,	  this	  suggests	  that	  both	  human	  and	  murine	  TMEM79	  proteins	  would	  have	  similar	  functions.	  	  	  Using	  the	  human	  TMEM79	  protein	  sequence,	  a	  multiple	  sequence	  alignment	  with	  TMEM79	  sequences	  from	  naked	  mole	  rat,	  chicken	  and	  zebrafish	  was	  carried	  out	  using	  the	  Clustal	  Omega	  program	  from	  The	  European	  Bioinformatics	  Institute	  (EBI)	  (Goujon	  et	  al.,	  2010;	  Sievers	  et	  al.,	  2011).	  The	  N-­‐terminal	  region	  of	  the	  protein	  is	  poorly	  conserved,	  but	  there	  are	  a	  high	  number	  of	  conserved	  residues	  seen	  within	  the	  predicted	  transmembrane	  domains	  (numbered	  red	  boxes).	  Of	  
	  	  
98	  particular	  interest,	  are	  the	  residues	  in	  between	  the	  transmembrane	  regions	  and	  at	  the	  C	  terminus	  (underlined	  in	  green),	  suggesting	  that	  these	  evolutionarily-­‐preserved	  regions	  probably	  contribute	  to	  functional	  importance	  (Figure	  3.	  9),	  as	  they	  are	  all	  in	  locations	  appropriate	  for	  protein-­‐protein	  interaction.	  
	  
Figure	  3.	  9	  Protein	  sequence	  alignment	  of	  TMEM79	  in	  humans,	  naked	  mole	  
rat,	  chicken	  and	  zebrafish.	  Numbered	  red	  boxes	  indicate	  transmembrane	  domains,	  and	  show	  remarkable	  identity	  match	  across	  species.	  Residues	  at	  the	  transmembrane	  domain	  and	  C-­‐terminal	  region	  showing	  conservation	  across	  species.	  	  ‘	  *	  ‘	  indicates	  identical	  residues,	  ‘	  :	  ‘	  and	  ‘	  .	  ‘	  indicates	  partial	  matches,	  and	  green	  underlined	  residues	  show	  remarkably	  high	  conservation	  at	  the	  C-­‐terminus	  end	  of	  TMEM79.
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3.3.4. Localization	  of	  human	  TMEM79	  tissue	  expression	  Immunofluorescence	  microscopy	  showed	  that	  the	  human	  ortholog	  of	  TMEM79	  was	  expressed	  in	  the	  upper	  granular	  layer	  of	  the	  epidermis	  (Figure	  3.	  10),	  with	  strong	  staining	  in	  the	  hair	  follicle	  (Figure	  3.	  10a),	  similar	  to	  the	  staining	  seen	  in	  mouse	  epidermis.	  The	  stronger	  staining	  seen	  in	  human	  skin	  compared	  to	  mouse	  skin	  could	  be	  attributed	  to	  the	  general	  thickness	  of	  the	  epidermis,	  compared	  to	  murine	  neonatal	  skin.	  Another	  reason	  could	  be	  antibody	  affinity,	  as	  the	  antibody	  used	  was	  raised	  against	  a	  human	  TMEM79	  sequence.	  Brightfield	  illumination	  in	  combination	  with	  immunofluorescence	  shows	  that	  the	  presence	  of	  TMEM79	  can	  clearly	  be	  seen	  in	  the	  layer	  beneath	  the	  stratum	  corneum	  (seen	  in	  red,	  Figure	  3.	  10c,	  d).	  An	  antibody	  to	  keratin	  10	  was	  used	  as	  a	  marker	  for	  the	  suprabasal	  layers	  (Figure	  3.	  11a),	  and	  although	  the	  antibody	  showed	  some	  non-­‐specific	  reactivity	  to	  the	  SC,	  there	  is	  clear	  cytoplasmic	  staining	  within	  the	  granular	  layers,	  and	  keratin	  10	  shows	  partial	  co-­‐localization	  with	  TMEM79	  within	  the	  upper	  layers.	  The	  basal	  cell	  layer	  was	  stained	  with	  a	  keratin	  14	  antibody	  (Figure	  3.	  11b).	  Co-­‐immunofluorescence	  with	  desmosomal	  junctional	  markers	  desmoglein	  1	  (DSG1;	  Figure	  3.	  11c)	  and	  desmoplakin	  1/2	  (DSP1/2;	  Figure	  3.	  11d)	  show	  that	  TMEM79	  expression	  in	  the	  upper	  granular	  layers	  shares	  a	  similar	  junctional	  staining	  pattern.	  Corneodesmosin	  (CDSN)	  showed	  a	  cytoplasmic	  staining	  pattern	  in	  the	  upper	  granular	  layers,	  before	  migrating	  to	  the	  corneodesmosome	  junctions	  between	  corneocytes	  (Figure	  3.	  12a).	  Kallikrein	  8	  (KLK8)	  is	  expressed	  at	  the	  topmost	  granular	  layers	  (Figure	  3.	  12b)	  and	  both	  LG-­‐secreted	  proteins	  show	  localization	  to	  the	  same	  upper	  granular	  layers	  as	  TMEM79.	  Stratum	  corneum	  markers	  such	  as	  filaggrin	  (FLG),	  involucrin	  (INV)	  and	  loricrin	  (LOR)	  show	  no	  colocalization	  with	  TMEM79	  (Figure	  3.	  12c	  -­‐	  e).	  This	  confirms	  that	  TMEM79	  is	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  located	  at	  the	  interface	  between	  the	  SG	  and	  SC	  as	  keratinocytes	  enter	  terminal	  differentiation	  from	  the	  granular	  to	  cornified	  layers.	  	  
	  
Figure	  3.	  10	  Immunofluorescent	  analysis	  of	  TMEM79	  expression	  pattern	  in	  




Figure	  3.	  11	  Co-­‐immunofluorescent	  analysis	  of	  TMEM79	  in	  human	  abdominal	  




Figure	  3.	  12	  Co-­‐immunofluorescent	  analysis	  of	  TMEM79	  in	  human	  abdominal	  
skin	  sections	  with	  terminal	  differentiation	  markers.	  Lamellar	  granule	  secreted	  proteins	  corneodesmosin	  (CDSN)	  and	  kallikrein	  8	  (KLK8)	  show	  localization	  to	  the	  same	  layers	  as	  TMEM79	  (a,	  b).	  No	  co-­‐localization	  was	  seen	  with	  stratum	  corneum	  markers;	  filaggrin	  (FLG)	  (c),	  involucrin	  (INV)	  (d)	  and	  loricrin	  (LOR)	  (e).	  Nuclei	  were	  stained	  with	  DAPI	  (blue).	  Scale	  bar	  =	  50	  μm	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3.3.5. Hair	  follicle	  expression	  As	  immunofluorescence	  of	  epidermis	  shows	  strong	  expression	  of	  TMEM79	  within	  the	  HF,	  further	  investigation	  of	  the	  human	  hair	  follicle	  using	  immunofluorescence	  confirmed	  that	  TMEM79	  is	  located	  in	  the	  inner	  root	  sheath	  in	  both	  longitudinal	  (Figure	  3.	  13a,	  c)	  and	  cross-­‐sections	  of	  hair	  follicles	  (Figure	  3.	  13b),	  in	  contrast	  to	  K17,	  a	  marker	  for	  the	  outer	  root	  sheath	  (ORS)	  of	  the	  hair	  follicle	  (Figure	  3.	  13;	  red).	  	  TMEM79	  appears	  to	  have	  a	  junctional,	  possibly	  punctate	  staining	  pattern	  upon	  examination	  at	  a	  higher	  magnification	  (Figure	  3.	  13d,	  e).	  Specific	  markers	  for	  the	  inner	  root	  sheath	  revealed	  that	  TMEM79	  co-­‐localized	  with	  keratin	  74,	  which	  is	  specific	  for	  the	  Huxley	  layer	  (Figure	  3.14,	  Panel	  B).	  This	  staining	  did	  not	  extend	  to	  the	  keratin	  32	  expression	  which	  is	  specific	  for	  the	  inner	  hair	  cuticle	  layer	  (Figure	  3.14;	  Panel	  A),	  or	  to	  the	  keratin	  75-­‐specific	  outer	  companion	  layer	  (Figure	  3.14;	  Panel	  C).	  It	  is	  possible	  that	  the	  Henley	  layer	  might	  stain	  positive,	  but	  there	  isn’t	  a	  specific	  antibody	  available	  for	  that	  layer.
	  





Figure	  3.	  14	  Immunofluorescent	  analysis	  of	  TMEM79	  in	  human	  hair	  follicle	  
sections	  with	  inner	  root	  sheath	  markers.	  Co-­‐localization	  of	  TMEM79	  is	  seen	  with	  the	  Huxley	  layer	  (keratin	  74;	  Panel	  B).	  TMEM79	  staining	  doesn’t	  extend	  beyond	  the	  Huxley	  layer,	  and	  show	  no	  co-­‐localization	  with	  the	  outer	  companion	  layer	  (keratin	  75;	  Panel	  C)	  or	  the	  inner	  hair	  cuticle	  (keratin	  32;	  Panel	  A).	  Leftmost	  column	  shows	  merged	  images	  for	  each	  immunofluorescent	  staining.	  Nuclei	  were	  stained	  with	  DAPI	  (blue).	  Scale	  bar	  =	  50	  μm
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Figure	  3.	  16	  Double	  immuno-­‐gold	  TMEM79	  labeling	  of	  human	  abdominal	  




Figure	  3.	  17	  Double	  immuno-­‐gold	  TMEM79	  labeling	  of	  human	  abdominal	  
epidermis	  with	  KLK8.	  TMEM79	  (10	  nm	  gold	  particles;	  arrows)	  and	  KLK8	  (15	  nm	  gold	  particles;	  arrowheads)	  shows	  no	  association	  of	  TMEM79	  with	  KLK8.	  SC1,	  stratum	  corneum;	  SG1,	  stratum	  granulosum.	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3.3.7. Detection	  of	  TMEM79	  from	  human	  skin	  and	  HaCaT	  cells	  To	  ensure	  that	  transfections	  with	  TMEM79	  constructs	  were	  performed	  correctly,	  extractions	  of	  total	  protein	  from	  normal	  human	  abdominal	  skin	  (ID9179)	  and	  HaCaT	  cells	  were	  analyzed	  for	  the	  presence	  of	  TMEM79	  protein.	  The	  resulting	  total	  protein	  extract	  from	  human	  skin	  was	  very	  viscous;	  therefore	  two	  different	  dilutions	  for	  human	  skin	  extracts	  were	  loaded.	  A	  diffuse	  band	  was	  seen	  at	  approximately	  the	  predicted	  size	  of	  ~39	  kDA	  for	  protein	  extracts	  from	  human	  skin,	  but	  not	  in	  HaCaT	  cells.	  TMEM79	  might	  undergo	  post-­‐translational	  modification,	  which	  may	  alter	  its	  size	  and	  explain	  the	  other	  non-­‐specific	  bands.	  The	  undetectable	  levels	  of	  TMEM79	  in	  HaCaT	  cells	  were	  expected	  as	  very	  low	  levels	  of	  TMEM79	  message	  were	  previously	  detected	  by	  semi-­‐quantitative	  RT-­‐PCR	  (Figure	  3.	  3a,	  page	  91).	  The	  bands	  seen	  for	  HaCaT	  cell	  total	  protein	  extracts	  could	  be	  due	  to	  antibody	  non-­‐specific	  binding	  or	  unknown	  isoforms	  of	  TMEM79.	  
	  
Figure	  3.	  18	  Western	  blot	  analysis	  of	  TMEM79	  in	  human	  skin	  and	  HaCaT	  
cells.	  Total	  protein	  extracts	  were	  analyzed	  by	  SDS-­‐PAGE	  and	  a	  band	  was	  detected	  at	  the	  predicted	  size	  of	  ~39	  kDa	  using	  an	  anti-­‐TMEM79	  rabbit	  polyclonal	  antibody.	  An	  antibody	  to	  keratin	  14	  was	  used	  as	  a	  control.	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3.3.8. Transient	  overexpression	  of	  TMEM79	  constructs	  in	  HaCaT	  cells	  
3.3.8.1. Myc-­‐TMEM79	  overexpression	  In	  an	  attempt	  to	  establish	  an	  expression	  system,	  HaCaT	  cells	  were	  transfected	  with	  a	  commercial	  construct,	  myc-­‐TMEM79,	  and	  incubated	  for	  24	  hours,	  following	  which	  cells	  were	  fixed	  and	  analyzed	  by	  immunofluorescence	  using	  an	  anti-­‐myc	  mouse	  monoclonal	  antibody.	  Two	  different	  localization	  patterns	  were	  observed	  (Figure	  3.	  20).	  At	  the	  lowest	  transfection	  concentration	  of	  0.5	  μg	  plasmid	  DNA	  per	  well	  of	  a	  6-­‐well	  dish,	  small	  aggregates	  could	  be	  seen	  in	  a	  vesicle-­‐like	  pattern,	  as	  well	  as	  a	  network-­‐pattern	  of	  expression.	  At	  concentrations	  above	  0.5	  μg	  per	  well,	  these	  small	  aggregates	  could	  no	  longer	  be	  seen,	  and	  transfected	  cells	  show	  a	  general	  distribution	  network	  of	  protein,	  in	  a	  punctate	  manner	  throughout	  the	  cell.	  	  Cells	  were	  also	  transfected	  and	  incubated	  for	  48	  and	  96	  hours	  prior	  to	  fixing	  and	  staining.	  Both	  incubation	  periods	  showed	  no	  distinctive	  expression	  of	  TMEM79	  (Figure	  3.	  21),	  suggesting	  that	  either	  the	  exogenous	  protein	  had	  been	  degraded,	  or	  that	  over-­‐expression	  of	  myc-­‐TMEM79	  was	  lethal	  to	  transfected	  cells	  over	  that	  time	  period.	  There	  was	  no	  expression	  seen	  in	  untransfected	  controls	  for	  24,	  48	  and	  96	  hours	  stained	  with	  anti-­‐myc	  mouse	  monoclonal	  antibody	  (Figure	  3.	  19).	  	  
	  




Figure	  3.	  20	  Immunofluorescent	  analysis	  of	  HaCaT	  cells	  transfected	  with	  




Figure	  3.	  21	  Immunofluorescent	  analysis	  of	  HaCaT	  cells	  transfected	  with	  
myc-­‐TMEM79	  and	  incubated	  for	  48	  and	  96	  hours.	  Cells	  were	  fixed	  and	  stained	  with	  an	  anti-­‐myc	  mouse	  monoclonal	  antibody	  (green),	  showing	  no	  expression	  of	  myc-­‐TMEM79.	  Nuclei	  were	  stained	  with	  DAPI	  (blue).	  Scale	  bar	  =	  10	  μm	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  Previously,	  transmission	  electron	  microscopy	  showed	  that	  TMEM79	  protein	  was	  seen	  on	  the	  membranes	  of	  LG	  in	  terminally	  differentiating	  keratinocytes	  (Figure	  3.	  15).	  Markers	  for	  intracellular	  transport	  from	  the	  endoplasmic	  reticulum	  (ER)	  to	  Golgi	  (β-­‐COPI),	  Golgi	  to	  ER	  (COPII)	  and	  the	  trans-­‐Golgi	  network	  (TGN46)	  were	  used	  in	  immunofluorescent	  analysis,	  but	  no	  co-­‐localization	  with	  TMEM79	  was	  seen	  (Figure	  3.	  22).	  Since	  the	  transfection	  efficacy	  using	  the	  myc-­‐TMEM79	  commercially	  available	  plasmid	  only	  yielded	  a	  detectable	  expression	  in	  <10%	  of	  cells,	  further	  investigation	  with	  an	  alternatively	  tagged	  TMEM79	  was	  designed	  for	  subsequent	  experiments.	  	  
	  
Figure	  3.	  22	  Co-­‐immunofluorescent	  analysis	  of	  transfected	  HaCaT	  cells	  with	  
markers	  for	  vesicle	  transport.	  HaCaT	  cells	  were	  transfected	  with	  0.5	  μg	  of	  myc-­‐TMEM79	  and	  incubated	  for	  24	  hrs.	  No	  co-­‐localization	  was	  seen	  with	  markers	  for	  vesicle	  transport	  from	  endoplasmic	  reticulum	  (ER;	  β-­‐COPI)	  to	  Golgi,	  Golgi	  to	  ER	  (COPII)	  and	  the	  trans-­‐Golgi	  network	  (TGN46).	  Leftmost	  column	  shows	  merged	  images	  for	  each	  co-­‐immunofluorescent	  staining.	  Nuclei	  were	  stained	  with	  DAPI	  (blue).	  Scale	  bar	  =	  10	  μm	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3.3.8.2. TMEM79/pEGFP	  overexpression	  TMEM79	  tagged	  with	  EGFP	  (using	  the	  vectors	  pEGFPC1	  or	  pEGFPN1)	  gave	  a	  higher	  detectable	  rate	  of	  transfection	  (~60%)	  than	  the	  previously	  used	  myc-­‐TMEM79	  construct.	  In	  Figure	  3.	  24,	  HaCaT	  cells	  were	  transfected	  TMEM79/pEGFPC1	  or	  TMEM79/pEGFPN1	  and	  incubated	  for	  24	  hours,	  before	  fixing.	  Autofluorescence	  of	  EGFP	  expression	  was	  analyzed	  by	  fluorescence	  microscopy.	  TMEM79/pEGFPC1	  produced	  small,	  vesicle-­‐like	  structures	  at	  the	  lowest	  transfection	  concentration	  of	  0.2	  μg	  per	  well	  (in	  a	  6	  well	  dish),	  and	  the	  size	  of	  these	  structures	  increased	  when	  higher	  amounts	  of	  TMEM79/pEFGPC1	  were	  transfected	  (Figure	  3.	  24;	  left	  panel).	  In	  contrast,	  transfection	  with	  TMEM79/pEGFPN1	  gave	  a	  similar	  expression	  pattern	  as	  myc-­‐TMEM79	  transfected	  cells,	  showing	  a	  sprawling	  network	  with	  the	  occasional	  aggregate	  of	  protein	  (Figure	  3.	  24;	  right	  panel).	  Controls	  for	  0.2	  μg	  pEGFPC1	  and	  pEGFPN1	  vector	  plasmids	  and	  untransfected	  HaCaT	  cells	  were	  fixed	  and	  analysed	  by	  immunofluorescence	  microscopy,	  showing	  no	  specific	  EGFP	  expression	  in	  Figure	  3.	  23.	  Total	  protein	  extracted	  from	  transfected	  cells	  was	  immunoblotted	  with	  anti-­‐EGFP	  and	  anti-­‐TMEM79	  antibodies	  and	  gave	  a	  band	  of	  the	  expected	  size	  of	  ~64	  kDa,	  confirming	  that	  the	  TMEM79-­‐EGFP	  fusion	  constructs	  were	  indeed	  being	  expressed	  (Figure	  3.	  25).	  Control	  transfections	  using	  only	  the	  EGFP	  vector	  plasmid	  showed	  that	  each	  EGFP-­‐expressed	  protein	  ran	  at	  a	  slightly	  different	  size;	  a	  band	  was	  detected	  at	  ~30	  kDa	  in	  cells	  transfected	  with	  pEGFPC1	  vector	  and	  a	  band	  of	  ~27	  kDa	  from	  cells	  transfected	  with	  pEGFPN1	  vector.	  This	  size	  difference	  is	  attributed	  to	  the	  size	  of	  the	  cloning	  nest	  sequence	  between	  the	  EGFP	  and	  TMEM79	  sequence.	  	  
	  	  




Figure	  3.	  23	  Autofluorescent	  analysis	  of	  HaCaT	  cells	  transfected	  with	  EGFP1	  




Figure	  3.	  24	  Autofluorescent	  analysis	  of	  HaCaT	  cells	  transfected	  with	  




Figure	  3.	  25	  Immunoblots	  of	  total	  protein	  extracts	  from	  transfected	  HaCaT	  




Figure	  3.	  26	  Co-­‐immunofluorescent	  analysis	  of	  HaCaT	  cells	  transfected	  with	  












Figure	  3.	  27	  Co-­‐immunofluorescent	  analysis	  of	  HaCaT	  cells	  transfected	  with	  
TMEM79/pEGFPN1	  together	  with	  markers	  for	  Golgi	  transport	  and	  
autophagy.	  Cells	  transfected	  with	  0.2	  μg	  TMEM79/pEGFPC1	  were	  incubated	  for	  24	  hrs.	  	  Leftmost	  column	  show	  merged	  images	  for	  each	  co-­‐immunofluorescent	  staining.	  No	  co-­‐localization	  was	  observed	  with	  TMEM79.	  Nuclei	  were	  stained	  with	  DAPI	  (blue).	  Scale	  bar	  =	  10μm	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3.3.8.3. Transmission	  electron	  microscopy	  of	  TMEM79/pEGFPC1	  




Figure	  3.	  28	  Transmission	  electron	  microscopy	  of	  HaCaT	  cells	  transfected	  
with	  TMEM79/pEGFPC1.	  Cells	  were	  incubated	  for	  24	  hours	  and	  a	  large	  number	  of	  autophagosomes	  were	  seen	  in	  transfected	  cells.	  The	  regions	  indicated	  by	  black	  arrowheads	  (a,	  c	  and	  e)	  are	  magnified	  in	  the	  right	  panel	  (b,	  d	  and	  f);	  young	  autophagosomes	  (b	  and	  d;	  black	  arrows)	  are	  easily	  distinguished	  from	  mature	  autophagosomes	  (d	  and	  f;	  white	  arrows).	  Over-­‐expressed	  TMEM79	  constructs	  appear	  to	  be	  degraded	  via	  autophagocytosis.	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3.3.8.4. Site-­‐directed	  mutagenesis	  and	  overexpression	  of	  




Figure	  3.	  29	  Autofluorescent	  analysis	  of	  HaCaT	  cells	  transfected	  with	  




Figure	  3.	  30	  Co-­‐immunofluorescent	  analysis	  of	  HaCaT	  cells	  transfected	  with	  
p.Y283*/pEGFPC1	  and	  stained	  with	  markers	  for	  Golgi	  transport	  and	  
autophagy.	  Partial	  co-­‐localization	  was	  seen	  with	  LC3,	  a	  marker	  for	  autophagosomes.	  Nuclei	  were	  stained	  with	  DAPI	  (blue).	  Scale	  bar	  =	  10μm	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3.3.8.5. Co-­‐overexpression	  of	  TMEM79/pEGFPC1	  and	  p.Y283*/pEGFPC1	  0.2	  μg	  of	  TMEM79/pEGFPC1	  and	  0.2	  μg	  of	  p.Y283*/pEGFPC1	  were	  transfected	  together	  in	  the	  same	  well	  to	  test	  for	  a	  dominant	  negative	  effect.	  It	  was	  hypothesized	  that	  the	  presence	  of	  p.Y283*/pEGFPC1	  may	  antagonize	  the	  wildtype	  TMEM79	  protein,	  leading	  to	  an	  altered	  expression	  pattern.	  Cells	  transfected	  with	  both	  plasmids	  displayed	  a	  similar	  honeycomb-­‐like	  structure	  (Figure	  3.	  31)	  to	  cells	  transfected	  with	  only	  the	  mutant	  p.Y283*/pEGFPC1	  construct	  (Figure	  3.	  29;	  Pattern	  1).	  Based	  on	  the	  expression	  pattern	  seen	  below,	  it	  is	  not	  possible	  to	  determine	  whether	  the	  mutant	  p.Y283*/pEGFPC1	  has	  a	  dominant	  negative	  effect.	  	  	  
	  
Figure	  3.	  31	  Autofluorescent	  analysis	  of	  HaCaT	  cells	  co-­‐transfected	  with	  





3.3.9. Transient	  overexpression	  of	  TMEM79/pEGFP	  in	  human	  primary	  
keratinocytes	  (HPK)	  As	  the	  previous	  experiments	  were	  performed	  on	  an	  immortalized	  keratinocyte	  cell	  line	  (HaCaT	  cells),	  HPK	  were	  used	  next	  to	  see	  if	  there	  was	  any	  difference	  in	  expression.	  HPK	  transfected	  with	  TMEM79/pGEFPN1	  and	  incubated	  for	  24	  hours	  showed	  a	  network-­‐like	  staining	  pattern	  (Figure	  3.	  34)	  when	  transfected	  with	  0.2	  μg	  of	  plasmid	  per	  well	  (in	  a	  6	  well	  dish),	  similar	  to	  HaCaT	  cells	  transfected	  with	  full-­‐length	  TMEM79/pEGFPN1	  (Figure	  3.	  24;	  right	  column,	  page	  118),	  but	  this	  expression	  pattern	  gradually	  became	  fainter	  as	  the	  concentration	  of	  transfected	  plasmid	  per	  well	  increased	  and	  were	  replaced	  by	  large	  aggregates.	  Visually,	  a	  small	  percentage	  of	  cells	  were	  seen	  to	  have	  this	  network-­‐like	  staining,	  but	  the	  majority	  of	  the	  cells	  showed	  large	  protein	  aggregates,	  which	  varied	  from	  1	  –	  5	  μm	  in	  diameter	  and	  this	  phenotype	  was	  seen	  in	  HPK	  transfected	  with	  both	  TMEM79/pEGFPC1	  (Figure	  3.	  33)	  and	  TMEM79/pEGFPN1	  (Figure	  3.	  34),	  when	  increasing	  concentrations	  of	  protein	  constructs	  were	  transfected	  into	  HPKs.	  Controls	  transfected	  with	  pEGFPC1	  and	  pEGFPN1	  show	  no	  specific	  expression	  pattern	  of	  EGFP,	  and	  untransfected	  controls	  were	  completely	  negative	  for	  any	  EGFP	  expression	  (Figure	  3.	  32).	  	  
	  
Figure	  3.	  32	  Human	  primary	  keratinocytes	  transfected	  with	  pEGFPC1	  or	  




Figure	  3.	  33	  Autofluorescent	  analysis	  of	  human	  primary	  keratinocytes	  




Figure	  3.	  34	  Autofluorescent	  analysis	  of	  human	  primary	  keratinocytes	  
transfected	  with	  TMEM79/pEGFPN1.	  Cells	  were	  incubated	  for	  24	  hours	  (green).	  Nuclei	  were	  stained	  with	  DAPI	  (blue).	  Scale	  bar	  =	  10	  μm	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3.4. DISCUSSION	  The	  location	  of	  TMEM79	  within	  the	  EDC	  on	  human	  chromosome	  3	  suggests	  a	  high	  likelihood	  that	  this	  protein	  may	  be	  involved	  with	  epidermal	  differentiation	  and	  maturation.	  Immunofluorescence	  of	  human	  abdominal	  skin	  samples	  showed	  that	  TMEM79	  was	  expressed	  in	  the	  upper	  granular	  layers	  and	  partially	  co-­‐localized	  with	  the	  upper	  suprabasal	  marker	  keratin	  10,	  and	  desmosomal	  marker	  desmoplakin	  1/2.	  Known	  markers	  for	  lamellar	  granules	  (LG)	  such	  as	  corneodesmosin	  and	  kallikrein	  8	  were	  seen	  in	  the	  same	  upper	  granular	  layers	  as	  TMEM79.	  Further,	  immunofluorescent	  analysis	  of	  hair	  follicles	  localized	  TMEM79	  to	  the	  Huxley	  layer	  of	  the	  IRS,	  and	  TMEM79	  could	  also	  be	  associated	  with	  the	  LG	  structures	  of	  the	  IRS.	  Future	  experiments	  involving	  immune-­‐gold	  labeling	  TMEM79	  in	  hair	  follicle	  sections	  should	  be	  performed	  to	  confirm	  the	  subcellular	  location	  of	  TMEM79	  within	  the	  cells	  of	  the	  IRS.	  In	  human	  epithelia,	  expression	  studies	  of	  multiple	  tissues	  show	  that	  TMEM79	  transcript	  variant	  1b	  is	  seen	  to	  have	  the	  highest	  expression	  in	  stratified	  tissues	  such	  as	  prostrate,	  cervix,	  skin	  and	  tongue.	  This	  suggests	  a	  possibility	  that	  TMEM79	  transcript	  variant	  1b	  may	  be	  involved	  in	  the	  differentiation	  process	  that	  is	  unique	  to	  stratified	  tissues.	  	  Transmission	  electron	  microscopy	  shows	  evidence	  for	  possible	  involvement	  with	  terminal	  differentiation	  of	  the	  epidermis,	  where	  TMEM79	  is	  associated	  with	  the	  membranes	  of	  LG	  at	  the	  SG-­‐SC	  junction.	  These	  LG	  are	  seen	  as	  membrane-­‐bound	  vesicular	  or	  tubular	  structures	  within	  keratinocytes	  of	  the	  upper	  granular	  layer,	  located	  close	  to	  the	  plasma	  membrane	  and	  are	  thought	  to	  contain	  distinct	  different	  cargoes,	  including	  glucosylceramides,	  kallikrein-­‐related	  peptidases	  5,	  7	  and	  8,	  cathepsin	  D	  and	  corneodesmosin.	  Although	  the	  mechanisms	  for	  transport	  of	  various	  LG	  cargos	  are	  still	  unknown,	  it	  has	  been	  suggested	  that	  segregation	  of	  these	  contents	  would	  allow	  control	  in	  concentration	  and	  secretion	  of	  these	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  different	  cargoes	  (Dannies,	  2001).	  CDSN	  has	  been	  documented	  to	  be	  expressed	  slightly	  earlier	  than	  KLK8	  in	  keratinocytes	  undergoing	  terminal	  differentiation	  (Ishida-­‐Yamamoto	  et	  al.,	  2004),	  which	  agreed	  with	  the	  images	  of	  gold-­‐labeled	  ultra-­‐thin	  sections	  of	  human	  epidermis	  shown	  in	  this	  chapter,	  with	  KLK8	  being	  located	  in	  LGs	  further	  away	  from	  the	  apical	  face	  at	  the	  SG-­‐SC	  interface	  whilst	  CDSN	  was	  already	  located	  at	  the	  desmoglea	  of	  desmosomes.	  A	  potential	  function	  for	  TMEM79	  could	  be	  as	  a	  label	  for	  a	  specific	  type	  of	  LG,	  as	  both	  CDSN	  and	  KLK8	  have	  been	  shown	  to	  be	  located	  within	  LG	  that	  are	  not	  labeled	  with	  TMEM79.	  This	  form	  of	  labeling	  could	  enable	  LG	  cargoes	  to	  be	  sorted	  and	  released	  at	  different	  times	  during	  differentiation.	  	  Multiple	  difficulties	  were	  encountered	  while	  trying	  to	  detect	  endogenous	  TMEM79	  from	  human	  epidermis	  by	  Western	  blotting.	  This	  could	  be	  attributed	  to	  the	  complications	  of	  working	  with	  a	  5-­‐pass	  transmembrane	  protein,	  which	  makes	  it	  more	  difficult	  to	  extract	  compared	  to	  a	  cytosolic	  protein.	  Samples	  also	  could	  not	  be	  sonicated,	  as	  this	  caused	  membranous	  proteins	  to	  go	  into	  insoluble	  aggregates.	  Lowering	  the	  denaturation	  temperature	  to	  37°C	  and	  incubating	  for	  an	  hour	  gave	  the	  best	  results.	  The	  antibody	  used	  to	  detect	  TMEM79	  was	  the	  same	  one	  used	  for	  immunofluorescence	  and	  TEM,	  and	  it	  is	  possible	  that	  the	  antibody	  does	  not	  work	  as	  well	  for	  Western	  blotting,	  as	  for	  the	  other	  techniques.	  Epitope	  conformation	  could	  also	  be	  different	  on	  a	  blot,	  than	  in	  tissue,	  and	  this	  could	  affect	  antibody	  binding.	  	  	  	  Overexpression	  of	  TMEM79	  in	  cell	  monolayers	  showed	  different	  localization	  patterns,	  and	  this	  could	  have	  been	  due	  to	  the	  different	  tags	  used	  and	  whether	  they	  were	  N-­‐terminal	  or	  C-­‐terminal.	  The	  expression	  patterns	  for	  TMEM79/pEGFPN1	  and	  myc-­‐TMEM79	  are	  consistently	  similar	  and	  it	  could	  deduced	  that	  the	  localization	  of	  TMEM79	  is	  affected	  by	  the	  position	  of	  tags	  on	  the	  C-­‐terminus	  of	  the	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  TMEM79	  construct,	  by	  blocking	  any	  potential	  protein-­‐binding	  or	  recognition	  sites.	  At	  the	  48	  and	  96	  hour	  time	  points	  after	  transfection,	  no	  expression	  of	  TMEM79	  constructs	  were	  seen	  in	  HaCaT	  cells	  and	  further	  investigation	  at	  the	  24	  hour	  time	  point	  showed	  some	  indication	  that	  the	  overexpression	  of	  TMEM79	  constructs	  caused	  the	  aggregation	  of	  these	  proteins	  that	  may	  have	  resulted	  in	  degradation	  via	  autophagy.	  Another	  possibility	  might	  be	  that	  the	  cells	  that	  are	  transfected	  die	  if	  the	  protein	  degradation	  machinery	  of	  the	  cell	  becomes	  overloaded.	  	  Co-­‐immunofluorescence	  suggests	  that	  a	  fraction	  of	  the	  aggregates	  co-­‐localize	  with	  LC3	  and	  this	  partial	  co-­‐localization	  could	  be	  due	  to	  the	  different	  maturation	  stages	  of	  an	  autophagosome,	  as	  there	  might	  be	  obstruction	  of	  the	  LC3	  epitope	  after	  an	  autophagosome	  fuses	  with	  a	  lysosome	  to	  form	  an	  autophagolysosome.	  To	  confirm	  that	  the	  double	  membrane	  structures	  are	  indeed	  autophagosomes,	  immuno-­‐gold	  labeling	  of	  transfected	  cells	  with	  antibody	  against	  LC3	  should	  be	  carried	  out.	  Even	  though	  TMEM79	  message	  was	  seen	  in	  both	  HaCaT	  cells	  and	  HPKs,	  no	  endogenous	  TMEM79	  was	  seen	  in	  either	  cell	  line	  by	  immunofluorescence.	  Transiently	  transfected	  TMEM79	  protein	  aggregated	  in	  large	  clumps	  for	  both	  cell	  lines,	  indicating	  that	  TMEM79	  protein	  is	  not	  normally	  expressed	  within	  these	  cells,	  and	  overexpression	  is	  causing	  TMEM79	  protein	  aggregation	  leading	  to	  eventual	  degradation.	  This	  result	  correlates	  well	  with	  the	  expression	  of	  TMEM79	  in	  normal	  human	  skin.	  TMEM79	  is	  found	  only	  in	  the	  upper	  granular	  layers,	  where	  the	  process	  of	  terminal	  differentiation	  would	  have	  already	  been	  well	  initiated,	  and	  so	  would	  not	  be	  normally	  expressed	  in	  a	  cultured	  monolayer.	  For	  future	  dominant	  negative	  experiments,	  transfections	  with	  differently	  tagged	  mutant	  protein	  constructs	  and	  wildtype	  protein	  constructs	  should	  be	  used	  so	  that	  positively	  transfected	  cells	  with	  both	  plasmids	  can	  be	  identified	  by	  co-­‐immunofluorescent	  staining.	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4.1. AIMS	  OF	  CHAPTER	  The	  overt	  allergic	  phenotype	  of	  the	  Mattma/ma	  mouse	  suggests	  a	  role	  for	  TMEM79	  in	  skin	  barrier	  function.	  Naturally,	  the	  next	  step	  is	  to	  explore	  the	  landscape	  of	  TMEM79	  within	  various	  atopic	  human	  populations	  and	  to	  identify	  if	  there	  is	  any	  association	  with	  allergic	  disease.	  In	  the	  previous	  chapter,	  ultrastructural	  investigations	  into	  the	  TMEM79	  protein	  revealed	  that	  it	  is	  located	  within	  the	  membranes	  of	  lamellar	  granules,	  and	  could	  result	  in	  abnormal	  LG	  secretion/transport	  when	  normal	  function	  is	  disrupted	  during	  disease	  states.	  To	  date,	  several	  ichthyosiform	  disorders	  have	  been	  linked	  to	  abnormal	  lipid	  lamellar	  granule	  secretion,	  and	  these	  have	  been	  linked	  to	  transmembrane	  transporter	  proteins,	  such	  as	  ABCA12	  in	  Harlequin	  ichthyosis,	  VPS33B	  in	  ARC	  syndrome	  and	  lipoxygenases	  in	  NCIE.	  In	  this	  final	  chapter	  of	  results,	  several	  different	  human	  populations	  were	  screened	  to	  uncover	  SNPs	  within	  the	  novel	  TMEM79	  gene,	  and	  whether	  these	  may	  have	  any	  potential	  impact	  on	  protein	  function	  in	  contributing	  to	  atopic	  susceptibility.	  The	  aim	  of	  this	  chapter	  was	  to	  screen	  pre-­‐existing	  populations	  of	  patients	  who	  share	  clinical	  phenotype	  with	  the	  Mattma/ma	  mouse	  without	  any	  known	  mutations	  in	  other	  genes,	  and	  to	  investigate	  for	  TMEM79	  variant	  impact.	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4.2. MATERIALS	  AND	  METHODS	  
4.2.1. Patient	  cohorts	  for	  TMEM79	  sequencing	  Human	  genomic	  samples	  were	  obtained	  with	  informed	  written	  consent	  from	  patients,	  together	  with	  approval	  from	  the	  relevant	  local	  authorities	  that	  complied	  with	  the	  Declaration	  of	  Helsinki	  Principles.	  A	  total	  of	  9	  patients	  with	  Netherton	  Syndrome-­‐like	  symptoms	  such	  as	  ichthyosiform	  erythroderma	  and	  trichorrhexis	  invaginata	  (Figure	  4.	  1)	  were	  recruited	  and	  screened	  by	  Professor	  Eli	  Sprecher	  (The	  Tel	  Aviv	  Sourasky	  Medical	  Center,	  Israel)	  (Table	  4.	  1),	  but	  were	  found	  to	  be	  negative	  for	  any	  SPINK5	  mutations.	  Atopic	  dermatitis	  (AD)	  Irish	  patients	  were	  diagnosed	  and	  recruited	  under	  the	  supervision	  of	  Dr.	  Alan	  Irvine	  and	  Dr.	  Rosemarie	  Watson	  (Our	  Lady’s	  Children’s	  Hospital	  for	  Sick	  Children,	  Ireland)	  (Table	  4.	  2).	  	  A	  second	  group	  of	  Irish	  atopic	  dermatitis	  patients	  with	  IgE	  >	  10,000	  were	  recruited	  from	  Ireland	  by	  Dr	  Jonathan	  Hourihane	  (Our	  Lady’s	  Children’s	  Hospital	  for	  Sick	  Children,	  Crumlin,	  Ireland)	  and	  Dr	  Lesley	  Anne	  Murphy	  (University	  Galway	  Hospital,	  Ireland).	  Population	  controls	  were	  obtained	  from	  the	  Irish	  Blood	  Transfusion	  Service	  Biobank.	  	  A	  cohort	  of	  55	  patients	  with	  inflammatory	  eye	  disease	  that	  were	  diagnosed	  with	  blepharokeratoconjunctivitis	  (BKC;	  Table	  4.	  2)	  was	  recruited	  by	  Professor	  Johnny	  Moore	  (Cathedral	  Eye	  Clinic,	  Northern	  Ireland)	  and	  Dr.	  Tara	  Moore	  (University	  of	  Coleraine,	  Northern	  Ireland).	  All	  patients	  were	  diagnosed	  with	  an	  early	  onset	  of	  blepharitis	  (indicating	  genetic	  predisposition)	  and	  anterior	  and/or	  posterior	  conjunctival	  inflammation.	  	  90	  AD	  patients	  and	  82	  ethnically	  matched	  population	  controls	  from	  the	  Xhosa	  population	  from	  South	  Africa	  were	  diagnosed	  and	  recruited	  by	  Dr.	  Fatema	  Thawer-­‐Esmail	  (The	  University	  of	  Cape	  Town,	  South	  Africa)	  (Table	  4.	  2).	  
	  	  Table	  4.	  1	  Clinical	  and	  phenotypic	  details	  of	  the	  9	  cases	  with	  Netherton	  Syndrome-­‐like	  features.	  *	  Eczema	  severity	  score	  (1	  to	  3)	  from	  mild,	  moderate	  and	  severe	  –	  dermatologist	  diagnosed.	  **	  Total	  IgE	  serum	  levels	  measured	  from	  blood	  samples	  by	  recruiting	  clinician.
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Figure	  4.	  1	  Clinical	  pictures	  of	  patients	  with	  Netherton	  Syndrome-­‐like	  features.	  Patient	  4	  (a;	  forearm),	  7	  (b;	  trunk)	  and	  8	  (c)	  showing	  extensive	  and	  severe	  ichthyosiform	  erythroderma,	  with	  widespread	  fine	  scaling	  as	  well	  as	  trichorrhexis	  invaginata	  (c).	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Demographic	  and	  clinical	  features	   Paediatric	  Irish	  AD	  cases	   Paediatric	  Irish	  AD	  cases	  with	  IgE	  >	  10,000	  (kU/L)*	   South	  African	  AD	  cases	   Northern	  Irish	  BKC	  cases	  Total	  number	  (Females/Males)	   36	  (25/11)	   7	  (2/5)	   90	  (50/40)	   55	  (26/29)	  Mean	  age	  (age	  range)	  (years)	   9	  (1.6	  to	  15.8)	   6.8	  (3.05	  to	  9.8)	   14	  (5	  to	  49)	   53	  (14	  to	  80)	  Eczema	  severity	  score	  mean	  (range)	   13.48	  (6	  to	  15)**	   13.86	  (9	  to	  15)**	   10.5	  (3	  to	  15)**	   NA	  




4.2.2. Sanger	  sequencing	  of	  TMEM79	  
TMEM79	  was	  screened	  using	  primers	  and	  conditions	  described	  in	  Chapter	  2.2.2	  (page	  48)	  and	  Table	  3.1	  (page	  76).	  All	  exons	  and	  intron/exon	  boundaries	  were	  sequenced.	  Amplification	  primers	  used	  cover	  all	  3	  variants	  that	  were	  discussed	  in	  Chapter	  3.3.1	  (page	  88).	  	  
4.2.3. TaqMan®	  allelic	  discrimination	  assays	  All	  cases	  and	  population	  controls	  were	  screened	  using	  TaqMan®	  allelic	  discrimination	  genotyping	  assays	  (Life	  Technologies	  Corporation,	  Applied	  Biosystems,	  California,	  USA)	  with	  a	  predesigned	  assay	  for	  SNV	  rs6684514	  (catalog	  number	  C_25986870_10).	  For	  other	  SNVs	  that	  had	  no	  commercially	  available	  TaqMan®	  probes,	  custom	  design	  probes	  were	  made	  (Table	  4.	  3).	  10	  ng	  of	  template	  DNA	  was	  amplified	  in	  a	  10	  μL	  reaction	  with	  Perfecta®	  qPCR	  ToughMix	  ROX	  (Quanta,	  BioSciences	  Inc.,	  Maryland,	  USA).	  The	  cycle	  conditions	  used	  were:	  95°C	  for	  10	  mins;	  40	  cycles	  of	  92°C	  for	  15	  seconds	  and	  60°C	  for	  1	  min.	  PCR	  reactions	  were	  analyzed	  using	  a	  7900HT	  Fast	  Real-­‐Time	  PCR	  System	  and	  data	  analyzed	  with	  the	  7900HT	  Sequence	  Detection	  System	  version	  2.4	  software	  (Life	  Technologies,	  Applied	  Biosystems,	  CA,	  USA).	  
	  	  




4.2.4. Statistical	  analysis	  To	  test	  for	  the	  association	  of	  TMEM79	  SNVs	  with	  AD,	  logistics	  regression	  was	  used	  to	  calculate	  the	  odds	  ratios	  for	  each	  SNV,	  by	  comparing	  allelic	  frequencies	  between	  patient	  cohorts	  and	  population-­‐matched	  controls.	  Power	  calculations	  were	  performed	  to	  calculate	  whether	  sample	  sizes	  were	  sufficient.	  All	  analyses	  were	  performed	  using	  the	  Sigmaplot™	  v12.5	  statistical	  package	  (Systat	  Software	  Inc.,	  London,	  United	  Kingdom).	  




4.3.1. Netherton	  syndrome-­‐like	  patients	  The	  TMEM79	  gene	  was	  sequenced	  in	  9	  patients	  with	  phenotypes	  that	  were	  similar	  to	  Netherton	  Syndrome,	  but	  who	  were	  negative	  for	  any	  SPINK5	  mutations.	  These	  patients	  came	  from	  a	  variety	  of	  genetic	  backgrounds	  (Table	  4.	  1).	  	  5	  SNVs	  within	  TMEM79	  were	  identified	  (Table	  4.	  4),	  with	  only	  one	  coding	  for	  a	  protein	  change,	  rs6684514	  (V147M).	  	  The	  odds	  ratio	  for	  this	  SNV	  could	  not	  be	  calculated	  as	  the	  patients	  were	  all	  from	  different	  ancestries,	  and	  population-­‐matched	  controls	  could	  not	  be	  obtained.	  
Chromosome	  1	  Position	   156,255,456	   156255833	   156,256,000	   156,261,491	   156,261,955	  mRNA	  position	   610	   -­‐	   -­‐	   1458	   1922	  dbSNP	  Reference	  No.	   rs6684514	   rs2842883	   rs6679145	   rs3795728	   -­‐	  dbSNP	  MAF	  	   0.2115	   0.0183	   0.2143	   0.2280	   -­‐	  Wildtype	  Allele	   G	   G	   T	   G	   C	  	   V147M	   intron	   intron	   3’	  UTR	   3’	  UTR	  1	   WT	   HOM	  C	   WT	   WT	   WT	  2	   WT	   HOM	  C	   WT	   HET	  C	   WT	  3	   HET	  A	   HOM	  C	   HET	  C	   HET	  C	   WT	  4	   WT	   HOM	  C	   WT	   WT	   WT	  5	   HET	  A	   HOM	  C	   HET	  C	   HET	  C	   WT	  6	   WT	   HOM	  C	   WT	   HOM	  C	   HET	  T	  7	   WT	   HOM	  C	   WT	   HET	  C	   WT	  8	   WT	   HOM	  C	   WT	   HET	  C	   WT	  9	   HOM	  A	   HOM	  C	   HOM	  C	   WT	   WT	  
Table	  4.	  4	  TMEM79	  SNVs	  found	  in	  patients	  displaying	  Netherton	  Syndrome-­‐
like	  phenotype.	  Only	  1	  variant	  within	  the	  protein	  coding	  region,	  V147M	  (rs6684514).	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4.3.2. Irish	  AD	  population	  The	  TMEM79	  gene	  was	  fully	  sequenced	  in	  43	  Irish	  patients	  with	  AD	  including	  7	  with	  high	  levels	  of	  IgE	  (>	  10,000	  kU/L)	  where	  the	  4	  common	  filaggrin	  mutations	  had	  already	  been	  excluded.	  A	  total	  of	  8	  SNVs	  were	  identified	  (Table	  4.	  6),	  with	  only	  1	  SNV,	  rs6684514	  (V147M)	  causing	  a	  missense	  mutation	  (Figure	  4.	  2a,	  page	  150).	  	  In	  order	  to	  determine	  whether	  rs6684514	  associated	  with	  AD	  risk,	  case-­‐control	  analysis	  was	  carried	  out	  using	  724	  Irish	  AD	  patients	  and	  1905	  population-­‐matched	  controls.	  The	  allelic	  frequency	  (Table	  4.	  5)	  showed	  that	  the	  minor	  allele	  (A)	  frequency	  (MAF)	  was	  the	  same	  in	  Irish	  AD	  cases	  and	  population-­‐matched	  controls.	  Rs6684514	  has	  no	  association	  with	  AD	  (P	  =	  0.129;	  OR	  =	  1.027,	  95%	  CI	  =	  0.900	  –	  1.172),	  indicating	  no	  significant	  association	  of	  rs6684514	  with	  AD	  among	  the	  Irish	  population.	  The	  alpha	  value	  for	  the	  performed	  test	  was,	  1.00,	  indicating	  that	  the	  population	  size	  is	  sufficient	  for	  this	  study.	  	  
	  	   rs6684514	  (V147M)	   MAF	   Odds	  ratio	   P	  value	   95%	  CI	  	  	   Minor	  allele	  (A)	   Major	  allele	  (G)	  Irish	  AD	   437	   1017	   0.301	   1.027	   0.129	   0.900	  -­‐	  1.172	  Irish	  controls	   1127	   2693	   0.295	  
Table	  4.	  5	  Logistics	  regression	  analysis	  of	  SNV	  rs6684514	  in	  Irish	  AD.	  No	  significant	  association	  was	  seen	  with	  V147M	  (rs6684514)	  within	  the	  Irish	  population.	  




4.3.3. Blepharokeratoconjunctivitis	  (BKC)	  patients	  The	  TMEM79	  gene	  was	  sequenced	  in	  30	  Irish	  patients	  diagnosed	  with	  blepharokeratoconjunctivitis	  (BKC).	  The	  same	  spectrum	  of	  SNVs	  were	  found	  as	  in	  the	  Irish	  AD	  patients	  with	  rs66844514	  being	  the	  only	  SNV	  found	  in	  the	  coding	  region.	  The	  allelic	  frequencies	  of	  rs6684514,	  showed	  no	  association	  with	  BKC	  (P	  =	  0.0622;	  OR	  =	  1.086,	  95%	  CI	  =	  0.702	  –	  1.682),	  indicating	  that	  the	  minor	  allele	  (A)	  does	  not	  affect	  BKC	  in	  the	  Irish	  population	  (Table	  4.	  7).	  The	  alpha	  value,	  1.000,	  indicates	  power	  of	  the	  test	  is	  significant	  for	  this	  study.	  
	  	   rs6684514	  (V147M)	   MAF	   Odds	  ratio	   P	  value	   95%	  CI	  	  	   Minor	  allele	  (A)	   Major	  allele	  (G)	  Irish	  BKC	   30	   66	   0.313	   1.086	   0.0622	   0.702	  –	  1.682	  Irish	  controls	   1127	   2693	   0.295	  
Table	  4.	  7	  Logistics	  regression	  analysis	  of	  Irish	  blepharokeratoconjunctivitis	  
(BKC)	  patients.	  The	  minor	  allele	  (A)	  rs6684514	  showed	  no	  association	  with	  BKC	  within	  the	  Irish	  population.	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4.3.4. Xhosa	  AD	  population	  
90	  AD	  patients	  from	  the	  Xhosa	  population	  of	  South	  Africa	  had	  previously	  been	  screened	  as	  wildtype	  for	  all	  of	  the	  4	  common	  European	  filaggrin	  mutations.	  Included	  in	  this	  cohort	  were	  31	  patients	  in	  which	  the	  entire	  FLG	  gene	  had	  been	  sequenced	  but	  no	  loss-­‐of-­‐function	  mutations	  were	  identified.	  A	  pilot	  study	  of	  31	  Xhosa	  patients	  were	  fully	  screened	  for	  SNVs	  within	  the	  TMEM79	  gene,	  and	  a	  total	  of	  11	  SNVs	  (Table	  4.	  8)	  were	  identified	  with	  4	  occurring	  within	  the	  coding	  regions	  (Figure	  4.	  2).	  Case	  control	  analysis	  was	  carried	  out	  using	  90	  Xhosa	  AD	  patients	  and	  82	  Xhosa	  South	  African	  controls.	  	  
Using	  chi2	  analysis,	  rs112826258	  (R31Q)	  and	  rs75902624	  (S104T)	  were	  not	  associated	  with	  AD	  as	  the	  P	  values	  were	  above	  0.05	  (Table	  4.	  9).	  Rs6684514	  (V147M)	  is	  not	  associated	  with	  AD	  in	  the	  Xhosa	  population	  (P	  =	  0.0152;	  OR	  =	  0.921,	  95%	  CI	  =	  0.511	  –	  1.660).	  The	  raw	  data	  suggests	  that	  the	  minor	  allele	  (A)	  may	  play	  a	  protective	  role	  in	  the	  Xhosa	  AD	  patients	  (Table	  4.	  9)	  since	  it	  is	  more	  common	  in	  the	  controls	  than	  cases.	  The	  alpha	  power	  of	  the	  three	  performed	  tests	  above	  were	  between	  1.000	  showing	  that	  the	  sample	  population	  size	  is	  sufficient.	  	  
Novel	  SNV,	  M354L,	  was	  identified	  in	  two	  individuals	  from	  the	  Xhosa	  AD	  cohort	  and	  was	  not	  found	  in	  any	  of	  the	  South	  African	  controls.	  Unfortunately,	  chi2	  analysis	  could	  not	  be	  performed	  since	  the	  expected	  frequency	  is	  less	  than	  1,	  the	  95%	  CI	  and	  the	  power	  of	  the	  performed	  test	  was	  0.047	  (less	  than	  0.800),	  suggesting	  that	  the	  sample	  population	  should	  be	  increased	  in	  order	  to	  be	  able	  to	  detect	  a	  difference	  between	  cases	  and	  controls.
	  




Figure	  4.	  2	  Sequencing	  chromatograms	  showing	  SNVs	  within	  the	  coding	  











value	   95%	  CI	  rs112826258	  (R31Q)	  Xhosa	  AD	   24	   156	   0.133	   0.817	   0.61	   0.448	  -­‐	  1.488	  South	  african	  controls	   26	   138	   0.159	  rs75902624	  (S104T)	  Xhosa	  AD	   6	   174	   0.033	   1.851	   0.59	   0.455	  –	  7.522	  South	  african	  controls	   3	   161	   0.018	  rs6684514	  (V147M)	  Xhosa	  AD	   28	   152	   0.156	   0.658	   0.18	   0.379	  –	  1.141	  South	  african	  controls	   35	   125	   0.219	  M354L	  Xhosa	  AD	   2	   176	   0.011	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  South	  african	  controls	   0	   154	   0	  
Table	  4.	  9	  Logistic	  regression	  analysis	  of	  SNVs	  identified	  within	  the	  Xhosa	  
population.	  Case-­‐control	  analysis	  shows	  that	  rs112826258,	  rs75902624	  and	  rs6684514	  are	  not	  associated	  with	  AD	  within	  the	  Xhosa	  population.	  Chi2	  analysis	  could	  not	  be	  performed	  for	  novel	  SNP	  M354L.	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4.4. DISCUSSION	  All	  exons	  of	  the	  TMEM79	  gene	  were	  sequenced	  in	  several	  discovery	  cohorts	  to	  identify	  any	  pathogenic	  variants.	  Besides	  having	  an	  overall	  non-­‐specific	  skin	  inflammatory	  phenotype,	  the	  Mattma/ma	  mouse	  also	  suffers	  from	  ocular	  and	  lung	  inflammation.	  Patients	  suffering	  from	  Netherton	  syndrome-­‐like	  symptoms	  appear	  to	  most	  closely	  resemble	  the	  Mattma/ma	  phenotype	  with	  eczema,	  high	  IgE	  levels,	  ocular	  inflammation,	  inflammatory	  lung	  condition	  and	  abnormal	  hair	  defects.	  Consequently,	  we	  sequenced	  these	  patients	  first,	  but	  the	  only	  coding	  variant	  found	  within	  these	  patients	  was	  the	  SNV,	  rs6684514.	  There	  was	  no	  association	  between	  the	  allelic	  frequencies	  of	  the	  minor	  allele	  with	  the	  severity	  of	  the	  patients’	  phenotype.	  The	  position	  of	  rs6684514	  within	  the	  N-­‐terminal	  region	  of	  the	  TMEM79	  protein	  (Figure	  4.	  3)	  causes	  an	  amino	  acid	  substitution	  from	  valine	  to	  methione	  at	  position	  147,	  but	  continues	  to	  retain	  the	  non-­‐polar	  properties	  of	  the	  original	  amino	  acid.	  Rs6684514	  was	  reported	  as	  having	  a	  MAF	  of	  0.21	  in	  a	  Genome	  Wide	  Association	  Study	  (GWAS)	  and	  had	  an	  association	  with	  erythrocyte-­‐related	  traits	  in	  ~14,700	  Japanese	  individuals	  (P	  =	  3.39	  x	  10-­‐9)	  (Kamatani	  et	  al.,	  2010).	  It	  is	  possible	  that	  TMEM79	  may	  be	  affiliated	  with	  the	  lipid	  bilayer	  of	  the	  erythrocyte,	  which	  has	  been	  shown	  to	  be	  associated	  with	  multiple	  membrane	  proteins	  with	  a	  range	  of	  functions	  including,	  transport	  of	  molecules,	  adhesive	  properties	  and	  maintaining	  structural	  integrity.	  This	  SNV	  was	  also	  reported	  in	  the	  Exome	  Variant	  Server	  (EVS)	  (NHLBI	  GO	  Exome	  Sequencing	  Project	  (ESP),	  Seattle,	  WA	  (URL:	  http://evs.gs.washington.edu/EVS/)	  [July,	  2013])	  as	  having	  a	  MAF	  of	  0.23	  within	  a	  normal	  population	  made	  up	  of	  European	  American	  and	  African	  American	  samples,	  which	  was	  similar	  to	  the	  allele	  frequencies	  seen	  in	  our	  control	  cohorts.	  Rs6684514	  was	  also	  present	  in	  the	  1000	  Genomes	  Project	  ((URL:	  www.1000genomes.org)	  
	  	  
153	  [July,	  2013]),	  with	  a	  MAF	  of	  0.211.	  With	  this	  SNV	  being	  present	  in	  20%	  of	  the	  general	  population,	  it	  suggests	  that	  this	  SNV	  may	  not	  be	  pathogenic.	  	  Have	  excluded	  TMEM79	  as	  a	  candidate	  for	  Netherton	  syndrome-­‐like	  disease,	  we	  were	  naturally	  interested	  to	  find	  out	  if	  there	  was	  any	  association	  between	  variants	  in	  TMEM79	  with	  atopic	  dermatitis	  since	  the	  matted	  mouse	  is	  characterized	  by	  elevated	  levels	  of	  IgE	  and	  a	  spontaneous	  dermatitis	  phenotype.	  The	  Xhosa	  AD	  patient	  cohort	  was	  screened	  for	  SNVs	  in	  TMEM79	  and	  a	  total	  of	  4	  missense	  variants	  were	  identified.	  This	  cohort	  had	  been	  found	  to	  have	  an	  absence	  of	  the	  common	  European	  FLG	  null	  mutations	  as	  well	  as	  any	  population-­‐specific	  FLG	  mutations,	  and	  is	  a	  prime	  candidate	  for	  the	  involvement	  of	  other	  epidermal	  proteins	  in	  the	  pathogenesis	  of	  AD.	  The	  missense	  SNV	  rs6684514,	  which	  was	  also	  found	  in	  the	  Irish	  AD	  cohort,	  was	  identified	  as	  having	  a	  protective	  effect	  within	  the	  Xhosa	  AD	  cohort.	  This	  was	  contrary	  to	  what	  was	  seen	  in	  the	  Irish	  AD	  cohort,	  but	  may	  be	  attributed	  to	  population	  differences.	  Missense	  variant	  rs112826258	  (R31Q)	  shows	  a	  similar	  odds	  ratio	  with	  rs6684514	  (V147M)	  within	  the	  Xhosa	  population,	  suggesting	  that	  these	  two	  SNVs	  might	  be	  weakly	  associated	  in	  a	  protective	  manner	  (odds	  ratio	  less	  than	  1).	  However,	  p	  values	  for	  rs112826258	  (R31Q)	  and	  rs75902624	  (S104T)	  are	  above	  0.05,	  indicating	  that	  there	  is	  no	  association	  between	  these	  two	  SNVs	  and	  AD	  in	  the	  Xhosa	  population.	  The	  two	  SNVs	  rs112826258	  and	  rs75902624	  were	  present	  at	  very	  low	  frequencies	  within	  NCBI	  dbSNP,	  EVS	  and	  1000	  Genomes,	  with	  a	  MAF	  of	  less	  than	  0.01	  for	  both.	  The	  novel	  missense	  variant,	  M354L,	  identified	  within	  the	  Xhosa	  AD	  cohort	  was	  not	  present	  in	  the	  control	  population	  and	  interestingly,	  was	  not	  present	  within	  NCBI	  dbSNP	  Database,	  Exome	  Variant	  Server	  and	  1000	  Genomes	  Project,	  suggesting	  that	  this	  SNV	  is	  rare.	  At	  the	  same	  position	  however,	  a	  SNV	  rs202080325	  (M354T)	  was	  identified	  in	  the	  CLINSEQ	  population	  (European	  descent)	  from	  NCBI	  dbSNP	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  Database	  and	  1000	  Genomes,	  but	  without	  any	  MAFs.	  As	  the	  number	  of	  affected	  individuals	  with	  this	  allele	  was	  small,	  case-­‐control	  analysis	  with	  the	  South	  African	  control	  population	  could	  not	  be	  done.	  The	  two	  Xhosa	  AD	  patients	  with	  the	  SNV	  M354L	  were	  clinically	  diagnosed	  with	  moderate-­‐severe	  AD	  severity,	  but	  records	  do	  not	  show	  any	  other	  noticeable	  clinical	  phenotype.	  Rs112826258	  (R31Q),	  rs75902624	  (S104T)	  and	  rs6684514	  (V147M)	  are	  located	  within	  the	  N-­‐	  terminal	  domain,	  while	  the	  novel	  variant	  M354L	  is	  within	  the	  fifth	  transmembrane	  region	  (Figure	  4.	  3).	  The	  change	  of	  a	  polar	  neutral	  methionine	  to	  leucine,	  which	  contains	  a	  hydrophobic	  side	  chain,	  may	  alter	  its’	  functional	  properties	  by	  causing	  structural	  changes	  within	  the	  fifth	  transmembrane	  domain	  of	  TMEM79.	  More	  investigations	  within	  various	  populations	  need	  to	  be	  done	  in	  order	  to	  clarify	  if	  this	  variant	  might	  have	  a	  functional	  impact	  on	  TMEM79	  protein	  properties.	  	  	  The	  Irish	  AD	  and	  Irish	  BKC	  patients	  that	  were	  sequenced	  in	  this	  chapter	  were	  selected	  as	  having	  a	  similar	  inflammatory	  phenotype	  (either	  epidermal	  or	  ocular)	  to	  the	  Mattma/ma	  animal,	  and	  were	  all	  wildtype	  for	  the	  4	  most	  common	  FLG	  null	  mutations	  found	  in	  Europeans.	  Only	  one	  SNV,	  rs6684514,	  was	  identified	  as	  causing	  an	  amino	  acid	  change	  in	  TMEM79	  but	  case-­‐control	  analysis	  showed	  that	  it	  was	  not	  associated	  with	  either	  AD	  or	  BKC	  in	  the	  Irish	  population.	  	  
	  
Figure	  4.	  3	  Location	  of	  SNVs	  within	  TMEM79	  cDNA.	  Untranslated	  regions	  are	  seen	  in	  grey	  and	  protein	  coding	  sequences	  in	  black,	  with	  transmembrane	  domains	  shown	  as	  boxes.	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  GWAS	  are	  particularly	  useful	  in	  confirming	  associations	  with	  complex	  trait	  diseases,	  which	  do	  not	  obey	  standard	  Mendelian	  patterns	  of	  inheritance.	  Complex	  diseases	  are	  caused	  by	  a	  combination	  of	  genetic,	  environmental	  and	  lifestyle	  factors,	  and	  although	  a	  genetic	  predisposition	  means	  an	  increased	  susceptibility	  to	  developing	  disease,	  it	  does	  not	  necessarily	  follow	  that	  the	  person	  is	  destined	  to	  develop	  the	  disease.	  Ideally,	  a	  GWAS	  case-­‐control	  study	  would	  require	  2,000	  or	  more	  cases	  and	  3,000	  ethinically-­‐matched	  unaffected	  controls.	  This	  method	  of	  identifying	  susceptibility	  loci	  for	  complex	  skin	  diseases	  has	  so	  far	  been	  used	  for	  10	  skin	  diseases	  including	  systemic	  lupid	  erythematosus,	  vitiligo,	  leprosy,	  AD,	  male-­‐pattern	  baldness,	  keloid,	  sarcoidosis,	  basal	  cell	  carcinoma,	  melanoma	  and	  cutaneous	  nevi	  (Zhang,	  2012).	  In	  terms	  of	  AD,	  two	  GWAS	  in	  European	  and	  Chinese	  Han	  populations	  have	  been	  carried	  out	  which	  identified	  four	  susceptibility	  loci	  in	  AD	  cases:	  1q21.3,	  5q22.1,	  11q13.5	  and	  20q13.33	  (Esparza-­‐Gordillo	  et	  al.,	  2009;	  Sun	  et	  al.,	  2011).	  Linkage	  disequilibrium	  was	  expected	  with	  FLG	  at	  1q21,	  but	  within	  the	  European	  population,	  a	  risk	  allele	  (rs7927894)	  was	  identified	  for	  AD	  as	  well	  as	  for	  Crohn’s	  disease	  (Barrett	  et	  al.,	  2008),	  and	  these	  two	  disorders	  share	  many	  inflammatory	  characteristics.	  New	  susceptibility	  loci	  identifying	  other	  candidate	  genes	  associated	  with	  the	  epidermal	  barrier	  and	  immune	  response	  suggests	  that	  there	  may	  be	  other	  mechanisms	  involved	  in	  the	  pathogenesis	  of	  AD.	  In	  case-­‐control	  GWAS,	  it	  may	  sometimes	  be	  difficult	  to	  spot	  rare	  variants	  especially	  for	  complex	  diseases	  with	  locus/allelic	  heterogeneity,	  if	  they	  are	  not	  present	  in	  multiple	  samples	  or	  if	  there	  is	  low	  coverage	  even	  in	  large	  cohorts	  and	  may	  not	  be	  picked	  up	  during	  the	  variant	  calling	  step.	  This	  might	  occur	  if	  the	  program	  algorithms	  for	  variant-­‐calling	  tools	  aren’t	  programmed	  for	  sensitivity	  towards	  such	  variation	  (Goldstein	  et	  al.,	  2013).	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  In	  this	  chapter,	  a	  small	  group	  of	  9	  NS-­‐like	  patients	  sharing	  a	  similar	  phenotype	  were	  sequenced	  for	  TMEM79.	  They	  are	  not	  good	  candidates	  for	  performing	  GWAS	  due	  to	  their	  small	  cohort	  size,	  heterogeneity	  of	  clinical	  phenotype	  and	  lack	  of	  ethnically	  matched	  controls	  due	  to	  mixed	  ancestries.	  It	  would	  be	  a	  better	  idea	  to	  perform	  whole	  exome	  sequencing	  on	  this	  group	  of	  patients,	  if	  ethical	  approval	  and	  appropriate	  normal	  controls	  could	  be	  obtained,	  as	  well	  as	  from	  non-­‐affected	  family	  members	  if	  possible.	  	  In	  the	  GWAS	  studies	  of	  AD	  described	  above,	  there	  was	  no	  significant	  association	  with	  the	  TMEM79	  locus.	  This	  suggests	  that	  TMEM79	  is	  not	  a	  genetic	  factor	  contributing	  towards	  AD	  and	  could	  explain	  why	  no	  association	  between	  variants	  in	  TMEM79	  and	  AD	  was	  found.	  However,	  it	  is	  possible	  that	  TMEM79	  may	  be	  indirectly	  associated	  with	  AD,	  perhaps	  via	  protein	  expression	  levels	  for	  example,	  akin	  to	  the	  down-­‐regulation	  of	  filaggrin	  expression	  seen	  in	  AD	  patients	  without	  any	  FLG	  null	  mutations.	  Whole	  transcriptome	  sequencing	  of	  patients	  with	  prostate	  cancer	  identified	  a	  unique	  RNA	  chimera	  of	  SMG5-­‐TMEM79	  in	  cancer	  tissues	  that	  was	  not	  seen	  in	  benign	  tissues,	  suggesting	  that	  this	  chimeric	  RNA	  could	  act	  as	  a	  potential	  biomarker.	  SMG5	  is	  a	  transcript	  located	  immediately	  upstream	  of	  TMEM79.	  In	  cancerous	  tissues,	  the	  chimeric	  RNA	  found	  consisted	  of	  part	  of	  the	  third	  intron	  of	  TMEM79	  spliced	  with	  two-­‐thirds	  of	  SMG5	  (Kannan	  et	  al.,	  2011).	  This	  was	  interesting	  to	  note,	  as	  I	  have	  showed	  that	  TMEM79	  transcript	  variant	  1b	  is	  highly	  expressed	  in	  prostate	  tissues.	  In	  another	  study	  concerning	  asymptomatic	  left	  ventricular	  dysfunction	  (ALVD),	  which	  is	  the	  preclinical	  stage	  of	  heart	  failure,	  7	  genes	  were	  identified	  as	  being	  associated	  with	  ALVD	  using	  white	  blood	  cell	  gene	  expression	  profiling	  by	  microarrays.	  TMEM79	  was	  one	  of	  these	  genes	  and	  showed	  a	  decreased	  expression	  in	  ALVD	  patients,	  and	  together	  with	  the	  other	  6	  genes,	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  have	  been	  shown	  to	  be	  an	  accurate	  diagnostic	  predictor	  for	  ALVD	  (Smih	  et	  al.,	  2011).	  Overall,	  these	  studies	  indicate	  as	  yet	  uncharacterised	  functions	  for	  TMEM79	  outwith	  the	  context	  of	  the	  skin.	  The	  screening	  of	  TMEM79	  within	  the	  relatively	  small	  Irish	  and	  Xhosa	  populations	  was	  performed	  to	  identify	  any	  potentially	  interesting	  SNVs	  that	  might	  help	  to	  better	  understand	  TMEM79	  protein	  function	  within	  the	  skin.	  Since	  only	  one	  variant	  appeared	  to	  show	  significance	  within	  the	  discovery	  cohorts,	  further	  genotyping	  of	  rs6684514	  was	  then	  carried	  out	  in	  other	  AD	  cohorts	  (England,	  UK,	  Ireland,	  Germany	  and	  Scotland)	  and	  the	  data	  is	  presented	  in	  Appendix	  VIII.	  I	  was	  involved	  in	  the	  screening	  of	  the	  English	  adult	  severe	  AD	  cohort,	  UK	  AD	  pediatric	  cases,	  Irish	  pediatric	  AD	  cases	  and	  their	  respective	  population	  controls.	  In	  a	  collaborative	  effort	  with	  various	  other	  institutes	  in	  an	  effort	  to	  screen	  different	  allergic	  patient	  populations,	  the	  missense	  mutation	  rs6684514,	  was	  further	  investigated	  for	  any	  association	  with	  AD	  (Appendix	  VIII).	  4,245	  AD	  cases	  from	  England,	  Scotland,	  Ireland,	  and	  Germany	  were	  combined	  and	  compared	  in	  a	  meta-­‐analysis	  with	  10,558	  population-­‐matched	  controls.	  The	  minor	  allele	  (A)	  appears	  to	  be	  protective	  for	  AD	  in	  all	  populations	  apart	  from	  the	  Irish	  cohort,	  which	  could	  be	  due	  to	  population	  or	  phenotypic	  differences.	  Figure	  1	  of	  Appendix	  VIII	  shows	  a	  meta-­‐analysis	  of	  all	  the	  data	  which	  shows	  that	  rs6684514	  has	  a	  small	  but	  significant	  effect	  on	  AD	  risk	  (P=	  0.078;	  OR	  =	  0.91,	  95%	  CI	  =	  0.86	  –	  0.96).	  Rs6684514,	  appears	  to	  be	  associated	  with	  AD	  risk	  in	  a	  small	  but	  significant	  manner	  across	  different	  AD	  populations.	  
In	  conclusion,	  if	  cost	  and	  time	  were	  not	  an	  issue,	  it	  would	  be	  more	  productive	  to	  sequence	  the	  Irish	  and	  Xhosa	  patient	  cohorts	  by	  whole	  exome	  analysis	  instead	  of	  performing	  traditional	  Sanger	  sequencing,	  as	  this	  might	  identify	  other	  potential	  
	  	  



















OVERALL	  CONCLUSION	  The	  Mattma/maFlgft/ft	  double	  mutant	  (DM)	  mouse	  first	  arose	  spontaneously	  on	  the	  background	  of	  the	  matted	  mouse,	  and	  the	  DM	  animal	  has	  been	  used	  as	  a	  model	  in	  skin	  barrier	  studies	  for	  human	  atopic	  dermatitis	  (AD)	  because	  it	  is	  filaggrin-­‐deficient.	  The	  mutation	  responsible	  for	  the	  flaky-­‐tail	  mouse	  phenotype	  had	  been	  identified	  earlier	  as	  a	  frameshift	  mutation	  in	  the	  Flg	  gene	  (Fallon	  et	  al.,	  2009)	  In	  this	  thesis,	  I	  set	  out	  to	  identify	  the	  gene	  responsible	  for	  the	  atopic	  appearance	  and	  hair	  shaft	  defect	  of	  the	  Mattma/ma	  mouse.	  Using	  data	  obtained	  from	  whole	  transcriptome	  sequencing	  and	  homozygozity	  mapping	  strategies,	  a	  novel	  gene	  was	  identified,	  Tmem79.	  This	  gene	  is	  encoded	  by	  4	  exons,	  and	  translates	  into	  a	  5	  transmembrane	  domain	  protein.	  Mattma/ma	  harbors	  a	  spontaneous	  mutation,	  c.840C>G	  or	  p.Y280*,	  within	  the	  third	  transmembrane	  region	  of	  Tmem79.	  Multiple	  sequence	  alignment	  shows	  that	  TMEM79	  is	  highly	  conserved	  across	  species,	  and	  protein	  prediction	  software	  analysis	  suggests	  distant	  homology	  to	  members	  of	  the	  MAPEG	  family.	  The	  results	  shown	  in	  Chapter	  2	  have	  been	  submitted	  to	  the	  Journal	  of	  Allergy	  and	  Clinical	  Immunology	  in	  July	  2013	  and	  have	  been	  accepted	  for	  publication	  in	  November	  2013.	  During	  the	  progression	  of	  this	  project,	  a	  second	  mutant	  mouse	  was	  identified	  as	  having	  a	  missense	  mutation	  in	  Tmem79	  (MGI	  Ref	  ID	  J:178673).	  The	  Jackson	  Laboratory	  reported	  this	  mutant	  in	  2011,	  known	  as	  129;FVB-­‐Tmem79m1J/GrsrJ,	  and	  was	  described	  as	  having	  an	  abnormal	  hair	  morphology	  with	  kinks,	  a	  sparse	  coat	  and	  some	  adults	  display	  mild	  irritation	  around	  the	  eyes	  (Figure	  5.	  1).	  Unlike	  




Figure	  5.	  1	  Phenotype	  of	  the	  129;FVB-­‐Tmem79m1j/GrsrJ	  mouse	  mutant.	  A	  mouse	  mutant	  with	  a	  reported	  missense	  mutation	  in	  Tmem79,	  p.G214A.	  Image	  screen	  captured	  from	  JAX®	  Mice	  Database.	  	  
	  
Figure	  5.	  2	  Location	  of	  murine	  mutations	  within	  TMEM79.	  Mattma/ma	  would	  result	  in	  a	  prematurely	  truncated	  protein	  and	  129;FVB-­‐Tmem79m1J/GrsrJ	  would	  still	  express	  the	  full-­‐length	  protein.	  	  In	  humans,	  this	  novel	  gene	  is	  located	  within	  the	  EDC	  and	  is	  expressed	  only	  in	  the	  upper	  granular	  layers	  of	  the	  epidermis	  where	  it	  is	  localized	  to	  the	  membranes	  of	  lamellar	  granules	  (LG).	  These	  are	  branched,	  tubular	  structures	  originating	  from	  the	  trans-­‐Golgi	  network	  (TGN)	  and	  contain	  various	  cargoes	  meant	  for	  secretion	  at	  the	  apical	  surface	  of	  the	  topmost	  granular	  cells	  (Ishida-­‐Yamamoto	  et	  al.,	  2004).	  These	  bulbous	  structures	  have	  been	  shown	  to	  contain	  proteins	  such	  as	  cornedesmosin	  (CDSN)	  and	  various	  hydrolytic	  enzymes	  such	  as	  kallikrein	  5,7	  and	  8	  (KLK5,	  KLK7	  and	  KLK8),	  cathepsin	  D	  (CatD)	  and	  glucosylceramides	  (GlcCer)	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  (Freinkel	  and	  Traczyk,	  1983;	  Freinkel	  and	  Traczyk,	  1985;	  Grayson	  et	  al.,	  1985;	  Ishida-­‐Yamamoto	  et	  al.,	  2004;	  Serre	  et	  al.,	  1991).	  Immunofluorescent	  imaging	  of	  TMEM79,	  CDSN	  and	  KLK8	  show	  granular	  aggregates,	  whilst	  transmission	  electron	  microscopy	  shows	  that	  these	  molecules	  are	  housed	  within	  distinct	  tubular	  reticulate	  structures.	  The	  contents	  of	  LG	  bodies	  must	  aggregate	  at	  specific	  storage	  locations	  before	  they	  are	  required,	  but	  the	  mechanisms	  and	  timing	  for	  the	  release	  of	  LG	  cargoes	  are	  still	  unknown.	  There	  is	  evidence	  to	  suggest	  that	  CDSN	  is	  expressed	  the	  earliest,	  followed	  by	  GlcCer	  and	  finally	  by	  KLK7	  and	  KLK8	  (Ishida-­‐Yamamoto	  et	  al.,	  2004).	  Through	  the	  course	  of	  this	  work,	  a	  collaborative	  partner	  laboratory	  independently	  identified	  and	  confirmed	  that	  the	  Tmem79	  gene	  is	  indeed	  responsible	  for	  the	  matted	  phenotype	  of	  the	  Mattma/ma	  animal	  (Sasaki	  et	  al.,	  2013).They	  identified	  the	  
Tmem79	  gene	  and	  mutation	  by	  performing	  backcrosses	  and	  applying	  target	  enrichment,	  followed	  by	  next	  generation	  sequencing.	  They	  then	  rescued	  the	  phenotype	  of	  the	  Mattma/ma	  mouse	  by	  introducing	  a	  wildtype	  Tmem79	  transgene	  under	  the	  control	  of	  Tmem79	  promoter,	  and	  showed	  that	  in	  these	  mutant	  mice,	  TMEM79	  was	  localized	  to	  the	  LG	  secretory	  system.	  Furthermore,	  they	  showed	  that	  
Mattma/ma	  mice	  have	  a	  decreased	  expression	  of	  LG-­‐secreted	  proteins	  such	  as	  KLK5,	  KLK7	  and	  LEKTI	  in	  comparison	  to	  wildtype	  mice	  and	  that	  cornified	  layers	  could	  be	  removed	  en	  bloc	  through	  epidermal	  tape-­‐stripping	  experiments.	  An	  antibody	  was	  made	  against	  the	  N-­‐terminus	  of	  TMEM79,	  and	  showed	  that	  the	  truncated	  form	  of	  TMEM79	  was	  still	  detectable	  in	  the	  upper	  granular	  layers,	  suggesting	  that	  the	  C-­‐terminus	  of	  the	  protein	  is	  functionally	  important.	  Their	  findings	  suggest	  that	  in	  
Mattma/ma	  mice,	  the	  impairment	  of	  TMEM79	  leads	  to	  SC	  barrier	  dysfunction.	  The	  characterization	  of	  the	  Mattma/ma	  mouse	  by	  our	  Japanese	  collaborators	  have	  produced	  results	  that	  correspond	  well	  with	  the	  work	  carried	  out	  in	  this	  thesis.	  
	  	  
163	  The	  role	  of	  TMEM79	  could	  be	  as	  a	  labeling	  molecule	  for	  identification	  of	  a	  particular	  cargo	  within	  a	  LG,	  or	  an	  anchoring	  protein	  that	  aids	  in	  the	  transport	  process	  of	  LG	  or	  during	  fusion	  with	  the	  cells’	  plasma	  membrane	  (Figure	  5.	  3).	  
	  
Figure	  5.	  3	  Cartoon	  showing	  the	  hypothetical	  role	  of	  TMEM79.	  Lamellar	  granules	  (LG)	  are	  connected	  to	  the	  TGN	  and	  transport	  the	  contents	  of	  LGs	  individually	  for	  secretion	  at	  the	  apical	  face	  of	  the	  most	  superficial	  granulocytes.	  	  The	  release	  of	  lipids	  is	  vital	  for	  the	  lipid	  envelope	  of	  the	  stratum	  corneum.	  Disruption	  of	  this	  envelope	  allows	  penetration	  of	  allergens	  causing	  an	  inflammatory	  response.	  Some	  diseases	  affected	  by	  an	  impaired	  epidermal	  lipid	  barrier	  have	  been	  detailed	  earlier	  in	  Chapter	  1.4.2,	  page	  33.	  To	  date,	  no	  human	  equivalent	  of	  the	  matted	  mutation	  has	  been	  identified	  in	  the	  populations	  that	  have	  been	  screened.	  The	  common	  SNV,	  rs6684514,	  appears	  to	  have	  a	  protective	  effect	  with	  AD.	  It	  was	  initially	  thought	  that	  blepharitis	  was	  a	  good	  candidate	  disease,	  as	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  both	  the	  Mattma/ma	  and	  129;FVB-­‐Tmem79m1J/GrsrJ	  mouse	  mutants	  display	  ocular	  inflammation,	  but	  no	  pathogenic	  mutations	  were	  identified	  in	  BKC	  patients.	  At	  the	  stage	  when	  screening	  for	  human	  disease	  association	  was	  carried	  out,	  the	  information	  regarding	  the	  involvement	  of	  TMEM79	  with	  lamellar	  granules	  was	  still	  not	  discovered,	  hence,	  human	  disorders	  resembling	  the	  eczema-­‐like	  inflammatory	  phenotype	  of	  the	  Mattedma/ma	  mouse	  were	  chosen	  as	  candidate	  groups.	  It	  is	  possible	  that	  the	  human	  diseases	  screened	  in	  this	  study	  were	  too	  mild,	  and	  that	  loss	  of	  TMEM79	  protein	  may	  result	  in	  a	  phenotype	  more	  severe	  than	  AD	  in	  humans.	  According	  to	  the	  subcellular	  location	  of	  the	  TMEM79	  protein	  within	  the	  membranes	  of	  LGs,	  a	  more	  accurate	  human	  clinical	  phenotype	  resulting	  from	  aberrant	  TMEM79	  expression	  may	  resemble	  a	  form	  of	  lamellar	  ichthyosis	  disease.	  	  	  	  
FUTURE	  WORK	  Double	  immuno-­‐gold	  labeling	  experiments	  performed	  in	  this	  thesis	  have	  ruled	  out	  any	  association	  between	  CDSN	  and	  KLK8	  with	  TMEM79-­‐labelled	  LGs.	  More	  labeling	  experiments	  need	  to	  be	  performed	  in	  order	  to	  identify	  the	  contents	  of	  TMEM79-­‐labelled	  secretory	  granules.	  Along	  with	  the	  known	  LG-­‐contents	  (listed	  above),	  an	  interesting	  candidate	  to	  look	  at	  would	  be	  caveolin-­‐1,	  which	  is	  a	  cholesterol-­‐binding	  protein	  that	  is	  thought	  to	  be	  involved	  in	  LG	  assembly	  or	  trafficking	  in	  keratinocytes	  of	  the	  epidermis	  (Sando	  et	  al.,	  2003).	  	  The	  commercial	  polyclonal	  antibody	  against	  TMEM79	  that	  was	  used	  in	  the	  immunofluorescent	  and	  immunoelectron	  microscopy	  imaging	  experiments	  is	  directed	  against	  the	  C-­‐terminus.	  It	  would	  be	  useful	  to	  develop	  an	  antibody	  against	  the	  N-­‐terminus	  of	  the	  TMEM79	  protein	  to	  allow	  the	  visualization	  of	  any	  truncated	  TMEM79	  protein	  in	  the	  epidermis	  of	  the	  Mattma/ma	  animal,	  and	  would	  also	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  overcome	  the	  difficulties	  of	  TMEM79	  fusion	  constructs,	  where	  the	  epitope	  could	  be	  blocked	  by	  different	  tags.	  A	  traditional	  approach	  to	  identify	  potential	  TMEM79	  partners	  would	  be	  to	  perform	  immunoprecipitation	  assays,	  but	  could	  be	  problematic	  due	  its	  transmembrane	  characteristics.	  Alternatively,	  a	  proximity	  ligation	  immunoassay	  or	  an	  affinity	  column	  of	  purified	  TMEM79	  could	  be	  used	  to	  detect	  protein-­‐protein	  interactions.	  These	  might	  also	  confirm	  if	  TMEM79	  has	  any	  glutathione	  binding/activity	  as	  bioinformatics	  analysis	  has	  predicted.	  	  Results	  obtained	  from	  overexpression	  assays	  performed	  with	  HaCaT	  cells	  and	  HPKs	  did	  not	  yield	  any	  conclusive	  results	  about	  the	  cellular	  location	  of	  TMEM79	  since	  overexpressed	  TMEM79	  aggregated	  and	  was	  disposed	  by	  autophagocytosis.	  	  Taking	  into	  account	  that	  TMEM79	  is	  only	  expressed	  in	  keratinocytes	  of	  the	  upper	  granular	  layer,	  cell	  lines	  could	  perhaps	  have	  been	  cultured	  in	  low	  calcium	  conditions	  (0.02	  –	  0.1	  mM)	  before	  stratifying	  in	  high	  calcium	  conditions	  (1.8	  –	  2.0	  mM).	  Preliminary	  experiments	  could	  be	  carried	  out	  to	  observe	  for	  any	  endogenous	  TMEM79	  expression	  under	  these	  conditions.	  Another	  alternative	  would	  be	  to	  establish	  a	  stable	  keratinocyte	  cell	  line	  with	  a	  tagged	  TMEM79	  construct,	  and	  this	  could	  be	  used	  in	  a	  3D-­‐culture	  to	  ensure	  keratinocyte	  stratification	  and	  TMEM79	  expression.	  Preliminary	  experiments	  were	  carried	  out	  trying	  to	  detect	  endogenous	  TMEM79	  in	  a	  3D-­‐culture,	  but	  none	  could	  be	  detected.	  This	  was	  probably	  due	  to	  having	  only	  very	  small	  amounts	  of	  sample,	  as	  well	  as	  an	  antibody	  that	  is	  not	  efficient	  at	  detecting	  proteins	  on	  an	  immunoblot.	  A	  way	  to	  accomplish	  this	  could	  be	  the	  use	  of	  a	  retroviral	  expression	  system	  with	  human	  primary	  keratinocytes,	  with	  the	  eventual	  aim	  of	  stratifying	  these	  stably	  transfected	  human	  primary	  keratinocytes	  in	  a	  3D	  skin	  model.	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  The	  same	  could	  also	  be	  performed	  using	  mouse	  keratinocytes,	  and	  Tmem79	  could	  conceivably	  be	  knocked	  out	  using	  siRNA	  targeted	  against	  Tmem79,	  and	  observing	  any	  abnormalities	  in	  stratification	  afterwards.	  This	  might	  allow	  the	  focus	  to	  be	  on	  the	  fundamental	  mechanism	  of	  TMEM79	  in	  vitro,	  without	  the	  secondary	  inflammatory	  effects	  that	  are	  so	  prevalent	  in	  the	  mouse	  model.	  	  Next	  Generation	  Sequencing	  could	  be	  carried	  out	  for	  the	  Xhosa	  and	  Irish	  AD	  patients	  who	  did	  not	  have	  any	  identified	  FLG	  mutations.	  In	  theory,	  it	  would	  be	  easier	  to	  flag	  up	  any	  susceptibility	  loci	  and	  candidate	  genes	  using	  this	  NGS	  approach.	  As	  ethnically-­‐matched	  controls	  for	  these	  populations	  already	  exist,	  the	  only	  requirement	  left	  would	  be	  to	  obtain	  informed	  consent	  from	  these	  patients	  to	  proceed.	  	  	  Finally,	  it	  should	  be	  noted	  that	  TMEM79	  might	  be	  involved	  with	  other	  pathophysiological	  mechanisms	  as	  discussed	  previously	  (e.g.	  erythrocyte-­‐related	  traits,	  ALVD	  and	  prostate	  cancer)	  and	  these	  could	  involve	  other	  TMEM79	  transcript	  variants.	  Disease	  pathology	  may	  appear	  different	  in	  humans	  with	  a	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Appendix	  I	  
Immune	  profile	  of	  Mattma/ma	  (matted)	  mice	  (Performed	  by	  Padraic	  Fallon	  et.	  
al.,	  Trinity	  College,	  Dublin)	  These	  Mattma/ma	  mice	  show	  diffuse	  epidermal	  hyperplasia	  (P	  <0.001)	  and	  hyperkeratosis	  of	  anuclear	  granular	  cells	  (orthokeratosis)	  (P	  <	  0.001)	  (Figure	  1.g)	  with	  dermal	  inflammatory	  infiltrates	  (P	  <0.001)	  (Figure	  1.d).	  A	  more	  severe	  phenotype	  compared	  to	  Flgft/ft	  mice	  which	  only	  had	  occasional	  foci	  of	  acanthosis,	  mild	  diffuse	  orthokeratosis	  and	  dermal	  infiltrates,	  and	  presented	  with	  no	  overt	  dermatitis	  (Figure	  1.g).	  Trans-­‐epidermal	  water	  loss	  (TEWL)	  is	  a	  method	  of	  measurement	  used	  to	  analyzed	  severity	  of	  skin	  inflammation	  of	  skin	  barrier	  integrity	  in	  atopic	  dermatitis	  patients	  (Eberlein-Konig	  et	  al.,	  2000; Gupta	  et	  al.,	  
2008).	  In	  the	  Mattma/ma	  and	  DM	  mice,	  TEWL	  values	  were	  significantly	  raised	  indicating	  a	  dysregulation	  in	  skin	  barrier	  integrity,	  but	  were	  unaltered	  in	  Flgft/ft	  mice	  (Figure	  1.f).	  Spontaneous	  elevated	  IgE	  levels	  were	  seen	  in	  all	  mutants,	  but	  were	  exaggerated	  in	  Mattma/ma	  and	  DM	  animals.	  House	  dust	  mite	  allergen	  was	  applied	  as	  a	  model	  to	  demonstrate	  percutaneous	  sensitization	  in	  Mattma/ma	  as	  compared	  to	  wild	  type	  mice,	  where	  there	  was	  an	  increase	  in	  IgE,	  IgG1	  and	  IgG2a	  responses	  following	  HDM	  allergen	  application	  in	  Mattma/ma,	  that	  was	  not	  seen	  in	  
Flgft/ft	  and	  wild	  type	  mice,	  indicating	  that	  Mattma/ma	  mice	  are	  more	  susceptible	  to	  percutaneous	  allergic	  sensitization	  due	  to	  a	  defective	  skin	  barrier	  (Figure	  1.a-­‐c).	  	  As	  shown	  in	  previous	  studies	  (Jarrett	  and	  Spearman,	  1957;	  Searle	  and	  Spearman,	  1957),	  the	  Mattma/ma	  and	  DM	  mice	  demonstrated	  what	  appears	  to	  be	  a	  keratinizing	  defect,	  causing	  clumping	  of	  hairs	  with	  brittles	  and	  longitudinal	  splitting.	  They	  also	  had	  distorted	  hair	  follicle	  morphogenesis	  with	  defective	  cuticle	  morphology.	  
	  	  
Figure	  I	  Immune	  profile	  of	  matted	  mouse	  showing	  elevated	  levels	  of	  IgE,	  IgG1,	  IgG2a	  (a	  -­‐	  c),	  following	  house	  dust	  mite	  (HDM)	  challenge.	  Comparison	  of	  dermal	  infiltrates	  and	  acanthosis	  levels	  (d,	  e).	  Transepidermal	  water	  loss	  was	  markedly	  elevated	  in	  ma/ma	  mouse	  when	  challenged	  with	  both	  HDM	  and	  vehicle.	  H&E	  sections	  showing	  gross	  hyperplasia	  and	  hyperkeratosis	  in	  DM	  and	  ma/ma	  (g).	  












Complete	  list	  of	  mapping	  primers	  designed	  to	  cover	  
murine	  chromosome	  3:	  87,000,000	  –	  95,000,000	  
	   	  
Appendix	  II	  Complete	  list	  of	  mapping	  primers	  designed	  to	  cover	  murine	  chromosome	  3:	  87,000,000	  –	  95,000,000.	  	  
Gene/mRNA	   	   Primer	  (5'	  -­‐	  3')	   Chromosomal	  location	  
gm16000	   exon	  1	  
CAA	  AAA	  ACA	  GAT	  TAG	  GGG	  TCA	  G	   chr3:81040296-­‐81040658	  CAT	  TGT	  TAT	  TCC	  ATA	  CCC	  CG	  
exon	  2	   ATG	  GGG	  TTC	  AGA	  GGC	  TAA	  G	   chr3:81037803-­‐81038391	  GGC	  TAT	  GGA	  AAG	  GAT	  TGG	  CAA	  TCC	  TTT	  CCA	  TAG	  CCC	   chr3:81037290-­‐81037819	  TTA	  TGT	  GGA	  AAC	  TAC	  CCT	  GC	  
gm9989	  
exon	  1	   CAC	  ACT	  CCA	  TCA	  TTG	  TCT	  CC	   chr3:81924017-­‐81924625	  	  CAG	  CAA	  GTG	  TCT	  TTA	  CCA	  GC	  exon	  2	   ATG	  GAC	  CCT	  GTG	  ATA	  GGT	  GGT	  G	   chr3:81923414-­‐81924163	  TGT	  GTG	  TCC	  ATC	  CAT	  CCA	  GC	  exon	  3	   GGA	  ATC	  TTA	  CTG	  TAT	  TGG	  GCT	  C	   chr3:81922892-­‐81923479	  	  TCA	  ACT	  CTT	  CAG	  AAA	  CCC	  G	  exon	  4	   AAG	  AGT	  TGA	  TGC	  CAC	  TTC	  C	   chr3:81922357-­‐81922900	  TGT	  GGA	  TGC	  CAA	  GTA	  AGC	  
4930564K09rik	  
exon	  1	   GAA	  AGG	  GAC	  TTG	  GAG	  TGG	   chr3:82876609+82877254	  	  TAG	  TGT	  ATT	  AGA	  TGT	  GGC	  TCA	  G	  exon	  2	   CAT	  AGA	  ACA	  GGA	  TAG	  TAG	  CAC	  AG	   chr3:82878581+82879201	  CAG	  TGC	  AAA	  GCT	  GTG	  GTT	  
exon	  3	  
GAT	  GCA	  TGC	  ATA	  CTC	  CTA	  AGG	  
chr3:82940566+82943774	  
GCA	  TCT	  TCC	  ACT	  TCA	  AGG	  G	  GCA	  GAC	  CTA	  TTG	  CCG	  TTT	  GAT	  CCT	  AGT	  TCC	  TTC	  TCC	  TCA	  C	  CAG	  ATA	  TAC	  ATG	  GGA	  TTT	  AAG	  G	  TGG	  ATG	  AGA	  CTG	  CCA	  TTC	  CAG	  CTA	  TAC	  TAT	  ATG	  TCC	  TGA	  A	  GGA	  TGA	  TGA	  GGG	  CAT	  AGA	  A	  CTG	  TGA	  CTC	  TAG	  TTC	  CAA	  GGG	  CAG	  TCA	  GCA	  GGT	  TGT	  TAA	  GG	  GCT	  ACC	  TGG	  AAC	  ACA	  ATG	  A	  TAG	  GAC	  CAT	  ATC	  CAT	  TAG	  AC	  
gm10710	  
	  	   CCA	  CTT	  TCC	  AAG	  GAC	  AAC	  T	  
chr3:83126696-­‐83129323	  	  
	  	   CTT	  AGA	  CTT	  GGT	  GCT	  GCT	  G	  	  	   GCA	  GCA	  GCA	  CCA	  AGT	  CTA	  AG	  	  	   CGA	  ATG	  TCA	  CCC	  ACC	  AGT	  GT	  	  	   TCA	  TCC	  GAG	  TCC	  TCC	  GAA	  AG	  	  	   CAT	  CGC	  TTT	  TTC	  TCT	  CTT	  CTT	  C	  	  	   GCA	  AAC	  AAA	  CGA	  AAA	  GAC	  C	  	  	   GCC	  GTT	  TTT	  TAG	  TCC	  TTC	  TAC	  	  	   GTA	  GAA	  GGA	  CTA	  AAA	  AAC	  GGC	  
	  	   GGT	  CAA	  TCC	  GCA	  CAT	  AAA	  TC	  
gm16790	  
	  	   GAG	  AGA	  AGG	  AGG	  AAC	  GAG	  AAA	   chr3:83594006-­‐83790084	  	  	   CAC	  CGT	  TCT	  CCC	  TCT	  CCC	  TTT	  	  	   CCT	  GGC	  TTC	  CAG	  TGG	  ATG	  TTC	  	  	   AAG	  CTA	  CAA	  TGA	  TTT	  AGT	  TTG	  	  	   CCA	  GGT	  CAA	  CTA	  CTA	  CGT	  ATA	  T	  	  	   TGT	  TGG	  CTT	  ATA	  CCG	  TGC	  AC	  
D930015E06Rik	  
	  	   GCT	  GGG	  CTA	  CGA	  TTC	  ATT	  C	   chr3:84039893-­‐84040547	  	  	   GCG	  AAC	  CCT	  CAC	  AGA	  TTT	  C	  	  	   GGC	  TGG	  GCA	  TTG	  TAT	  TTG	   chr3:84038966-­‐84039558	  	  	  	   TTA	  GAG	  ACA	  GCC	  GTG	  GAG	  AC	  	  	   CCA	  GAG	  GGT	  AGA	  GTT	  ACA	  GGT	  G	   chr3:84031374-­‐84031902	  	  	   TCT	  GAA	  CAA	  GAG	  GGA	  AGG	  C	  	  	   CTA	  TTG	  ATG	  ATG	  GAG	  ACT	  TTG	  G	   chr3:83962026-­‐83962661	  	  	  	   CCA	  AAC	  TTA	  GGG	  CTT	  CTC	  TG	  	  	   GAG	  AAG	  CCC	  TAA	  GTT	  TGG	  TC	   chr3:83961429-­‐83962043	  	  	  	   AAA	  GGG	  CAG	  GAA	  ATC	  TCT	  C	  	  	   GGT	  CCC	  ACA	  TCA	  GAA	  GAG	  AAG	   chr3:83960282-­‐83960941	  	  	  	   TGA	  GCC	  CAT	  AGC	  CCA	  ATA	  G	  	  	   GCT	  GTT	  TGG	  AAC	  TCA	  CTG	  TAT	  G	   chr3:83942312-­‐83942920	  	  	  	   TTA	  TGG	  ATG	  AGG	  CAG	  GAC	  C	  	  	   TGG	  AGA	  GTC	  TAT	  GGC	  TTT	  TTG	   chr3:83940435-­‐83941001	  	  	  	   CCT	  GAG	  TGA	  AAC	  TGC	  CAA	  C	  	  	   CCT	  CCC	  CAA	  ACT	  CTT	  CTT	  TAC	   chr3:83938618-­‐83939116	  	  	   AAC	  TGG	  GGT	  TCA	  GGA	  GAA	  G	  	  	   GGT	  ATT	  TCC	  TGA	  GTT	  GTA	  TTG	  G	   chr3:83937853-­‐83938395	  	  	  	   GCC	  ACA	  ACT	  GAA	  CTA	  AAA	  GC	  	  	   TTT	  AGT	  CAT	  AGC	  GAG	  TGC	  G	   chr3:83937180-­‐83937645	  	  	   GCA	  CAG	  AGG	  AAG	  GAA	  ACT	  G	  	  	   CAC	  TGA	  TGA	  TTG	  TCC	  AGA	  GG	   chr3:83935737-­‐83936288	  	  	   TCT	  CTC	  ACA	  AAA	  GCA	  CAA	  GC	  	  	   CTC	  ATA	  GTT	  TGT	  GAA	  GTT	  TGG	  C	   chr3:83934432-­‐83935031	  	  	   TGC	  TGG	  CTG	  AAG	  TGC	  TAA	  C	  	  	   CAT	  TCC	  TCC	  TCT	  CCT	  CTG	  AC	   chr3:83931539-­‐83931982	  	  	   GCA	  CAG	  TGA	  CAA	  AGA	  AGG	  TG	  	  	   TGT	  AGG	  ATG	  AGG	  TCA	  AGA	  GTT	  G	   chr3:83930288-­‐83930819	  	  	   CAC	  TAA	  AAA	  GGA	  ATG	  CTA	  AGG	  G	  	  	   TGG	  CAT	  TTT	  AGT	  CTG	  TGA	  GAG	   chr3:83926853-­‐83927293	  	  	   GGG	  AAA	  GAG	  TCA	  AAC	  AAC	  TTC	  	  	   AAG	  TGA	  AGT	  GTA	  TGA	  AAC	  CTG	  C	   chr3:83897985-­‐83898545	  	  	   CCA	  TAA	  GGT	  CCT	  CTT	  CTA	  AAG	  C	  gm6525	   	  	   AAT	  AGT	  AGC	  CAT	  AAA	  GGT	  CGC	   chr3:84174453+84175072	  	  	  	   TTT	  CTC	  TTC	  TTG	  TCG	  CCT	  C	  
BM937755	   	  	   GCT	  TGG	  ACT	  CTA	  AAC	  AAA	  CCA	  C	   chr3:84257587+84258259	  	  	  	   AAG	  AGC	  AGG	  AGT	  GAT	  TCA	  GAG	  	  	   ACA	  GGA	  CGG	  GAA	  TGT	  AGT	  G	   chr3:84258158+84258764	  	  	  	   AGG	  GCA	  CAG	  ATA	  GCG	  TTA	  G	  
	  	   CAA	  ACT	  GTC	  ACA	  AGA	  ACA	  ACC	   chr3:84258516+84259070	  	  	  	   CTC	  TTT	  GAA	  GGA	  ACT	  ACT	  CAG	  C	  	  	   AAA	  GGC	  AAC	  ATC	  TCC	  ACC	   chr3:84258960+84259573	  	  	  	   GGG	  ACT	  GAG	  CAC	  AGA	  ATG	  
BC048678	   exon	  1	  
GAA	  ACA	  GAC	  ATT	  TAG	  GCC	  TAG	  T	   chr3:85317409+85317943	  TCT	  AAT	  GGA	  AAG	  CGA	  GCC	  exon	  2	   GTA	  TTT	  AAA	  TAC	  CCA	  AGG	  TG	   chr3:85330853+85331456	  	  CTA	  TAG	  ACT	  CTG	  CCA	  TGC	  T	  exon	  3	   GGC	  TTT	  GGT	  ATG	  TTA	  ACC	  AT	   chr3:85331687+85332127	  	  AGT	  TAG	  AAG	  TGT	  CCC	  AGG	  C	  
AK086005	   exon	  1	   GAG	  ACA	  ACA	  GAC	  AGC	  TTC	   chr3:85553065-­‐85553635	  TCC	  CTG	  CAT	  ATA	  CAT	  ATG	  exon	  2	   CAG	  GTA	  TCC	  AGA	  AGC	  ACT	  GG	   chr3:85544182-­‐85544765	  CTT	  TTC	  TAA	  AAG	  GAA	  GGG	  TTT	  G	  
gm15535	   exon	  2	  
GTG	  GTT	  AAG	  CCC	  CTT	  CTA	  C	   chr3:85556976-­‐85557580	  TGA	  TTA	  TAC	  AGT	  GTT	  CTG	  CC	  CAT	  GGC	  AGC	  ATA	  TGA	  GTG	  TG	   chr3:85556576-­‐85557170	  	  CAC	  GGC	  CTC	  TGC	  ATC	  AG	  CTC	  AAG	  CAG	  GTC	  AGG	  AAG	  CAG	   chr3:85556066-­‐85556616	  	  AAC	  CTG	  GAG	  TTC	  ACT	  GAT	  TTG	  G	  AGA	  CAG	  ATC	  CCT	  GGG	  ATT	  ACA	  G	   chr3:85555776-­‐85556122	  	  TTG	  CTT	  TTG	  AAT	  CAC	  ATG	  GC	  gm9790	   	  	   AGT	  CAA	  ACC	  ATT	  GGC	  TCT	  C	   chr3:85915526+85916108	  	  	   TCT	  AAC	  TAA	  AGC	  AAG	  CAC	  TTC	  C	  gm3788	   	  	   AAA	  TCA	  GTG	  GAC	  CAG	  AAG	  G	   chr3:86671655-­‐86672325	  	  	  	   CAG	  CAT	  TTT	  CTC	  ATT	  GTG	  C	  BY319657	   	  	   CCC	  TCT	  CAT	  TCT	  GAC	  CAC	  TTC	   chr3:87365512+87366166	  	  	   ATG	  ACC	  ATC	  TGG	  GGC	  ATA	  G	  BE847318	   	  	   GCC	  CTC	  TTC	  TTA	  TGT	  TTG	  C	   chr3:87382566+87383140	  	  	  	   GCT	  CGT	  GTA	  TGA	  ACT	  ACC	  CTA	  C	  AW494178	   	  	   CTT	  CAT	  TTC	  CAG	  TCA	  TAC	  ACG	   chr3:87445869+87446464	  	  	  	   TAA	  TAC	  TCC	  CCT	  GCG	  TCA	  C	  DY243455	   	  	   CCC	  TCC	  ACA	  TTT	  GTT	  CTA	  TTC	   chr3:87531735+87532371	  	  	   CAA	  GGT	  TTC	  TCT	  TTT	  AGC	  CC	  CK137060	   	  	   CCT	  TCT	  TTC	  TAC	  GAG	  CAC	  G	   chr3:87539251+87539704	  	  	  	   CCT	  CAC	  CAC	  TAC	  TGT	  TCA	  CAC	  CF805084	   	  	   ATC	  TCT	  CCA	  GCC	  CTG	  AAA	  C	   chr3:87557673+87558299	  	  	  	   CGG	  ACC	  TAA	  AAC	  CTT	  CAC	  AC	  BE865208	   	  	   AGA	  GAG	  ACT	  TTC	  GGA	  GCC	  TG	   chr3:87617775+87618380	  	  	   GCA	  GAC	  AGA	  TAA	  AAG	  CCA	  TCC	  gm6570	   	  	   GGG	  AGG	  AAG	  CAA	  AGA	  AGA	  G	   chr3:87679693-­‐87680329	  	  	  	   AGA	  ATC	  ACC	  TGG	  GTC	  AAT	  G	  
AK040918	   	  	   GTG	  TGT	  CTG	  GAG	  ATG	  GCT	  AC	   chr3:87691123+87691806	  	  	   TGA	  GAA	  AGC	  AGG	  GTT	  GAC	  	  	   TTC	  TGC	  TTC	  ATA	  GCC	  ACC	  G	   chr3:87692246+87692842	  	  	   CGG	  TTC	  CTG	  TAA	  GCA	  GTC	  AC	  	  	   AAA	  CAG	  TCT	  CAC	  GGT	  CAC	  C	   chr3:87692772+
	  	   GGG	  TAT	  GTA	  TGA	  ACA	  GGT	  GC	   87693383	  	  	  	   GCT	  GGA	  GAG	  ATG	  ATT	  CTA	  TGG	   chr3:87693223+87693805	  	  	  	   TAC	  TTC	  CAG	  GTT	  TCT	  CTC	  CTC	  
4933430H15rik	  
exon	  1	   GCG	  AAA	  TGG	  TAA	  AGA	  TGG	  G	   chr3:87748307-­‐87748942	  	  GGA	  TTT	  TTT	  GGC	  TCG	  TCC	  exon	  2-­‐3	   GCA	  AAG	  CAG	  CTT	  CCA	  CTT	  G	   chr3:87745537-­‐87746118	  	  AGG	  CCA	  AAG	  TCA	  TCT	  CAG	  G	  exon	  4-­‐5	   CTC	  ACG	  GGC	  TCA	  CAA	  TTC	  A	   chr3:87745004-­‐87745592	  TCC	  CTG	  TGA	  TTC	  CTA	  CAG	  AGA	  exon	  6-­‐7	   CTA	  TCC	  TTA	  GGC	  TCA	  GAT	   chr3:87742874-­‐87743469	  	  AGA	  ACA	  GAG	  TGA	  CTT	  GTA	  AG	  exon	  8	   GCT	  TAC	  AAG	  TCA	  CTC	  TGT	  TCT	   chr3:87742256-­‐87742894	  	  CAG	  CAG	  ATT	  TTG	  TTG	  AAC	  TA	  exon	  9	   CAA	  AGT	  GAG	  CCA	  TTT	  CCC	  TGT	   chr3:87741495-­‐87742044	  CCA	  GAG	  CCC	  AGC	  TTC	  TCT	  T	  exon	  10	   CAT	  TAT	  AGC	  TGT	  CCC	  CAT	  GT	   chr3:87740600-­‐87741197	  	  AGG	  AAG	  ACC	  TCC	  TAA	  GGA	  AG	  exon	  11	   CAT	  CTG	  ACA	  TCA	  CTG	  GCA	  GCC	   chr3:87739494+87739747	  	  GGG	  ATG	  GAC	  TTG	  ATT	  CTC	  CAA	  exon	  12	   GTT	  TCT	  CCA	  GCA	  CCT	  GGG	  AC	   chr3:87739252-­‐87740073	  	  GTT	  TTA	  GGG	  CTG	  TTG	  AAC	  GG	  
exon	  13	  
GTT	  TGT	  TTC	  CTG	  CAA	  TTA	  G	   chr3:87738724-­‐87739323	  	  CAA	  ACA	  CAT	  GGA	  GAT	  AGC	  GGA	  ACC	  CAG	  CCT	  TCT	  CTG	  A	   chr3:87738174-­‐87738761	  	  CCG	  GTG	  TGT	  AGA	  CCT	  TCT	  CAG	  CTG	  GGC	  CAG	  AGC	  CAG	  TTG	  T	   chr3:87737594-­‐87738223	  GGG	  AGG	  TCT	  CCC	  AGA	  TTC	  CA	  GAC	  ACT	  GAG	  AAG	  GCC	  TAG	  G	   chr3:87737003-­‐87737668	  	  TCA	  AAT	  GTA	  GCC	  AGC	  GTC	  CTG	  TGG	  GAA	  GAT	  GGT	  GAG	  G	   chr3:87736640-­‐87737043	  	  CCC	  CCA	  GAA	  CCT	  TCT	  ATT	  TAT	  G	  AK185634	   	  	   GGA	  AAC	  CAA	  TAG	  TGA	  GTG	  AGC	   chr3:87749141+87749692	  	  	  	   TCT	  TTG	  CTC	  AGA	  GGA	  TTG	  C	  BM940369	   	  	   TTC	  GGG	  ACA	  GGA	  AGG	  TTA	  C	   chr3:87778640+87779197	  	  	  	   CAA	  GCA	  CTG	  AGA	  GAA	  GGA	  ATG	  BB365020	   	  	   CGT	  TTT	  GTG	  TTC	  AAC	  CTG	  AC	   chr3:87804416+87804935	  	  	  	   AAC	  CTC	  TGT	  TGC	  CCT	  CTT	  C	  BB160298	   	  	   TTA	  CCC	  ACT	  CTC	  TCC	  AAG	  G	   chr3:87849217+87849865	  	  	   TTT	  TGA	  AAG	  TGG	  AGG	  TTC	  C	  AA008399	   	  	   CCC	  ACA	  TCA	  ACC	  ATC	  AAG	   chr3:87899438+87900008	  	  	  	   CAA	  AAC	  CCA	  GGT	  CCT	  TAT	  G	  CJ043528	   	  	   GGA	  CTT	  CCA	  GTT	  GCT	  CTC	  TG	   chr3:87911129+87911777	  	  	  	   CCT	  AAG	  CAA	  TGT	  GAA	  GGC	  TG	  BY607175	   	  	   TCT	  GGT	  CAA	  GGG	  ACT	  TCT	  AAC	   chr3:87922507+87923081	  	  	  	   CCC	  ATC	  CTC	  AAC	  TTA	  CCA	  G	  S78708	   	  	   AAG	  GGG	  TGG	  TGG	  TGG	  TGT	  TTA	  C	   chr3:87970546+87971229	  	  	   AGA	  TTC	  TTC	  CCC	  GAC	  GCA	  AC	  
EL608440	   	  	   TTC	  AGA	  CAC	  AGC	  GAT	  GAG	  C	   chr3:87992458+87992926	  	  	  	   TTT	  TCT	  GTC	  TCT	  CCC	  CGT	  G	  	  	   GAC	  GGA	  AGT	  GAC	  AGA	  ATG	  G	   chr3:87992869+87993475	  	  	  	   TCA	  GAA	  ACA	  GAG	  CAT	  TCA	  CTC	  
CN720784	   	  	   AGT	  TCC	  AGG	  ATA	  GCC	  AAT	  G	   chr3:88026129+88026681	  	  	   TAC	  CGC	  AAA	  GTG	  CCT	  AAG	  	  	   GGA	  CTC	  CAT	  TCA	  CAC	  AAG	  C	   chr3:88026551+88027108	  	  	  	   TGA	  CTT	  AGT	  GTG	  CTG	  CGT	  G	  CF583689	   	  	   GGG	  GTC	  TTG	  CTA	  CAA	  TGA	  TAC	   chr3:88056339+88056956	  	  	  	   GTG	  CTC	  AAA	  CCT	  GGC	  TAA	  G	  BB200528	   	  	   GCC	  TGA	  TTA	  TGC	  TAT	  GTA	  GAC	  C	   chr3:88069327+88069991	  	  	  	   GAA	  CTT	  CCC	  GAT	  AGA	  CAC	  TTG	  
BG807888	   	  	   GGT	  AGT	  TCA	  GTC	  GGT	  CCT	  TC	   chr3:88107777+88108347	  	  	  	   TAG	  GGG	  CAA	  ACC	  AAT	  GAG	  	  	   ACC	  TAT	  GAA	  AAC	  AGA	  GGC	  G	   chr3:88108203+88108817	  	  	   ATG	  GGC	  TGA	  GTC	  TGT	  GAA	  C	  
1700113A16rik	  
exon	  1	   CGG	  AAA	  TGG	  ATG	  TTA	  GGC	   chr3:88177289-­‐88177907	  TCC	  AGC	  CTT	  GTG	  ATT	  GTG	  exon	  2	   AGG	  TGG	  ATT	  TCT	  GCG	  TTC	   chr3:88175660-­‐88176184	  	  GGT	  GTA	  GTG	  TAG	  CCT	  GGT	  TG	  
exon	  3	  
TTG	  CTG	  CTT	  CGG	  CAC	  CAA	   chr3:88172102-­‐88172505	  TGA	  TTT	  CTT	  TGG	  TGC	  GGC	  G	  AGC	  CTG	  CCC	  TCC	  AAA	  TCA	   chr3:88171578-­‐88172180	  	  GTT	  TGG	  AGA	  GAC	  AGA	  AAT	  GAT	  G	  CCC	  CTT	  CTG	  CTT	  ATG	  TAG	  AGG	   chr3:88171435-­‐88171732	  TCA	  GGG	  ATA	  GTG	  GGA	  CCG	  
1700021C14Rik	  
exon	  1	   GAA	  AGG	  CAA	  GGC	  AAG	  TTA	  GAT	  AG	   chr3:88296353-­‐88297031	  	  AGA	  GCA	  ATA	  GAT	  GGT	  CCC	  G	  exon	  2	   CCA	  GAC	  ACC	  TCT	  ATG	  AGA	  TAG	   chr3:88295020-­‐88295572	  	  CCA	  AGT	  AAC	  CAA	  GTA	  GCA	  G	  exon	  3	   CCT	  GCT	  GGA	  TAC	  ACT	  CAA	  TCA	   chr3:88282674-­‐88283282	  	  CAC	  ACA	  CAC	  AGA	  ACA	  TAA	  CGC	  
0610031J06rik	  
exon	  1	   AAA	  TAC	  CTG	  TTC	  ACC	  TTG	  AGC	   chr3:88324912+88325432	  	  TGT	  TCC	  TGG	  GCT	  ACA	  ATG	  exon	  2	   GCC	  TGT	  GAG	  CAT	  ACC	  TGA	   chr3:88325624+88326072	  TTT	  CTC	  TTG	  AAT	  ATC	  CCT	  CC	  exon	  3-­‐4	   CAA	  GCC	  TCT	  TCC	  ACT	  CTA	  CC	   chr3:88326085+88326668	  	  TTA	  CAT	  TCC	  CAC	  CCA	  TCT	  ATC	  exon	  5	   CCT	  TTT	  AGT	  ATG	  GGG	  TTG	  C	   chr3:88327511+88328106	  	  GGT	  AGT	  ATT	  GGT	  CCC	  AGT	  AGC	  exon	  6	   GGC	  TAC	  TGG	  GAC	  CAA	  TAC	  TAC	   chr3:88328085+88328717	  CCA	  CAC	  TGC	  ACA	  TCC	  ATA	  C	  
tmem79	   exon	  1	   TTT	  GGA	  GAC	  ACA	  GGC	  AAG	   chr3:88334036-­‐88334485	  TCT	  CTA	  CAG	  CCA	  AGG	  GTC	  A	  exon	  2	   TTC	  CTC	  CCC	  ACA	  GTG	  TTC	  T	   chr3:88333308-­‐88333808	  	  AAT	  GGC	  TCC	  TCC	  GAC	  TTA	  G	  exon	  3	   CAG	  AGG	  CAC	  CTA	  CTA	  AGT	  CG	   chr3:88332779-­‐
AGT	  GGC	  AGG	  TTC	  AGG	  ATA	  C	   88333338	  	  
exon	  4	  
GGT	  TTC	  TCT	  TCA	  TTC	  TGC	  TG	  
chr3:88328481-­‐88332829	  	  
AAG	  GCA	  ATG	  GAT	  TCA	  ACA	  C	  GGT	  GTT	  TGG	  AGT	  AGT	  ATC	  GGC	  TTT	  TCC	  TTC	  TCC	  TTG	  GCG	  ACA	  CTT	  CCT	  TCT	  TGG	  GCA	  G	  GCT	  TGG	  AAG	  GCA	  GTT	  AGT	  TTC	  CAA	  GCC	  TCT	  CTC	  TGT	  CTT	  CC	  TGC	  TCC	  CAG	  TAA	  GTT	  GTC	  C	  DV045339	   	  	   GAA	  ACA	  GAT	  GTG	  GAG	  GAC	  TTC	   chr3:88689412+88690082	  	  	   GGC	  AAA	  GTC	  TCT	  CAG	  TGA	  AAC	  AI561824	   	  	   TCT	  ATG	  GGC	  TTT	  AGG	  GAA	  TC	   chr3:88692975+88693600	  	  	   TCT	  TGC	  CAA	  AAC	  CTA	  CTC	  C	  BB664182	   	  	   TCC	  TCT	  TGC	  CAG	  ATA	  AGT	  CC	   chr3:88696063+88696661	  	  	  	   AAT	  AAG	  AGC	  AGC	  CTG	  GAC	  C	  GH455320	   	  	   AGT	  GCT	  GGG	  AAA	  GAG	  GGT	  AG	   chr3:88704494+88705157	  	  	  	   TCT	  GGG	  GAA	  CTC	  TGG	  GAT	  AC	  AW764307	   	  	   GCA	  CCT	  TTA	  GGC	  ACA	  CTT	  G	   chr3:88712445+88713132	  	  	   TGT	  TGG	  GCA	  GGG	  TTT	  ATG	  
gm15998	  
exon	  1	   AGA	  GAG	  TGT	  GTG	  GGC	  AAA	  G	   chr3:89315287+89315605	  	  CAC	  AGC	  CCT	  TAC	  CAG	  TTT	  G	  AAT	  AGG	  CAA	  ACT	  GGT	  AAG	  GG	   chr3:89315581+89316108	  	  AGT	  GTC	  TGA	  GGA	  TGA	  AGG	  TG	  exon	  2	   GGA	  AAG	  TCA	  GGG	  CCA	  GGA	   chr3:89315920+89316688	  	  CAC	  TAC	  AAC	  AGC	  TCA	  GGG	  C	  
exon	  3	   CCC	  AGG	  ATA	  GGC	  AGA	  GTA	  AC	   chr3:89317762+89318313	  	  TTA	  CCC	  ATC	  TGC	  CTC	  GTT	  CC	  CCT	  GTC	  ATT	  ACC	  CAA	  CAT	  CG	   chr3:89318239+89318953	  TGC	  CAG	  CAG	  GTT	  TTG	  AAC	  
4731419I09Rik	  
exon	  1	   GGA	  ACT	  CAA	  CGT	  TCT	  TTC	  AC	   chr3:89337450+89338099	  GGA	  AAG	  TTA	  CCC	  AGG	  GCT	  
exon	  2	  
CCC	  TAG	  AAA	  TGC	  AAA	  GAT	  
chr3:89345062+89347949	  
GCC	  CCA	  TCA	  CTA	  TCT	  TAC	  AGG	  GCT	  GGA	  AGA	  ACT	  AAA	  AG	  TCT	  GTC	  CTT	  GGT	  CCA	  CTA	  TG	  GAA	  GAA	  GAC	  CTC	  ACA	  GGG	  ATG	  GAG	  ATT	  ACA	  CTA	  CAG	  TGT	  G	  GTG	  TTC	  CAG	  GCA	  CCA	  GTT	  CTA	  ATG	  TGG	  CTT	  CCC	  TGC	  TGT	  AG	  CTG	  ATC	  CCA	  GAG	  CAG	  GCA	  GCC	  TGA	  GTT	  CGT	  ACA	  GTT	  ATA	  G	  CAC	  ACA	  GAT	  GAG	  CTG	  TCG	  CT	  ACA	  GAC	  TGG	  TTT	  ACC	  TGA	  GGC	  4632404H12Rik	   exon	  1	   CAG	  CGC	  TTC	  CCT	  GTC	  ACA	  T	   chr3:89772220-­‐89773323	  	  TTT	  CAG	  GAC	  CCT	  CCG	  TTG	  TC	  GGC	  ACT	  ATC	  ACA	  AAG	  GAC	  AAC	  ACC	  CTC	  AGC	  CCT	  TAT	  TTA	  TTA	  G	  
exon	  2	  
ACA	  TTG	  GAA	  ATC	  TGC	  CCG	   chr3:89769042-­‐89769650	  GCC	  AGG	  AGA	  AGC	  TGA	  GCT	  G	  CTC	  AGT	  ACT	  GGC	  AAC	  TCC	   chr3:89768491-­‐89769109	  GGA	  CTC	  ATT	  CTG	  TAG	  ACA	  GTC	  TCC	  CAG	  CAT	  TCA	  GGA	  AGC	   chr3:89767996-­‐89768559	  TGA	  TAC	  AGA	  TAC	  ACA	  CAC	  CGC	  
4933434E20Rik	  
exon	  1	   GCT	  TCC	  TCT	  TAC	  TGG	  CGT	  A	   chr3:90052744+90053225	  	  CTG	  AAG	  AAC	  AAA	  GAC	  AGA	  ACG	  exon	  2	   CCA	  GGG	  ATT	  TTG	  AAA	  GTG	  AAC	   chr3:90053436+90053927	  	  TAA	  GCA	  AGC	  ACA	  ATG	  GGC	  exon	  3-­‐4	   CCA	  AGC	  ATT	  TAC	  AAA	  CCA	  CAC	  C	   chr3:90056074+90056640	  	  GCT	  CAT	  CTT	  TCT	  GTT	  CCA	  TAG	  G	  exon	  5-­‐6	   ACA	  CGG	  GGT	  TTC	  TTG	  AT	   chr3:90058397+90059343	  GTG	  TAG	  CTC	  TTC	  TGT	  ATT	  CTC	  C	  GTC	  TAC	  ACC	  AGA	  CCA	  GGC	  T	  AAA	  GCA	  CAA	  AGA	  GGA	  CCC	  
1700094D03Rik	  
exon	  1-­‐2	   TAG	  GGT	  CAT	  TGT	  TGG	  ACG	  CC	   chr3:90062732+90063332	  TCA	  CGG	  AGA	  GCA	  GAT	  TTC	  GG	   	  	  exon	  3	   AGT	  CAG	  TTC	  AAA	  GCA	  GCG	   chr3:90064355+90064821	  	  GCT	  AAA	  AGA	  GCA	  TCT	  CAC	  CTG	   	  	  
exon	  4	  
GAA	  GAG	  CCG	  ACA	  CCA	  AAC	   chr3:90065470+90066017	  TGA	  CTT	  CAG	  ACA	  CTA	  GAA	  GAG	  G	   	  	  
CCC	  ATA	  ATG	  AAA	  TCT	  GAT	  GC	   chr3:90065976+90066664	  CTG	  AAC	  AGC	  AGC	  ACT	  ATC	  G	   	  	  
CCC	  GGC	  AAT	  GGC	  TAA	  TAT	  TT	   chr3:90066610+90067195	  	  TCA	  AAG	  CCT	  GCT	  TTC	  CCC	   	  	  
GGC	  TTT	  GAA	  CAG	  GAG	  TTA	  CAA	  G	   chr3:90067188+90067645	  	  TGC	  ATG	  GGT	  GTT	  TTA	  TCT	  GC	   	  	  
GGA	  CCA	  GGC	  AAA	  CGC	  ATG	   chr3:90067596+90068232	  	  GTT	  GAT	  TAA	  CTC	  AGG	  TCA	  TCG	  GG	   	  	  
2500003M10rik	  
exon	  1	   AAA	  GTC	  AGT	  GGG	  GAT	  TCG	   chr3:90508945-­‐90509604	  	  TTT	  GAG	  GCC	  AAA	  CCA	  CTA	  C	  
exon	  2	  
ACT	  CAA	  AGG	  GAG	  CCA	  CCT	  AC	  
chr3:90505752-­‐90507824	  	  
TCT	  TGC	  AGC	  CAG	  GAT	  ATA	  CC	  TTT	  AAA	  AGA	  CTC	  CTC	  ACA	  CC	  CTT	  AGT	  AAC	  ACA	  TGA	  ATA	  CAG	  G	  GCA	  CAT	  GTG	  CTT	  CTC	  TGT	  TCA	  TCC	  ATC	  TGC	  TGG	  GCC	  AGT	  GAA	  CAA	  ACA	  GCC	  GAT	  GC	  AAG	  AAG	  TGA	  ACC	  TGG	  GAC	  C	  exon	  3	   TGG	  CTC	  TGC	  TGT	  TGT	  AGA	  C	   chr3:90502894-­‐
CCT	  CTC	  ACC	  ATT	  ACA	  CAT	  CAT	   90503521	  exon	  4	   GTA	  TGC	  CTC	  CTC	  TCC	  AAG	  GTC	   chr3:90501797-­‐90502271	  	  GTG	  ATG	  GTG	  GTG	  GCA	  ACA	  
EL605591	   	  	   TGA	  AAC	  CCC	  AAA	  GTC	  CAT	  AC	   chr3:91054885+91055818	  	  	  	   GGT	  TTC	  CTT	  GGC	  ATA	  GAA	  TG	  	  	   TCT	  AAG	  ATA	  AAG	  TGG	  AAT	  CCC	  C	  	  	   TAT	  GGA	  CTC	  CCT	  TGC	  CTG	  AC	  
4930529C04rik	  
	  	   GGA	  GGG	  CAT	  AGG	  AAA	  TGA	  AG	  
chr3:91071327+91075389	  
	  	   ACA	  GAC	  AGT	  GGC	  GAT	  GAA	  C	  	  	   GAA	  AAT	  GGA	  AGT	  CTA	  TCG	  GC	  	  	   AAG	  GGG	  AAT	  CTC	  AAC	  TCC	  G	  	  	   CCA	  GTT	  GTT	  TGA	  TGC	  GAC	  	  	   CAC	  TTG	  ACC	  TTC	  AGC	  CAT	  AC	  	  	   ATT	  GGC	  ATC	  ACT	  GTC	  ACT	  AAC	  	  	   GAG	  AGC	  CTT	  TGG	  TCA	  CTT	  GCA	  C	  	  	   TAG	  TCA	  TCC	  TCA	  CTC	  TCG	  GC	  	  	   AGA	  GAG	  TGA	  GGG	  GAA	  AAG	  G	  	  	   AGG	  ACT	  CTT	  TGA	  CTT	  GTT	  TGC	  	  	   ACA	  ACT	  GGT	  GCC	  AAC	  ATC	  	  	   GGG	  TCA	  GGT	  ATT	  CAC	  GAG	  TC	  	  	   CAT	  CCT	  CTG	  GCT	  CTT	  GAT	  AG	  	  	   CTT	  CCT	  CCA	  AAT	  ACG	  CAA	  G	  	  	   TGG	  GCT	  TCT	  GAA	  AAC	  GCA	  CC	  AK078932	  (9130204L05Rik)	  
exon	  1-­‐2	   TGT	  AGA	  CTT	  GGC	  AGG	  GTC	  AC	   chr3:91090240-­‐91090915	  	  CCA	  AAC	  TCA	  GGA	  ACA	  AGA	  CC	  exon	  3	   TCC	  ATA	  GAG	  AAA	  AAT	  GTG	  GG	   chr3:91088071-­‐91088728	  	  CAA	  CTG	  ATG	  CTC	  ATT	  CGC	  map0.2	   	  	   CCT	  GGG	  CAA	  AGC	  AAG	  GA	   chr3:91108492-­‐91108826	  	  	   ACG	  TAT	  GTG	  ACA	  CAC	  CAC	  A	  map0.3	   	  	   GTG	  TCA	  GCC	  TTT	  CTG	  GTA	  CC	   chr3:91160352-­‐91161039	  	  	   GTT	  TGG	  GCT	  GAG	  GCC	  CAG	  GAA	  map0.4	   	  	   GCC	  TCA	  GCA	  ATC	  GCA	  GGT	   chr3:91208775-­‐91209359	  	  	   AAC	  AGC	  CTG	  GCA	  ACA	  AA	  map0.10	   	  	   CAT	  AAG	  TGG	  T	  TA	  GCT	  TCT	  G	   chr3:91510991-­‐91511509	  	  	   AAT	  CCA	  TAA	  ACC	  CAC	  A	  map0.11	   	  	   CAT	  GAA	  ACT	  CAA	  GAG	  GAA	  CGA	  AA	   	  chr3:91561439-­‐91561687	  	  	   GAA	  CTG	  GAA	  ATA	  ATC	  ACC	  CA	  map0.12	   	  	   TGA	  CAT	  ACA	  TAG	  GAG	  GTT	  T	   chr3:91608323-­‐91608869	  	  	   TTG	  AGG	  GTC	  TAT	  GCC	  TTT	  G	  map1.5	   	  	   CCA	  GGA	  AAA	  CTT	  ACA	  ACG	  GAA	   chr3:91671237-­‐91671835	  	  	   CTT	  CAA	  CAC	  TCC	  ACT	  CTC	  map1.11	   	  	   GTT	  TGG	  GTA	  TGT	  TGT	  GGC	  TT	   chr3:91733235-­‐91733906	  	  	   CAA	  CCA	  TTT	  GCT	  TGG	  AAA	  ATT	  map1.12	   	  	   TGT	  GTT	  GAT	  GTC	  TTC	  TAT	  GTT	   chr3:91943487-­‐91944191	  	  	   GGA	  AGC	  AAA	  ATA	  GGG	  CTC	  AG	  map1.1f	   	  	   GCA	  GCA	  CCC	  TCT	  GAA	  GAT	  GA	   chr3:91996416+91996718	  	  	  	   GCT	  AAG	  CAC	  TTG	  TGG	  CTC	  AC	  
map1.16	   	  	   TAT	  GGC	  TGC	  CTC	  TAA	  GCT	  CCT	  G	   chr3:92034176-­‐92034817	  	  	   GAA	  TCT	  GGC	  AAT	  CAC	  AGC	  A	  map1.17	   	  	   AAT	  TCT	  CCA	  ATA	  TTA	  ATG	  TAA	  A	   chr3:92045514-­‐92046222	  	  	   GAG	  CTG	  GGA	  AGT	  AAA	  GCA	  CA	  map1.18	   	  	   GCT	  TCT	  GAA	  TTC	  TCA	  ATG	  CC	   chr3:92054107-­‐92054785	  	  	   GTG	  TCC	  CTC	  TTT	  TCC	  CCA	  CAT	  C	  CX208588	   	  	   CCA	  TAA	  CCA	  GAG	  GGC	  TAT	  TC	   chr3:92083395+92084085	  	  	   GGA	  TTC	  CTG	  CTT	  GGT	  AGA	  CC	  
BB176842	   	  	   CAG	  AAC	  ACT	  TTT	  CCT	  TCC	  AAT	  C	   chr3:92084183+92085136	  	  	   ATC	  CTG	  GGT	  GTT	  CCT	  GTT	  C	  	  	   AAG	  TTG	  AGA	  AGC	  CTG	  CCC	  TC	  	  	   GGG	  GTC	  TAT	  TAG	  GGA	  CTT	  GG	  
BB658268	   	  	   AAG	  ACT	  GAA	  CTT	  TAT	  GCT	  GTG	  C	   chr3:92097160+92098205	  	  	   GGT	  CAA	  CAG	  GGC	  AAG	  TTT	  AC	  	  	   AGG	  AAG	  ACC	  TTG	  AGG	  ATG	  AC	  	  	   GAG	  GAA	  GAA	  AGA	  CAA	  ACA	  AGG	  
BB471038	   	  	   CAT	  TGC	  TTC	  TAA	  CTC	  TGT	  GCC	   chr3:92098830+92099879	  	  	   CAG	  GGC	  AAT	  AAT	  GGT	  GAA	  G	  	  	   CCA	  CCA	  GCA	  TTG	  AAA	  ATA	  CC	  	  	   CAG	  AAA	  AAA	  AAA	  CCC	  CAC	  C	  CJ061957	   	  	   CAA	  AAA	  TGT	  TGT	  GGG	  CAA	  TC	   chr3:92112866+92113510	  	  	   TGG	  GGA	  GAG	  AAG	  ATA	  GGA	  GTC	  map2.1	   	  	   GGC	  ACC	  TTT	  ATT	  TCT	  CTC	  TGC	   chr3:92121810+92122092	  	  	  	   CAA	  AAC	  ATC	  AGC	  AGA	  AAG	  ACC	  A030004J04Rik	   	  	   CCA	  CTC	  GCA	  ATC	  TTT	  CAC	   chr3:92122894-­‐92123443	  	  	  	   GAT	  ACC	  CAC	  AGG	  AGA	  AGG	  TC	  BY089468	   	  	   CTT	  GCT	  CTG	  GGG	  TTC	  TAA	  G	   chr3:91928538-­‐91929000	  	  	   CCA	  TCA	  CTG	  GAA	  AGA	  GAG	  G	  
EH097951	   	  	   AAG	  CAC	  TAC	  ACA	  TCT	  GCC	  AC	   chr3:92131423+92132720	  	  	   AAC	  AGG	  TTC	  CAT	  CTT	  GCT	  G	  	  	   ATT	  AGT	  TCT	  GGT	  GCC	  TGG	  G	  	  	   AAG	  CAA	  GAA	  ATG	  CCT	  CAA	  C	  
lelp1	   exon	  1	  
CAT	  AGC	  TAG	  ATT	  CTC	  ATG	  TCC	   chr3:92142466-­‐92142877	  	  GGA	  GGC	  AGC	  TCT	  TTA	  AAT	  
exon	  2	   GAG	  ATG	  GTC	  CAG	  AGA	  CTG	  AAC	  A	   chr3:92134908-­‐92135876	  	  TTG	  CCC	  ATG	  GTG	  CCT	  CAC	  TTT	  CCA	  AAA	  AGG	  ATG	  TGT	  CAA	  GC	  ATC	  TCT	  CAG	  TGC	  CAG	  GGA	  TT	  
AK137696	  
exon	  1	   GTG	  AGC	  TGC	  AAC	  ATG	  AAT	  CA	   chr3:92170151+92170546	  CCA	  ATC	  TGG	  CTT	  ATA	  TGA	  GA	  exon	  2	   TTC	  CCT	  TTC	  CTT	  GGC	  TGG	  TC	   chr3:92170933+92171465	  AGT	  GAT	  TCT	  GTC	  GTG	  AGG	  GC	  exon	  3	   TGT	  GAC	  CTG	  AAA	  TGA	  GCC	   chr3:92171998+92172492	  	  CTG	  GTA	  GTA	  GCA	  CCT	  TGA	  C	  exon	  4	   GTT	  TCT	  GGA	  AGC	  TTC	  ATT	  TGC	  C	   chr3:92173482+92178122	  	  AGA	  TGG	  TCC	  GTC	  CTT	  TCG	  TC	  CTT	  GGT	  GAC	  TGT	  TAC	  CTA	  A	  
CCC	  ACT	  GTC	  AAA	  CGA	  AGC	  GCA	  TGG	  CTA	  CCC	  AAC	  ATG	  A	  CCC	  TCT	  TAC	  TCT	  TAT	  ATA	  CCC	  C	  CCA	  CTG	  CAA	  CTG	  CCT	  GAA	  TC	  CAT	  CCA	  GAG	  ACT	  GCC	  ATA	  CC	  CAT	  CCA	  CAA	  TAG	  TGC	  CTG	  GG	  GGA	  ATG	  TTC	  CTC	  TTT	  CTC	  TAC	  CTA	  CCT	  CAC	  ACC	  AGT	  CAG	  AAT	  A	  GCT	  CTT	  GTG	  CAA	  CTC	  CAG	  TG	  GGT	  CCC	  TTG	  ATA	  GAA	  CTA	  CTT	  GAT	  GTA	  GTC	  CCA	  TTT	  GTC	  C	  CAC	  TGG	  ACA	  AAT	  GGG	  ACT	  AC	  TGT	  AAC	  AAA	  CAT	  GGC	  ATG	  CAG	  G	  map3.1f	   	  	   CAC	  TCT	  ACC	  ACC	  ACA	  ATC	  TGT	  C	   chr3:92214798+92215068	  	  	   GAA	  GCA	  AAA	  GAT	  ACC	  AAG	  TGC	  
AK033478	  
	  	   CCC	  CAT	  AAG	  TGT	  AAC	  CAC	  G	  
chr3:92256377+92258533	  
	  	   GTC	  CAG	  CCT	  CAT	  CTA	  CAG	  AAC	  A	  	  	   CTA	  GTA	  CTA	  GCT	  GTT	  CTT	  GAA	  C	  	  	   AGC	  AAG	  AAA	  AGG	  AGG	  TTA	  GC	  	  	   AAC	  CTT	  ACA	  TAA	  CTT	  TAG	  CCC	  C	  	  	   CTG	  AAT	  CAT	  TGT	  ACC	  CCT	  CTT	  T	  	  	   TGT	  CAT	  TGT	  GAT	  AAG	  GGT	  CTC	  	  	   CAC	  CTG	  CTA	  TCT	  CTG	  CTC	  TG	  DT930973	   	  	   TCT	  CAT	  CCT	  GCC	  CAA	  ACA	  C	   chr3:92262832+92263669	  	  	   TAG	  GAC	  AGA	  GGG	  AGG	  TTA	  GG	  AK138172	   	  	   ACA	  AAA	  ACA	  ACC	  CTC	  CCC	  CC	   chr3:92282613+92283369	  	  	  	   GAG	  CCA	  TTG	  TTT	  TAG	  CAC	  C	  
AK029022	  
exon	  1	   GCT	  GAG	  CAC	  TTT	  TTC	  ACG	   chr3:92277470+92278889	  CAC	  CAA	  GGG	  GCA	  ACT	  GA	  GTT	  CAC	  CAG	  AGG	  CAA	  AAC	  AG	  TGA	  TAC	  CAA	  CCC	  TTG	  TCG	  G	  
exon	  2	   TAA	  CTT	  CCT	  GAT	  TCC	  CGA	  C	   chr3:92278857+92279831	  	  CAT	  CTC	  AAG	  TCC	  TTC	  TAT	  GAG	  G	  GCA	  TGG	  TAG	  GTA	  AGT	  TAC	  TGA	  GCT	  ACT	  GCT	  GTT	  TTC	  TGA	  CC	  
exon	  3	   GCT	  CTG	  CAC	  AAC	  TCA	  TCT	  CTG	   chr3:92279749+92280809	  GAT	  CCC	  TCT	  GTC	  TCC	  TAT	  AAT	  T	  CAA	  ACA	  TTA	  GGC	  AGA	  GCT	  CA	  GCA	  AGA	  CTT	  CCA	  GTG	  GAG	  GG	  exon	  4	   ACT	  CCC	  ACA	  GTT	  TTT	  GAG	  C	   chr3:92280697+92281112	  AAT	  CAG	  GTG	  TAA	  CCG	  TGC	  C	  map3.1a	   	  	   TGC	  TGT	  CTT	  TTT	  CCC	  ACT	  G	   chr3:92287510+92288072	  	  	  	   CAC	  AAA	  GAA	  TAA	  ACA	  GGC	  TGA	  G	  map3.1b	   	  	   CAG	  TGT	  TGG	  GGA	  AGA	  GAA	  G	   chr3:92307494+92308026	  	  	  	   ATC	  CAG	  TCT	  CAT	  TGT	  CAA	  GG	  map3.1c	   	  	   AGA	  TTC	  TTA	  GGG	  AAA	  GTG	  GC	   chr3:92317219+92317775	  	  	   TAC	  TTC	  CCA	  GTC	  CTG	  ATG	  AC	  
map3.1d	   	  	   TGC	  TCT	  ACA	  TTG	  ACC	  CCT	  TC	   chr3:92327483+92328016	  	  	   CAT	  CCA	  CAT	  AAT	  AGC	  AGG	  ACC	  map3.1e	   	  	   GAT	  GGG	  GAT	  AGC	  ATT	  GAA	  TC	   chr3:92337393+92337942	  	  	   TTT	  CTG	  CCC	  TAA	  ATA	  CAG	  TCC	  map3.1g	   	  	   CAT	  TGT	  TTG	  TGA	  GTT	  GGT	  CTG	   chr3:92347434+92348065	  	  	   GAC	  TCC	  CTT	  CTT	  CCA	  ATG	  TC	  map3.1i	   	  	   TGG	  AAG	  AAA	  CCC	  ACA	  GTG	   chr3:92367468+92367920	  	  	  	   GTA	  GGC	  AGG	  AGT	  GGA	  TAG	  TAT	  G	  map4.1f	   	  	   ATG	  CCA	  GAA	  CTT	  GAG	  ATT	  GC	   chr3:92374334+92374609	  	  	   TAC	  ATC	  AAA	  ATG	  CTT	  AGG	  GG	  map4.1a	   	  	   TGT	  TAG	  CAG	  CAG	  TAA	  AAG	  CAG	   chr3:92378450+92379024	  	  	   AAC	  TCT	  CAG	  TGA	  TGG	  TGG	  C	  map4.1b	   	  	   GGC	  TCT	  TCT	  CCA	  TTT	  TTT	  GTC	   chr3:92388194+92388731	  	  	   TGG	  GAA	  AGA	  GGA	  CTG	  AGA	  GTA	  G	  map4.1c	   	  	   CCC	  TTT	  TAG	  TTG	  GTG	  AAT	  AGT	  G	   chr3:92398146+92398634	  	  	   CTG	  TTG	  GTA	  AGA	  CAT	  TGT	  GAT	  G	  map4.1d	   	  	   TTC	  TTT	  CAT	  TTG	  GCA	  GGC	   chr3:92408203+92408827	  	  	   GAG	  GAC	  AAG	  GTT	  CAG	  GAC	  AC	  map4.1e	   	  	   AGG	  TAG	  GTG	  GTT	  GAA	  CAG	  CG	   chr3:92418326+92418952	  	  	  	   TAG	  GAC	  TCT	  GGG	  CAC	  TTT	  GC	  map4.1g	   	  	   AAG	  AAG	  CCA	  TTT	  GTA	  GAG	  CC	   chr3:92438343+92438838	  	  	  	   ATT	  TAC	  CCT	  CAG	  GCA	  GGT	  C	  map4.1h	   	  	   GCT	  CAC	  AGG	  TAT	  GTA	  GGC	  AC	   chr3:92448248+92448709	  	  	  	   CTC	  CTG	  ATT	  CCT	  GGC	  TAT	  G	  map4.1j	   	  	   TCT	  CTC	  TTT	  CTT	  TCT	  CCT	  ACC	  C	   chr3:92468437+92468898	  	  	   AGT	  CTC	  AGG	  ACA	  AAT	  GAA	  GTT	  G	  map4.1k	   	  	   AAG	  ACA	  CAT	  TAG	  CAC	  ACA	  TCA	  G	   chr3:92478331+92478814	  	  	  	   CAG	  GTC	  CTC	  TAA	  AAG	  AAC	  ACC	  map4.1l	   	  	   GTT	  CTA	  TCC	  ATT	  TGT	  CGG	  C	   chr3:92488339+92488988	  	  	  	   GCT	  GGT	  GCC	  AAG	  TCT	  AAA	  G	  
AK214076	  
	  	   GTG	  TGT	  AAA	  GAG	  GAA	  TCC	  CC	   chr3:92428114-­‐92429476	  	  	   GGT	  TGT	  TCA	  GAC	  ACT	  CGT	  TG	  	  	   CAA	  GAC	  TGA	  CCA	  AGA	  TGA	  GG	  	  	   TGT	  GCT	  GGT	  TCC	  ATT	  ACC	  	  	   GGT	  AAT	  GGA	  ACC	  AGC	  ACA	  G	  	  	   ACC	  ACT	  ACG	  GAA	  TCA	  CAC	  AG	  sprr3	   	  	   AAG	  ACT	  TCA	  GCA	  GCA	  GGT	  G	   chr3:92456763+92457409	  	  	  	   CAC	  ACA	  GAT	  GTT	  CCA	  CAA	  CC	  map5.1	   	  	   GGG	  GCA	  GTG	  GAT	  TAT	  TTT	  CT	   chr3:92504884+92505256	  	  	  	   GCT	  GGA	  GTT	  TCT	  CAA	  GTT	  TTG	  map5.1a	   	  	   TGA	  CTG	  TTG	  TCT	  GTG	  AAT	  CTT	  G	   chr3:92514263+92514825	  	  	   TCT	  CAC	  CAA	  CAG	  ATA	  AGT	  CAC	  C	  map5.2	   	  	   GCA	  GTA	  GAT	  GAA	  AA	  GCA	  GAA	  TC	   chr3:92509258+92509814	  	  	  	   GAG	  AGG	  GTC	  AAG	  TA	  TGTC	  AGC	  map5.3	   	  	   TGG	  TAT	  GGT	  GAC	  AAA	  CAG	  G	   chr3:92519331+92519939	  	  	  	   TTT	  TCA	  GCA	  GTT	  CGG	  TAT	  TC	  
map5.1b	   	  	   AGG	  TGT	  GTG	  GCT	  TCA	  TTT	  C	   ch3:92328000-­‐92329000	  	  	   CAC	  AAA	  GAA	  TAA	  ACA	  GGC	  TGA	  G	  map5.4	   	  	   TAT	  CAG	  CAG	  ACC	  TGG	  GAG	  AC	   chr3:92529377+92529933	  	  	   GCC	  ACC	  AGG	  TAG	  TTT	  TAT	  GC	  map5.5	   	  	   CTG	  TGG	  CTC	  AGA	  CTT	  TTG	  AC	   chr3:92539187+92539710	  	  	  	   CTC	  AGC	  ACA	  TAG	  CAG	  GTA	  TTC	  map5.1c	   	  	   GCC	  TTA	  GAG	  CAA	  ATG	  TTT	  TCA	  C	   chr3:92544237+92544699	  	  	  	   ATT	  AGA	  GAC	  CAG	  GAG	  CCA	  GG	  map5.6	   	  	   CCA	  CAC	  TTC	  AGT	  CTT	  CAT	  TCT	  C	   chr3:92351414+92351923	  	  	   GAT	  GTG	  GAG	  AAA	  GAG	  GAA	  CAC	  map5.1d	   	  	   AGA	  CTC	  TGC	  TGG	  CAA	  GGT	  AG	   chr3:92554250+92554762	  	  	  	   TCC	  TGC	  TGA	  CTG	  CTT	  GAA	  G	  map5.7	   	  	   TTA	  GGG	  AGT	  TTT	  CGG	  AGG	   chr3:92559416+92559980	  	  	  	   CCC	  TGT	  AGG	  AAC	  TAT	  GAC	  CTC	  map5.1e	   	  	   CTC	  ACA	  GCC	  ATC	  CAT	  TAG	  AC	   chr3:92564480+92565076	  	  	  	   CTT	  CTG	  TAG	  TGT	  GGC	  TTA	  TGG	  map5.8	   	  	   CAC	  CTC	  CAG	  CAG	  AAA	  GAT	  G	   chr3:92569253+92569764	  	  	  	   GAA	  TGA	  ACA	  CAG	  ACC	  CAG	  C	  map5.1g	   	  	   TGG	  TTC	  ACT	  TCA	  GGC	  AAA	  G	   chr3:92574388+92574913	  	  	   TGA	  ATC	  TTT	  GAA	  TCC	  AAG	  GC	  map5.9	   	  	   GCT	  TAT	  TAG	  CAG	  AGA	  GGG	  TTG	   chr3:92579183+92579752	  	  	  	   AGA	  GTG	  AAG	  TTG	  GAG	  CAC	  AG	  map5.1h	   	  	   AAG	  AGC	  AGC	  AGG	  TAG	  GTT	  G	   chr3:92584229+92584721	  	  	  	   TTA	  CCC	  TGG	  AGA	  TTT	  AGA	  TGC	  map5.10	   	  	   TCT	  GTA	  TGC	  TCA	  TTG	  TCC	  AAG	   chr3:92599528+92600064	  	  	   TTG	  AAA	  CCT	  CAC	  CTG	  AAG	  TG	  map5.11	   	  	   CAA	  CAC	  TGA	  AGA	  AGG	  CTG	  G	   chr3:92610322+92610938	  	  	   CAA	  AAG	  TCA	  TTC	  AGA	  TAG	  CCA	  G	  map5.1i	   	  	   TAA	  GGA	  GGG	  GCA	  TAG	  TGT	  C	   chr3:92614140+92614720	  	  	  	   AAA	  TGC	  CCA	  CAT	  CAT	  AAC	  AG	  map5.12	   	  	   CCT	  GGG	  ATG	  AAA	  TCT	  ACT	  TGG	   chr3:92626325+92626880	  	  	   GTG	  TTT	  TGT	  TCC	  CAT	  TGC	  TAA	  G	  AK019072	   	  	   TGA	  GTG	  CTA	  ATG	  CTG	  GCT	  C	   chr3:92620109-­‐92620641	  	  	   TTG	  AAC	  TGA	  AAG	  GGT	  AGG	  C	  map6.1	   	  	   GGC	  ATC	  AAA	  TGA	  AGT	  TAG	  CA	   chr3:92631383+92631730	  	  	  	   TCC	  TAA	  TGT	  CAA	  GTT	  CAC	  AGG	  map6.2	   	  	   GGA	  AGG	  GAG	  CAT	  TTA	  TTT	  ACT	  G	   chr3:92635279+92635906	  	  	  	   TGT	  TCT	  TCT	  TCT	  CCA	  CCC	  C	  CR514969	   	  	   CCT	  CTA	  TTT	  CTA	  TCG	  GCA	  CC	   chr3:92638914+92639499	  	  	   CCT	  TAT	  TCC	  TAC	  AGA	  GTG	  AGA	  A	  map6.3	   	  	   CGA	  TGG	  AAA	  AAC	  CTC	  AGC	   chr3:92640211+92640613	  	  	  	   TCT	  TCT	  AAG	  CCC	  TCT	  AAG	  CG	  map6.4	   	  	   GCA	  AAA	  GGA	  TGT	  GTA	  GCA	  AAC	   chr3:92645330+92645883	  	  	   GGG	  TTA	  GGA	  ATG	  TGG	  TTC	  AG	  map6.5	   	  	   CGT	  CAT	  TTA	  TTG	  TGT	  GGG	  AG	   chr3:92650501+92650898	  	  	  	   CAG	  GTA	  AGG	  AAA	  TAC	  AAA	  ACC	  C	  map6.5a	   	  	   CTT	  GCT	  CTT	  CCT	  CAG	  GTT	  G	   chr3:92651084+
	  	   TGA	  TAC	  TGG	  CTC	  AGG	  AAC	  AC	   92651515	  	  map6.6	   	  	   CCT	  CGT	  GTT	  CTA	  AGG	  TTT	  CC	   chr3:92655081+92655658	  	  	  	   GCA	  AAC	  ACG	  AGT	  AAA	  CTT	  GTG	  map6.7	   	  	   CTC	  AGC	  ATT	  CTT	  TAG	  TTG	  CC	   chr3:92660587+92660981	  	  	  	   CCA	  CAG	  ATA	  AGT	  GTC	  ATC	  CC	  map6.8	   	  	   GTT	  GTA	  AAA	  GAA	  CTG	  CTG	  AAG	  G	   chr3:92665278+92665808	  	  	  	   CTT	  CCC	  ATT	  CTG	  TAG	  GCT	  G	  map6.9	   	  	   GGA	  TGT	  GTA	  TGA	  ATG	  GAG	  ATG	   chr3:92670302+92670743	  	  	  	   CTC	  TTT	  GAC	  TTT	  CAC	  AAG	  CC	  map6.10	   	  	   CTG	  ATA	  AGC	  CAT	  TGT	  TCC	  AC	   chr3:92675212+92675834	  	  	   CAT	  CCA	  CCA	  GGA	  ACT	  AAC	  ATA	  G	  map6.11	   	  	   AAA	  ATG	  CCC	  CCC	  TAA	  ATG	   chr3:92680360+92680878	  	  	   GAA	  GAA	  AGG	  GAT	  TAG	  GTC	  ATT	  G	  map6.12	   	  	   GCA	  AAG	  AGG	  CAT	  TGT	  CAT	  C	   chr3:92685533+92686002	  	  	   CCT	  AAG	  TGT	  CCT	  CCC	  AAA	  TG	  
lce1d	   	  	   AGG	  CTA	  CAG	  CAG	  GAA	  GAC	  AC	   chr3:92685956+92686594	  	  	  	   CAG	  ACA	  TTT	  CAT	  TGA	  GGG	  AAT	  C	  	  	   GTG	  ATT	  CCC	  TCA	  ATG	  AAA	  TG	   chr3:92686571+92687111	  	  	   GAT	  GAG	  AGA	  TGG	  AGG	  AGA	  GAC	  AK202131	   	  	   GCT	  GGT	  GAT	  GAC	  AAG	  AAA	  GG	   chr3:92689825+92690352	  	  	  	   CTA	  AAG	  TTA	  ACT	  GGC	  TCT	  ACT	  C	  map6.13	   	  	   CTG	  GAC	  CAC	  TTC	  ATT	  TTC	  TAT	  C	   chr3:92691529+92691934	  	  	  	   GTT	  CTT	  TGG	  AAT	  AAC	  CTG	  ACC	  map6.14	   	  	   TCT	  TGT	  GTT	  TCC	  TTG	  GAT	  GTA	  G	   chr3:92696426+92697065	  	  	  	   CAG	  AGA	  AAA	  GAG	  AAA	  CAG	  AGG	  C	  map6.15a	   	  	   GAT	  GTG	  TTC	  TTG	  GAT	  TCA	  GTG	   chr3:92702374+92702768	  	  	   AAA	  ACC	  TGG	  ATG	  AAA	  TGG	  AC	  map6.16a	   	  	   CCA	  TTT	  CAA	  AGT	  GTT	  CGC	   chr3:92707188+92707595	  	  	  	   AAG	  ACT	  TCA	  GAC	  AAA	  TGG	  GAC	  map6.17	   	  	   GAA	  TAG	  GAA	  GGA	  TAG	  CAG	  GC	   chr3:92710134+92710651	  	  	  	   TTG	  GGT	  TTC	  TTT	  GGG	  AAC	  map6.18	   	  	   TTG	  TGG	  CTA	  TTG	  TGA	  CTG	  G	   chr3:92715566+92716077	  	  	  	   ACC	  ACC	  AAA	  CCC	  AAA	  GAC	  map6.19	   	  	   TAG	  TCA	  CCA	  CCT	  TTC	  CTC	  C	   chr3:92720485+92720975	  	  	  	   GGA	  TGC	  TTT	  ATT	  TCT	  GTG	  AGA	  C	  map6.20	   	  	   TGT	  TTG	  GGG	  ATT	  TCT	  ATG	  G	   chr3:92725231+92725851	  	  	   TCC	  TTT	  CCT	  CCA	  GTT	  TAT	  GTC	  map6.21	   	  	   CAA	  GTC	  AGG	  TGA	  AGC	  AAG	  C	   chr3:92730543+92731077	  	  	  	   GGG	  AGA	  GAA	  GAA	  GCA	  GAC	  ATA	  C	  map6.22	   	  	   GCA	  AGG	  AGG	  AAA	  ACA	  AAT	  G	   chr3:92735431+92736027	  	  	  	   GGT	  CCA	  GGT	  TTG	  TTG	  ACT	  C	  map6.23a	   	  	   GGA	  CTT	  GCT	  CAG	  GAC	  TCT	  ATG	   chr3:92741101+92741593	  	  	  	   TGT	  AAT	  AAC	  CTG	  GGC	  AAG	  AG	  map6.24	   	  	   ACT	  GTG	  GGC	  ATC	  ACT	  AAA	  AC	   chr3:92745481+92746009	  	  	  	   GGT	  TGC	  TTC	  TGT	  ATC	  CTG	  G	  map6.25	   	  	   ACA	  AGA	  AAC	  AGG	  ATG	  GGC	   chr3:92750319+92750944	  	  	  	   AGT	  GTC	  AGA	  CCC	  CAA	  AGT	  G	  
map6.26	   	  	   GGA	  GAG	  GAA	  AAG	  TAT	  GCC	  TG	   chr3:92755301+92755898	  	  	  	   GAT	  AAG	  CAT	  TTG	  GCA	  CTG	  G	  map6.28	   	  	   AGT	  GAC	  TGG	  AGA	  CAG	  GAT	  GC	   chr3:92752401+92753043	  	  	  	   CCA	  CCT	  TTC	  AAC	  TGA	  TGT	  CTT	  C	  map6.29	   	  	   GCT	  AAA	  AGC	  CAA	  AGG	  TGG	   chr3:92757246+92757689	  	  	  	   TGT	  GTT	  GTG	  TTT	  GGT	  GAG	  G	  map6.27	   	  	   CCC	  TGA	  GAT	  TCT	  GTC	  CTA	  CAA	  C	   chr3:92761467+92762073	  	  	  	   CCT	  ATG	  ACT	  ATT	  TTG	  TCC	  CCC	  map7.1	   	  	   GGT	  GGT	  GTC	  CTG	  TTG	  AGT	  GA	   chr3:92764574+92764879	  	  	  	   GAG	  GCA	  ATG	  GTG	  TCT	  GTG	  AC	  map7.2	   	  	   GCC	  AGA	  AGT	  TCA	  GTG	  AGT	  TG	   chr3:92769112+92769697	  	  	   AAA	  GAG	  AAT	  GTT	  GGT	  GTC	  TGA	  G	  map7.3	   	  	   CAG	  AGA	  CTG	  AGC	  CAC	  AAA	  TC	   chr3:92774141+92774747	  	  	   TAT	  TGG	  ATG	  GGT	  CAC	  ACG	  map7.4	   	  	   AGG	  TGC	  CAT	  TCT	  GAA	  AGT	  C	   chr3:92779369+92779970	  	  	   CCA	  TCT	  CCA	  TCC	  ACT	  GTT	  TAG	  
BY708731	   	  	   AGG	  GTA	  AGG	  GGT	  CAG	  TAT	  GG	   chr3:92788605-­‐92789555	  	  	  	   AAG	  TCT	  TCC	  TCA	  CCC	  AGG	  TC	  	  	   ATC	  TCT	  CCA	  TCG	  CCA	  TCG	  TC	  	  	   CAA	  CTC	  CCT	  GGA	  CAT	  TGA	  G	  map7.5	   	  	   AAC	  TAC	  CCC	  AAC	  TAA	  TGA	  GGT	  C	   chr3:92793078+92793591	  	  	  	   TGG	  TAT	  GCT	  CTT	  CTC	  TGG	  G	  BY708617	   	  	   TGA	  ATC	  AGA	  ACG	  GAC	  AAG	  AG	   chr3:92806321-­‐92806971	  	  	  	   TGA	  AAC	  ACA	  GAA	  GGG	  GTA	  GC	  map7.19	   	  	   TTC	  CTA	  CCT	  CAA	  CTT	  GCC	  C	   chr3:92809105+92809692	  	  	  	   GCC	  AAC	  TAC	  TCC	  TGG	  ACA	  TAA	  G	  map7.6a	   	  	   CTT	  GAC	  TCT	  CTT	  TCA	  GAC	  TTG	  G	   chr3:92812216+92812643	  	  	   GGC	  ACT	  GTT	  GTC	  AGG	  AAT	  AG	  map7.7	   	  	   GCC	  CAG	  AGG	  AAT	  AGC	  ATA	  ATC	   chr3:92816238+92816859	  	  	   GGT	  TCT	  CAA	  CTT	  GTC	  TAC	  AGG	  G	  map7.20	   	  	   GGC	  ATT	  GTC	  TCC	  CTT	  TTT	  AC	   chr3:92819267+92819766	  	  	  	   CAT	  CCC	  TGT	  CTC	  TCC	  AGA	  TAC	  map7.21	   	  	   GAT	  TGC	  TGA	  GTT	  GGC	  TTT	  G	   chr3:92922996+92923418	  	  	  	   AGT	  CAG	  AGT	  TTG	  AGC	  AGT	  GG	  kprp	   	  	   GTG	  AGA	  ATC	  TGA	  GGC	  AAG	  G	   chr3:92826953-­‐92827583	  	  	  	   CTT	  CTC	  CAG	  GGA	  CAA	  CAA	  G	  map7.23	   	  	   CTC	  TAT	  TGA	  AGG	  AAG	  TCA	  GGG	   chr3:92836391+92837040	  	  	  	   GGG	  TGT	  TCT	  AAA	  GTG	  GCT	  TAT	  C	  map7.9a	   	  	   CTT	  CCT	  GGG	  CAT	  TTT	  AGC	   chr3:92838221+92838869	  	  	   AAC	  CTT	  TGA	  GTT	  GGT	  GCT	  TAG	  map7.24	   	  	   AAC	  CTA	  TGC	  TAT	  GGC	  TAC	  CC	   chr3:92942557+92943169	  	  	  	   CGT	  TCT	  TCG	  TTC	  TTC	  TTG	  AG	  BG068233	   	  	   CAC	  AGT	  CAG	  GCA	  AAA	  AGG	   chr3:92843226+92843879	  	  	   TTT	  TCC	  CTT	  CTT	  TTC	  CCC	  map7.25	   	  	   GTT	  CTT	  GGC	  AAA	  AAA	  ACC	  TC	   chr3:92846516+92847165	  	  	   GCT	  GTT	  ATG	  TGG	  AGG	  AAC	  G	  map7.10a	   	  	   AGG	  AGG	  AAG	  TTT	  GTT	  GTC	  ATC	   chr3:92847315+
	  	   CAT	  CAT	  TAC	  CTG	  CCC	  AGT	  AG	   92847841	  
lce1l	  
	  	   GAA	  AAA	  CAC	  CAT	  ACC	  CCA	  TC	   chr3:92849620+92850065	  	  	   TCC	  CTC	  CCT	  TCT	  TGT	  TTT	  C	  	  	   AAT	  AGC	  AGG	  CAG	  GAA	  CAG	  G	   chr3:92850068+92850659	  	  	  	   AGT	  TTG	  TCT	  TGG	  AAT	  CAG	  TGT	  C	  	  	   AAA	  GCC	  ATC	  AGC	  AGA	  AGT	  ATC	   chr3:92850587+92851104	  	  	   GCT	  GAA	  GTT	  ATC	  TTT	  GCG	  TAT	  G	  	  	   CGA	  GAT	  GAG	  ACT	  GAA	  AAA	  CAA	  C	   chr3:92851111+92851673	  	  	   CAT	  TGT	  AAA	  CCA	  TTG	  CTT	  GC	  map7.11	   	  	   GAG	  GTT	  ATT	  ACA	  GGC	  TTT	  TGC	   chr3:92852163+92852762	  	  	  	   GAT	  GCT	  TGA	  ACT	  TCC	  TTG	  G	  map7.26	   	  	   AGG	  CTG	  CTA	  TGA	  ACC	  AAA	  G	   chr3:92854300+92854873	  	  	  	   TCT	  TTT	  ACT	  GAA	  CGG	  CTG	  TC	  map7.12a	   	  	   ATG	  CCT	  CTA	  TGG	  GTT	  GTA	  TG	   chr3:92856326+92856896	  	  	   GGT	  GAA	  TAC	  TCT	  TGA	  CTG	  CTG	  map7.27	   	  	   TGA	  AGG	  AGG	  GTT	  GCT	  ACT	  C	   chr3:92858303+92858967	  	  	  	   CAG	  AAC	  AAT	  GGC	  AGT	  ATC	  AAC	  map7.13a	   	  	   TCT	  CAC	  GCA	  GCA	  GAT	  GTT	  C	   chr3:92861286+92861775	  	  	  	   AGA	  GGG	  AGA	  GAG	  GAA	  ACT	  GG	  2310050C09Rik	  (AK009900)	   	  	   AAA	  TCC	  CCA	  GCA	  GGA	  ATG	   chr3:92869995-­‐92870597	  	  	  	   CCT	  GGT	  TCT	  CTT	  GAA	  GTC	  CC	  map7.14	   	  	   CAT	  AAC	  TCT	  GTG	  ATG	  GGG	  C	   chr3:92871177+92871711	  	  	  	   CCT	  TTA	  CTC	  CTG	  ACA	  GAC	  AGT	  G	  map7.15	   	  	   CTT	  GCT	  GTG	  GAC	  TTC	  ACT	  G	   chr3:92876098+92876700	  	  	  	   GGA	  CCA	  GAA	  AAG	  AAA	  ATC	  CTC	  map7.16	   	  	   CCT	  TTG	  TGT	  GTA	  GTT	  GAA	  GCC	   chr3:92881386+92882074	  	  	   GAA	  AAC	  AAG	  GAC	  AAA	  TAC	  ACC	  C	  map7.17a	   	  	   CCC	  CTG	  ATG	  TGA	  AAA	  GAA	  C	   chr3:92885263+92885755	  	  	  	   GAA	  CAG	  AGT	  ATG	  GAA	  GAA	  GCA	  G	  map7.18a	   	  	   AAG	  AGG	  TTT	  CAA	  GTC	  AGA	  TGC	   chr3:92890347+92890953	  	  	   CTC	  TGT	  TGG	  ATG	  TAG	  GTT	  GG	  map8.1	   	  	   AAG	  CCT	  CCA	  TTT	  TCT	  CTA	  TT	   chr3:92893942+92894275	  	  	   AGG	  TTC	  TTT	  GGT	  TTC	  TCT	  TAG	  C	  map8.2	   	  	   GCA	  TAG	  CCT	  CAC	  AAG	  AGA	  CAG	   chr3:92745902-­‐92746505	  	  	   TCC	  AGC	  AAT	  ACC	  TCT	  CCT	  G	  BY364870	   	  	   AGT	  TTT	  CAT	  CTG	  TGC	  CCC	   chr3:92901946+92902595	  	  	  	   TGG	  GTT	  ATC	  GGT	  GAG	  TGA	  G	  map8.11	   	  	   CTA	  CAC	  TCC	  ACC	  TCA	  GTT	  TAC	  C	   chr3:92906205+92906876	  	  	   TTC	  TCA	  GGC	  TCA	  CAG	  TAG	  TTG	  map8.12	   	  	   CAT	  CTC	  ACT	  ACC	  TTG	  CTC	  ATT	  G	   chr3:92911078+92911606	  	  	   TGA	  CCT	  GGT	  TCA	  CTT	  CTT	  CAG	  map8.13	   	  	   GGG	  TCT	  GGA	  AGT	  CAA	  ATA	  GC	  	   chr3:92916081+92916685	  	  	  	   AAA	  TCT	  GCC	  TGG	  AAG	  TGG	  map8.23	   	  	   CTG	  GTG	  AGT	  CAG	  TGT	  TCT	  GTC	   chr3:92918370+92918948	  	  	   ACA	  CTG	  ATG	  GAT	  ACT	  CCT	  GAA	  G	  map8.14	   	  	   CAT	  CAC	  TGT	  CTA	  CAT	  CTG	  GGG	   chr3:92921099+
	  	   AGT	  GGG	  AAA	  AAA	  GGC	  AGC	   92921642	  AV087208	   	  	   TTC	  CCA	  CAG	  AAG	  TCC	  TTT	  G	   chr3:92925074+92925713	  	  	  	   CCA	  AAG	  AGC	  ACA	  ACA	  CAG	  TG	  
CJ238734	  (lce3a)	  
exon	  1	   GCT	  TGT	  GAA	  TGA	  ATG	  GGG	   chr3:92925888-­‐92926495	  	  CCT	  GAC	  CTA	  TCT	  GCT	  TCC	  TAA	  G	  
exon	  2	   GAA	  GGA	  GTG	  TTT	  GGC	  TTA	  CAG	   chr3:92925421-­‐92926073	  	  TGA	  AGA	  AAG	  AAC	  AAG	  CCA	  AC	  CTT	  CGT	  GCT	  GTG	  CTA	  CAA	  G	   chr3:92925109-­‐92925679	  	  AGG	  CGT	  TAT	  TTC	  TTC	  ATT	  CC	  map8.15	   	  	   CCC	  AGG	  AAA	  ACC	  AAA	  AGG	   chr3:92930080+92930594	  	  	   AAG	  GCA	  AAG	  GTC	  AGC	  AGT	  C	  AK009001	  (lce3b)	  (EH107862)	   	  	   GAT	  TAC	  CAG	  ACA	  GAC	  TCA	  GCC	   chr3:92933392+92934019	  	  	   TGT	  GAA	  CAT	  CAG	  ACA	  ATC	  AGA	  G	  map8.16a	   	  	   GAT	  AAC	  ACA	  CTC	  CCT	  ACA	  GGC	   chr3:92938646+92939248	  	  	  	   TCC	  TGG	  TAG	  TTA	  GCA	  TTA	  GTG	  C	  map8.22	   	  	   ACC	  AAA	  CCT	  ACA	  TTG	  TCA	  GC	   chr3:92941980+92942583	  	  	   CTT	  TGC	  TGG	  GTA	  GCC	  ATA	  G	  AK009306	  (lce3c)	   	  	   AGT	  TTG	  GGT	  GTG	  TCT	  GCT	  C	   chr3:92944200+92944764	  	  	   AGG	  TAA	  CCA	  CAA	  AGG	  CTC	  C	  	  	   ATG	  CCT	  TGC	  CAG	  ACA	  TTG	   chr3:92944949+92945647	  	  	   CAT	  CAG	  ACA	  GGC	  AGA	  GAA	  GAC	  AV081052	   	  	   ACA	  GTC	  TGG	  AGG	  AAT	  CAG	  C	   chr3:92945555+92946178	  	  	  	   CAT	  TTT	  CCT	  GAA	  TCC	  AAG	  C	  U6	   	  	   CTG	  ACT	  GTC	  TGT	  CCC	  GTT	  AC	   chr3:92949020+92949653	  	  	  	   TCA	  GAT	  TTC	  TTT	  ACG	  GAT	  GG	  map8.3	   	  	   GCT	  CCT	  TGT	  GTG	  ACT	  TTC	  AG	   chr3:92950406+92951071	  	  	  	   GTT	  TTA	  GCA	  AGG	  CGA	  AGG	  map8.1a	   	  	   CTT	  AGG	  CAA	  ATG	  GGT	  GAA	  C	   chr3:92955474+92956027	  	  	   CTT	  GGG	  TGG	  TGG	  TTT	  AGA	  C	  
EH095282	   exon	  1	   GGC	  AGA	  CCT	  GAG	  TGA	  AAA	  GTC	   chr3:92957193+92957595	  	  AGG	  CTC	  TTG	  TCC	  ATT	  TCC	  C	  exon	  2	   TTA	  GGA	  AGC	  AGA	  TAG	  GTC	  AGG	   chr3:92957961+92958649	  	  TGA	  GTT	  AGA	  GGG	  GAA	  GAA	  CAC	  map8.21	   	  	   CAC	  AGA	  GGA	  AAT	  CTT	  ATC	  CAA	  C	   chr3:92959255+92959864	  	  	  	   AGG	  GCT	  ATC	  CTG	  GTT	  TCT	  AC	  map8.4	   	  	   TCA	  CCA	  CAC	  AGT	  AGC	  CTT	  G	   chr3:92961386+92961901	  	  	  	   ATA	  ACT	  TGC	  TGT	  GTA	  ACG	  GG	  map8.20	   	  	   GAA	  AAA	  GAA	  GAA	  GGT	  TCC	  TCA	  C	   chr3:92963230+92963740	  	  	  	   TGG	  CTG	  CTC	  TTT	  CAG	  AAT	  AC	  map8.1b	   	  	   TGC	  CCT	  TCT	  TCT	  AAT	  GAT	  GC	   chr3:92965475+92966068	  	  	   GCA	  CAA	  AAA	  AAG	  GAA	  CGA	  G	  map8.19	   	  	   GTC	  TTT	  TCC	  ATT	  CCC	  AGG	   chr3:92968108+92968706	  	  	   GAC	  CTT	  CAT	  CAA	  CAG	  TCC	  C	  map8.1c	   	  	   AGG	  CAA	  ATA	  GAT	  GGA	  CCT	  G	   chr3:92975472+92976018	  	  	   CTC	  CAG	  GGT	  ATT	  GGT	  TAG	  TTC	  map8.6a	   	  	   CAC	  TCC	  AAA	  AGA	  ATG	  TGT	  GTC	   chr3:92980111+
	  	   AAA	  GAA	  CAC	  AGA	  GGT	  GGT	  TG	   92980573	  map8.18	   	  	   GAA	  AGG	  CTT	  GGG	  ATT	  TAC	  TG	   chr3:92983186+92983867	  	  	   AGC	  AAT	  GTC	  TGG	  GAG	  AAA	  TAG	  map8.1d	   	  	   AAA	  GCC	  AAA	  GGA	  CAC	  TGA	  C	   chr3:92985482+92985972	  	  	  	   AGT	  CAA	  CAT	  AGC	  AAA	  GGG	  ATA	  C	  map8.7a	   	  	   GCT	  GCC	  TGT	  TGA	  TTG	  TTG	   chr3:92991193+92991762	  	  	  	   TGT	  GGG	  AGG	  CAG	  AAC	  TAA	  C	  
BC060281	   exon	  1	   TGA	  GAA	  TCA	  GGA	  GCA	  AAT	  CAC	   chr3:92991840+92992377	  	  CAC	  TTT	  CTG	  CTG	  CCT	  TCA	  C	  exon	  2	   GCC	  TTT	  GTA	  AAC	  CTC	  GTT	  G	   chr3:92992649+92993368	  	  CCA	  GGC	  AGT	  TAT	  CAA	  AAG	  C	  EH105059	   	  	   AAC	  CTC	  AAA	  TGT	  TCA	  GTC	  CTC	   chr3:92993219+92993734	  	  	  	   CCT	  TTA	  CTT	  CCT	  TAC	  TCT	  TGG	  C	  map8.8	   	  	   GAC	  CTG	  GCA	  GTG	  AAT	  AAG	  G	   chr3:92996415+92996894	  	  	   TCT	  TGA	  AAT	  ACA	  GCA	  CCT	  CC	  
CB841495	   	  	   AAA	  GGC	  TCC	  TGA	  GAA	  GTC	  C	   chr3:92998924+92999462	  	  	   CTA	  AGC	  GTA	  GGT	  GAA	  AGC	  C	  	  	   CCA	  GGT	  TGT	  CTC	  AGG	  AAA	  C	   chr3:92999347+92999940	  	  	   TCT	  CTT	  TTT	  TTC	  TCC	  CGC	  map8.9	   	  	   CAG	  GTA	  ACA	  TCC	  CTC	  AAG	  TG	   chr3:93002148+93002689	  	  	   GTA	  ACA	  TCT	  TTT	  GTC	  ACC	  TTC	  C	  map8.1e	   	  	   TCC	  AGA	  GAG	  AGG	  AAG	  TTG	  AAC	   chr3:93005494+93005996	  	  	  	   CTG	  TAG	  CAA	  TCT	  GGA	  ACT	  GG	  map8.10	   	  	   GAG	  GTC	  AAA	  GCA	  AGA	  TGT	  CTA	  C	   chr3:93010342+93010849	  	  	   CTC	  CTT	  GAT	  TTG	  GTA	  GAA	  CTT	  G	  map9.1	   	  	   TCC	  CAG	  AAG	  CAT	  TCA	  TCA	  CT	   chr3:93015786+93016126	  	  	  	   CTA	  TGA	  AAG	  ACA	  AGA	  ACC	  AAG	  G	  
crct1	   exon	  1	  
GAC	  CTG	  GAC	  TTG	  TTG	  GAA	  TC	   chr3:93015484-­‐93015737	  	  ATA	  GGC	  AAC	  ACA	  AAA	  GGC	  TG	  exon	  2-­‐3	   GCC	  AGA	  CAG	  ACTTT	  TCT	  CTA	  AG	   chr3:93014444-­‐93014947	  ACT	  ACT	  ATG	  GAG	  GAC	  TGG	  GTG	  exon	  3	   GGA	  AGC	  CAA	  AGG	  TCT	  CAA	  C	   chr3:93014104-­‐93014585	  	  GTG	  TTT	  GTT	  CTC	  CTT	  CAG	  GC	  CB590687	   	  	   GAA	  AGG	  GAC	  TAT	  GAC	  TTG	  GTG	   chr3:93017735+93018560	  	  	   AAC	  CTC	  TTC	  CTG	  CTG	  TAG	  CC	  map9.1h	   	  	   AAA	  GGA	  GTC	  CAT	  TCA	  ACC	  C	   chr3:93027320+93027864	  	  	   GGC	  AGG	  CTG	  ATA	  CTT	  CTC	  TC	  map9.1i	   	  	   GCA	  AAG	  ATT	  CTA	  TGC	  CCC	   chr3:93037487+93037978	  	  	   CAC	  AGC	  CAA	  ACT	  TTC	  TAA	  GC	  map9_3	   	  	   CTC	  CAT	  TTC	  TGG	  TAG	  G	   chr3:93041572+93042589	  	  	  	   ATC	  ACC	  ATC	  CCT	  GAC	  CTC	  map9.1j	   	  	   TGA	  AAC	  CTG	  TGT	  CGG	  AAG	   chr3:93047457+93047942	  	  	  	   CAA	  GAT	  TCC	  CAA	  GTG	  TAT	  GG	  AV159627	   	  	   CAG	  GTT	  AGT	  TGC	  TTC	  TGT	  TGG	   chr3:93063361+93063894	  	  	  	   TGT	  GAG	  AGG	  GTA	  TCT	  GGT	  TTG	  AA261290	   	  	   GAA	  AAG	  GGA	  TGT	  AGA	  AAT	  CAC	  G	   chr3:93064325+93064848	  	  	   GAC	  TCC	  TAC	  AAA	  GAC	  AGC	  ACC	  
gm4858	  (EG229571)	   exon	  1	   CTC	  ATC	  TGG	  ACT	  ACC	  TCT	  TG	   chr3:93068567+93069122	  GAA	  CTT	  TGT	  ATG	  AGC	  TTG	  G	  exon	  2	   AAT	  GCC	  AAG	  GGT	  GAA	  AAA	  TG	   chr3:93796683+93797909	  GCT	  TTC	  TTT	  CCC	  CTT	  TAC	  TTC	  map9.1L	   	  	   GAT	  GAA	  CCC	  AGG	  AAA	  ACA	  G	   chr3:93086127+93086626	  	  	  	   AAA	  CAC	  CTG	  AGT	  AGA	  CGG	  G	  BC112282	   	  	   CTG	  TAG	  ATA	  AGG	  GAT	  TCT	  GGG	   chr3:93100193-­‐93100744	  	  	  	   TTT	  GTT	  TTT	  GCC	  ACG	  AGG	  AV208954	   	  	   TAT	  GGT	  TCC	  CTC	  AGA	  AGC	  C	   chr3:93099783+93100385	  	  	   CAA	  GAT	  GGA	  CAC	  GAA	  CCA	  C	  AV132146	   	  	   CTT	  AGC	  AGG	  AAT	  TAA	  A	   chr3:93099990+93100593	  	  	   CAG	  ACA	  AGC	  TGG	  ACA	  TG	  AV208954	   	  	   TAT	  GGT	  TCC	  CTC	  AGA	  AGC	  C	   chr3:93099783+93100385	  	  	   CAA	  GAT	  GGA	  CAC	  GAA	  CCA	  C	  BY702609	   	  	   CAG	  GGT	  TTC	  TCT	  GTG	  TAG	  CC	   chr3:92904976-­‐92905360	  	  	   TGT	  ATT	  GTG	  TCC	  ACC	  CTT	  CTC	  map9.1a	   	  	   CAA	  TGC	  TGG	  GAA	  AGA	  AAA	  AG	   chr3:93103091+93103656	  	  	  	   GCA	  AAG	  GAG	  AAC	  CAC	  TGT	  C	  CK377705	   	  	   TGG	  TCT	  CTC	  AGG	  AAC	  TAA	  AAG	  G	   chr3:93113090+93113583	  	  	   AGT	  TGC	  CAG	  AAA	  CCG	  ATG	  map9.1b	   	  	   ACT	  CTT	  GCT	  CCT	  CAG	  AAG	  CC	   chr3:93114950+93115532	  	  	  	   CAG	  AAG	  AGT	  CCG	  CCT	  CAT	  AG	  map9.1c	   	  	   AGT	  GGT	  TTT	  GTT	  TTG	  GGC	   chr3:92929902-­‐92930410	  	  	   TTA	  CTG	  TAT	  CAT	  CCT	  TTC	  GCT	  C	  map9.1d	   	  	   GAT	  GTT	  CCT	  GCT	  GAA	  GAC	  C	   chr3:93136063+93136529	  	  	  	   CCT	  TTT	  GTC	  CTC	  CCT	  TTG	  CRNN	   intron	  1	   ATG	  GAG	  GAA	  GAG	  GCT	  ATG	  C	   chr3:93145202+93145707	  	  ACA	  AAG	  GAA	  GAC	  GGA	  AGC	  CJ189654	   	  	   GAC	  TTT	  TCC	  CGA	  TTC	  CAG	   chr3:93149470+93149936	  	  	   TCG	  CAT	  ACA	  TTC	  TTT	  CAA	  CC	  map9.1e	   	  	   ACA	  ATG	  AAA	  ATG	  GGG	  CAG	   chr3:93156135+93156743	  	  	  	   GCT	  TCT	  CCT	  CTT	  CCT	  ATT	  CAA	  G	  BY765199	   	  	   TCT	  GGC	  TGG	  TAA	  AAA	  GGT	  C	   chr3:93173490+93174312	  	  	  	   TTC	  ACA	  ACA	  TCC	  TGC	  CTC	  
BY750919	   	  	   TGG	  TAG	  AAG	  TTG	  GGA	  TGA	  TTA	  G	   chr3:93178228+93178845	  	  	  	   GCC	  CTG	  AGT	  TTG	  ATT	  CAT	  AGC	  	  	   TGT	  CAG	  AAA	  TGT	  AGT	  GGT	  TCA	  G	   chr3:93178715+93179199	  	  	   CCT	  TCC	  AGA	  GAT	  GCC	  TAC	  TTC	  map9.1g	   	  	   TTT	  GTT	  CTC	  ATT	  TAC	  TGC	  CG	   chr3:93187985+93188532	  	  	   ATA	  GGT	  CAC	  TCT	  CTC	  CAA	  ACT	  G	  map10.1	   	  	   CCACCTTCTTTGAATGCTAT	   chr3:93196979+93197318	  	  	   AAA	  GGA	  ACA	  AGT	  AGG	  ATA	  AGG	  C	  
FLG2	   exon	  1	   AAA	  TGA	  ATC	  AGC	  CCA	  TCC	   chr3:93197201+93197567	  CAA	  AGG	  TTG	  AGA	  ATC	  ACT	  GG	  intron	  1	   TCT	  GGA	  AGG	  ACA	  ACT	  ACA	  GG	   chr3:93277680+93278101	  ACG	  ATG	  TCA	  CTC	  CAA	  CGA	  G	  
exon	  2	   AGG	  GGA	  GTC	  ACT	  ACA	  ACA	  TAA	  G	   chr3:93200023+93200475	  	  AGA	  TTT	  ATG	  ATG	  ACC	  TAG	  CCC	  intron	  2	   TGA	  GAA	  AAC	  CCC	  AGT	  AAT	  AGT	  C	   chr3:93200429+93200978	  	  ACG	  CCT	  ATG	  CTT	  CTT	  TGA	  C	  map11.2	   	  	   CAG	  GAA	  GAG	  TAG	  AAC	  CAG	  AGG	   chr3:93220670+93221181	  	  	  	   CTA	  AAA	  GTA	  TGT	  CCC	  TTG	  CTT	  C	  map11.2a	   	  	   GCT	  CAA	  AGC	  ACA	  CAT	  TGC	   chr3:93228009+93228536	  	  	   TTT	  TTG	  GAG	  GCA	  CTC	  AGA	  G	  
SF3A	  
	  	   AGG	  CAT	  TAT	  CAT	  GAG	  GAG	  AAG	  G	   chr3:93234942+93236468	  	  	   GAG	  CAG	  CCC	  TTG	  TCT	  TTC	  CAG	  	  	   GGG	  GCT	  ACA	  ACA	  GAA	  GAT	  CAG	  A	  
sequencing	  primers	  
	  	   GTG	  TGC	  CAA	  TGT	  CAA	  TGG	  	  	   TGA	  AAG	  AGA	  CAA	  GCA	  GCG	  	  	   CAG	  TGA	  GAG	  CAA	  AAG	  TGA	  GG	  	  	   TCT	  TCA	  CTT	  GGA	  TTC	  TCT	  CG	  	  	   GGA	  GAA	  TCT	  GGA	  GAG	  GTC	  AAG	  	  	   TCA	  TCC	  TCA	  CTT	  TTG	  CTC	  TC	  	  	   AAT	  CTG	  CCA	  GCG	  TGT	  CTT	  G	  map11.2b	   	  	   AAG	  GGC	  ATA	  AAT	  GGG	  GAG	   chr3:93242063+93242675	  	  	  	   GTT	  GGG	  AGT	  GAG	  TTT	  TCT	  TTT	  C	  map11.2d	   	  	   AAG	  GAG	  GAA	  ATC	  TTG	  GGG	   chr3:93262312+93262904	  	  	   CAG	  ACC	  TCT	  ATC	  CAA	  TGC	  TTG	  map12.1	   	  	   CCC	  CAT	  CTT	  CCT	  CAA	  TAC	  CC	   chr3:93272858+93273302	  	  	  	   TGG	  TGA	  GTT	  TCA	  GTA	  AGG	  GTC	  
BY722912	   	  	   TGA	  CAT	  TGG	  AGA	  AAT	  AGA	  GGT	  G	   chr3:93273389+93273912	  	  	  	   GGC	  ATA	  CTT	  ATT	  GGT	  TGT	  TTG	  C	  	  	   TTC	  TTT	  GTC	  CAG	  TTC	  TGC	  TG	   chr3:93273791+93274389	  	  	  	   ATC	  ACA	  GAG	  TTG	  ACT	  GGG	  C	  FLG	   intron	  1	   CAC	  TGA	  GAT	  TCG	  GGC	  TAT	  G	   chr3:93278425+93279043	  	  TTC	  CTT	  AGA	  CTC	  TTC	  CTT	  TGC	  BY787539	   	  	   AGT	  CCG	  ATT	  CCC	  AGC	  ATC	  AG	   chr3:93282124+93282872	  	  	   TCC	  TCG	  CTG	  TGT	  TCT	  TGC	  TC	  AK076261	   	  	   AGT	  CCG	  ATT	  CCC	  AGC	  ATC	  AG	   chr3:93282124+93282872	  	  	  	   TCC	  TCG	  CTG	  TGT	  TCT	  TGC	  TC	  map13.1	   	  	   CAG	  CCT	  CAG	  TCA	  CAC	  CTT	  TA	   chr3:93317570+93317903	  	  	   TTC	  TCT	  GCT	  CAT	  TTT	  TGT	  GG	  map14.2	   	  	   GTT	  TCT	  GGC	  TCA	  GGT	  CAC	  TC	   chr3:93323174+93323599	  	  	   ATT	  TTG	  TCC	  TGA	  AGT	  GGA	  TG	  CN689430	   	  	   CAA	  CAG	  GAT	  TGG	  AGC	  CTA	  C	   chr3:93352513+93353252	  	  	  	   AGT	  AAT	  CTG	  CCT	  GCC	  CTT	  G	  
RPTN	   exon	  1	  
CCA	  ACC	  AGA	  GTA	  GAC	  AGT	  AAG	  G	   chr3:93394632+93395345	  TTA	  TCA	  CGA	  GGA	  AGA	  GAA	  CAA	  C	  
exon	  2	   TTT	  GGA	  GAC	  ATC	  CTT	  CGG	   chr3:93395099+93395624	  TTA	  TGA	  TGG	  CAG	  GCT	  TGG	  TGG	  AAC	  ACT	  TGG	  ACC	  GAG	  AC	   chr3:93395534+93396224	  CTC	  TCT	  GTC	  TGA	  CTG	  TTG	  CC	  TCHH	   exon	  1	   TGA	  AAT	  GAA	  AAC	  AGG	  GGG	   chr3:93442034+
TCA	  TCA	  GTG	  GTA	  ATG	  CCC	   93442722	  intron	  1	   GGT	  CTT	  GAT	  GGC	  ATT	  GTT	  AG	   chr3:93442662+93443265	  	  GCT	  GGA	  GAG	  ATG	  GTT	  TAG	  CC	  exon	  2	   TAC	  AGA	  TGG	  GGT	  TGT	  GAG	  CCA	  C	   chr3:93443165+93443748	  	  AGT	  CTC	  TGC	  TCT	  TCA	  TCG	  C	  map15.1	   	  	   GCC	  CAG	  TTT	  TCT	  CCC	  ATA	  GTC	   chr3:93463077+93463519	  	  	   AAT	  GTT	  TGT	  GTG	  GGT	  AAT	  GC	  BY367048	   	  	   TCT	  CAG	  TGG	  CAA	  TGG	  GGT	  AG	   chr3:93459816+93460670	  	  	   CAC	  AGT	  GCC	  AAA	  GGA	  ATG	  
S100A11	   exon	  1	  
ACC	  TAC	  TTG	  ATG	  AGC	  ACG	  AC	   chr3:93520213+93520739	  GTA	  ATT	  TTA	  GGG	  CTT	  CCT	  CG	  exon	  2	   TGG	  AAT	  AAA	  AGG	  GCA	  TAC	  G	   chr3:93523933+93524682	  	  TCT	  TGC	  TCA	  TTC	  TGT	  CTT	  TAC	  C	  exon	  3	   GGA	  TTT	  GTG	  TCC	  AGG	  TCT	  G	   chr3:93525849+93526418	  	  GAT	  TCT	  GGT	  TCC	  ATC	  GTT	  C	  
DV066316	   exon	  1	   ACC	  TAC	  TTG	  ATG	  AGC	  ACG	  AC	   chr3:93520213+93520715	  	  CTC	  CAC	  TCT	  TCT	  CTA	  ATT	  GCC	  exon	  3	   GGA	  TTT	  GTG	  TCC	  AGG	  TCT	  G	   chr3:93525849+93526418	  	  GAT	  TCT	  GGT	  TCC	  ATC	  GTT	  C	  BX518736	   	  	   GAT	  GTC	  TGG	  GCA	  CAA	  ATG	   chr3:93528637+93529287	  	  	  	   GGA	  AGA	  AAT	  GAC	  CAC	  TTA	  GGC	  CR6077335	   	  	   TTG	  GGA	  GTT	  GTC	  TGA	  AGG	  C	   chr3:93530292-­‐93530783	  	  	  	   GCT	  GGA	  TAC	  TGA	  ACA	  CAC	  G	  map16.1	   	  	   CCT	  GTT	  CCT	  GTT	  CTA	  ATG	  TGC	   chr3:93592781+93593080	  	  	  	   GAT	  AGT	  TTG	  GGA	  TTA	  GGG	  GAG	  
S100A10	   exon	  1	  
GTT	  AGT	  CTG	  TTG	  GCA	  GAG	  TG	   chr3:93554880+93555428	  AAG	  GAG	  AAC	  AGA	  ACA	  GCG	  G	  exon	  2	   CCA	  ATA	  CCT	  GAA	  GTG	  TCT	  GTT	  G	   chr3:93560767+93561300	  CAC	  CTG	  CAG	  ATT	  GAG	  AGT	  TCT	  T	  exon	  3	   CCT	  TAT	  GCA	  CGT	  GGC	  TGT	  CA	   chr3:93564119+93564794	  CCT	  GAG	  AGG	  AGA	  ATG	  CTT	  TCC	  C	  AI561653	   	  	   GGA	  AAA	  ATA	  TTT	  CCC	  AGT	  TGC	   chr3:93628599+93629848	  	  	  	   AGT	  TAT	  CTA	  TTA	  TTG	  TAT	  CJ058258	   	  	   ACT	  CCT	  CAC	  AAC	  CAT	  CTG	  G	   chr3:93640863+93641544	  	  	  	   TCT	  ACC	  CCA	  GAC	  ACA	  GAT	  TG	  tdpoz2	   	  	   CCA	  ACA	  GGA	  AGA	  AGA	  ATA	  AAT	  A	   chr3:93651548-­‐93652737	  	  	  	   TGT	  TGG	  TCA	  TAT	  CTG	  TCT	  AGC	  TC	  BB709516	   	  	   CAA	  ACT	  GTG	  ACT	  CCC	  CAT	  C	   chr3:93669214+93669833	  	  	  	   CCC	  TCT	  TCT	  GGT	  CTC	  CAT	  AG	  BY382353	   	  	   GTT	  GGA	  TTT	  TAG	  AAG	  GCA	  GAA	  G	   chr3:93680414+93680908	  	  	  	   TTC	  TTC	  CTT	  CAT	  CTT	  CTC	  TCC	  AK139746	   	  	   CAG	  AAC	  TCG	  CTG	  GGA	  TAA	  GA	   chr3:93920908+93921457	  	  	  	   AGA	  ATA	  AAA	  CAG	  GGC	  GTC	  CC	  tdpoz1	  (tz1)	   exon	  2	   CTA	  TAA	  TTG	  TAT	  CTA	  ACA	  GGA	  TA	   chr3:93873476-­‐93874475	  	  ATG	  TTG	  TGG	  AGG	  TCA	  GCC	  AG	  CN711625	   	  	   TGG	  TTT	  GTC	  ATT	  TTG	  TGG	  AG	   chr3:93781192+93782049	  	  	  	   TAA	  GGC	  TGC	  TCT	  GGG	  AAA	  CG	  
	  	   TCA	  ACC	  TGT	  GTT	  TTT	  GGC	  	  	   AAA	  GGG	  TGC	  TGC	  TAA	  CTG	  GC	  BB712653	   	  	   CAG	  AAG	  TCA	  GAG	  AAT	  CCT	  GC	   chr3:93786587+93787164	  	  	   TTT	  CTT	  CAT	  CCC	  CTG	  TTT	  C	  map17.1	   	  	   ACA	  AGC	  AAC	  AGA	  TTA	  CAC	  AGG	   chr3:93802925+93803213	  	  	   TGA	  CTT	  CTT	  GGG	  AAT	  CTG	  TG	  tdpoz4	   	  	   CAT	  AGA	  AGG	  GGC	  TAT	  TTA	  GGA	  G	   chr3:93796258+93797685	  	  	  	   TTC	  CAG	  ATT	  CCA	  ATG	  CTG	  TC	  tdpoz3	   	  	   TTG	  TAT	  CCA	  ACA	  GGA	  GGA	  AG	   chr3:93825937+93827104	  	  	   GAT	  TCT	  AAG	  ACC	  ACA	  TTT	  GGC	  CN716290	   	  	   CAG	  AGA	  AAC	  AGT	  GGG	  ACA	  GTC	   chr3:93918928+93919523	  	  	   CAC	  AGA	  TTT	  TGT	  CAG	  CAG	  TTC	  AA415113	   	  	   TGT	  GTA	  ACC	  ACT	  TGC	  TCC	  C	   chr3:93942894+93943473	  	  	  	   CAG	  CAT	  CTA	  CTG	  AGG	  AAC	  ACC	  AU259387	   	  	   TCC	  CAC	  CCT	  GGA	  TTT	  GAT	  GG	   chr3:93950844+93951460	  	  	  	   CAA	  GGG	  GTA	  AAT	  GAC	  TGA	  GC	  tdpoz5	   	  	   TGG	  ATA	  GAA	  TAG	  CCA	  AAA	  CG	   chr3:93961373-­‐93961541	  	  	  	   TTA	  CTC	  TTC	  ATC	  CCG	  TTG	  G	  BB288298	   	  	   CTT	  ACA	  AGG	  TTC	  AGG	  GTG	  G	   chr3:93978562+93979034	  	  	  	   CGT	  GTC	  TTA	  TCC	  TTG	  TTA	  TTC	  G	  AA671366	   	  	   GTG	  TGT	  GTT	  TTC	  CTG	  TCT	  CAC	   chr3:93982925+93983680	  	  	  	   TGA	  GGG	  CAG	  TAA	  TGA	  CAA	  AC	  map18.1	   	  	   GTG	  AGC	  ATA	  GTG	  GGA	  GCC	  TT	   chr3:94010375+94010692	  	  	  	   GAG	  GTT	  TGG	  CAA	  CTT	  CCC	  AG	  AA684350	   	  	   CAT	  TCC	  ACT	  TTC	  TGG	  GTC	  C	   chr3:94010955+94011543	  	  	  	   GGT	  GGT	  TGA	  AAA	  ACT	  CTC	  CTG	  BB798131	   	  	   GCA	  GTG	  GCA	  CAG	  ATG	  ATT	  ATC	   chr3:94020895+94021532	  	  	  	   GGA	  GGA	  TGT	  TGA	  TTG	  ACC	  TG	  
tdpoz1	   	  	   AAC	  CTC	  CAA	  AAC	  TCC	  TCC	  AG	   chr3:94048143-­‐94050144	  TTG	  ACC	  CAC	  AAA	  CAC	  TTC	  TC	  GAG	  AAA	  GAA	  AAA	  CAG	  TGT	  AGA	  GT	   sequencing	  primers	  TGC	  TGT	  CCC	  ACC	  AGT	  AGT	  AG	  gm9125	  (AK033449)	   	  	   CTT	  CTA	  GTT	  CTT	  CTT	  CTC	  AGA	  C	   chr3:94048656-­‐94050173	  	  	  	   TTC	  TCC	  TTT	  CCT	  CTG	  ACC	  AC	  	  	   CTT	  TTG	  AAA	  TCA	  GTC	  TGG	  ATT	  CC	   chr3:94048067-­‐94048395	  	  	  	   AGA	  TGA	  GGT	  TAT	  ATA	  CAT	  GTG	  BY382353	  (ii)	   	  	   GAG	  GTT	  GGA	  TTT	  TAG	  AAG	  GC	   chr3:94058961+94059524	  	  	  	   ACC	  TGT	  GGC	  TCT	  TTC	  AGA	  C	  gm10697	   	  	   TGT	  AAC	  CAA	  CAG	  GAT	  GAA	  GAG	   chr3:94071505-­‐94072726	  	  	  	   CAC	  TGG	  TTA	  TTG	  CTA	  TTG	  GAA	  G	  AI467280	   	  	   CGA	  GAA	  TGT	  CAA	  CAA	  AGT	  CC	   chr3:94089722+94090444	  	  	  	   GCA	  TAA	  AAC	  CTT	  GTC	  TGT	  TGG	  AI605421	   	  	   GAG	  AAA	  ATA	  GTC	  AGT	  GGC	  AAA	  C	   chr3:94095337+94096031	  	  	  	   TGG	  ACA	  TTA	  GGT	  ATT	  GCC	  TG	  CN707578	   	  	   GAC	  ACT	  GTT	  TTT	  TGC	  CAT	  TC	   chr3:94113332+94114109	  	  	  	   TTG	  GTC	  GTC	  TAC	  CTT	  CCC	  TC	  BB802563	   	  	   TGG	  CAC	  AGA	  TGA	  TTA	  GCA	  C	   chr3:94133155+
	  	   AGG	  ATG	  TTG	  ATT	  GAC	  CTG	  C	   94133789	  AA547104	   	  	   TTT	  AGG	  TGT	  TTG	  AGT	  GAG	  GG	   chr3:94157638+94158335	  	  	  	   CCT	  CAT	  CTC	  TCA	  TCT	  ATG	  TCG	  G	  gm10696	  (tdpoz1)	   	  	   CAG	  ATC	  AAC	  TTA	  AAT	  CTC	  GA	   chr3:94174318-­‐94176539	  	  	  	   CCG	  ATT	  TGT	  CCA	  GAA	  CTA	  TTC	  C	  	  	   GAG	  TGC	  TGA	  GAA	  AGA	  CTG	  ATG	  	  	   CGA	  GAA	  TGT	  CAA	  CAA	  AGT	  CC	  BB709439	   	  	   GAC	  CAA	  CAT	  CTG	  TCT	  TCC	  AAC	   chr3:94199472+94200172	  	  	  	   CAC	  AAA	  CAT	  CCA	  GAG	  CAG	  AG	  BB706344	   	  	   TAT	  CAC	  GAA	  GCA	  GTG	  GCA	  C	   chr3:94209295+94209874	  	  	  	   TCT	  TTT	  GGG	  GAA	  GTC	  CAG	  G	  BY683238	   	  	   TTG	  TGA	  AGA	  GAA	  CCT	  GAA	  GC	   chr3:94220809+94221349	  	  	   AGG	  TGG	  TTG	  TGT	  ATG	  AGG	  C	  map19.1	   	  	   GTG	  TTG	  GTT	  CCC	  CTC	  AGT	  TC	   chr3:94386613+94386865	  	  	  	   CAC	  CTG	  CTC	  AGT	  CCT	  TCA	  AG	  c2cd4d	   exon	  2	   CCA	  GGC	  GCA	  GCA	  CGC	  TGT	  CCT	  T	   chr3:94363210-­‐94364035	  	  GAC	  TTC	  ACC	  TGT	  TCT	  TTT	  ACC	  TG	  
Ling04	   exon	  1	   CCC	  CAA	  GAG	  GGG	  CAG	  GGG	  CAC	  	   chr3:94399207-­‐94399506	  CAA	  CAG	  GGT	  TGC	  TGC	  AGA	  CT	  exon	  2	   GTTGTGTGCCACACTTACTGGCA	   chr3:94401699+94403684	  GAGACCTTAGTCCTACTTCTCC	  
AK018134	  
	  	   AAA	  GAC	  ATC	  AAG	  GAA	  GGA	  GC	   chr3:94432142+94432814	  	  	  	   AAT	  GGC	  AGA	  AGC	  AGC	  ATA	  G	  	  	   TGA	  GGT	  CTG	  TCA	  CTG	  CTA	  CG	   chr3:94432673+94433382	  	  	   TTG	  CTG	  TTT	  CTT	  GGT	  GGG	  	  	   TCC	  CTC	  CCA	  CCA	  AGA	  AAC	  AG	   chr3:94433360+94434053	  	  	  	   CTG	  AAA	  AAA	  GCA	  AAG	  CCA	  AC	  	  	   TTG	  GAG	  TGA	  TAG	  ACA	  CGG	  GC	   chr3:94433760+94434522	  	  	   GGA	  GAA	  AAC	  CAA	  TGT	  GGA	  C	  	  	   CCA	  ATC	  TGA	  CCT	  TGA	  GTG	  C	   chr3:94434091+94434748	  	  	  	   AGT	  CCT	  TTC	  CTC	  CAC	  GAA	  CC	  map20.1f	   	  	   AGC	  AGC	  ATG	  GGT	  AAG	  GAA	  AA	   chr3:94693653+94693874	  	  	   GGT	  CCC	  TTT	  CTG	  TTC	  CTT	  AG	  
2310007A19Rik	  
exon	  4	   GTT	  CTT	  ACT	  AGC	  TCC	  CC	   chr3:94472121+94472399	  GGT	  TAC	  CTC	  AAG	  AGA	  AAA	  TCC	  exon	  5	   ACT	  CCA	  CAA	  AAA	  GTC	  CCG	  GG	   chr3:94466792+94467056	  GCT	  TCC	  TAA	  AGA	  GCA	  AGA	  TGG	  GGC	  exon	  6	   GTG	  ACA	  CAG	  AGA	  CCA	  ATT	  CCA	   chr3:94465587+94465975	  	  GGA	  CAA	  AGC	  ATC	  CGA	  TGT	  T	  exon	  7	   CTC	  CAG	  GAG	  AAA	  AGG	  AGT	  CA	   chr3:94464906+94465145	  	  TCC	  ACC	  TAA	  GGC	  CCC	  ACT	  CC	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APPENDIX	  III	  Complete	  list	  of	  SNPs	  discovered	  in	  Mattma/ma	  F6	  mice	  compared	  to	  C57BL/6J	  animals.	  Identified	  between	  murine	  chromosome	  3:	  87,000,00	  –	  95,000,000	  by	  homozygosity	  mapping.	  	  
Position on chr3 SNPs 
82,744,991 HET A>G 
82,745,248 HET T>C 
82,745,544 HET A>G 
82,745,764 HETA>G 
82,746,140 HET G>T 
82,746,437 HET G>A 
82,747,124 HET T>C 
82,747,535 HET C>T 
82,933,030 HET G>A 
83,741,298 HET A>G 
83,742,594 HET A>G 
83,742,634 HET C>T 
83,764,295 HET T>C 
83,764,353 HET T>C 
83,764,398 HET INS 2 
83,764,465 HET T>C 
83,764,583 HET G>A 
83,766,091 HET INS 2 
83,766,151 HET T>C 
83,766,444 HET A>C 
83,843,288 HET G>C 
85,378,143 HET DEL 4 
85,719,618 HET DEL 1 
85,719,655 HET A>G 
85,719,677 HET C>A 
85,719,683 HET G>A 
85,719,683 HET del 
87,249,933 HET C>A 
87,249,934 HET G>A 
87,249,951 HET G>T 
87,250,005 HET G>T 
87,250,034 HET C>T 
87,335,789 DEL 17bp 
87,335,916 HET G>A 
87,483,228 HOM T>C 
87,483,926 HOM G>A 
87,483,949 HOM C>T 
87,495,710 HOM T>C 
87,495,808 HOM T>G 
87,495,828 HOM T>G 
87,495,995 HOM A>G 
87,496,248 HOM A>G 
87,496,527 HOM C>T 
87,496,588 HOM G>A 
87,496,656 HOM C>T 
87,497,092 HOM A>C 
87,497,199 HOM G>A 
87,540,755 HOM A>G 
87,540,771 HOM A>C 
87,540,969 HOM T>A 
87,541,022 HOM A>G 
87,541,031 HOM G>A 
87,541,162 HOM C>T 
87,544,483 HOM DEL 8 
87,544,594 HOM A>C 
87,543,577 HOM G>A 
87,546,241 HOM C>G 
87,546,333 HOM A>G 
87,546,514 HOM G>A 
87,547,384 HOM G>T 
87,547,732 HOM A>G 
87,547,964 HOM INS 1bp 
87,553,243 HOM A>G 
87,553,531 HOM G>A 
87,653,590 HOM INS 8bp 
87,703,806 HOM C>A 
87,715,662 HOM G>A 
87,726,536 HOM 2bp INS 
87,726,927 HOM C>G 
87,830,377 HOM A>G 
87,830,601 HOM G>T 
87,830,703 HOM DEL2 
87,830,750 HOM T>C 
87,830,778 HOM C>T 
87,830,896 HOM T>C 
87,830,902 HOM A>G 
87,830,904 HOM T>C 
87,830,932 HOM C>T 
88,136,484	   HOM G>C 
88,508,770 HET DEL 4 
88,516,875 HET INS 1 
92,559,736 HET C>A 
92,613,205 HET A>C 
92,613,207 HET A>C 
92,620,581 HET T>G 
92,658,480 HET C>T 
92,710,491 HET T>C 
92,787,451 HET C>G 
92,787,663 HET C>T 
92,795,888 HET ins 1 
92,796,086 HET A>G 
92,796,105 HET G>A 
92,796,106 HET A>C 
92,796,148 HET C>T 
92,796,184 HET A>T 
92,796,706 HET T>G 
92,796,709 HET T>G 
92,796,711 HET T>C 
92,796,712 HET G>A 
92,796,718 HET C>G 
92,796,741 HET A>C 
92,796,759 HET delG:ins4 
92,797,056 HET G>A 
92,797,057 HET C>T 
92,797,081 HT G>C 
92,797,144 HET ins3 
92,797,151 HET G>A 
92,806,140 HET G>T 
92,806,148 HET A>G 
92,806,225 HET T>C 
92,806,393 HET A>G 
92,806,475 HET A>G 
92,831,634 HET T>C 
92,845,913 HET T>C 
92,846,091 HET A>G 
92,904,126 HET A>G 
92,904,346 HET del 13 
92,907,097 HET A>G 
92,907,319 HET G>A 
92,919,253 HET ins/del 5 Gs 
92,930,010 HET C>T 
92,930,041 HET T>A 
92,940,197 HET A>G 
92,940,280 HET G>A 
92,948,823 HET T>C 
92,951,438 HET G>A 
92,951,451 HET T>A 
92,951,587 HET G>T 
92,951,632 HET T>G 
92,951,714 HET G>A 
92,952,141 HET G>A 
92,952,150 HET T>C 
92,952,427 HET G>A 
92,952,934 HET T>A 
92,952,939 HET A>G 
92,977,775 HET G>A 
93,004,013 HET G>T 
93,004,386 HET T>C 
93,066,337 HET G>A 
93,066,427 HET G>A 
93,077,695 HET C>G 	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Appendix	  IV	  383	  unique	  SNPs	  and	  InDels	  identified	  in	  F6	  Mattma/ma	  by	  whole	  transcriptome	  analysis	  (performed	  by	  Dr	  Christian	  Cole,	  University	  of	  Dundee).	  Regions	  between	  chromosome	  3:	  87,000,000	  –	  95,000-­‐000	  were	  analyzed	  using	  the	  Integrated	  Genome	  Browser	  (Nicol	  et	  al.,	  2009).	  210	  SNPs	  and	  InDels	  (orange)	  were	  located	  within	  the	  critical	  homozygous	  region	  chr3:87,336,555	  –	  88,392,125.	  Homozygous	  SNPs	  were	  investigated	  by	  checking	  all	  possible	  ORFs	  and	  transcripts	  in	  that	  region	  to	  shortlist	  those	  that	  caused	  a	  protein	  change	  (green).	  A	  single	  base	  change	  G>C	  was	  identified	  at	  88,136,484	  to	  cause	  a	  nonsense	  mutation,	  TYR>STOP	  (red).	  	  Information	  legend:	  DP	  =	  Raw	  read	  depth	  VDB	  =	  Variant	  Distance	  Bias	  AF1	  =	  Max	  likelihood	  estimate	  of	  the	  first	  ALT	  allele	  frequency	  (assuming	  HWE)	  AC1	  =	  Max	  likelihood	  estimate	  of	  the	  first	  ALT	  allele	  count	  (no	  HWE	  assumption)	  DP4	  =	  #	  high-­‐quality	  ref-­‐forward	  bases,	  ref-­‐reverse,	  alt-­‐forward	  and	  alt-­‐reverse	  bases	  MQ	  =	  Root	  mean	  square	  mapping	  quality	  of	  covering	  reads	  FQ	  =	  Phred	  probability	  of	  all	  samples	  being	  the	  same	  	   Position	   Reference	  Base	   Alternate	  Base	   Quality	   Information	  87052836	   C	   A	   999	   DP=26;VDB=0.0400;AF1=1;AC1=6;DP4=0,0,13,13;MQ=42;FQ=-­‐48.7	  87055005	   C	   T	   999	   DP=72;VDB=0.0329;AF1=1;AC1=6;DP4=0,0,69,2;MQ=27;FQ=-­‐66.8	  87055011	   C	   T	   999	   DP=74;VDB=0.0372;AF1=1;AC1=6;DP4=0,0,67,2;MQ=27;FQ=-­‐66.9	  87055054	   G	   A	   999	   DP=97;VDB=0.0417;AF1=1;AC1=6;DP4=0,0,62,32;MQ=34;FQ=-­‐96.5	  87055112	   G	   A	   999	   DP=197;VDB=0.0477;AF1=1;AC1=6;DP4=0,0,87,91;MQ=39;FQ=-­‐146	  87055140	   T	   G	   999	   DP=208;VDB=0.0525;AF1=1;AC1=6;DP4=0,0,107,78;MQ=41;FQ=-­‐157	  87055176	   T	   C	   999	   DP=197;VDB=0.0522;AF1=1;AC1=6;DP4=0,0,107,73;MQ=40;FQ=-­‐154	  87055190	   T	   G	   999	   DP=199;VDB=0.0522;AF1=1;AC1=6;DP4=0,0,116,64;MQ=40;FQ=-­‐148	  87056614	   T	   C	   999	   DP=299;VDB=0.0471;AF1=1;AC1=6;DP4=0,0,146,126;MQ=40;FQ=-­‐182	  87056617	   A	   C	   999	   DP=289;VDB=0.0436;AF1=1;AC1=6;DP4=0,0,149,124;MQ=40;FQ=-­‐175	  87061255	   A	   G	   999	   DP=72;VDB=0.0029;AF1=1;AC1=6;DP4=0,0,35,35;MQ=39;FQ=-­‐85	  
87061311	   T	   C	   999	   DP=184;VDB=0.0517;AF1=1;AC1=6;DP4=0,0,94,75;MQ=43;FQ=-­‐148	  87061405	   T	   C	   999	   DP=164;VDB=0.0480;AF1=1;AC1=6;DP4=0,0,66,75;MQ=39;FQ=-­‐118	  87061417	   A	   G	   999	   DP=159;VDB=0.0513;AF1=1;AC1=6;DP4=0,0,72,81;MQ=39;FQ=-­‐112	  87061441	   A	   C	   999	   DP=151;VDB=0.0495;AF1=1;AC1=6;DP4=0,0,70,69;MQ=40;FQ=-­‐100	  87061495	   T	   C	   999	   DP=83;VDB=0.0047;AF1=1;AC1=6;DP4=0,0,40,42;MQ=42;FQ=-­‐74.2	  87061510	   C	   T	   999	   DP=70;VDB=0.0026;AF1=1;AC1=6;DP4=0,0,34,35;MQ=42;FQ=-­‐69	  87063385	   G	   A	   999	   DP=104;VDB=0.0481;AF1=1;AC1=6;DP4=1,0,54,43;MQ=41;FQ=-­‐88.9;PV4=1,1,1,1	  87063487	   C	   T	   151	   DP=105;VDB=0.0528;AF1=0.8395;AC1=5;DP4=0,1,9,8;MQ=43;FQ=-­‐17;PV4=1,0.00098,0.15,1	  87067404	   C	   A	   999	   DP=85;VDB=0.0036;AF1=1;AC1=6;DP4=0,0,4,77;MQ=37;FQ=-­‐75.9	  87067464	   A	   G	   999	   DP=50;VDB=0.0225;AF1=1;AC1=6;DP4=0,1,1,46;MQ=36;FQ=-­‐38;PV4=1,1,0.00096,0.16	  87329777	   C	   T	   999	   DP=40;VDB=0.0350;AF1=1;AC1=6;DP4=0,0,24,14;MQ=40;FQ=-­‐65.6	  87330260	   T	   C	   999	   DP=22;VDB=0.0414;AF1=1;AC1=6;DP4=0,0,11,10;MQ=47;FQ=-­‐42.4	  87333542	   C	   T	   999	   DP=47;VDB=0.0425;AF1=1;AC1=6;DP4=0,0,21,24;MQ=49;FQ=-­‐68.2	  87333810	   CTTT	   CTT	   999	   INDEL;DP=129;VDB=0.0510;AF1=1;AC1=6;DP4=0,0,35,82;MQ=49;FQ=-­‐126	  87333864	   C	   T	   999	   DP=88;VDB=0.0508;AF1=1;AC1=6;DP4=0,0,15,66;MQ=48;FQ=-­‐96.9	  87333939	   CGGGG	   CGGG	   23.8	   INDEL;DP=21;VDB=0.0309;AF1=0.7538;AC1=5;DP4=0,1,2,1;MQ=41;FQ=-­‐20.3;PV4=1,0.33,0.21,1	  87334829	   G	   T	   999	   DP=27;VDB=0.0452;AF1=1;AC1=6;DP4=0,0,8,16;MQ=42;FQ=-­‐52.5	  87334852	   A	   C	   999	   DP=20;VDB=0.0422;AF1=1;AC1=6;DP4=0,0,6,13;MQ=45;FQ=-­‐42.9	  87335336	   T	   C	   13.6	   DP=25;VDB=0.0386;AF1=0.1751;AC1=1;DP4=13,7,2,1;MQ=43;FQ=14.5;PV4=1,0.00013,0.022,1	  87335361	   A	   G	   999	   DP=23;VDB=0.0411;AF1=1;AC1=6;DP4=0,0,9,12;MQ=36;FQ=-­‐42.8	  87335365	   A	   G	   999	   DP=23;VDB=0.0374;AF1=1;AC1=6;DP4=0,0,9,14;MQ=37;FQ=-­‐42.8	  87335778	   C	   T	   999	   DP=21;VDB=0.0475;AF1=1;AC1=6;DP4=0,0,12,9;MQ=50;FQ=-­‐48.7	  87335915	   G	   A	   999	   DP=20;VDB=0.0457;AF1=1;AC1=6;DP4=0,0,7,13;MQ=45;FQ=-­‐47.6	  87336555	   A	   C	   999	   DP=32;VDB=0.0396;AF1=1;AC1=6;DP4=0,0,19,10;MQ=47;FQ=-­‐56.6	  87338156	   G	   A	   999	   DP=25;VDB=0.0410;AF1=1;AC1=6;DP4=0,0,14,8;MQ=46;FQ=-­‐50.2	  87338161	   CA	   CAA	   999	   INDEL;DP=26;VDB=0.0443;AF1=1;AC1=6;DP4=0,0,17,9;MQ=43;FQ=-­‐58.9	  87340061	   C	   T	   999	   DP=653;VDB=0.0421;AF1=1;AC1=6;DP4=1,0,242,357;MQ=47;FQ=-­‐
288;PV4=0.41,0.00014,1,1	  
87340262	   G	   T	   999	   DP=711;VDB=0.0528;AF1=1;AC1=6;DP4=0,0,411,261;MQ=48;FQ=-­‐288	  87340393	   T	   C	   999	   DP=663;VDB=0.0503;AF1=1;AC1=6;DP4=0,0,248,378;MQ=48;FQ=-­‐288	  87340851	   T	   C	   999	   DP=679;VDB=0.0459;AF1=1;AC1=6;DP4=1,0,346,282;MQ=44;FQ=-­‐288;PV4=1,1,0.013,1	  87341147	   T	   C	   999	   DP=686;VDB=0.0509;AF1=1;AC1=6;DP4=0,1,358,145;MQ=39;FQ=-­‐288;PV4=0.29,1,1,1	  87341169	   C	   T	   999	   DP=832;VDB=0.0494;AF1=1;AC1=6;DP4=0,1,343,304;MQ=40;FQ=-­‐288;PV4=0.47,0.39,1,1	  87341384	   A	   G	   999	   DP=413;VDB=0.0519;AF1=1;AC1=6;DP4=0,0,155,195;MQ=48;FQ=-­‐286	  
87341513	   ATTTTCTTTTTCTTTTTCTTTTTC	  
ATTTTCTTTTTCTTTTTC	   999	   INDEL;DP=356;VDB=0.0421;AF1=1;AC1=6;DP4=0,0,254,40;MQ=34;FQ=-­‐277	  87341855	   T	   A	   999	   DP=1424;VDB=0.0392;AF1=1;AC1=6;DP4=0,0,845,510;MQ=44;FQ=-­‐288	  87342038	   A	   G	   999	   DP=1021;VDB=0.0523;AF1=1;AC1=6;DP4=0,0,377,581;MQ=44;FQ=-­‐288	  87342382	   G	   A	   999	   DP=895;VDB=0.0526;AF1=1;AC1=6;DP4=1,1,234,332;MQ=49;FQ=-­‐207;PV4=1,1.8e-­‐09,1,0.38	  87342549	   G	   A	   999	   DP=1417;VDB=0.0517;AF1=1;AC1=6;DP4=1,1,820,429;MQ=49;FQ=-­‐288;PV4=1,7.4e-­‐07,0.31,1	  87342794	   A	   G	   999	   DP=922;VDB=0.0528;AF1=1;AC1=6;DP4=0,0,265,500;MQ=49;FQ=-­‐288	  87342954	   C	   T	   999	   DP=1094;VDB=0.0522;AF1=1;AC1=6;DP4=1,0,272,322;MQ=49;FQ=-­‐224;PV4=0.46,8.3e-­‐16,0.43,1	  87343374	   G	   A	   999	   DP=620;VDB=0.0517;AF1=1;AC1=6;DP4=0,0,328,256;MQ=48;FQ=-­‐288	  
87343505	   TAAAAAAAAAAAA	  
TAAAAAAAAAAA,TAAAAAAAAAA,TAAAAAAAAA	   186	  
INDEL;DP=619;VDB=0.0461;AF1=1;AC1=6;DP4=3,11,196,252;MQ=50;FQ=-­‐122;PV4=0.11,1,0.35,0.22	  
87422049	   G	   T	   999	   DP=91;VDB=0.0494;AF1=1;AC1=6;DP4=0,0,42,41;MQ=47;FQ=-­‐98.2	  
87422125	   TTTTTGTTTTGTTTTGTTTTGTTTT	  
TTTTTGTTTTGTTTTGTTTTGTTTTGTTTT	   999	  
INDEL;DP=70;VDB=0.0466;AF1=1;AC1=6;DP4=0,0,29,23;MQ=33;FQ=-­‐79.5	  
87422209	   ATTTTTTTTTT	  
ATTTTTTTTTTTTT,ATTTTTTTTTTTTTT,ATTTTTTTTTTTT	  
999	   INDEL;DP=79;VDB=0.0406;AF1=1;AC1=6;DP4=0,0,21,48;MQ=42;FQ=-­‐78.4	  
87422423	   CT	   CTTTTT,CTTTT	   110	   INDEL;DP=53;VDB=0.0375;AF1=1;AC1=6;DP4=0,0,5,2;MQ=29;FQ=-­‐39.3	  
87422441	   TTTCTT	   TTTCTTCTT	   999	   INDEL;DP=77;VDB=0.0457;AF1=1;AC1=6;DP4=0,0,23,7;MQ=29;FQ=-­‐63.7	  87422503	   C	   T	   999	   DP=164;VDB=0.0281;AF1=1;AC1=6;DP4=0,0,110,43;MQ=45;FQ=-­‐145	  87491844	   T	   C	   999	   DP=259;VDB=0.0519;AF1=1;AC1=6;DP4=0,1,110,132;MQ=36;FQ=-­‐200;PV4=1,0.4,1,0.18	  87501985	   AGG	   AG	   30.5	   INDEL;DP=25;VDB=0.0127;AF1=0.6228;AC1=4;DP4=1,0,2,1;MQ=41;FQ=3.23;PV4=1,0.013,0,0.00066	  87521343	   C	   A	   4.95	   DP=25;VDB=0.0053;AF1=0.1679;AC1=1;DP4=4,15,2,1;MQ=40;FQ=5.51;PV4=0.17,1.1e-­‐07,0.16,0.47	  87526274	   TG	   TGG	   76.7	   INDEL;DP=26;VDB=0.0147;AF1=0.3726;AC1=2;DP4=4,4,2,3;MQ=42;FQ=78.8;PV4=1,1,0.046,0.00082	  87530398	   T	   G,A	   999	   DP=191;VDB=0.0076;AF1=1;AC1=6;DP4=0,0,77,110;MQ=37;FQ=-­‐194	  87531381	   A	   G	   999	   DP=188;VDB=0.0076;AF1=1;AC1=6;DP4=0,0,89,77;MQ=36;FQ=-­‐163	  87531890	   C	   T,G	   999	   DP=70;VDB=0.0004;AF1=1;AC1=6;DP4=0,0,9,25;MQ=36;FQ=-­‐59.1	  87532452	   T	   C	   999	   DP=104;VDB=0.0007;AF1=1;AC1=6;DP4=0,0,34,64;MQ=38;FQ=-­‐96.8	  87533405	   A	   G	   117	   DP=54;VDB=0.0000;AF1=0.9323;AC1=5;DP4=0,1,9,8;MQ=39;FQ=-­‐27.1;PV4=1,2.7e-­‐10,0.16,0.00073	  87533576	   TA	   TAA	   23.7	   INDEL;DP=58;VDB=0.0018;AF1=0.6263;AC1=4;DP4=1,4,6,0;MQ=38;FQ=27.9;PV4=0.015,0.00018,0.074,0.042	  87536587	   G	   A	   999	   DP=73;VDB=0.0114;AF1=1;AC1=6;DP4=0,0,34,32;MQ=42;FQ=-­‐81.9	  87538170	   G	   A	   999	   DP=22;VDB=0.0246;AF1=1;AC1=6;DP4=0,0,12,6;MQ=48;FQ=-­‐41.9	  87538873	   T	   C	   999	   DP=21;VDB=0.0433;AF1=1;AC1=6;DP4=0,0,10,10;MQ=45;FQ=-­‐47.6	  87541061	   G	   A	   999	   DP=730;VDB=0.0520;AF1=1;AC1=6;DP4=0,0,434,243;MQ=39;FQ=-­‐288	  87541097	   A	   G	   999	   DP=708;VDB=0.0520;AF1=1;AC1=6;DP4=0,0,384,292;MQ=40;FQ=-­‐288	  87541294	   A	   G	   999	   DP=760;VDB=0.0528;AF1=1;AC1=6;DP4=1,0,257,447;MQ=44;FQ=-­‐288;PV4=0.37,0.059,0.021,0.46	  87541653	   A	   G	   999	   DP=638;VDB=0.0517;AF1=1;AC1=6;DP4=0,1,327,276;MQ=44;FQ=-­‐288;PV4=0.46,0.32,0.033,0.33	  87551922	   G	   A	   999	   DP=30;VDB=0.0459;AF1=1;AC1=6;DP4=0,0,13,14;MQ=49;FQ=-­‐45.9	  87552005	   A	   G	   999	   DP=43;VDB=0.0348;AF1=1;AC1=6;DP4=0,0,27,12;MQ=38;FQ=-­‐52	  87552010	   G	   A	   999	   DP=44;VDB=0.0297;AF1=1;AC1=6;DP4=0,0,27,14;MQ=38;FQ=-­‐52	  87552429	   G	   A	   999	   DP=29;VDB=0.0503;AF1=1;AC1=6;DP4=0,0,15,13;MQ=49;FQ=-­‐51.9	  87552560	   C	   T	   999	   DP=38;VDB=0.0314;AF1=1;AC1=6;DP4=0,0,20,16;MQ=46;FQ=-­‐57.8	  87552569	   T	   C	   999	   DP=45;VDB=0.0419;AF1=1;AC1=6;DP4=0,0,22,19;MQ=45;FQ=-­‐57.8	  87552622	   A	   T	   999	   DP=51;VDB=0.0424;AF1=1;AC1=6;DP4=0,0,19,31;MQ=48;FQ=-­‐61	  
87552820	   T	   G	   999	   DP=49;VDB=0.0467;AF1=1;AC1=6;DP4=0,0,14,34;MQ=46;FQ=-­‐69.8	  87552836	   T	   C	   999	   DP=49;VDB=0.0456;AF1=1;AC1=6;DP4=0,0,15,30;MQ=45;FQ=-­‐63.9	  87553242	   A	   G	   999	   DP=136;VDB=0.0530;AF1=1;AC1=6;DP4=0,1,66,57;MQ=49;FQ=-­‐124;PV4=0.47,0.0075,0.41,0.15	  87553530	   G	   A	   999	   DP=191;VDB=0.0397;AF1=1;AC1=6;DP4=0,0,78,102;MQ=48;FQ=-­‐166	  87553820	   T	   A	   106	   DP=118;VDB=0.0509;AF1=1;AC1=6;DP4=0,0,6,4;MQ=50;FQ=-­‐36	  87553902	   G	   T,C	   999	   DP=260;VDB=0.0523;AF1=1;AC1=6;DP4=0,0,157,78;MQ=49;FQ=-­‐226	  87554032	   G	   A	   999	   DP=504;VDB=0.0528;AF1=1;AC1=6;DP4=0,0,269,160;MQ=47;FQ=-­‐248	  87555066	   A	   G	   999	   DP=235;VDB=0.0070;AF1=1;AC1=6;DP4=0,0,102,114;MQ=38;FQ=-­‐185	  87555168	   G	   A	   999	   DP=228;VDB=0.0480;AF1=1;AC1=6;DP4=0,0,69,141;MQ=38;FQ=-­‐182	  87555381	   C	   T	   999	   DP=37;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,10,26;MQ=36;FQ=-­‐46	  87555576	   T	   G	   999	   DP=27;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,12,6;MQ=35;FQ=-­‐46.5	  87555619	   A	   G	   999	   DP=145;VDB=0.0221;AF1=1;AC1=6;DP4=0,0,46,34;MQ=35;FQ=-­‐96.7	  87555620	   C	   T	   999	   DP=152;VDB=0.0235;AF1=1;AC1=6;DP4=0,0,41,34;MQ=35;FQ=-­‐93.5	  87555666	   G	   A	   999	   DP=116;VDB=0.0045;AF1=1;AC1=6;DP4=0,0,61,50;MQ=36;FQ=-­‐120	  87555696	   CT	   CTT	   999	   INDEL;DP=30;VDB=0.0044;AF1=1;AC1=6;DP4=0,0,16,9;MQ=35;FQ=-­‐53	  87555788	   T	   C	   999	   DP=80;VDB=0.0011;AF1=1;AC1=6;DP4=0,0,41,27;MQ=36;FQ=-­‐81.7	  
87556028	   C	   T	   7.9	   DP=27;VDB=0.0000;AF1=0.483;G3=5.005e-­‐08,1,1.203e-­‐37;HWE=0.0467;AC1=3;DP4=6,1,2,4;MQ=46;FQ=10.3;PV4=0.1,1.3e-­‐08,0.12,0.00011	  87556195	   A	   G	   999	   DP=193;VDB=0.0281;AF1=1;AC1=6;DP4=0,1,84,106;MQ=39;FQ=-­‐169;PV4=1,0.26,0.069,0.23	  87558498	   G	   A	   999	   DP=317;VDB=0.0500;AF1=1;AC1=6;DP4=0,1,179,129;MQ=36;FQ=-­‐287;PV4=0.42,1,0.0077,1	  87559852	   G	   A	   999	   DP=154;VDB=0.0017;AF1=1;AC1=6;DP4=0,1,78,72;MQ=39;FQ=-­‐136;PV4=0.48,0.47,1,0.086	  87560037	   C	   T	   999	   DP=103;VDB=0.0001;AF1=1;AC1=6;DP4=1,0,25,53;MQ=38;FQ=-­‐95.7;PV4=0.33,0.0003,1,1	  87560049	   G	   A	   999	   DP=179;VDB=0.0010;AF1=1;AC1=6;DP4=0,0,58,104;MQ=40;FQ=-­‐165	  87560581	   A	   G	   999	   DP=251;VDB=0.0520;AF1=1;AC1=6;DP4=0,0,74,152;MQ=39;FQ=-­‐185	  87561962	   G	   A	   999	   DP=307;VDB=0.0507;AF1=1;AC1=6;DP4=1,0,201,78;MQ=42;FQ=-­‐221;PV4=1,1.8e-­‐08,0.18,0.19	  87562009	   T	   C	   999	   DP=347;VDB=0.0531;AF1=1;AC1=6;DP4=0,1,152,155;MQ=44;FQ=-­‐231;PV4=1,3.5e-­‐05,0.22,1	  
87566201	   ATT	   ATTT	   115	   INDEL;DP=20;VDB=0.0069;AF1=0.5003;G3=4.645e-­‐09,1,1.85e-­‐08;HWE=0.0418;AC1=3;DP4=1,8,2,4;MQ=37;FQ=118;PV4=0.53,1,1,0.36	  87671334	   T	   TG	   999	   INDEL;DP=128;VDB=0.0002;AF1=1;AC1=6;DP4=1,0,105,16;MQ=37;FQ=-­‐125;PV4=1,1,0.0064,0.00017	  87673799	   C	   T	   999	   DP=1501;VDB=0.0510;AF1=1;AC1=6;DP4=3,0,745,660;MQ=49;FQ=-­‐288;PV4=0.25,6.3e-­‐15,0.3,1	  87710637	   G	   A	   8.42	   DP=69;VDB=0.0001;AF1=0.5696;AC1=4;DP4=3,0,4,1;MQ=43;FQ=11.6;PV4=1,7.2e-­‐06,0.026,0.006	  87719017	   C	   T	   999	   DP=4523;VDB=0.0484;AF1=1;AC1=6;DP4=0,1,1685,2686;MQ=41;FQ=-­‐288;PV4=1,1,0.24,0.16	  87720039	   C	   T	   999	   DP=147;VDB=0.0014;AF1=0.8354;AC1=5;DP4=0,7,2,105;MQ=47;FQ=-­‐11.3;PV4=1,2.9e-­‐09,0.098,1	  87723551	   T	   A	   999	   DP=613;VDB=0.0467;AF1=1;AC1=6;DP4=0,0,490,91;MQ=43;FQ=-­‐288	  
87723928	   ACCCCCCCCCCCC	  
ACCCCCCCCCC,ACCCCCCCCCCC,ACCCCCCCCC	   70.2	  
INDEL;DP=74;VDB=0.0421;AF1=1;AC1=6;DP4=0,0,18,18;MQ=47;FQ=-­‐46.4	  
87723979	   A	   G	   999	   DP=124;VDB=0.0481;AF1=1;AC1=6;DP4=0,0,56,46;MQ=44;FQ=-­‐120	  87724007	   C	   A	   999	   DP=140;VDB=0.0482;AF1=1;AC1=6;DP4=0,0,83,53;MQ=43;FQ=-­‐157	  87725443	   A	   G	   29.5	   DP=92;VDB=0.0015;AF1=0.33;AC1=2;DP4=1,82,0,8;MQ=49;FQ=31.2;PV4=1,1,1.7e-­‐17,1	  87725448	   A	   G	   13.1	   DP=92;VDB=0.0004;AF1=0.468;AC1=3;DP4=1,72,0,19;MQ=49;FQ=15.6;PV4=1,5.8e-­‐29,0.084,0.17	  87725564	   T	   C	   262	   DP=33;VDB=0.0296;AF1=1;AC1=6;DP4=0,0,16,4;MQ=42;FQ=-­‐47.6	  87725609	   A	   G	   7.71	   DP=100;VDB=0.0328;AF1=0.3231;AC1=2;DP4=65,14,16,3;MQ=36;FQ=9.12;PV4=1,2.4e-­‐21,1,1	  
87726828	   ATTTTTTTTTTTTT	   ATTTTTTTTTTT,ATTTTTTTTTTTT	   246	   INDEL;DP=60;VDB=0.0510;AF1=1;AC1=6;DP4=0,0,17,18;MQ=45;FQ=-­‐66.6	  87726926	   C	   G	   999	   DP=1482;VDB=0.0449;AF1=1;AC1=6;DP4=1,2,689,659;MQ=40;FQ=-­‐288;PV4=0.62,8.5e-­‐11,1,1	  87728507	   C	   G	   999	   DP=95;VDB=0.0522;AF1=1;AC1=6;DP4=0,0,51,39;MQ=49;FQ=-­‐106	  87729141	   T	   C	   999	   DP=234;VDB=0.0526;AF1=1;AC1=6;DP4=0,0,90,133;MQ=48;FQ=-­‐215	  87729935	   G	   T	   999	   DP=21;VDB=0.0476;AF1=1;AC1=6;DP4=0,0,12,8;MQ=48;FQ=-­‐48.4	  87731484	   C	   A	   5.24	   DP=21;VDB=0.0007;AF1=0.3372;AC1=2;DP4=4,3,3,1;MQ=46;FQ=6.52;PV4=1,6.6e-­‐06,0.002,0.0037	  87732377	   A	   G	   249	   DP=25;VDB=0.0493;AF1=1;AC1=6;DP4=0,0,14,9;MQ=49;FQ=-­‐45	  87732464	   A	   T	   228	   DP=21;VDB=0.0253;AF1=1;AC1=6;DP4=0,0,8,13;MQ=50;FQ=-­‐47.8	  
87733197	   T	   G	   999	   DP=60;VDB=0.0522;AF1=1;AC1=6;DP4=0,0,28,12;MQ=49;FQ=-­‐63	  87734692	   T	   C	   999	   DP=36;VDB=0.0487;AF1=1;AC1=6;DP4=0,0,15,18;MQ=48;FQ=-­‐57.4	  87735221	   T	   C	   999	   DP=58;VDB=0.0356;AF1=1;AC1=6;DP4=0,0,45,11;MQ=44;FQ=-­‐72.8	  87735633	   AAAGAAGAA	   AAAGAAGAAGAA	   999	   INDEL;DP=288;VDB=0.0510;AF1=1;AC1=6;DP4=0,0,81,143;MQ=30;FQ=-­‐211	  87735674	   A	   G	   999	   DP=302;VDB=0.0471;AF1=1;AC1=6;DP4=0,0,162,129;MQ=36;FQ=-­‐251	  87736062	   A	   G	   999	   DP=1435;VDB=0.0504;AF1=1;AC1=6;DP4=1,0,761,544;MQ=41;FQ=-­‐288;PV4=1,1,1,0.16	  87736074	   T	   C	   999	   DP=1471;VDB=0.0523;AF1=1;AC1=6;DP4=1,0,748,560;MQ=40;FQ=-­‐288;PV4=1,1,1,0.37	  87743985	   A	   G	   999	   DP=499;VDB=0.0484;AF1=1;AC1=6;DP4=0,0,245,200;MQ=46;FQ=-­‐288	  87744075	   C	   G	   999	   DP=624;VDB=0.0436;AF1=1;AC1=6;DP4=0,0,332,248;MQ=32;FQ=-­‐288	  87756996	   C	   T	   999	   DP=1919;VDB=0.0510;AF1=1;AC1=6;DP4=1,1,895,904;MQ=43;FQ=-­‐288;PV4=1,0.00021,1,0.13	  87757110	   A	   C	   999	   DP=1301;VDB=0.0504;AF1=1;AC1=6;DP4=1,0,329,914;MQ=46;FQ=-­‐288;PV4=0.27,1.4e-­‐07,0.26,0.37	  87757183	   C	   T	   999	   DP=724;VDB=0.0457;AF1=1;AC1=6;DP4=0,2,83,601;MQ=44;FQ=-­‐288;PV4=1,0.38,0.04,1	  87775838	   G	   A	   999	   DP=180;VDB=0.0461;AF1=1;AC1=6;DP4=0,0,69,103;MQ=44;FQ=-­‐188	  87778767	   A	   G	   999	   DP=25;VDB=0.0011;AF1=1;AC1=6;DP4=0,0,17,7;MQ=38;FQ=-­‐52.5	  87779341	   A	   T	   999	   DP=29;VDB=0.0001;AF1=0.8314;AC1=5;DP4=0,2,7,16;MQ=39;FQ=-­‐4.7;PV4=1,0.31,0.022,0.03	  87779419	   A	   G	   999	   DP=211;VDB=0.0503;AF1=1;AC1=6;DP4=0,0,124,82;MQ=44;FQ=-­‐172	  87779590	   C	   T	   999	   DP=199;VDB=0.0526;AF1=1;AC1=6;DP4=0,0,94,77;MQ=48;FQ=-­‐160	  87779650	   A	   G	   999	   DP=220;VDB=0.0514;AF1=1;AC1=6;DP4=0,0,109,91;MQ=48;FQ=-­‐182	  87779729	   A	   T	   999	   DP=193;VDB=0.0519;AF1=1;AC1=6;DP4=0,0,78,89;MQ=47;FQ=-­‐182	  87779961	   T	   A	   999	   DP=137;VDB=0.0447;AF1=1;AC1=6;DP4=0,0,55,75;MQ=47;FQ=-­‐133	  87779987	   G	   A	   999	   DP=147;VDB=0.0478;AF1=1;AC1=6;DP4=0,0,61,82;MQ=47;FQ=-­‐145	  87780029	   G	   A	   999	   DP=166;VDB=0.0520;AF1=1;AC1=6;DP4=0,0,73,88;MQ=48;FQ=-­‐175	  87780066	   C	   T	   999	   DP=133;VDB=0.0528;AF1=1;AC1=6;DP4=0,0,52,65;MQ=48;FQ=-­‐129	  87780117	   T	   C	   999	   DP=130;VDB=0.0398;AF1=1;AC1=6;DP4=0,0,63,62;MQ=49;FQ=-­‐115	  87780274	   G	   A	   999	   DP=181;VDB=0.0517;AF1=1;AC1=6;DP4=0,0,82,90;MQ=48;FQ=-­‐172	  87780298	   A	   G	   999	   DP=194;VDB=0.0521;AF1=1;AC1=6;DP4=0,0,68,102;MQ=48;FQ=-­‐184	  87780376	   G	   A	   999	   DP=142;VDB=0.0447;AF1=1;AC1=6;DP4=0,0,74,64;MQ=44;FQ=-­‐142	  
87780532	   G	   A	   999	   DP=110;VDB=0.0425;AF1=1;AC1=6;DP4=1,0,75,31;MQ=36;FQ=-­‐112;PV4=1,1,0.15,1	  87780559	   A	   T	   146	   DP=74;VDB=0.0509;AF1=0.679;AC1=4;DP4=16,1,40,8;MQ=15;FQ=-­‐5.61;PV4=0.43,1.2e-­‐20,0.33,1	  87780622	   C	   A	   999	   DP=128;VDB=0.0345;AF1=1;AC1=6;DP4=0,0,72,44;MQ=32;FQ=-­‐136	  87780909	   T	   C	   999	   DP=133;VDB=0.0429;AF1=1;AC1=6;DP4=0,0,15,12;MQ=41;FQ=-­‐53.8	  87780910	   G	   A	   999	   DP=133;VDB=0.0429;AF1=1;AC1=6;DP4=0,0,16,13;MQ=41;FQ=-­‐53.9	  87780921	   A	   G	   999	   DP=131;VDB=0.0476;AF1=1;AC1=6;DP4=0,0,80,48;MQ=45;FQ=-­‐124	  87781057	   A	   C	   999	   DP=196;VDB=0.0527;AF1=1;AC1=6;DP4=0,0,96,79;MQ=48;FQ=-­‐148	  87781379	   A	   G	   999	   DP=244;VDB=0.0482;AF1=1;AC1=6;DP4=1,2,113,98;MQ=49;FQ=-­‐151;PV4=0.6,9.7e-­‐15,0.32,1	  87781933	   G	   A	   999	   DP=307;VDB=0.0484;AF1=1;AC1=6;DP4=0,1,106,183;MQ=47;FQ=-­‐236;PV4=1,0.00057,0.28,1	  87782080	   AG	   AGTGG	   999	   INDEL;DP=233;VDB=0.0449;AF1=1;AC1=6;DP4=0,0,85,139;MQ=46;FQ=-­‐250	  87782338	   A	   G	   999	   DP=402;VDB=0.0510;AF1=1;AC1=6;DP4=0,1,141,230;MQ=48;FQ=-­‐287;PV4=1,4e-­‐08,0.29,0.18	  87782401	   G	   A	   999	   DP=460;VDB=0.0461;AF1=1;AC1=6;DP4=0,0,230,215;MQ=48;FQ=-­‐288	  87782567	   G	   A	   999	   DP=344;VDB=0.0513;AF1=1;AC1=6;DP4=0,1,92,233;MQ=48;FQ=-­‐211;PV4=1,0.00085,0.29,0.4	  87782585	   G	   A	   999	   DP=350;VDB=0.0461;AF1=1;AC1=6;DP4=0,1,127,201;MQ=48;FQ=-­‐219;PV4=1,1.5e-­‐08,0.31,0.2	  87783129	   C	   T	   999	   DP=489;VDB=0.0419;AF1=1;AC1=6;DP4=0,0,258,216;MQ=49;FQ=-­‐288	  87783286	   C	   A	   999	   DP=267;VDB=0.0517;AF1=1;AC1=6;DP4=1,0,60,179;MQ=49;FQ=-­‐212;PV4=0.25,1.2e-­‐09,1,0.18	  87783407	   A	   G	   999	   DP=325;VDB=0.0444;AF1=1;AC1=6;DP4=0,0,240,66;MQ=47;FQ=-­‐250	  87783412	   G	   A	   999	   DP=330;VDB=0.0444;AF1=1;AC1=6;DP4=1,0,247,75;MQ=47;FQ=-­‐288;PV4=1,0.00043,1,1	  87783616	   T	   A	   999	   DP=430;VDB=0.0495;AF1=1;AC1=6;DP4=0,0,214,176;MQ=48;FQ=-­‐288	  87783819	   G	   A	   999	   DP=370;VDB=0.0524;AF1=1;AC1=6;DP4=3,1,179,149;MQ=48;FQ=-­‐283;PV4=0.63,0.00092,1,1	  87783989	   TGGGGGG	   TGGGGGGGG	   999	   INDEL;DP=184;VDB=0.0481;AF1=1;AC1=6;DP4=0,0,88,76;MQ=46;FQ=-­‐176	  87784005	   C	   T	   999	   DP=258;VDB=0.0490;AF1=1;AC1=6;DP4=0,0,132,106;MQ=47;FQ=-­‐216	  87784180	   T	   C	   999	   DP=472;VDB=0.0529;AF1=1;AC1=6;DP4=0,0,151,289;MQ=48;FQ=-­‐277	  87784204	   A	   G	   999	   DP=476;VDB=0.0517;AF1=1;AC1=6;DP4=0,0,137,302;MQ=48;FQ=-­‐288	  
87858381	   AT	   ATT	   999	   INDEL;DP=29;VDB=0.0043;AF1=0.7856;AC1=5;DP4=0,2,7,12;MQ=33;FQ=-­‐20.1;PV4=0.53,1,1,0.0001	  87858954	   A	   G	   999	   DP=332;VDB=0.0421;AF1=1;AC1=6;DP4=0,0,138,182;MQ=40;FQ=-­‐288	  87859337	   C	   T	   999	   DP=594;VDB=0.0500;AF1=1;AC1=6;DP4=0,0,296,273;MQ=47;FQ=-­‐288	  87860731	   G	   A	   999	   DP=27;VDB=0.0462;AF1=1;AC1=6;DP4=0,0,11,14;MQ=48;FQ=-­‐52.8	  87860892	   A	   AT	   14.8	   INDEL;DP=36;VDB=0.0470;AF1=0.1667;AC1=1;DP4=22,8,2,1;MQ=47;FQ=15.6;PV4=1,0.075,0.17,0.00073	  87862299	   T	   C	   999	   DP=902;VDB=0.0345;AF1=1;AC1=6;DP4=0,0,98,103;MQ=41;FQ=-­‐212	  87862300	   G	   A	   999	   DP=907;VDB=0.0361;AF1=1;AC1=6;DP4=0,1,94,101;MQ=41;FQ=-­‐199;PV4=1,0.28,1,1	  87905349	   G	   A	   21.2	   DP=36;VDB=0.0000;AF1=0.58;AC1=4;DP4=3,5,0,8;MQ=44;FQ=24.8;PV4=0.2,1.4e-­‐11,0,0.00012	  87908295	   GT	   GTT	   5.16	   INDEL;DP=22;VDB=0.0213;AF1=0.4253;AC1=3;DP4=2,3,3,0;MQ=35;FQ=6.84;PV4=0.2,0.048,0.13,0.027	  87912435	   G	   GA	   999	   INDEL;DP=25;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,15,5;MQ=41;FQ=-­‐52.9	  87913417	   AGG	   AG	   18.2	   INDEL;DP=55;VDB=0.0024;AF1=0.1846;AC1=1;DP4=1,7,2,1;MQ=48;FQ=19.1;PV4=0.15,0.031,0.0028,0.067	  87919821	   C	   T	   8.83	   DP=46;VDB=0.0043;AF1=0.3904;AC1=2;DP4=1,1,1,1;MQ=50;FQ=10.6;PV4=1,0.045,0.21,0.23	  87950762	   T	   A	   27.3	   DP=21;VDB=0.0340;AF1=0.6661;AC1=4;DP4=1,1,1,2;MQ=49;FQ=16;PV4=1,0.016,0.027,1	  87959598	   A	   T	   10.1	   DP=63;VDB=0.0000;AF1=0.2746;AC1=2;DP4=13,8,6,3;MQ=47;FQ=11.3;PV4=1,1.8e-­‐14,0.007,0.00031	  
87971431	   C	   CAA	   123	   INDEL;DP=27;VDB=0.0299;AF1=0.4967;G3=1.6e-­‐08,1,3.988e-­‐26;HWE=0.0424;AC1=3;DP4=2,6,0,10;MQ=40;FQ=126;PV4=0.18,1,0.001,0.016	  87972884	   A	   G	   999	   DP=466;VDB=0.0421;AF1=1;AC1=6;DP4=0,0,283,145;MQ=49;FQ=-­‐245	  88049071	   C	   T	   999	   DP=236;VDB=0.0044;AF1=1;AC1=6;DP4=0,0,55,126;MQ=38;FQ=-­‐182	  88051435	   A	   G	   999	   DP=506;VDB=0.0459;AF1=1;AC1=6;DP4=0,1,161,324;MQ=38;FQ=-­‐288;PV4=1,0.2,1,0.18	  88083371	   CTTTT	   CTT	   18.8	   INDEL;DP=55;VDB=0.0510;AF1=0.1667;AC1=1;DP4=7,41,1,1;MQ=49;FQ=19.5;PV4=0.3,1,1,0.096	  88091016	   T	   TG	   11.1	   INDEL;DP=22;VDB=0.0416;AF1=0.1675;AC1=1;DP4=5,13,0,2;MQ=49;FQ=11.8;PV4=1,1,0,0.0016	  88101194	   T	   A	   44.5	   DP=75;VDB=0.0000;AF1=0.5571;AC1=3;DP4=1,2,8,0;MQ=40;FQ=47.6;PV4=0.055,4.6e-­‐06,0.00014,0.00055	  88101195	   T	   A	   35.9	   DP=69;VDB=0.0000;AF1=0.5481;AC1=3;DP4=1,2,6,0;MQ=42;FQ=39.3;PV4=0.083,0.00041,0,0.00096	  
88130237	   G	   GCC	   170	   INDEL;DP=88;VDB=0.0009;AF1=0.5;G3=1.555e-­‐14,1,3.505e-­‐22;HWE=0.0414;AC1=3;DP4=3,14,2,11;MQ=48;FQ=173;PV4=1,0.00053,0.34,0.00053	  88132037	   T	   TC	   36.9	   INDEL;DP=154;VDB=0.0092;AF1=0.1754;AC1=1;DP4=10,9,6,0;MQ=49;FQ=37.8;PV4=0.057,1.5e-­‐05,0.11,0.0035	  88134642	   G	   T	   999	   DP=58;VDB=0.0457;AF1=1;AC1=6;DP4=1,0,12,27;MQ=50;FQ=-­‐49.8;PV4=0.32,0.0017,1,1	  
88136484	   G	   C	   999	   DP=318;VDB=0.0494;AF1=1;AC1=6;DP4=0,0,177,124;MQ=40;FQ=-­‐269	  88136812	   A	   AG	   28.6	   INDEL;DP=40;VDB=0.0257;AF1=0.2839;AC1=2;DP4=20,7,4,1;MQ=49;FQ=30;PV4=1,1,0.2,0.0099	  88138840	   TCTCAC	   TC	   156	   INDEL;DP=48;VDB=0.0509;AF1=0.5063;AC1=3;DP4=2,0,3,4;MQ=42;FQ=-­‐6.26;PV4=0.44,0.28,1,1	  88138983	   AGT	   A	   7.54	   INDEL;DP=71;VDB=0.0453;AF1=0.1667;AC1=1;DP4=40,26,1,1;MQ=49;FQ=8.2;PV4=1,0.17,1,1	  88146362	   G	   A	   999	   DP=62;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,10,13;MQ=38;FQ=-­‐48.9	  88154757	   G	   A	   61.9	   DP=36;VDB=0.0000;AF1=1;AC1=6;DP4=0,0,2,4;MQ=37;FQ=-­‐34	  88154897	   T	   A	   20.8	   DP=38;VDB=0.0000;AF1=1;AC1=6;DP4=0,0,3,1;MQ=46;FQ=-­‐30.4	  88159661	   A	   AG	   47.8	   INDEL;DP=104;VDB=0.0077;AF1=0.3341;AC1=2;DP4=9,15,7,0;MQ=45;FQ=49.5;PV4=0.0068,0.0057,7.5e-­‐05,0.00042	  88199735	   G	   GC	   10.5	   INDEL;DP=39;VDB=0.0438;AF1=0.3883;AC1=2;DP4=12,14,5,0;MQ=50;FQ=12.4;PV4=0.048,0.011,1,0.0012	  88203629	   TC	   TCC	   18.6	   INDEL;DP=81;VDB=0.0391;AF1=0.3768;AC1=2;DP4=14,14,0,6;MQ=45;FQ=20.5;PV4=0.031,0.11,0.0012,0.00043	  
88215576	   ATTTTTTTTTTTTTT	  
ATTTTTTTTTTTTTTT,ATTTTTTTTTTTTTTTT,ATTTTTTTTTTTTTTTTT	  
62.7	   INDEL;DP=271;VDB=0.0500;AF1=1;AC1=6;DP4=4,7,37,41;MQ=49;FQ=-­‐71.6;PV4=0.54,1,0.17,0.042	  
88224499	   G	   A	   999	   DP=350;VDB=0.0512;AF1=1;AC1=6;DP4=0,0,163,176;MQ=42;FQ=-­‐288	  88241176	   T	   TA	   136	   INDEL;DP=27;VDB=0.0069;AF1=0.7962;AC1=5;DP4=1,1,12,1;MQ=39;FQ=8.27;PV4=0.26,0.0036,0.0021,0.0014	  88241825	   GA	   G	   28.7	   INDEL;DP=27;VDB=0.0090;AF1=0.4998;AC1=3;DP4=1,2,5,0;MQ=48;FQ=31.7;PV4=0.11,0.0038,0.24,0.0097	  88243665	   CAGAGA	   CAGA	   48.1	   INDEL;DP=26;VDB=0.0326;AF1=0.1849;AC1=1;DP4=8,10,0,3;MQ=50;FQ=49;PV4=0.26,0.052,1,1	  
88244799	   CA	   CAA	   106	   INDEL;DP=66;VDB=0.0091;AF1=0.4989;G3=3.894e-­‐10,1,6.157e-­‐13;HWE=0.0419;AC1=3;DP4=8,8,7,2;MQ=45;FQ=109;PV4=0.23,0.34,0.00022,0.00027	  
88253599	   C	   CT	   13.7	   INDEL;DP=36;VDB=0.0008;AF1=0.399;AC1=2;DP4=4,0,0,3;MQ=42;FQ=15.9;PV4=0.029,0.016,0.13,0.12	  
88257055	   T	   A	   21.2	   DP=41;VDB=0.0001;AF1=0.4841;G3=6.951e-­‐08,1,4.209e-­‐14;HWE=0.0475;AC1=3;DP4=2,3,0,6;MQ=39;FQ=24;PV4=0.18,1.7e-­‐08,1,0.00018	  
88285855	   GAAAAAAAAAAAAAA	  
GAAAAAAAAAAAAA,GAAAAAAAAAAAA	   27.7	  
INDEL;DP=494;VDB=0.0375;AF1=1;AC1=6;DP4=17,10,98,61;MQ=46;FQ=-­‐66.6;PV4=1,1,0.38,0.27	  88331385	   G	   A	   999	   DP=21;VDB=0.0367;AF1=1;AC1=6;DP4=0,0,5,12;MQ=48;FQ=-­‐44	  88333638	   T	   C	   999	   DP=20;VDB=0.0342;AF1=1;AC1=6;DP4=0,0,3,14;MQ=49;FQ=-­‐44	  88341855	   T	   C	   999	   DP=265;VDB=0.0509;AF1=1;AC1=6;DP4=0,0,127,116;MQ=47;FQ=-­‐275	  
88343716	   TAAAAAAAAAAA	  
TAAAAAAAAAAAAA,TAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAA	  
266	   INDEL;DP=52;VDB=0.0239;AF1=1;AC1=6;DP4=0,0,14,30;MQ=48;FQ=-­‐53.4	  
88346621	   A	   AGC	   9.27	   INDEL;DP=152;VDB=0.0034;AF1=0.2767;AC1=2;DP4=14,12,2,3;MQ=44;FQ=10.4;PV4=0.65,0.0084,0.016,0.0027	  88346705	   T	   A	   999	   DP=735;VDB=0.0001;AF1=1;AC1=6;DP4=2,5,441,150;MQ=32;FQ=-­‐260;PV4=0.015,2.3e-­‐05,1.5e-­‐07,1	  88346708	   C	   A	   9.64	   DP=447;VDB=0.0000;AF1=0.4407;AC1=3;DP4=2,4,5,0;MQ=43;FQ=11.8;PV4=0.061,7.2e-­‐06,0.00025,0.0013	  88359256	   A	   AG	   32.6	   INDEL;DP=22;VDB=0.0390;AF1=0.2033;AC1=1;DP4=7,3,1,2;MQ=43;FQ=33.5;PV4=0.51,0.2,0.079,0.005	  
88363699	   G	   T	   17.2	   DP=86;VDB=0.0001;AF1=0.4831;G3=5.611e-­‐08,1,3.522e-­‐60;HWE=0.0468;AC1=3;DP4=7,9,9,1;MQ=45;FQ=20;PV4=0.037,2.6e-­‐11,9.3e-­‐05,0.00034	  88367545	   T	   TA	   999	   INDEL;DP=32;VDB=0.0440;AF1=1;AC1=6;DP4=0,0,15,15;MQ=50;FQ=-­‐59.5	  88367708	   C	   A	   999	   DP=67;VDB=0.0458;AF1=1;AC1=6;DP4=0,0,32,31;MQ=44;FQ=-­‐78.9	  88369870	   G	   A	   999	   DP=24;VDB=0.0495;AF1=1;AC1=6;DP4=0,0,8,8;MQ=47;FQ=-­‐43.8	  
88383614	   T	   G	   53.3	   DP=41;VDB=0.0026;AF1=0.5005;G3=1.155e-­‐09,1,1.848e-­‐08;HWE=0.0418;AC1=3;DP4=11,0,8,0;MQ=34;FQ=56.3;PV4=1,3.1e-­‐07,0.22,0.0066	  88383672	   A	   G	   999	   DP=27;VDB=0.0482;AF1=1;AC1=6;DP4=0,0,22,2;MQ=33;FQ=-­‐48.4	  88383688	   TGGGC	   TGGGCGGTTCTCGGGGC	   242	   INDEL;DP=29;VDB=0.0430;AF1=1;AC1=6;DP4=0,0,4,8;MQ=29;FQ=-­‐44	  88383703	   G	   C	   249	   DP=29;VDB=0.0390;AF1=1;AC1=6;DP4=0,0,10,9;MQ=35;FQ=-­‐36.9	  




25.2	   INDEL;DP=34;VDB=0.0456;AF1=1;AC1=6;DP4=0,0,0,2;MQ=50;FQ=-­‐35	  
88714342	   TG	   TGG	   170	   INDEL;DP=88;VDB=0.0002;AF1=1;AC1=6;DP4=0,0,31,0;MQ=43;FQ=-­‐62	  88716701	   C	   CA	   36.4	   INDEL;DP=30;VDB=0.0119;AF1=0.4926;AC1=3;DP4=1,1,4,1;MQ=37;FQ=7.2;PV4=1,0.013,0.27,0.0012	  88716851	   TG	   T	   120	   INDEL;DP=42;VDB=0.0001;AF1=0.3459;AC1=2;DP4=9,1,9,1;MQ=36;FQ=122;PV4=1,1,0.24,1	  
88737484	   T	   TC	   38.6	   INDEL;DP=56;VDB=0.0027;AF1=0.2049;AC1=1;DP4=5,1,0,9;MQ=40;FQ=39.6;PV4=0.002,0.12,4.6e-­‐06,0.00095	  
88740178	   A	   T	   10.3	   DP=51;VDB=0.0000;AF1=0.488;G3=1.304e-­‐07,1,2.007e-­‐18;HWE=0.0451;AC1=3;DP4=4,4,2,4;MQ=42;FQ=13;PV4=0.63,7.7e-­‐10,0.00062,0.0022	  88805795	   AGG	   AG	   999	   INDEL;DP=23;VDB=0.0017;AF1=1;AC1=6;DP4=0,0,12,3;MQ=35;FQ=-­‐43.3	  88855908	   TA	   T	   48.8	   INDEL;DP=25;VDB=0.0005;AF1=0.6572;AC1=4;DP4=0,1,4,0;MQ=48;FQ=-­‐23;PV4=0.2,1,0.34,0.0011	  88862563	   G	   A	   6.62	   DP=38;VDB=0.0000;AF1=0.5098;AC1=3;DP4=1,3,3,1;MQ=41;FQ=9.22;PV4=0.49,0.013,0.067,0.012	  88867840	   G	   GAA	   152	   INDEL;DP=36;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,8,0;MQ=36;FQ=-­‐39.5	  88870344	   TGAG	   TG	   97.8	   INDEL;DP=101;VDB=0.0004;AF1=0.1718;AC1=1;DP4=5,11,6,3;MQ=44;FQ=98.7;PV4=0.12,0.14,0.0048,1	  
88871074	   TA	   T	   170	   INDEL;DP=21;VDB=0.0169;AF1=0.4992;G3=2.451e-­‐09,1,3.794e-­‐10;HWE=0.0424;AC1=3;DP4=4,1,9,2;MQ=39;FQ=86.9;PV4=1,0.055,0.00023,0.00022	  88874570	   T	   G	   26.9	   DP=26;VDB=0.0009;AF1=1;AC1=6;DP4=0,0,1,3;MQ=42;FQ=-­‐30.3	  88904754	   CT	   C	   72.3	   INDEL;DP=72;VDB=0.0039;AF1=0.3421;AC1=2;DP4=9,25,8,3;MQ=28;FQ=74.1;PV4=0.011,0.19,1,0.1	  
88973538	   AG	   A	   72.7	   INDEL;DP=83;VDB=0.0480;AF1=0.4997;G3=1.219e-­‐09,1,3.741e-­‐71;HWE=0.0415;AC1=3;DP4=26,26,4,7;MQ=42;FQ=75.7;PV4=0.51,1,0.012,0.00013	  88979953	   TAAAA	   TAA	   36.7	   INDEL;DP=92;VDB=0.0407;AF1=0.1667;AC1=1;DP4=30,55,2,2;MQ=49;FQ=37.5;PV4=0.62,1,1,0.024	  
88984811	   GTA	   G	   999	   INDEL;DP=143;VDB=0.0003;AF1=0.5129;G3=2.009e-­‐57,1,2.131e-­‐07;HWE=0.0455;AC1=3;DP4=2,8,43,20;MQ=43;FQ=75.2;PV4=0.0055,0.11,0.0016,0.35	  88992067	   G	   GGC	   44.5	   INDEL;DP=21;VDB=0.0348;AF1=0.4001;AC1=2;DP4=6,5,3,0;MQ=47;FQ=46.7;PV4=0.26,0.45,1,0.0017	  89009367	   A	   AAC	   111	   INDEL;DP=72;VDB=0.0034;AF1=0.5998;AC1=4;DP4=2,1,0,7;MQ=39;FQ=80.7;PV4=0.067,0.07,0.00078,0.034	  89012351	   G	   A	   90.4	   DP=87;VDB=0.0001;AF1=0.5771;AC1=3;DP4=1,3,3,16;MQ=38;FQ=29.2;PV4=1,7.2e-­‐15,0.13,0.00067	  
89020808	   AGG	   AG	   142	   INDEL;DP=68;VDB=0.0111;AF1=0.484;G3=6.448e-­‐07,1,2.651e-­‐25;HWE=0.0465;AC1=3;DP4=2,7,11,3;MQ=40;FQ=142;PV4=0.013,0.05,0.17,0.00077	  
89025032	   G	   GT	   999	   INDEL;DP=80;VDB=0.0007;AF1=1;AC1=6;DP4=0,1,28,21;MQ=36;FQ=-­‐61.4;PV4=0.44,0.4,0.11,0.0036	  89052995	   G	   GA	   202	   INDEL;DP=26;VDB=0.0211;AF1=0.6285;AC1=4;DP4=9,3,0,11;MQ=41;FQ=207;PV4=0.00034,1,0.1,0.27	  
89072521	   C	   CG	   162	   INDEL;DP=70;VDB=0.0007;AF1=0.501;G3=4.902e-­‐15,1,3.209e-­‐08;HWE=0.0417;AC1=3;DP4=2,2,5,3;MQ=44;FQ=53.8;PV4=1,0.28,0.049,0.0049	  89148133	   C	   A	   6.46	   DP=111;VDB=0.0001;AF1=0.1709;AC1=1;DP4=6,11,1,2;MQ=45;FQ=7.11;PV4=1,0.00056,0.012,0.046	  89149862	   C	   CG	   4.57	   INDEL;DP=53;VDB=0.0085;AF1=0.1672;AC1=1;DP4=15,7,2,0;MQ=42;FQ=5.11;PV4=1,1,0.26,0.1	  89228662	   CA	   C	   8.39	   INDEL;DP=22;VDB=0.0332;AF1=0.1675;AC1=1;DP4=8,11,2,0;MQ=49;FQ=9.08;PV4=0.21,0.49,1,1	  89236368	   C	   CT	   5.86	   INDEL;DP=29;VDB=0.0376;AF1=0.3557;AC1=2;DP4=1,9,0,3;MQ=47;FQ=7.3;PV4=1,0.4,1.4e-­‐06,0.00071	  89249603	   T	   TA	   3.16	   INDEL;DP=52;VDB=0.0188;AF1=0.2674;AC1=2;DP4=6,8,3,0;MQ=48;FQ=3.86;PV4=0.21,0.02,0,0.0094	  89250197	   A	   AG	   16.6	   INDEL;DP=22;VDB=0.0194;AF1=0.47;AC1=3;DP4=5,3,0,5;MQ=44;FQ=19.3;PV4=0.075,0.13,0.024,0.00012	  89250334	   G	   GC	   16.7	   INDEL;DP=22;VDB=0.0301;AF1=0.2606;AC1=1;DP4=3,3,2,1;MQ=45;FQ=18;PV4=1,0.0049,2.2e-­‐05,0.048	  89252189	   T	   TC	   191	   INDEL;DP=63;VDB=0.0003;AF1=0.8138;AC1=5;DP4=1,1,10,0;MQ=43;FQ=10.5;PV4=0.17,1,0.087,0.02	  89268369	   GG	   GGCTG	   999	   INDEL;DP=169;VDB=0.0001;AF1=0.815;AC1=5;DP4=2,2,46,0;MQ=30;FQ=-­‐19.9;PV4=0.0049,1,5.5e-­‐10,0.0012	  89544201	   GT	   GTTT	   46.5	   INDEL;DP=44;VDB=0.0022;AF1=0.6283;AC1=4;DP4=0,2,10,0;MQ=39;FQ=26.7;PV4=0.015,1.2e-­‐07,0,0.00012	  89551090	   G	   A	   120	   DP=35;VDB=0.0001;AF1=0.6664;AC1=4;DP4=2,3,1,12;MQ=39;FQ=92.5;PV4=0.17,7.5e-­‐08,0.00057,0.00088	  
89554154	   C	   CT	   46.9	   INDEL;DP=40;VDB=0.0262;AF1=0.4748;G3=7.256e-­‐07,1,4.219e-­‐34;HWE=0.0498;AC1=3;DP4=7,2,0,8;MQ=42;FQ=49.7;PV4=0.0023,0.00041,0.15,0.0036	  89564934	   G	   A	   3.71	   DP=25;VDB=0.0132;AF1=0.1689;AC1=1;DP4=11,12,0,2;MQ=49;FQ=4.19;PV4=0.49,1,0.06,1	  89583491	   TG	   TGG	   123	   INDEL;DP=51;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,9,1;MQ=29;FQ=-­‐45.5	  89758216	   G	   C	   999	   DP=60;VDB=0.0002;AF1=0.8329;AC1=5;DP4=1,2,13,19;MQ=39;FQ=26.1;PV4=1,3.7e-­‐07,0.024,0.03	  89758521	   C	   CA	   37	   INDEL;DP=24;VDB=0.0115;AF1=0.7018;AC1=4;DP4=2,1,3,1;MQ=45;FQ=41.6;PV4=1,0.033,0.026,0.038	  
89819222	   A	   T	   11.3	   DP=27;VDB=0.0000;AF1=0.6148;AC1=4;DP4=2,3,7,0;MQ=36;FQ=15;PV4=0.045,0.00053,0.008,0.00025	  89820618	   TA	   T	   149	   INDEL;DP=102;VDB=0.0001;AF1=0.5999;AC1=4;DP4=4,1,3,6;MQ=41;FQ=67.7;PV4=0.27,0.08,0.079,0.00014	  89823268	   G	   GCC	   999	   INDEL;DP=60;VDB=0.0002;AF1=0.6667;AC1=4;DP4=2,2,20,0;MQ=39;FQ=46.8;PV4=0.022,0.00024,0.00071,0.0003	  89847735	   G	   GT	   999	   INDEL;DP=98;VDB=0.0000;AF1=1;AC1=6;DP4=1,0,14,0;MQ=35;FQ=-­‐37;PV4=1,1,0.32,1	  89848775	   C	   A	   999	   DP=166;VDB=0.0001;AF1=1;AC1=6;DP4=0,1,67,58;MQ=34;FQ=-­‐116;PV4=0.47,7.2e-­‐08,0.0017,0.00018	  
89862405	   A	   T	   180	   DP=53;VDB=0.0000;AF1=0.5;G3=1.789e-­‐13,1,1.467e-­‐14;HWE=0.0414;AC1=3;DP4=7,3,12,0;MQ=41;FQ=183;PV4=0.078,0.028,0.03,0.0016	  89869429	   C	   T	   10.9	   DP=34;VDB=0.0001;AF1=0.1785;AC1=1;DP4=8,13,0,4;MQ=47;FQ=11.7;PV4=0.27,4.9e-­‐06,1.6e-­‐05,0.0049	  89903449	   G	   T	   26.5	   DP=159;VDB=0.0002;AF1=0.3131;AC1=2;DP4=119,16,7,9;MQ=29;FQ=28;PV4=0.00012,1,1,1	  




84.4	   INDEL;DP=67;VDB=0.0486;AF1=0.4872;G3=2.047e-­‐07,1,1.064e-­‐126;HWE=0.0454;AC1=3;DP4=19,17,3,4;MQ=48;FQ=87.2;PV4=0.7,0.12,0.34,0.44	  
90155494	   CCA	   CCACA	   999	   INDEL;DP=110;VDB=0.0002;AF1=0.898;AC1=5;DP4=3,2,52,0;MQ=44;FQ=-­‐33.2;PV4=0.0063,1,0.27,0.0081	  90191372	   C	   CG	   47	   INDEL;DP=52;VDB=0.0005;AF1=0.8116;AC1=5;DP4=1,0,8,0;MQ=43;FQ=-­‐14;PV4=1,8.2e-­‐06,0.21,0.022	  
90196813	   GCT	   GCTCT	   43.8	   INDEL;DP=63;VDB=0.0216;AF1=0.4979;G3=2.659e-­‐09,1,6.069e-­‐29;HWE=0.042;AC1=3;DP4=8,10,7,0;MQ=45;FQ=46.8;PV4=0.02,2.7e-­‐08,0.036,0.0018	  90199059	   C	   G	   21.2	   DP=20;VDB=0.0009;AF1=0.356;AC1=2;DP4=2,2,1,4;MQ=36;FQ=23;PV4=0.52,1.3e-­‐05,6.2e-­‐05,0.0084	  90206228	   A	   C	   999	   DP=41;VDB=0.0001;AF1=0.8535;AC1=5;DP4=2,0,23,6;MQ=37;FQ=-­‐21;PV4=1,2.6e-­‐05,0.0016,0.00012	  90207904	   T	   G	   29.4	   DP=45;VDB=0.0001;AF1=0.7721;AC1=5;DP4=0,1,0,4;MQ=32;FQ=4.6;PV4=1,0.013,0,0.00034	  90207906	   C	   T	   127	   DP=61;VDB=0.0001;AF1=0.8246;AC1=5;DP4=1,1,2,12;MQ=35;FQ=24.3;PV4=0.35,2.6e-­‐05,0.075,0.044	  90208527	   G	   C	   88.7	   DP=70;VDB=0.0001;AF1=1;AC1=6;DP4
=0,0,0,11;MQ=38;FQ=-­‐39.3	  90217450	   A	   C	   20.3	   DP=32;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,1,2;MQ=30;FQ=-­‐29.8	  90219075	   CTT	   CT	   34.2	   INDEL;DP=24;VDB=0.0011;AF1=0.5406;AC1=3;DP4=1,1,0,3;MQ=42;FQ=15.6;PV4=0.4,0.4,0.00026,0.0029	  90219529	   CT	   CTT	   8.02	   INDEL;DP=39;VDB=0.0022;AF1=0.3032;AC1=2;DP4=1,2,2,2;MQ=37;FQ=9.45;PV4=1,0.18,0.071,0.035	  
90225742	   C	   A	   62.5	   DP=38;VDB=0.0001;AF1=0.4949;G3=9.858e-­‐08,1,1.535e-­‐14;HWE=0.043;AC1=3;DP4=0,10,9,1;MQ=44;FQ=65.5;PV4=0.00012,4e-­‐09,0,0.0016	  90227921	   C	   G	   42.3	   DP=26;VDB=0.0076;AF1=0.5773;AC1=4;DP4=1,0,1,1;MQ=46;FQ=8.44;PV4=1,0.44,0,1	  
90259941	   GC	   G	   999	   INDEL;DP=39;VDB=0.0032;AF1=0.5005;G3=1.676e-­‐34,1,4.875e-­‐09;HWE=0.0416;AC1=3;DP4=1,4,9,11;MQ=38;FQ=66.7;PV4=0.61,0.24,0.013,0.00018	  90261001	   TG	   T	   78.6	   INDEL;DP=51;VDB=0.0435;AF1=0.3256;AC1=2;DP4=8,10,4,3;MQ=47;FQ=80.3;PV4=0.67,4e-­‐05,0.00046,0.0014	  
90284521	   TC	   T	   65.7	   INDEL;DP=21;VDB=0.0259;AF1=0.4997;G3=1.15e-­‐09,1,9.448e-­‐12;HWE=0.0415;AC1=3;DP4=3,2,0,7;MQ=39;FQ=68.7;PV4=0.045,1,0.0046,0.002	  90289608	   TCAG	   T	   31.3	   INDEL;DP=157;VDB=0.0080;AF1=0.1934;AC1=1;DP4=20,21,7,0;MQ=45;FQ=32.3;PV4=0.014,1.2e-­‐10,0.0073,0.00012	  90293519	   T	   TG	   4.91	   INDEL;DP=44;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,2,0;MQ=37;FQ=-­‐35	  90307207	   G	   T	   67.7	   DP=126;VDB=0.0001;AF1=0.3893;AC1=2;DP4=34,20,14,3;MQ=37;FQ=69.9;PV4=0.23,0.028,1,0.026	  90319968	   G	   GT	   15.3	   INDEL;DP=156;VDB=0.0001;AF1=0.6364;AC1=4;DP4=1,1,6,0;MQ=36;FQ=14.9;PV4=0.25,1.8e-­‐08,0.002,0.012	  90328271	   T	   TC	   270	   INDEL;DP=33;VDB=0.0001;AF1=1;AC1=6;DP4=0,0,4,18;MQ=34;FQ=-­‐49.5	  90330823	   TAA	   TA	   13.9	   INDEL;DP=55;VDB=0.0459;AF1=0.1675;AC1=1;DP4=15,3,1,1;MQ=49;FQ=14.7;PV4=0.37,1,1,0.04	  
90343949	   TGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA	  
TGAGAGAGAGAGAGAGAGAGAGAGAGAGA	   92	  
INDEL;DP=30;VDB=0.0363;AF1=0.3432;AC1=2;DP4=8,7,1,3;MQ=50;FQ=93.8;PV4=0.58,1,1,1	  
90404196	   T	   G	   19.4	   DP=41;VDB=0.0003;AF1=0.3342;AC1=2;DP4=27,2,8,0;MQ=42;FQ=21.1;PV4=1,8.7e-­‐07,0.045,0.00069	  90455797	   A	   G	   999	   DP=668;VDB=0.0000;AF1=1;AC1=6;DP4=1,1,1,639;MQ=32;FQ=-­‐222;PV4=0.0062,2.4e-­‐05,0.026,0.011	  90455816	   A	   G	   999	   DP=668;VDB=0.0000;AF1=1;AC1=6;DP4=1,2,1,654;MQ=32;FQ=-­‐288;PV4=0.0091,1,0.062,1	  
90692497	   TA	   T	   188	   INDEL;DP=85;VDB=0.0006;AF1=0.4935;G3=2.454e-­‐07,1,6.219e-­‐21;HWE=0.0434;AC1=3;DP4=1,9,10,3;MQ=46;FQ=191;PV4=0.0028,4.4e-­‐08,0.0074,0.00013	  92190533	   A	   T	   69.1	   DP=59;VDB=0.0000;AF1=0.8016;AC1=5;DP4=1,0,12,0;MQ=48;FQ=-­‐11.3;PV4=1,1.5e-­‐07,0.35,1	  92241511	   A	   G	   65.4	   DP=23;VDB=0.0042;AF1=1;AC1=6;DP4=0,0,0,9;MQ=50;FQ=-­‐35.5	  92415221	   TCC	   TC	   35	   INDEL;DP=21;VDB=0.0310;AF1=0.3426;AC1=2;DP4=12,4,3,1;MQ=49;FQ=36.9;PV4=1,1,0.27,0.00073	  92494860	   TC	   T	   10.4	   INDEL;DP=31;VDB=0.0512;AF1=0.6976;AC1=4;DP4=4,0,3,0;MQ=30;FQ=-­‐11.4;PV4=1,1,1,0.14	  92554944	   C	   CAA	   33.8	   INDEL;DP=24;VDB=0.0282;AF1=0.3942;AC1=2;DP4=4,7,1,3;MQ=47;FQ=36;PV4=1,1.6e-­‐13,1,0.021	  
92822563	   T	   TCA	   99.7	   INDEL;DP=369;VDB=0.0001;AF1=0.4999;G3=2.33e-­‐11,1,6.639e-­‐63;HWE=0.0414;AC1=3;DP4=2,71,2,15;MQ=41;FQ=103;PV4=0.16,0.00022,1,0.00085	  93038935	   A	   G	   101	   DP=20;VDB=0.0381;AF1=1;AC1=6;DP4=0,0,15,0;MQ=14;FQ=-­‐41.9	  93038939	   T	   C	   136	   DP=21;VDB=0.0406;AF1=1;AC1=6;DP4=0,0,20,0;MQ=17;FQ=-­‐44.9	  93039686	   A	   T	   177	   DP=57;VDB=0.0000;AF1=1;AC1=6;DP4=0,0,3,10;MQ=30;FQ=-­‐38.8	  93040051	   A	   G	   211	   DP=23;VDB=0.0435;AF1=1;AC1=6;DP4=0,0,17,5;MQ=19;FQ=-­‐50.2	  93040056	   A	   G	   167	   DP=26;VDB=0.0497;AF1=0.85;AC1=5;DP4=1,0,19,5;MQ=21;FQ=-­‐20;PV4=1,8.3e-­‐06,0.00012,1	  93040058	   T	   C	   161	   DP=26;VDB=0.0497;AF1=0.8498;AC1=5;DP4=1,0,18,5;MQ=21;FQ=-­‐20;PV4=1,1.7e-­‐06,0.00017,1	  93040065	   T	   C	   140	   DP=25;VDB=0.0453;AF1=0.8379;AC1=5;DP4=1,0,16,5;MQ=22;FQ=-­‐15.1;PV4=1,2.3e-­‐07,0.00038,1	  93040077	   T	   C	   155	   DP=21;VDB=0.0346;AF1=0.8353;AC1=5;DP4=1,0,14,3;MQ=21;FQ=-­‐14.1;PV4=1,0.26,0.00027,0.28	  93040122	   A	   G	   30.1	   DP=49;VDB=0.0030;AF1=0.7105;AC1=5;DP4=1,0,7,0;MQ=28;FQ=-­‐11.1;PV4=1,0.00064,0.019,1	  93040125	   T	   C	   29.2	   DP=48;VDB=0.0006;AF1=0.7216;AC1=5;DP4=1,0,9,0;MQ=27;FQ=-­‐16.7;PV4=1,2.7e-­‐06,0.0082,1	  93040310	   T	   A	   75.6	   DP=83;VDB=0.0044;AF1=1;AC1=6;DP4=0,0,0,7;MQ=28;FQ=-­‐34.8	  93082568	   T	   C	   37.2	   DP=31;VDB=0.0005;AF1=0.5476;AC1=4;DP4=3,4,9,9;MQ=24;FQ=38.4;PV4=1,4.9e-­‐05,0.0073,0.0076	  93246389	   GGTA	   G	   999	   INDEL;DP=687;VDB=0.0004;AF1=0.8417;AC1=5;DP4=6,11,177,73;MQ=29;FQ=-­‐24.5;PV4=0.005,1.3e-­‐14,1.4e-­‐32,0.0008	  
93253331	   AGCC	   A	   27.1	   INDEL;DP=22;VDB=0.0162;AF1=0.4933;G3=9.607e-­‐09,1,6.168e-­‐15;HWE=0.0437;AC1=3;DP4=4,9,0,5;MQ=36;FQ=30;PV4=0.28,0.0025,0.29,1	  93329166	   ATGTGTGTGTGTGTGT	   ATGTGTGTGTGTGT	   12.2	   INDEL;DP=45;VDB=0.0421;AF1=0.3301;AC1=2;DP4=12,14,1,2;MQ=47;FQ=13.8;PV4=1,0.28,0.18,0.16	  94148325	   C	   G	   26.6	   DP=34;VDB=0.0001;AF1=0.6192;AC1=4;DP4=3,1,7,1;MQ=46;FQ=30.7;PV4=1,3.9e-­‐05,0.3,0.029	  94195130	   T	   A	   213	   DP=32;VDB=0.0002;AF1=0.695;AC1=4;DP4=0,3,13,3;MQ=42;FQ=27.1;PV4=0.021,0.0033,0.065,0.33	  94324191	   GAA	   G	   7.58	   INDEL;DP=23;VDB=0.0060;AF1=0.4994;AC1=3;DP4=1,1,2,0;MQ=40;FQ=10.2;PV4=1,0.2,0.2,0.22	  94418645	   C	   CA	   999	   INDEL;DP=52;VDB=0.0035;AF1=0.8334;AC1=5;DP4=1,1,16,21;MQ=36;FQ=-­‐6.59;PV4=1,0.41,9.6e-­‐08,0.0011	  94418749	   G	   C	   8.1	   DP=51;VDB=0.0000;AF1=0.3317;AC1=2;DP4=13,5,1,6;MQ=44;FQ=9.61;PV4=0.021,1.2e-­‐13,0.0064,0.00043	  94432116	   T	   G	   3.21	   DP=57;VDB=0.0001;AF1=0.3934;AC1=2;DP4=2,7,0,5;MQ=43;FQ=4.45;PV4=0.51,3.6e-­‐07,9.2e-­‐09,0.0013	  94432415	   CA	   CAGA	   15	   INDEL;DP=20;VDB=0.0434;AF1=0.3351;AC1=2;DP4=9,6,2,0;MQ=48;FQ=16.7;PV4=0.51,1,1,1	  94454523	   T	   A	   8.04	   DP=20;VDB=0.0132;AF1=0.1688;AC1=1;DP4=6,10,0,2;MQ=47;FQ=8.73;PV4=0.53,0.016,4.7e-­‐05,1	  94552257	   T	   A	   20.3	   DP=20;VDB=0.0197;AF1=0.1683;AC1=1;DP4=7,10,1,1;MQ=48;FQ=21.1;PV4=1,1,0.18,0.35	  94574625	   CT	   CTT	   5.77	   INDEL;DP=24;VDB=0.0232;AF1=1;AC1=6;DP4=0,0,3,0;MQ=20;FQ=-­‐35.7	  94578123	   G	   GGT	   999	   INDEL;DP=29;VDB=0.0206;AF1=0.6662;AC1=4;DP4=3,3,1,22;MQ=34;FQ=111;PV4=0.02,1,4.6e-­‐08,0.00059	  94676350	   G	   C	   6.63	   DP=24;VDB=0.0000;AF1=0.7471;AC1=5;DP4=0,1,2,1;MQ=32;FQ=-­‐9.2;PV4=1,0.014,1,0.025	  94676351	   T	   C	   5.89	   DP=24;VDB=0.0000;AF1=0.7467;AC1=5;DP4=0,1,2,1;MQ=32;FQ=-­‐9.2;PV4=1,0.012,1,0.013	  
94747517	   GGTGTGTGTGTGTGTGTGTGTGTGTGTGT	  
GGTGTGTGTGTGTGTGTGTGTGTGTGT	   48.1	  
INDEL;DP=48;VDB=0.0416;AF1=0.3651;AC1=2;DP4=14,5,3,3;MQ=46;FQ=50;PV4=0.34,1,1,1	  
94748323	   TC	   T	   999	   INDEL;DP=188;VDB=0.0003;AF1=0.3333;AC1=2;DP4=12,64,5,34;MQ=40;FQ=999;PV4=0.79,1,0.014,1	  94758173	   G	   GCT	   69.8	   INDEL;DP=36;VDB=0.0364;AF1=0.4542;AC1=3;DP4=12,8,9,0;MQ=44;FQ=72.4;PV4=0.033,1,1.4e-­‐10,0.0011	  94760529	   G	   A	   44.8	   DP=29;VDB=0.0001;AF1=0.3531;AC1=2;DP4=6,10,3,4;MQ=38;FQ=46.7;PV4=1,2.1e-­‐10,0.089,0.014	  
94761702	   A	   T	   114	   DP=22;VDB=0.0087;AF1=0.4967;G3=1.551e-­‐08,1,2.6e-­‐23;HWE=0.0424;AC1=3;DP4=6,2,3,4;MQ=42;FQ=117;PV4=0.31,0.0066,0.0014,0.0025	  94787901	   C	   CG	   68.2	   INDEL;DP=23;VDB=0.0251;AF1=0.1853;AC1=1;DP4=7,3,0,7;MQ=43;FQ=69.1;PV4=0.0098,0.076,0.00018,0.0011	  94811990	   T	   TGG	   999	   INDEL;DP=22;VDB=0.0148;AF1=0.6629;AC1=4;DP4=2,1,0,14;MQ=44;FQ=22.2;PV4=0.022,0.4,0.43,0.002	  94812840	   CT	   C	   43.7	   INDEL;DP=57;VDB=0.0014;AF1=0.3935;AC1=3;DP4=2,10,2,2;MQ=46;FQ=45.7;PV4=0.24,0.42,1,0.23	  94814263	   T	   A	   141	   DP=86;VDB=0.0000;AF1=0.8861;AC1=5;DP4=0,1,2,17;MQ=43;FQ=-­‐24.9;PV4=1,2.3e-­‐07,0.22,0.00086	  94868252	   C	   T	   11.8	   DP=40;VDB=0.0000;AF1=0.3337;AC1=2;DP4=10,2,1,5;MQ=45;FQ=13.4;PV4=0.013,1e-­‐07,0.00014,0.023	  94871981	   A	   AT	   18.2	   INDEL;DP=20;VDB=0.0159;AF1=0.5922;AC1=4;DP4=2,0,0,5;MQ=37;FQ=6.91;PV4=0.048,0.047,0.25,0.0043	  94874934	   C	   CA	   999	   INDEL;DP=40;VDB=0.0002;AF1=1;AC1=6;DP4=1,0,19,9;MQ=41;FQ=-­‐40.6;PV4=1,0.18,0.087,0.011	  94932334	   G	   GC	   63.9	   INDEL;DP=21;VDB=0.0073;AF1=0.5966;AC1=4;DP4=1,2,4,1;MQ=46;FQ=40.8;PV4=0.46,0.27,0.13,0.089	  94948565	   TG	   TGTCAGG	   999	   INDEL;DP=736;VDB=0.0531;AF1=1;AC1=6;DP4=2,2,90,547;MQ=24;FQ=-­‐296;PV4=0.1,1,5.4e-­‐05,0.34	  94968439	   A	   C	   6.72	   DP=21;VDB=0.0076;AF1=0.2932;AC1=2;DP4=2,1,3,0;MQ=41;FQ=7.98;PV4=1,0.012,0.22,0.0029	  94968440	   G	   C	   5.23	   DP=20;VDB=0.0023;AF1=0.2931;AC1=2;DP4=2,1,3,0;MQ=41;FQ=6.37;PV4=1,0.00097,0.22,0.004	  94993073	   TA	   T	   71.9	   INDEL;DP=33;VDB=0.0455;AF1=0.3339;AC1=2;DP4=9,10,5,2;MQ=44;FQ=73.7;PV4=0.39,0.011,0.29,0.00043	  	  
	  









Differential	  gene	  expression	  between	  Mattma/ma	  and	  
C57BL/6J	  using	  DSeq	  (v1.61)	  
	   	  
APPENDIX	  V	  Complete	  list	  of	  114	  genes	  with	  different	  expression	  between	  F6	  Mattma/ma	  and	  C57BL6/J	  mice	  using	  DSeq	  (v1.61),	  with	  p	  <	  0.01	  over	  the	  entire	  genome.	  The	  only	  gene	  that	  mapped	  to	  the	  minimum	  region,	  chr3:	  87,336,555	  -­‐	  88,392,125,	  was	  
Transmembrane79	  (highlighted	  in	  red).	  All	  genes	  were	  classified	  according	  to	  their	  Gene	  Ontology-­‐associated	  biological	  processes.	  





log2	  Fold	  Change	   Gene	  Ontology	  
H2-­‐Ea-­‐ps	   histocompatibility	  2,	  class	  II	  antigen	  E	  alpha,	  pseudogene	  	   17	   0.282	   765	   11.4	   Immune	  response	  Gm18733	   predicted	  gene,	  18733	  	   17	   8.91	   207	   4.54	   pseudogene	  H2-­‐Bl	   histocompatibility	  2,	  blastocyst	  	   17	   14.7	   213	   3.86	   Immune	  response	  Tpsab1	   tryptase	  alpha/beta	  1	  	   17	   17.7	   187	   3.4	   Protein	  metabolic	  process	  Npw	   neuropeptide	  W	  	   17	   4.41	   42.8	   3.28	   Signal	  transduction	  RP23-­‐381B19.7.1	   none	   11	   79.8	   620	   2.96	   Unknown	  Expi	   extracellular	  proteinase	  inhibitor	  	   11	   119	   745	   2.65	   Metabolic	  process	  Gm10499	   predicted	  gene	  10499	  	   17	   33.9	   206	   2.6	   pseudogene	  Gm15921	   predicted	  gene	  15921	  	   5	   26.2	   135	   2.36	   pseudogene	  H2-­‐K2	   histocompatibility	  2,	  K	  region	  locus	  2	  	   17	   135	   649	   2.26	   Immune	  response	  Cd300lf	   CD300	  antigen	  like	  family	  member	  F	  	   11	   11.8	   55.5	   2.23	   Cell	  differentation	  C920025E04Rik	   RIKEN	  cDNA	  C920025E04	  gene	  	   17	   122	   545	   2.16	   pseudogene	  Wdfy1	   WD	  repeat	  and	  FYVE	  domain	  containing	  1	  	   1	   690	   2920	   2.08	   Lipid	  metabolic	  process	  1500011B03Rik	   RIKEN	  cDNA	  1500011B03	  gene	  	   5	   47.1	   193	   2.03	   pseudogene	  H2-­‐Q1	   histocompatibility	  2,	  Q	  region	  locus	  1	  	   17	   429	   1690	   1.98	   Immune	  response	  H2-­‐Q10	   histocompatibility	  2,	  Q	  region	  locus	  10	  	   17	   197	   668	   1.76	   Immune	  response	  4933404O12Rik	   RIKEN	  cDNA	  4933404O12	  gene	  	   5	   261	   870	   1.74	   lincRNA	  2300002M23Rik	   RIKEN	  cDNA	  2300002M23	  gene	  	   17	   32.5	   106	   1.7	   Extracellular	  structure	  organization	  Gm9000	   predicted	  gene	  9000	  	   13	   9310	   29500	   1.66	   Unknown	  
Slc13a3	   solute	  carrier	  family	  13	  (sodium-­‐dependent	  dicarboxylate	  transporter),	  member	  3	  	   2	   171	   526	   1.62	  
Transmembrane	  transport	  
Il12rb1	   interleukin	  12	  receptor,	   8	   44.1	   133	   1.6	   Immune	  
beta	  1	  	   response	  Efcab7	   EF-­‐hand	  calcium	  binding	  domain	  7	  	   4	   130	   387	   1.58	   Ion	  binding	  Msh5	   mutS	  homolog	  5	  (E.	  coli)	  	   17	   160	   456	   1.51	   Metabolic	  process	  Stk19-­‐ps1	   serine/threonine	  kinase	  19,	  pseudogene	  1	  	   17	   50.2	   140	   1.48	   Unknown	  Zfp605	   zinc	  finger	  protein	  605	  	   5	   263	   655	   1.31	   Ion	  binding	  5430403G16Rik	   RIKEN	  cDNA	  5430403G16	  gene	  	   5	   105	   259	   1.3	   Ion	  binding	  RP24-­‐201C14.6.1	   none	   3	   61.5	   150	   1.29	   Unknown	  Tnfrsf9	   tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  9	  	   4	   62.2	   148	   1.25	   Cell	  proliferation	  H2-­‐DMb2	   histocompatibility	  2,	  class	  II,	  locus	  Mb2	  	   17	   82.1	   190	   1.21	   Immune	  response	  Cntn1	   contactin	  1	  	   15	   152	   335	   1.14	   Cell	  adhesion	  Tmem171	   transmembrane	  protein	  171	  	   13	   96.1	   211	   1.13	   Transmembrane	  protein	  Cxcl10	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  10	  	   5	   104	   227	   1.13	   Immune	  response	  Gm14038	   predicted	  gene	  14038	  	   2	   864	   1860	   1.1	   pseudogene	  Rpl21-­‐ps10	   ribosomal	  protein	  L21,	  pseudogene	  10	  	   3	   366	   773	   1.08	   ribosomal	  protein	  H2-­‐Q7	   histocompatibility	  2,	  Q	  region	  locus	  7	  	   17	   451	   939	   1.06	   Immune	  response	  Fam129c	   family	  with	  sequence	  similarity	  129,	  member	  C	  	   8	   167	   350	   1.06	   Unknown	  Nnt	   nicotinamide	  nucleotide	  transhydrogenase	  	   13	   1480	   3060	   1.05	   NADP	  binding	  Car3	   carbonic	  anhydrase	  3	  	   3	   46400	   95600	   1.04	   Catalytic	  activity	  4930522L14Rik	   RIKEN	  cDNA	  4930522L14	  gene	  	   5	   322	   649	   1.01	   Ion	  binding	  Gm5590	   predicted	  gene	  5590	  	   7	   299	   596	   0.995	   pseudogene	  Casp1	   caspase	  1	  	   9	   144	   287	   0.994	   Catalytic	  activity	  Dio3	   deiodinase,	  iodothyronine	  type	  III	  	   12	   261	   508	   0.959	   Catalytic	  activity	  BC064078	   cDNA	  sequence	  BC064078	  	   6	   258	   492	   0.933	   pseudogene	  Tctex1d2	   Tctex1	  domain	  containing	  2	  	   16	   209	   395	   0.922	   Unknown	  Gm11127	   predicted	  gene	  11127	  	   17	   186	   350	   0.915	   Unknown	  Lyz2	   lysozyme	  2	  	   10	   3260	   5980	   0.874	   Catalytic	  activity	  Cd1d1	   CD1d1	  antigen	  	   3	   942	   1700	   0.854	   Lipid	  metabolic	  process	  Pttg1	   pituitary	  tumor-­‐transforming	  gene	  1	  	   11	   540	   945	   0.809	   Enzyme	  regulator	  activity	  Rps2-­‐ps13	   ribosomal	  protein	  S2,	  pseudogene	  13	  	   X	   9060	   15400	   0.766	   ribosomal	  protein	  Car2	   carbonic	  anhydrase	  2	  	   3	   404	   684	   0.762	   Catalytic	  activity	  Prune2	   prune	  homolog	  2	  (Drosophila)	  	   19	   504	   847	   0.748	   Catalytic	  activity	  Fam177a	   family	  with	  sequence	  similarity	  177,	  member	  A	  	   12	   1670	   2780	   0.736	   Unknown	  Gm6166	   predicted	  gene	  6166	  	   9	   36600	   59600	   0.703	   pseudogene	  Ocel1	   occludin/ELL	  domain	   8	   807	   1300	   0.685	   Unknown	  
containing	  1	  	  Rps2-­‐ps10	   ribosomal	  protein	  S2,	  speudogene	  10	  	   18	   15500	   24900	   0.681	   ribosomal	  protein	  
Nfkbiz	   nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  inhibitor,	  zeta	  	   16	   863	   1370	   0.67	  
Immune	  response	  
Katnal1	   katanin	  p60	  subunit	  A-­‐like	  1	  	   5	   932	   1470	   0.66	   Catalytic	  activity	  1700047I17Rik2	   RIKEN	  cDNA	  1700047I17	  gene	  2	  	   12	   1730	   2720	   0.654	   Unknown	  Gm10240	   predicted	  gene	  10240	  	   15	   4980	   7740	   0.637	   Unknown	  Lpl	   lipoprotein	  lipase	  	   8	   34700	   53700	   0.629	   Lipid	  metabolic	  process	  Gm10163	   predicted	  pseudogene	  10163	  	   9	   5170	   7880	   0.608	   pseudogene	  Spon1	   spondin	  1,	  (f-­‐spondin)	  extracellular	  matrix	  protein	  	   7	   4870	   3220	   -­‐0.597	   Cell	  adhesion	  Gm5786	   predicted	  pseudogene	  5786	  	   12	   4870	   3150	   -­‐0.63	   pseudogene	  Thbs4	   thrombospondin	  4	  	   13	   3690	   2350	   -­‐0.65	   Ion	  binding	  Odz3	   odd	  Oz/ten-­‐m	  homolog	  3	  (Drosophila)	  	   8	   3150	   2010	   -­‐0.651	   Unknown	  Gfra1	   glial	  cell	  line	  derived	  neurotrophic	  factor	  family	  receptor	  alpha	  1	  	   19	   1620	   998	   -­‐0.696	   Cell	  migration	  Fads6	   fatty	  acid	  desaturase	  domain	  family,	  member	  6	  	   11	   825	   501	   -­‐0.719	   Lipid	  metabolic	  process	  1110005A03Rik	   RIKEN	  cDNA	  1110005A03	  gene	  	   11	   984	   574	   -­‐0.778	   Methylation	  Glb1	   galactosidase,	  beta	  1	  	   9	   1620	   940	   -­‐0.786	   Catalytic	  activity	  Ppp1r35	   protein	  phosphatase	  1,	  regulatory	  subunit	  35	  	   5	   718	   406	   -­‐0.824	   Enzyme	  regulator	  activity	  Rps2	   ribosomal	  protein	  S2	  	   17	   20500	   11400	   -­‐0.847	   ribosomal	  protein	  Epha3	   Eph	  receptor	  A3	  	   16	   715	   392	   -­‐0.865	   Catalytic	  activity	  Fabp5	   fatty	  acid	  binding	  protein	  5,	  epidermal	  	   3	   19500	   10400	   -­‐0.899	   Lipid	  metabolic	  process	  Serpine1	   serine	  (or	  cysteine)	  peptidase	  inhibitor,	  clade	  E,	  member	  1	  	   5	   546	   291	   -­‐0.905	   Cell	  proliferation	  2610035D17Rik	   RIKEN	  cDNA	  2610035D17	  gene	  	   11	   581	   308	   -­‐0.915	   lincRNA	  Rpl35a	   ribosomal	  protein	  L35A	  	   16	   952	   461	   -­‐1.04	   ribosomal	  protein	  C4b	   complement	  component	  4B	  (Childo	  blood	  group)	  	   17	   1180	   559	   -­‐1.08	   Immune	  response	  Gm10395	   predicted	  gene	  10395	  	   14	   2400	   1120	   -­‐1.1	   Unknown	  Entpd4	   ectonucleoside	  triphosphate	  diphosphohydrolase	  4	  	   14	   3090	   1430	   -­‐1.11	   Metabolic	  process	  D14Ertd449e	   DNA	  segment,	  Chr	  14,	  ERATO	  Doi	  449,	  expressed	  	   14	   2250	   1030	   -­‐1.13	   Unknown	  Gm9746	   predicted	  gene	  9746	  	   14	   2390	   1080	   -­‐1.14	   Unknown	  H2-­‐D1	   histocompatibility	  2,	  D	  region	  locus	  1	  	   17	   19800	   8780	   -­‐1.18	   Immune	  response	  
Gm14109	   predicted	  gene	  14109	  	   2	   356	   156	   -­‐1.19	   pseudogene	  Tmem221	   transmembrane	  protein	  221	  	   8	   202	   84.8	   -­‐1.25	   Transmembrane	  protein	  Gm12411	   predicted	  gene	  12411	  	   4	   4210	   1540	   -­‐1.45	   pseudogene	  Rps3a	   ribosomal	  protein	  S3A	  	   3	   6480	   2370	   -­‐1.45	   ribosomal	  protein	  Glt1d1	   glycosyltransferase	  1	  domain	  containing	  1	  	   5	   321	   118	   -­‐1.45	   Catalytic	  activity	  Gm10393	   predicted	  gene	  10393	  	   14	   1230	   444	   -­‐1.47	   pseudogene	  Plac9	   placenta	  specific	  9	  	   14	   1540	   533	   -­‐1.53	   Unknown	  Gm14127	   predicted	  gene	  14127	  	   2	   627	   217	   -­‐1.53	   pseudogene	  Gm9780	   predicted	  gene	  9780	  	   14	   1500	   518	   -­‐1.54	   pseudogene	  Stfa1	   stefin	  A1	  	   16	   1180	   397	   -­‐1.58	   Enzyme	  regulator	  activity	  Gcnt1	   glucosaminyl	  (N-­‐acetyl)	  transferase	  1,	  core	  2	  	   19	   2240	   739	   -­‐1.6	   Metabolic	  process	  Gm12261	   predicted	  gene	  12261	  	   11	   255	   77.9	   -­‐1.71	   pseudogene	  Cyp3a57	   cytochrome	  P450,	  family	  3,	  subfamily	  a,	  polypeptide	  57	  	   5	   181	   54.8	   -­‐1.72	   Metabolic	  process	  Tmem79	   transmembrane	  protein	  79	  	   3	   2330	   695	   -­‐1.75	   Transmembrane	  protein	  
B3gnt3	   UDP-­‐GlcNAc:betaGal	  beta-­‐1,3-­‐N-­‐acetylglucosaminyltransferase	  3	  	   8	   533	   150	   -­‐1.82	  
Catalytic	  activity	  
Cpsf4l	   cleavage	  and	  polyadenylation	  specific	  factor	  4-­‐like	  	   11	   874	   236	   -­‐1.89	   Unknown	  Ccdc122	   coiled-­‐coil	  domain	  containing	  122	  	   14	   265	   66.7	   -­‐1.99	   Unknown	  Rpl21-­‐ps8	   ribosomal	  protein	  L21,	  pseudogene	  8	  	   18	   1480	   338	   -­‐2.13	   ribosomal	  protein	  Gm9104	   predicted	  gene	  9104	  	   17	   748	   167	   -­‐2.16	   Unknown	  Rpl21	   ribosomal	  protein	  L21	  	   5	   2770	   561	   -­‐2.3	   ribosomal	  protein	  1700030C10Rik	   RIKEN	  cDNA	  1700030C10	  gene	  	   12	   43	   8.16	   -­‐2.4	   Unknown	  Wdr95	   WD40	  repeat	  domain	  95	  	   5	   61.5	   7.22	   -­‐3.09	   Unknown	  Gm11131	   predicted	  gene	  11131	  	   17	   47.9	   5.15	   -­‐3.22	   lincRNA	  Rps18	   ribosomal	  protein	  S18	  	   17	   11800	   1040	   -­‐3.51	   ribosomal	  protein	  Rps18-­‐ps1	   ribosomal	  protein	  S18,	  pseudogene	  1	  	   4	   3200	   227	   -­‐3.82	   ribosomal	  protein	  4732490B19Rik	   RIKEN	  cDNA	  4732490B19	  gene	  	   11	   53.9	   3.66	   -­‐3.88	   lincRNA	  Gm16867	   predicted	  gene,	  16867	  	   14	   320	   20.2	   -­‐3.99	   lincRNA	  H2-­‐Q8	   histocompatibility	  2,	  Q	  region	  locus	  8	  	   17	   122	   6.3	   -­‐4.27	   Immune	  response	  Rpl21-­‐ps11	   ribosomal	  protein	  L21,	  pseudogene	  11	  	   3	   529	   21.4	   -­‐4.63	   ribosomal	  protein	  Gm12944	   predicted	  gene	  12944	  	   4	   632	   22.1	   -­‐4.83	   pseudogene	  Mmrn1	   multimerin	  1	  	   6	   551	   1.2	   -­‐8.84	   Unknown	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Designation of sample - Mouse Skin Sample 
Code No. C57/BL6/J1 Wild Type 
Submitted by - University of Dundee 
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TLC Report 
Extraction 
The sample of mouse skin was defrosted then extracted following a method adaptation of that 
described by Folch et at. (Folch,J. , Lees,M. and Stanley,G.H.S. J. Bioi. Chern. , 226, 497-509 
(1957)) involving chloroform-methanol-potassium chloride in the ratio 2 : 1 : 0.88 v/v/v. 
1-D Lipid Class Identification (see attached labelled scans) 
A portion of mouse skin extract was dissolved in solvent and spotted onto a TLC plate along with 
standards for Lipid Class identification. The Plate was separated in one direction using solvent 
mixture 80:20:2 iso-hexane/diethyl ether/formic acid. (see attached labelled scan) 
The mouse skin extract was seen to contain the following lipid classes:-
Mostly TAG with, in varying amounts CE, FFA, FC, DAG, MAG and PL. 
2-D Phospholipid Species Identification (see attached labelled scans) 
A second portion of s mouse skin extract was separated into phospholipid species using a two-
dimensional solvent system. Direction 1 chloroform /methanol/water (65:25:4) followed by 
direction 2 chloroform/methanol/acetic acid/water (80: 12: 15:4 ). 
The following species were identified Sphingomyeline, phosphatidylethanolamine, 
phosphatidylcholine, phosphatidylserine (slightly overlapped by PC) and phosphatidylinositol. 
Two other spots seen are probably Cardiolipid (DPG) and a Lysolipid (possibly lysoPC). 
Further small spots were seen on the plate which did not match our ID standards. 
1-D Separation for Ceramide (see attached labelled scans) 
A third portion of mouse skin extract was separated to show ceramide content. The extract was 
separated in one direction using three different solvent mixtures. 
Mixture 1 dichlormethane/ethyl acetate/acetone (80:16:4) 
Mixture 2 chloroform/acetone/methanol (76:8:16) 
Mixture 3 isohexane/ chloroform/acetone (6:80:10:4) 
Numerous bands were detected in the area where Ceramides are known to be found but we are 
unable to positively identify them. 
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TLC Report 
Extraction 
The sample of mouse skin was extracted following a method which is an adaptation of that 
described by Felch eta/. (Folch,J. , Lees,M. and Stanley,G.H.S. J. Bioi. Chem. , 226, 497-509 
(1957)) involving chloroform-methanol-potassium chloride in the ratio 2 : 1 : 0.88 v/v/v. 
Lipid Class Identification (see attached labelled scans) 
A portion of mouse skin extract was dissolved in solvent and spotted onto a TLC plate along with 
standards for Lipid Class identification. The Plate was separated in one direction using solvent 
mixture 80:20:2 iso-hexane/diethyl ether/formic acid. 
The mouse skin extract was seen to contain the following lipid classes:-
Mostly TAG with, in varying amounts CE, FFA, FC, DAG, MAG and PL. 
2-D Phospholipid Species Identification (see attached labelled scans) 
A second portion of s mouse skin extract was separated into phospholipid species using a two-
dimensional solvent system. Direction 1 chloroform /methanol/water (65:25:4) fol lowed by 
direction 2 chloroform/methanol/acetic acid/water (80:12:15:4). 
The following species were identified Sphingomyeline, phosphatidylethanolamine, 
phosphatidylcholine, phosphatidylserine (slightly overlapped by PC) and phosphatidylinositol. 
Two other spots seen are probably Cardiolipid (DPG) and a Lysolipid (possibly lysoPC). 
Further small spots were seen on the plate which did not match our ID standards. 
1-D Separation for Ceramide (see attached labelled scans) 
A third portion of mouse skin extract was separated to show ceramide content. The extract was 
separated in one direction using three different solvent mixtures. 
Mixture 1 dichlormethane/ethyl acetate/acetone (80:16:4) 
Mixture 2 chloroform/acetone/methanol (76:8: 16) 
Mixture 3 isohexane/ chloroform/acetone (6:80:10:4) 
Numerous bands were detected in the area where Ceramides are known to be found but we are 
unable to positively identify them. 
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Plate sprayed with phosphomolybdic acid and charred @ 120°C
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Protein	  analysis	  of	  TMEM79	  
Appendix	  VIII	  Protein	  analysis	  of	  TMEM79	  performed	  by	  Dr	  George	  Schneider	  (Bioinformatics	  Institute,	  A*STAR,	  Singapore).	  
	  	  
Figure	  1	  Multiple	  protein	  sequence	  alignment	  of	  TMEM79,	  MPGES1,	  LTC4	  and	  FLAP	  together	  with	  additional	  members	  of	  the	  MAPEG	  family.	  Key	  residues	  highlighted	  in	  this	  figure	  are	  detailed	  in	  Table	  1	  –	  3.	  














	   	  





Bioinformatics	  analysis	  of	  TMEM79	  Protein	  	  	  
1.	  	  Summary	  	  A	  preliminary	  sequence	  analysis	  of	  TMEM79	  (NP_115699.1	  |	  CAI14162.1)	  was	  performed	  using	  ANNOTATOR	  analysis	  framework	  (Schneider	  et	  al.	  2010;	  Ooi	  et	  al.	  2009).	  	  There	  seems	  to	  be	  evidence	  from	  computational	  predictions	  and	  the	  comparison	  to	  published	  structures	  to	  support	  the	  following	  findings:	  	  1.	  TMEM79	  and	  its	  orthologs	  are	  distantly	  related	  to	  the	  MAPEG	  (Membrane	  Associated	  Proteins	  in	  Eicosanoid	  and	  Glutathione	  metabolism)	  superfamily	  many	  of	  whose	  members	  are	  involved	  in	  inflammation	  pathways.	  	  2.	  Although	  sequence	  identity	  is	  very	  low,	  a	  multiple	  sequence	  alignment	  of	  MPGES1	  and	  TMEM79	  together	  with	  other	  canonical	  members	  of	  the	  MAPEG	  family	  shows	  that	  a	  large	  percentage	  of	  the	  key	  residues	  involved	  in	  glutathione	  binding	  in	  MPGES1	  are	  also	  present	  in	  TMEM79	  (see	  section	  3).	  	  3.	  Since	  MAPEG	  family	  members	  catalyze	  glutathione-­‐dependent	  transformations	  of	  lipophilic	  substrates	  harvested	  from	  the	  lipid	  bilayer	  (Martinez	  Molina	  et	  al.	  2008),	  experimentally	  establishing	  Glutathione	  binding	  of	  TMEM79	  could	  serve	  as	  a	  first	  step	  to	  validate	  the	  above	  predictions	  and	  decide	  on	  whether	  to	  continue	  with	  a	  search	  for	  a	  lipophilic	  substrate	  (see	  section	  4).	  	  	  	  
2.	  	  General	  Sequence	  Analysis	  
	  A	  segment	  based	  strategy	  for	  functional	  analysis	  was	  used.	  	  Around	  30	  algorithms	  were	  applied	  to	  try	  to	  distinguish	  non-­‐globular	  segments	  from	  globular	  domains.	  	  The	  non-­‐globular	  segments	  are	  often	  regions	  of	  low-­‐sequence	  complexity	  or	  compositional	  bias,	  but	  may	  carry	  out	  important	  structural	  functions	  or	  contain	  signals	  for	  posttranslational	  modification	  or	  localization.	  	  On	  the	  other	  hand,	  conserved	  globular	  domains	  with	  a	  fairly	  stable	  three-­‐dimensional	  structure	  might	  carry	  out	  enzymatic	  function	  or	  serve	  as	  an	  interface	  in	  protein-­‐protein	  interactions	  or	  have	  general	  scaffolding	  roles.	  	  The	  results	  can	  be	  seen	  in	  (Figure	  1)	  and	  show	  that	  TMEM79	  has	  a	  long	  N-­‐terminal	  region	  of	  low	  sequence	  complexity.	  	  No	  further	  analysis	  of	  this	  region	  was	  undertaken.	  The	  C-­‐terminal	  half	  of	  the	  protein	  is	  dominated	  by	  five	  predicted	  trans-­‐membrane	  segments.	  After	  this	  sequence	  motif	  and	  architecture	  analysis,	  orthologous	  sequences	  were	  gathered	  which	  were	  subjected	  to	  a	  similar	  analysis	  as	  above	  to	  look	  for	  emerging	  patterns.	  Subsequently,	  the	  analysis	  was	  extended	  to	  individual	  segments	  to	  not	  only	  include	  orthologs	  but	  also	  remote	  homologs,	  which	  were	  gathered	  with	  an	  iterative	  procedure.	  	  The	  ortholog	  collection	  algorithm	  was	  used	  to	  find	  a	  number	  of	  orthologs	  and	  subsequent	  analysis	  of	  these	  found	  an	  enrichment	  for	  PFAM	  domain	  hits	  (PF01124)	  against	  the	  MAPEG	  protein	  family	  	  Further	  evidence	  for	  membership	  in	  the	  MAPEG	  family	  was	  uncovered:	  
	  1.	  Inspection	  of	  the	  HMMER	  result	  on	  TMEM79	  finds	  a	  sub-­‐significant	  hit	  (E-­‐value:	  0.029)	  against	  the	  MAPEG	  domain	  (PF01124)	  	  2.	  PSI-­‐BLAST	  finds	  members	  of	  the	  MAPEG	  family	  starting	  from	  round	  2.	  	  3.	  The	  locally	  installed	  version	  of	  HHPRED	  (Soding	  et	  al.	  2005)	  finds	  a	  clear	  hit	  (E-­‐value:	  9.7E-­‐11)	  against	  the	  MAPEG	  domain	  (PF01124)	  	  	  A	  number	  of	  caveats	  should	  be	  mentioned:	  	  •	  	  All	  the	  well-­‐studied	  MAPEG	  members	  only	  have	  four	  TM	  segments,	  while	  TMEM79	  has	  five.	  The	  region	  of	  homology	  clearly	  only	  extends	  to	  the	  last	  four	  segments	  of	  TMEM79.	  	  •	  	  All	  MAPEG	  members	  appear	  to	  only	  as	  long	  as	  the	  TM	  segments	  together.	  There	  are	  no	  long	  N-­‐terminal	  unstructured	  regions,	  as	  found	  in	  TMEM79/mattrin.	  	  •	  	  All	  known	  structures	  of	  MAPEG	  members	  show	  the	  formation	  of	  a	  homotrimer.	  	  	  	  
3.	  	  Comparison	  of	  TMEM79	  and	  MPGES1	  	  There	  are	  a	  number	  of	  publications	  that	  provide	  detailed	  structural	  information	  as	  well	  as	  results	  of	  site-­‐directed	  mutagenesis	  for	  MPGES1	  (Microsomal	  prostaglandin	  E	  synthase	  1)	  (Jegerschöld	  et	  al.	  2008),	  LTC4S	  (Leukotriene	  C4	  synthase)	  (Molina	  et	  al.	  2007;	  Ago	  et	  al.	  2007)	  and	  FLAP	  (5-­‐Lipoxygenase-­‐activating	  protein)	  (Ferguson	  et	  al.	  2007)	  with	  the	  last	  one	  lacking	  enzymatic	  activity.	  	  A	  multiple	  sequence	  alignment	  was	  constructed	  using	  locally	  installed	  MAFFT	  (Katoh	  et	  al.	  2005)	  and	  taking	  as	  input	  the	  orthologs	  of	  TMEM79,	  MPGES1	  and	  the	  seed	  sequences	  for	  the	  MAPEG	  domain	  in	  PFAM	  (PF01124).	  	  Since	  the	  seed	  only	  contained	  xenopus	  sequences	  for	  LTC4S	  and	  FLAP,	  the	  rat	  and	  human	  orthologs	  were	  added	  respectively.	  	  A	  small	  number	  of	  MAPEG	  seed	  sequences	  with	  very	  long	  loop	  regions	  were	  removed.	  	  The	  alignment	  shown	  in	  (Figure	  1),	  above,	  presents	  alignment	  with	  only	  the	  core	  members	  shown.	  The	  first	  two	  sequences	  are	  orthologs	  (YP_617596.1	  and	  ZP_05250079.1)	  of	  TMEM79,	  which	  were	  retained	  to	  provide	  some	  visual	  guidance	  and	  context.	  The	  third	  and	  fourth	  sequences	  are	  TMEM97	  and	  MPGES1	  respectively	  (they	  are	  surrounded	  by	  a	  red	  dotted	  box).	  They	  are	  followed	  by	  two	  sequences	  of	  LTC4	  and	  FLAP	  each.	  The	  last	  two	  sequences	  belong	  to	  the	  MAPEG	  seed	  and	  are	  again	  left	  there	  to	  provide	  some	  context.	  	  Tables	  1	  -­‐	  3	  contain	  assessment	  which	  was	  done	  by	  comparing	  features	  and	  individual	  residues	  mentioned	  in	  (Molina	  et	  al.	  2007)	  among	  the	  different	  sequences.	  	  Mismatches	  between	  residues	  are	  classified	  and	  color-­‐coded	  as	  explained	  below.	  The	  same	  numbers	  and	  color-­‐codes	  are	  indicated	  in	  the	  multiple	  
sequence	  alignment	  shown	  in	  (Figure	  1).	  	  	  	  
4.	  	  Summary	  	  In	  summary,	  there	  seems	  to	  be	  a	  sufficient	  match	  between	  key	  residues	  TMEM79	  of	  glutathione	  binding	  to	  merit	  further	  experimental	  investigation	  as	  a	  MAPEG-­‐like	  protein.	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APPENDIX	  VIII	  
Case-­‐control	  studies	  for	  meta-­‐analysis	  of	  atopic	  dermatitis	  patients	  from	  
England,	  UK,	  Ireland,	  Germany	  and	  Scotland.	  
Authors	  involved:	  Christabelle	  S.	  M.	  Goh1,	  Stephan	  Weidinger2,	  Hansjörg	  Baurecht2,	  Young-­‐Ae	  Lee3,	  Jonathan	  N.	  W.	  N.	  Barker4,	  Nick	  J.	  Reynolds5,	  Heather	  J.	  Cordell5,	  Sara	  J.	  Brown1,	  Alan	  D.	  Irvine6,	  W.H.	  Irwin	  McLean1,	  Aileen	  Sandilands1	  
1.	  University	  of	  Dundee,	  United	  Kingdom;	  2.	  University	  of	  Kiel,	  Germany;	  3.	  Charite,	  
Berlin;	  4.	  King’s	  College	  London,	  United	  Kingdom;	  5.	  Newcastle	  University,	  United	  
Kingdom;	  6.	  Trinity	  College	  Dublin,	  Ireland	  	  Five	  independently	  recruited	  AD	  case	  collections	  were	  compared	  with	  ethnically	  matched	  population	  controls.	  Statistical	  and	  meta-­‐analysis	  was	  conducted	  by	  Dr.	  Sara	  J.	  Brown	  (University	  of	  Dundee).	  	  (1)	  English	  adult	  severe	  AD	  is	  early	  onset,	  persistent	  and	  severe	  disease,	  diagnosed	  by	  experienced	  dermatologists	  in	  secondary	  and	  tertiary	  care.	  
(2)	  UK	  mild-­‐moderate	  pediatric	  AD	  includes	  cases	  collected	  from	  an	  English	  population	  birth	  cohort	  (n=177)	  and	  a	  Scottish	  Primary	  Care	  collection	  (n=161).	  AD	  is	  defined	  using	  the	  UK	  refinement	  of	  the	  Hanifin	  and	  Rajka	  diagnostic	  criteria.	  
(3)	  Irish	  pediatric	  AD	  cases	  were	  collected	  in	  secondary	  and	  tertiary	  care	  clinics	  in	  Ireland,	  defined	  by	  experienced	  dermatologists.	  
(4)	  German	  AD	  cases	  are	  adults	  and	  children	  diagnosed	  by	  experienced	  dermatologists	  and	  pediatricians	  using	  standard	  criteria	  for	  AD,	  in	  tertiary	  care	  clinics.	  
(5)	  Scottish	  asthma	  cases	  with	  AD	  are	  individuals	  with	  physician-­‐diagnosed	  asthma	  in	  primary	  and	  secondary	  care,	  with	  parent-­‐	  or	  self-­‐reported	  history	  of	  ever	  having	  had	  AD.	  
The	  following	  matched	  control	  populations	  were	  used:	  
(1)	  1958	  Birth	  Cohort	  comprises	  unselected	  English	  population	  controls.	  
(2)	  English	  pediatric	  controls	  were	  ascertained	  not	  to	  have	  AD	  at	  the	  age	  of	  7-­‐9	  years.	  They	  are	  the	  hyper-­‐normal	  controls	  from	  the	  same	  English	  population	  birth	  cohort	  from	  which	  the	  English	  mild-­‐moderate	  pediatric	  AD	  cases	  were	  recruited.	  
(3)	  Irish	  population	  controls	  are	  healthy	  adult	  blood	  donors	  in	  Dublin,	  Ireland.	  	  
(4)	  German	  population	  controls	  include	  pediatric	  and	  adult	  cohorts	  from	  Germany.	  
(5)	  Scottish	  population	  controls	  are	  healthy	  adult	  blood	  donors	  from	  throughout	  Scotland.	  
	  
	  
Figure	  1	  Forrest	  plot	  showing	  results	  of	  meta-­‐analysis	  of	  five	  case-­‐control	  studies	  to	  investigate	  the	  association	  of	  rs6684514	  and	  AD.	  	  Study	  populations	  used	  were:	  English,	  English	  adult	  severe	  AD	  vs	  English	  population	  controls	  from	  the	  1958	  Birth	  Cohort;	  UK;	  UK,	  UK	  mild-­‐moderate	  pediatric	  AD	  vs	  English	  pediatric	  controls	  without	  AD;	  Irish,	  Irish	  pediatric	  AD	  vs	  Irish	  adult	  population	  controls;	  German,	  German	  AD	  cases	  vs	  German	  population	  controls;	  Scottish;	  Scottish	  asthma	  cases	  with	  AD	  vs	  Scottish	  population	  controls.	  	  ES	  =	  estimated	  odds	  ratio;	  CI	  =	  confidence	  interval.	  Meta-­‐analysis	  carried	  out	  using	  the	  “metan”	  function	  in	  Stata®	  (StataCorp,	  College	  Station,	  Texas).











Tmem79/Matt is the matted mouse gene and is a
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Background: Atopic dermatitis (AD) is a major inflammatory
condition of the skin caused by inherited skin barrier
deficiency, with mutations in the filaggrin gene predisposing to
development of AD. Support for barrier deficiency initiating AD
came from flaky tail mice, which have a frameshift mutation in
Flg and also carry an unknown gene, matted, causing a matted
hair phenotype.
Objective: We sought to identify the matted mutant gene in mice
and further define whether mutations in the human gene were
associated with AD.
Methods: A mouse genetics approach was used to separate the
matted and Flg mutations to produce congenic single-mutant
strains for genetic and immunologic analysis. Next-generation
sequencing was used to identify the matted gene. Five
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independently recruited AD case collections were analyzed to
define associations between single nucleotide polymorphisms
(SNPs) in the human gene and AD.
Results: The matted phenotype in flaky tail mice is due to a
mutation in the Tmem79/Matt gene, with no expression of the
encoded protein mattrin in the skin of mutant mice. Mattft mice
spontaneously have dermatitis and atopy caused by a defective
skin barrier, with mutant mice having systemic sensitization
after cutaneous challenge with house dust mite allergens. Meta-
analysis of 4,245 AD cases and 10,558 population-matched
control subjects showed that a missense SNP, rs6694514, in the
human MATT gene has a small but significant association with
AD.
Conclusion: In mice mutations in Matt cause a defective skin
barrier and spontaneous dermatitis and atopy. A common SNP
in MATT has an association with AD in human subjects.
(J Allergy Clin Immunol 2013;nnn:nnn-nnn.)
Key words: Allergy, association, atopic dermatitis, atopy, eczema,
filaggrin, flaky tail, Matt, mattrin, mouse, mutation, Tmem79
Atopic dermatitis (AD) is the most common diagnosis in
dermatology, affecting approximately 1 in 5 children in the
developedworld,1 and is frequently associated with atopic asthma
and a wide range of allergies.2 AD is a highly heritable complex
trait; however, environmental influences also play a role in trig-
gering the atopic diathesis.3 Genome-wide association studies
in AD have identified several susceptibility loci4-7; however, the
major and only functionally characterized genetic factor is the
filaggrin gene (FLG), which encodes the skin barrier protein filag-
grin.3 Prevalent loss-of-function variants in FLG were identified
as the cause of the single-gene disorder ichthyosis vulgaris (dry
flaky skin).8 Soon thereafter, these variants were shown to be
strongly associated with AD,9 with heterozygous odds ratios
(ORs) of greater than 7 and homozygous ORs of greater than
150 in case-control studies in which both prevalent and rare var-
iants were analyzed.10
The hypothesis that skin barrier deficiency in the context of
FLG mutations is an initiator of AD was confirmed experimen-
tally by using the flaky tail mouse mutant,11 which was shown
to carry a frameshift mutation in the murine Flg gene.12 Flaky
tail mice have a defective skin barrier, with increased percuta-
neous transfer of antigens and chemical haptens.12-15 The ft
mutation arose spontaneously in 1958 in the progeny of crosses
between heterogeneous stocks of mice with the recessive muta-
tion matted (ma), and these mutations are maintained as a
double-mutant (DM) strain known as maft. The matted hair
phenotype was used for many years as a surrogate marker
for the ft mutation because, remarkably, the ft and ma muta-
tions are closely linked on chromosome 3 in the mouse.16
The DM maft mice have been routinely used for studies of
skin barrier–deficient AD in recent years.13-15,17 In mice and
human subjects the FLG gene resides in the epidermal differ-
entiation complex, a cluster of more than 70 genes encoding
proteins involved in skin barrier formation and differentiation
of stratified epithelia,18 including those within the hair
follicle.18-21 We suspected the nearby ma gene might also be
involved in epithelial barrier function, and in this study we
set out to separate this allele from Flgft and identify the caus-
ative defect.
METHODS
Isolation of the matted mouse strain
DMMattma/maFlgft/ft mice were provided by Dr John P. Sundberg (Jackson
Laboratory, Bar Harbor, Me).12 DMmicewere crossed with C57BL/6Jmice to
generateMattma/1Flgft/1mice. The Flgft andMattmamutations were separated
and backcrossed to congenic C57BL/6J background in accordance with the
breeding strategy outlined (see Fig E1 in this article’s Online Repository at
www.jacionline.org). C57BL/6J micewere used as wild-type (WT) control an-
imals. B6.CBAGr-ma/J (JAXMattma/ma) mice were obtained from the Jackson
Laboratory. Mice were housed in specific pathogen-free conditions, with irra-
diated diet and bedding and water ad libitum. All animal experiments were per-
formed in compliancewith IrishDepartment ofHealth andChildren regulations
and approved byTrinityCollegeDublin’s BioResources Ethical ReviewBoard.
Gene mapping
Skin sampleswere obtained fromneonatalmice, andDNAwas extracted by
using the DNA Purification Kit (Promega, Madison, Wis). Genomic DNA
extracted from murine neonatal blood was amplified with the GoTaq Flexi
DNA Polymerase kit (Promega). All samples were sequenced by using the
ABI 3730 DNA Systems (Applied Biosystems, Foster City, Calif). Mapping
primers were used to amplify and sequence murine chromosome 3 (see Table
E1, A, in this article’s Online Repository at www.jacionline.org). Matted
genomic sequences were comparedwith C57BL/6J for regions of congenicity.
Next-generation sequencing and bioinformatics
Three replicates from each sample (WTandMattma/ma) were submitted for
next-generation sequencing. The replicates were run multiplexed on an Illu-
mina GAIIx and HiSeq 2000 (Illumina, San Diego, Calif) by using v3
sequencing chemistry and the Roche 454 Titanium workflow (Roche, Man-
nheim, Germany). For further details on sequencing, bioinformatics, and sin-
gle nucleotide polymorphism (SNP) and InDel methodologies, see the
Methods section in this article’s Online Repository at www.jacionline.org.
Analysis and identification of murine Tmem79/Matt
gene
Each of the 4 exons was amplified individually by using PCR with the
following conditions for all exons: 1 cycle of 948C for 5 minutes; 35 cycles of
948C for 30 seconds, 548C for 30 seconds, and 728C for 1 minute; and a final
extension at 728C for 5 minutes.
Semiquantitative RT-PCR
Mouse tissue samples were lysed with TissueLyser LT (Qiagen, Hilden,
Germany), and RNA was extracted with the RNeasy kit (Qiagen). RNA was
reverse transcribed with the ImProm-II Reverse Transcription System
(Promega). An intron-spanning amplification was carried out on Tmem79/
Matt across exons 3 and 4. Krt14 was used as a loading control. RT-PCR
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Mouse genotyping
The 644-bp PCR product of the third Tmem79/Matt exon was digested with
the restriction enzyme CviQI (New England Biolabs, Ipswich, Mass), and di-
gested fragments were separated on agarose gel by using electrophoresis.
Primers used are shown in Table E1, A. The Flgft mutation was genotyped,
as previously described.12
Immunoblotting
The epidermis was separated from the dermis of neonatal mice after
immersion in 5mmol/LEDTAat 508C for 5minutes, followed by cooling in ice-
cold PBS. The separated epidermis was extracted in urea/Tris buffer containing
protease inhibitor cocktail (Halt; Thermo Scientific, Erembodegem, Belguim)
by means of homogenization. Protein samples were separated on SDS-
polyacrylamide gels and transferred to polyvinylidene difluoride membranes
(Millipore, Temecula, Calif), which were probed with rabbit polyclonal
antibodies specific for human mattrin (TMEM79; Novus Biologicals, Littleton,
Colo). Primary antibodies were detected by means of incubation with a
horseradish peroxidase–conjugated goat anti-rabbit secondary antibody (Dako,
Stockport, United Kingdom). Immunolabeled proteins were visualized by using
chemiluminescence with the ECL detection system (Millipore).
Immunofluorescence and Nile Red staining
Dorsal murine sections were obtained from 4-day-old neonatal mice and
snap-frozen immediately. All frozen samples were then cryosectioned at 4 to 5
mm and stored at 808C until use. After drying, sections were fixed in 50%
methanol acetone, washed in PBS, and incubated with primary antibodies.
Nuclei were stained with 49-6-diamidino-2-phenylindole (Sigma-Aldrich, St
Louis, Mo), and slides were fixed in Hydromount (National Diagnostics,
Atlanta, Ga). Primary antibodies used in whole mounts were as follows:
polyclonal TMEM79 (TMEM79; Novus Biologicals) and monoclonal CK-13
against cytokeratin 17 (Sigma-Aldrich). Frozen mouse skin sections were
stainedwithNile Red and 6-diamidino-2-phenylindole. Imageswere collected
with a Zeiss LSM700 confocal microscope (Zeiss, Oberkochen, Germany).
Quantitative PCR of human cDNA tissue array
Expression of TMEM79/MATT cDNA was quantified across a multiple-
tissue panel containing cDNA from 48 different human tissues (Origene Tech-
nologies, Rockville, Md). This was done with the TaqMan Gene Expression
Assay, C_25986870_10 (Life Technologies, Carlsbad, Calif), which spans
exons 3 to 4 to result in amplicon length of 65 bp in cDNA sequence. The stan-
dard used in this assay was a commercially available plasmid containing the
full-length WT TMEM79/MATT (Origene Technologies). A standard curve
was calculated by using the formulae provided by Applied Biosystems.
Phenotypic scoring
The severity of inflammation and AD-like pathology was scored by using
themacroscopic diagnostic criteria described for the skin inflammation seen in
the Nc/Nga mouse model of AD.22 Briefly, a scoring system (0, none; 1, mild;
2, moderate; and 3, severe) was applied to the symptoms of pruritus, edema,
erosion, scaling, and erythema. Pruritus (scratch behavior) was observed for
5 minutes. Total scores for each mouse were calculated from the sum of indi-
vidual scores.
Cutaneous challenge with house dust mite antigen
Mice were challenged with house dust mite (HDM) to induce allergic skin
sensitization, as previously described.13 Briefly, HDM (Greer Laboratories,
Lenoir, NC) was topically applied to intact skin of WT and Mattma mice by
using Finn chamber patch tests (SmartPractice, Phoenix, Ariz) and secured
with Scanpor tape (Bio-Diagnostics, Worcester, United Kingdom). The
regimen involved five 1-week exposures to the allergen patch separated by
2-week intervals. Hair was clipped 24 hours before application of HDM that
was prepared in endotoxin-free Dulbecco PBS and vehicle to a concentration
of 1 mg/mL. Dulbecco PBS was used as the control. Mice were assessed 24
hours after the final HDM challenge.
ELISA
Serum levels of HDM-specific IgE, IgG1, and IgG2a were detected by
means of direct ELISA. Total serum IgE levels were measured with a sand-
wich ELISA, according to the manufacturer’s instructions (BD PharMingen,
San Jose, Calif).
Histology
Dorsal skin sectionswere removed and fixed in 10% formal saline. Paraffin-
embedded sections were stained with hematoxylin and eosin and examined in
blinded fashion by 2 observers independently. To quantify dermal cell
numbers, we used a previously described scoring system.12 The total number
of cells per high-power field (hpf) of view were counted on 20 hpfs per mouse.
For skin sections, an arbitrary histologic scoring system was used to quantify
acanthosis and hyperkeratosis. Acanthosis scoring was based on the magni-
tude of epidermal hyperplasia, and hyperkeratosis scoring was based on the
magnitude of stratum corneum thickening, with scores (0, basal; 1, mild; 2,
moderate; 3, marked; 4, very marked; and 5, extreme pathology) for each
parameter based on measurements per hpf in sections.
Measurement of transepidermal water loss
A Courage and Khazaka Tewameter TM210 (Enviroderm, Evesham,
United Kingdom) was used for measurement of transepidermal water loss
(TEWL), which was measured on the dorsal flank of mice 24 hours after hair
clipping. TEWL was recorded at an ambient temperature of 198C to 218C and
humidity of 50%6 5%. In mice sensitized to HDM, TEWL was measured in
PBS- and HDM-treated mice before and after the HDM challenge regimen.
Electron microscopy
For scanning electron microscopy, hair fibers were removed frommice and
fixed in cacodylate-buffered glutaraldehyde. Samples were prepared for
scanning electron microscopy by using established procedures11 and exam-
ined in a Zeiss Supra scanning electron microscope.
Statistical analysis of mouse studies
GraphPad Prism software (GraphPad Software, La Jolla, Calif) was used
for data analysis. Differences between groups were determined by using the
Student t test and 2-way ANOVA. Results are presented as means 6 SEMs.
Differences, indicated as 2-tailed P values, were considered significant at a
P value of less than .05.
SNP identification in human subjects
Human samples from England, Scotland, and Ireland were obtained with
consent from patients and Institutional Ethics Committee approval complying
with the principles of the Declaration of Helsinki. HumanMATTwas sequenced
by using primers listed in Table E1, C, in this article’s Online Repository at
www.jacionline.org. Conditions for all exons except exon 2.2 were as follows:
1 cycle of 948C for 5minutes; 35 cycles of 948C for 30 seconds, 548C for 30 sec-
onds, and 728C for 1 minute; and a final extension at 728C for 5 minutes. An an-
nealing temperature of 588C was used for exon 2.2. SNP rs6684514 (see Table
E2 in this article’s Online Repository at www.jacionline.org) was genotyped
across the case-control study populations by using the TaqMan allelic discrim-
ination genotyping assay (C_25986870_10, Life Technologies Corporation).
Case-control studies
Five independently recruited AD case collections were compared with
ethnically matched population control subjects (see the Methods section in
this article’s Online Repository). Case definitions are described in the
Methods section in this article’s Online Repository, and demographic data
relating to these AD case collections and control subjects are summarized
in Table E3 in this article’s Online Repository at www.jacionline.org.
Genotype imputation
For in silico replication, we used the 2 German AD case-control selections
(see Table E3), which had been genotyped on Illumina 300k and Affymetrix
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6.0p (Affymetrix, Santa Clara, Calif), respectively, and imputed based on the
1000 Genomes database (phase I integrated variant set release, March 2012).
Previous imputation data sets were curated, and samples with a greater than
5% missing rate, excess of heterozygosity (65 SDs away from the sample
mean), and unexpected relatedness (PI_HAT>0.1875, halfway between ex-
pected IBD for third- and second-degree relatives) were excluded. Further out-
liers from the multidimensional scaling of the pairwise IBS matrix were
removed. Imputation was carried out with SHAPEIT and IMPUTE2. The
SNP rs6684514 investigated in silico had an imputation quality of 0.996
(proper info) and a CR of 0.997.
Statistical genetics
Case-control comparisons for each case collection and population control
subjects were performed by using logistic regression analysis in Stata 12.0
(StataCorp, College Station, Tex). Meta-analysis (under fixed- and random-
effects models) of the resulting log ORs and their SEs was performed with the
‘‘metan’’ function in Stata 12.0.
RESULTS
Identification of Matt as the gene mutation in
matted mice
To separate the 2 mutations in the DM maft mice, we used the
backcross-intercross protocol outlined in Fig E1. Mice with the
Flgft mutant allele (Flg c.5303delA) were genotyped, as previ-
ously described.12 Progeny from putative heterozygous inter-
crosses were checked for the recessive matted hair phenotype to
identify ma/ma homozygotes. By this means, we separated both
alleles. Because SNP analysis showed that the initial DM maft
mouse was maintained on a mixed-strain background, we gener-
ated single-mutant N12 mice congenic on the C57BL/6J back-
ground. By using this backcross-intercross strategy to generate
congenic ma/ma homozygous mice (see Fig E1), the recessive
disease–causing locus should be ultimately visible as a small
area of homozygosity flanked by 2 unequal heterozygous regions
(see Fig E2, A, in this article’s Online Repository at www.
jacionline.org). To map this, we sequenced several short PCR
fragments across the region from C57BL/6J congenic ma/ma ho-
mozygotes (see Table E1, A) to identify SNPs. By this means, a
1.05-Mb critical interval was defined (Fig 1, A). In parallel, we
used epidermal transcriptomic sequencing to compare WT
C57BL/6J and congenic ma/ma homozygotes. A nonsense muta-
tion, p.Y280*, in the Tmem79 gene, located within the interval
(Fig 1, A), was identified in the RNAseq data (not shown). The
mutation in Tmem79 was confirmed by using conventional
sequencing of genomic PCR products (Fig 1,B) and restriction di-
gests (see Fig E2, B). This mutant transcript was expressed at
approximately 30% of the WT levels in ma/ma epidermis
(Fig 1, C). By using a commercially available antibody against
the C-terminus of the encoded protein, a single band of approxi-
mately 49 kDa was seen in epidermal extracts from WTand con-
genic Flgft/ftmice, with the protein absent in congenicma/ma and
DMmice (Fig 1,D), indicating the presence of a truncated protein
or an absence of protein in these mice. Interestingly, epidermal
extracts from Flgft/ft mice had increased expression of protein
relative to WT extracts. Tmem79 was renamed Matt, encoding
the protein mattrin; similarly, the human ortholog was renamed
MATT (approved by the Genome Nomenclature Committee).
By convention, after identification of the gene, the ma mutant
allele was redesignated as Mattma.
Mattrin is expressed in mouse and human skin
Matt is a compact 5-exon gene on mouse 3qF1 spanning 5781
bp of genomic DNA, encoding a 391-amino-acid protein with a
calculated molecular weight of 43.5 kDa. The human ortholog,
MATT, which is syntenic on 1q23.1, has an identical organization.
Mattrin is a transmembrane domain protein with no previously
ascribed function (Fig 1, E). Bioinformatics analysis predicts a
long internal N-terminal domain, 5 transmembrane domains,
and a short C-terminus (Fig 1, E, and see Fig E3 in this article’s
Online Repository at www.jacionline.org). The mutation
p.Y280* occurs before the third transmembrane domain
(Fig 1, E). Immunohistochemistry revealed that mattrin was pre-
sent in epidermal granular layer keratinocytes in WT mice
(Fig 2, A) but was absent fromMattma/ma animals (Fig 2, B). Simi-
larly, the protein was observed in granular layer cells in human
epidermis (see Fig E4, A and B, in this article’s Online Repository
at www.jacionline.org) and was also found in the hair follicles of
mice (Fig 2,A) and human subjects (see Fig E4,C andD). In addi-
tion, the mRNA is widely expressed in human tissues and, consis-
tent with immunohistochemistry, is strongly expressed in skin
(see Fig E4, E).
Expression quantitative trait locus analysis23 showed thatMatt
is in a network of proteins expressed late in epidermal differenti-
ation, with an expression quantitative trait locus profile closely
matching that of Rhbg (transporter protein) and Rab25 (mem-
brane trafficking, data not shown). Mattrin shows distant
sequence homology to the Membrane-Associated Proteins in
Eicosanoid and Glutathione metabolism (MAPEG) protein fam-
ily (see Fig E3),24 members of which have roles in lipid catabo-
lism.25 Immunohistochemistry with the lipophilic dye Nile Red
revealed highly organized stacks of cornified cell envelopes in
the stratum corneum of WT animals (Fig 2, C) that were highly
disorganized in Mattma/ma mice, with discontinuous, uneven,
and highly disorganized cornified cell envelopes (Fig 2, D).
Mattma/ma mice have spontaneous dermatitis
Gross examination of adult Flgft/ft andMattma/ma mice demon-
strates that the 2 strains differ considerably from each other (Fig 3,
A). Macroscopic clinical scoring22 demonstrated Mattma/ma and
DM mice spontaneously having progressive dermatitis-like skin
inflammation, which did not occur in adult Flgft/ft animals (see
Fig E5, A, in this article’s Online Repository at www.jacionline.
org). Although all Mattma/ma and DM mice had marked skin
inflammation, there was a broad spectrum of pathology, with
some animals exhibiting profound lesions and excoriation and oc-
casional blepharitis and eyelid dermatitis (see Fig E6, B, in this
article’s Online Repository at www.jacionline.org). Interestingly,
both neonatal Flgft/ft and DM mice have significant ichthyosis
(P < .001) compared with WT mice, but Mattma/ma mice did
not, indicating the postnatal importance of filaggrin (see Fig E5,
A, and E6, A).
With respect to the matted hair phenotype,11,26 bothMattma/ma
and DM animals had the keratinization defect, with hairs forming
clumps11,26 and hair breakage and occasional alopecia evident at
32 weeks (Fig 3, A, and see Fig E6, B). Scanning electron micro-
scopy confirmedMattma/ma and DM mice had fragile hairs prone
to longitudinal splitting and breakage with defective cuticle
morphology (see Fig E7, A, in this article’s Online Repository
at www.jacionline.org). Furthermore, Mattma/ma mice had dis-
torted hair follicle morphogenesis (see Fig E7, B).
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Skin histology (Fig 3, B) showed that Mattma/ma and DM mice
have marked acanthosis (P < .001) and prominent orthokeratosis
(P < .001) with dermal inflammatory infiltrates (P < .001; see Fig
E5, B). In contrast, Flgft/ftmice had occasional foci of acanthosis,
mild diffuse orthokeratosis, and increased dermal cell infiltration
relative to WT mice (P <.001). However, the phenotype in Flgft/ft
mice was subclinical, with no overt dermatitis (Fig 3, A, and see
Fig E5, A).
Mattma/ma mutant mice are atopic and have a
defective skin barrier
All mutant strains spontaneously had increased IgE levels
relative to WT mice, which was markedly more pronounced in
Mattma/ma and DM animals relative to Flgft/ft mice (P < .001; see
Fig E5, D). Because the severity of skin inflammation in AD par-
allels barrier permeability,27,28 TEWL was analyzed to quantify
skin barrier dysregulation in mouse strains. TEWL was signifi-
cantly increased in adult Mattma/ma and DM mice (P < .001; see
Fig E5, C). In contrast, TEWL was unaltered in Flgft/ft mice rela-
tive to that seen in WT animals (see Fig E5, C).
HDM allergen was applied to the intact skin of Mattma/ma and
WT mice to address whether the altered skin barrier inMattma/ma
mice influences allergen sensitization. Percutaneous sensitization
with allergen led to enhanced skin inflammation in Mattma/ma
mice (Fig 4, A-C). Consistent with the defective barrier, TEWL
was significantly upregulated (P < .001) in HDM-treated
Mattma/ma mice after allergen application (Fig 4, D). Crucially,
FIG 1. Identification of Tmem79/Matt as the matted gene. A, A region of homozygous ma/ma on
chromosome 3 indicated by regions in red and heterozygous regions in blue, with the homozygous
C57BL6/J genome shown in black. B, The ma mutation in Tmem79/Matt identified by means of epidermal
transcriptome sequencing was confirmed by using Sanger sequencing, causing a C to G substitution at
position 88,136,485 on chromosome 3. This predicts the protein change p.Y280X in the Tmem79 (mattrin)
protein. The mutant allele was renamedMattma. C, Semiquantitative RT-PCR of epidermal mRNA showed a
reduction in expression of Matt in Mattma/ma animals. D, Mattrin detected in immunoblotting of skin from
WT and Flgft/ft mice but no protein expression in Mattma/ma and DM mice. E, Bioinformatics shows
mattrin consists of 5 transmembrane helices with a long intracellular N-terminus and short extracellular
C-terminus.
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HDM-specific IgE responses were significantly (P < .05) evoked
in the sera of HDM-treated Mattma/ma mice, as well as
HDM-specific IgG1 and IgG2a responses (Fig 4, E). In contrast,
the skin of WT (Fig 4) and Flgft/ft (data not shown) mice was
refractory to cutaneous HDM exposure. Collectively, these data
demonstrate that Mattma/ma mice have spontaneous AD and a
defective skin barrier that facilitates percutaneous allergic
sensitization.
A mutation in MATT is associated with AD
To investigate whetherMATT is associated with human AD, all
exons of humanMATTwere sequenced in 55 Irish AD cases who
were negative for FLG null mutations. Several noncoding SNPs
and 1 known missense SNP, rs6684514, were identified (see
Table E2 in this article’s Online Repository at www.jacionline.
org). Case-control analyses conducted on 2 independent AD
case collections, English adult AD and United Kingdom pediatric
AD, with separate population-matched control subjects (see Table
E3) showed a significant association between rs6684514 and AD
(Table I). The minor allele (A) is protective for disease in both the
English adult AD (OR, approximately 0.791; P5 .0038) and UK
pediatric AD (OR, approximately 0.770; P 5 .0143) populations
(Table I). Notably, when controlling for the strong and significant
FLG null mutations, it was shown that the association of
rs6684514 with AD is independent of FLG (Table I and see
Table E4 in this article’s Online Repository at www.jacionline.
org). The association of rs6684514 with AD was further repli-
cated in a German AD case-control analysis in which the OR after
controlling for FLGmutations was 0.86 (95% CI, 0.76-0.97; P5
.0161; Table I). However, this association was not replicated in
Irish or Scottish case-control analyses (Table I). A meta-
analysis using a fixed-effects model of all 4,245 AD cases from
England, Scotland, Ireland, and Germany with 10,558
population-matched control subjects did not show significant het-
erogeneity between the study groups (P5 .078). A small but sig-
nificant effect of rs6684514 on AD risk was confirmed in the
meta-analysis (OR, 0.91; 95% CI, 0.86-0.96; P 5 .001; Fig 5;
see Table E4). A random-effects meta-analysis also produced
similar results (OR, 0.90; 95% CI, 0.82-0.98; P 5 .015; see Fig
E8 in this article’s Online Repository at www.jacionline.org).
DISCUSSION
Previously, we demonstrated that FLG loss-of-function muta-
tions have a very strong relevance for the common inflammatory
skin disease AD and associated atopic phenotypes3,9,10 and iden-
tified an analogous mutation in the murine homolog Flg in the
spontaneously occurring flaky tail DM (maft) mouse.12 Subse-
quently, these DMmice have been widely used as a model of her-
itable skin barrier deficiency and spontaneous dermatitis13-15,17
and as a model of filaggrin deficiency–associated AD pathogen-
esis in patients.29 In this study we have identified the matted
phenotype in the DM mouse as arising from a second mutation
in Matt (Tmem79). The Mattma mutation results in defective
expression of the transmembrane protein mattrin, which is highly
expressed in the upper granular layer of epidermal keratinocytes,
with a predicted role in lipid homeostasis. These studies have
elucidated the relative contributions of the Flg and Matt muta-
tions in the DM mouse. The Mattma mutation led to the striking
development of spontaneous AD-like skin pathology and atopy
in adult mice. These data indicate that the DM mouse is not a
true model of filaggrin deficiency–associated AD-like skin
FIG 2. Mattrin expression and disorganized lipid morphology in the
epidermis of Mattma mice. A and B, Immunohistochemistry detection of
mattrin expression confined to the epidermal granular layer of WT (Fig 2,
A) but notMattma/ma (Fig 2, B) animals, including hair follicles (arrow). Scale
bar 5 20 mm. C and D, Nile Red staining of lipids in the epidermis of WT
(Fig 2, C) andMattma/ma (Fig 2, D) mice revealed uneven and highly disorga-
nized cornified cell envelopes in the stratum corneum of Mattma/ma mice.
Scale bar 5 50 mm.
FIG 3. Mattmamice are phenotypically distinct from Flgft/ftmice, with histo-
pathology demonstrating enhanced cutaneous inflammation at 32 weeks.
A, Gross phenotype of WT, DM, Mattma/ma, and Flgft/ft mice. Flgft/ft mice
are indistinguishable from WT mice, apart from the stubbed tail and short-
ened ear pinnae, which are phenotypic features shared with the DMmouse.
All mice are age-matched homozygous males. B, Representative skin
biopsy specimens from WT, DM, Mattma/ma, and Flgft/ft mice at 32
weeks, showing markedly increased cutaneous inflammation in DM and
Mattma/ma mice in comparison with that seen in WT and Flgft/ft mice.
Scale bar 5 50 mm.
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inflammation. It is notable that the Flgft mutation has a neonatal
influence, whereas the Mattma mutation has a progressive influ-
ence with age. This indicates the polygenic nature of the DM
mouse as an AD model and indicates the differential influence
of both the Flgft and Mattma mutations. Recently, Flg2/2 mice
were shown to have no overt dermatitis with age,30 with the au-
thors unable to sensitize Flg2/2 mice by means of application
of OVA, an allergen commonly used in models of skin inflamma-
tion,31 to the intact skin barrier, results similar to our data.
Notably, Flgft/ft mice were not sensitized to HDM (data not
shown), indicating an impermissibility of the Flgft/ft skin barrier
to protein antigen ingress. These data indicate that the DMmouse
is not a truemodel of filaggrin deficiency–associated AD-like skin
inflammation.
In this study we adopted a translational approach and also
addressed whether mattrin was implicated in human AD.
A missense SNP in MATTwas shown to have a small but signif-
icant effect on the risk for human AD. Because mattrin shows
FIG 4. Mattmamice have exacerbated AD-like inflammation and HDM-specific responses after allergen chal-
lenge to intact skin. A, Representative skin biopsy specimens from age-matched WT and Mattma/ma mice
treated with HDM or vehicle, with increased inflammation in HDM-treated Mattma/ma mice relative to that
seen in HDM-treated WT and vehicle-treatedMattma/mamice. Scale bar5 50 mm. B, HDM treatment induces
increased dermal cell infiltration in Mattma/ma mice relative to that seen in HDM-treated WT and vehicle-
treated Mattma/ma mice. C, Acanthosis is increased in HDM-treated Mattma/ma mice relative to that seen in
HDM-treated WT and vehicle-treated Mattma/ma mice. D, Epicutaneous HDM treatment results in signifi-
cantly increased TEWL in Mattma/ma mice relative to that seen in HDM-treated WT mice. E, HDM-treated
Mattma/ma mice have increased HDM-specific serum IgE, IgG1, and IgG2 levels relative to those seen in
HDM-treated WT mice. Cell numbers and acanthosis were scored on 15 to 20 hpfs (31000 magnification)
on hematoxylin and eosin–stained sections from WT, DM, Mattma/ma, and Flgft/ft mice. Data represent the
mean and error bars represent 6 SEMs from 6 to 8 mice and are representative of 2 separate experiments.
The Student t test or 2-way ANOVA was used to determine statistical differences between groups. NS, Not
significant, *P > .05. ***P < .001.
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distant sequence homology to MAPEG family members,24 which
are known to catalyze glutathione-dependent transformations of
lipophilic substrates at the lipid bilayer, sequence homology sug-
gests a possible role for mattrin in the biology of lipids or lipid-
like molecules.25 Epidermal transcriptomic analysis of WT
versusMattma/mamice has revealed changes in several transcripts
involved in fatty acid and lipid biology (data not shown). Howev-
er, 1-dimensional and 2-dimensional thin-layer chromatography
of epidermal lipid extracts did not reveal any differences in the
migration or abundance of ceramides, phospholipids, or polar
or nonpolar lipids between WT and Mattma/ma mice (data not
shown). Future work will require analysis of the glutathione
binding of mattrin, elucidation of lipophilic substrates of mattrin,
and an investigation of the downstream signaling pathways and
local immunologic milieu in Mattma mice.
In summary, using a translational mouse-patient strategy, we
have identified a new gene mutation that leads to dermatitis in
mice and have further demonstrated that a variant in the human
gene is associated with AD.
We thank the patients affected by eczema and their families for their interest
and participation. We also thank Masa Amagai and his research group from
Keio University, Tokyo, Japan, for their open and enthusiastic collaboration,
discussion, and sharing of data.
TABLE I. Results of case-control analyses to investigate the association of rs6684514 and AD in 5 populations




rs6684514 OR 95% CI




English adult severe AD vs English population control
subjects from the 1958 Birth Cohort
505 1919 .0038 0.791 0.674-0.929 .0008
UK mild-moderate pediatric AD vs English pediatric
control subjects without AD
338 538 .0153 0.770 0.622-0.953 .0328
Irish pediatric AD vs Irish adult population control subjects 724 1905 .1300 1.025 0.896-1.172 .7905
German AD cases vs German population control subjects 1543 2005 .0794 0.912 0.822-1.011 .0161
Scottish asthma cases with AD vs Scottish population
control subjects
1135 4189 .1365 0.922 0.831-1.023 NA
English adult severe AD is defined as early-onset, persistent, and severe disease. UK mild-moderate pediatric AD includes cases collected from an English population birth cohort
(n5 177) and a Scottish General Practice collection (n5 161); the English pediatric control subjects were ascertained not to have AD at the age of 7 to 9 years. Irish pediatric AD
cases were collected in secondary and tertiary care clinics in Ireland; Irish population control subjects are healthy adult blood donors. Scottish asthma cases with AD are subjects
with physician-diagnosed asthma and parent-reported AD. The German case and control rs6684514 genotypes were ascertained by imputation from genome-wide SNP analysis
data; all other SNP genotypes and FLG null mutations were analyzed by using TaqMan allelic discrimination assays. In the English, United Kingdom, and Irish collections, 4
prevalent FLG null mutations were analyzed (R501X, 2282del4, R2447X, and S3247X), whereas in the German population 2 FLG null mutations were analyzed (R501X and
2282del4). Statistical analysis was performed through logistic regression in Stata 10.0 software (StataCorp).
NA, FLG genotype data not available.
FIG 5. Forrest plot showing results of a fixed-effects meta-analysis of 5 case-control studies to investigate
the association of rs6684514 and AD. Study populations used were as follows: English, English adult severe
AD versus English population control subjects from the 1958 Birth Cohort; UK, UK mild-moderate pediatric
AD versus English pediatric control subjects without AD; Irish, Irish pediatric AD versus Irish adult popula-
tion controls; German, German AD cases versus German population control subjects; Scottish, Scottish
asthma cases with AD versus Scottish population control subjects. ES, Estimated odds ratio. Meta-
analysis was carried out with the ‘‘metan’’ function in Stata software (StataCorp).
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Clinical implications: The role of MATT mutations in suscepti-
bility to AD and related allergic conditions should be further
investigated.
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